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ABSTRACT
The mammalian synapse is essential for transmission of electrical impulses from presynaptic
terminals to postsynaptic sites. The translation of this information into a long-term physical
modification of the synapse is believed to be central to the process of learning and memory.
This physical modification may be manifested by changes in the composition and post-
translational modification of synaptic proteins, which together alter the signalling properties
of a synapse. Reversible protein phosphorylation mediated by kinases, phosphatases and
regulatory molecules, is an essential mechanism of signal transduction in living cells.
Although phosphorylation is the most intensively studied of the several hundred known
post-translational modifications on proteins, until recently the rate of identification of
phosphorylation sites has remained low. Historically, synapse phosphorylation and its
importance in regulating neuronal signal transduction and brain function has been studied
at the level of single molecules, but new proteomic strategies lend themselves to the global
characterisation of the signalling properties of the synapse proteome.
We have developed upon existing immobilised metal-affinity chromatography (IMAC)
techniques for capturing phosphopeptides, to selectively purify phosphoproteins from
complex mixtures. Using this novel approach, combining both protein and peptide IMAC
and mass spectrometry (MS) data acquisition strategies, comprehensive mapping of both the
mouse forebrain cytosolic and synaptic phosphoproteomes was achieved. In total, 1138
phosphorylation events were detected, corresponding to 652 phosphorylation sites, of which
618 are unique from the two phosphoproteomes. 331 unique phosphorylation sites were
mapped on synaptic phosphoproteins and 92% of these phosphorylation sites are novel,
indicating a previously underestimated complexity in synaptic signalling. Bioinformatic and
in vitro phosphorylation assays of peptide arrays suggest a small number of kinases
phosphorylate many proteins and each substrate is phosphorylated by many kinases. 321
unique phosphorylation sites were mapped to cytosolic phosphoproteins and bioinformatic
analysis revealed that this dataset was rich in intrinsic protein disorder, providing insight
into the possible functions of phosphorylation in the regulation of these proteins.
In recent years, MS-based analyses of the postsynaptic density (PSD) and receptor
complexes, have established for the first time a detailed list of its molecular components. In
order to provide a coherent map of the molecular components of the synapse proteome, a
bioinformatic approach was used to combine six PSD and three postsynaptic receptor
complex datasets into a single database of synaptic proteins. This process of data integration
allowed comparisons of analytical approaches used and revealed the most effective
biochemical and MS-based methodologies. This data was used as a framework, on which
multiple data sources were integrated and allowed the derivation of proteome-wide
molecular network maps at the level of gene regulation, protein interaction and protein
phosphorylation. These maps were merged with functional or phenotype data from
individual molecule studies to derive new models of synapse function. This work
significantly increases our existing knowledge of synapse protein phosphorylation and
together with our analysis of the postsynaptic proteome; we observe evidence of multiple
levels of organisation These data indicate the existence of a tightly regulated and highly
complex signalling network for translating electrical information into biochemical changes.
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1. Introduction
1.1 Introduction and Aims
The field of proteomics aims to provide a comprehensive view of the characteristics
and function of every protein present within a given biological system. The genome,
which encodes the entire complement of genes in an organism, has been seen as the
fundamentally complex component of cells. However it has emerged in recent years
that its complexity is overshadowed by that of the transcriptome, which describes
the full complement of mRNA transcripts transcribed from the genome of the cell.
This in turn gives rise to yet another level of complexity see in that of the cellular
proteome. This proteome is derived from the variety of alternative splicing events
that occur at the level of transcription and the use of alternative start and stop sites
and frame-shifting which occurs at the level of translation. This complexity is
compounded by the 300 or more different protein modifications, which have been,
reported (Aebersold and Goodlett, 2001) of which phosphorylation and
glycosylation are prototypic (Figure 1.1).
Comprehensive proteome analysis also seeks to elucidate protein sub-cellular
distribution and protein-protein interactions, which are crucial in determining the
integration of large numbers of proteins into interaction networks, and functional
molecular complexes that ultimately perform a myriad of cellular functions (Figure
1.1). Finally, the proteome is highly dynamic and temporal and thus describes the
complement of proteins expressed in a cell at a single time point. The synapse is a
sub-cellular specialisation that converts patterns of electrical activity into cellular
memory. This processing of electrical information is mediated by the protein
components of the synapse and the phosphorylation of these components is very
important in this process. This specialised proteome can be isolated and
characterised by mass spectrometry in terms of its components and
phosphorylation. Establishment of such a molecular map permits insight into the
organisation and functioning of the synaptic proteome.
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Figure 1.1 - Overview of levels of proteome complexity. (A) There are at least six
points where the complexity of the information encoded in the genome is increased by
transcriptional, translational and post-translational control. At the post-translational level,
more than 300 different types of modifications, including protein phosphorylation exist.
These processes would easily transform the 22, 000 gene loci in the human genome into
an estimated 1 million different polypeptide forms, greatly increasing genome to proteome
complexity. (B) Once a polypeptide has undergone splicing, post-translational
modifications etc, there are further levels of proteome complexity in how proteins exist in
a cell. Proteomes from different species, tissues or cell types differ not only in their
composition but in their protein interactions, protein complexes, and organelles. Complex
diseases are usually caused by changes in more than one level in this complexity and
therefore disease proteomics should take this into account. An essential point about this
complexity is the need for adequate bioinformatic approaches to integrate such proteome
data.
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1.2 Proteomics in neuroscience
There are many approaches used to study large-numbers of proteins in the brain,
from comparative analysis of protein expression to mapping molecular complexes.
A number of examples of such approaches will be reviewed to highlight the
diversity of proteomic applications to neuroscience.
1.2.1 Two-dimensional electrophoresis
The biochemical approach of two-dimensional electrophoresis which has become
the classical proteomic approach to whole proteome analysis has the capacity to
display a large number of proteins expressed the studied system under given
physiological conditions. Construction of global expression maps for defined
proteomes is the most widely used application of proteomics and when used in
combination with mass spectrometry (MS) techniques can be a powerful approach.
There have been a number of studies focused on global neuroproteomics from
whole brain analysis to the analysis of synaptic components. Two-dimensional
maps have been constructed for whole human (Langen et al., 1999) mouse (Gauss et
al., 1999) and rat brains (Fountoulakis et al., 1999) to analyse the entire brain
proteome. These studies yielded more than 200 discrete proteins with significant
overlap between datasets. The mouse brain proteome study is the most
comprehensively characterised to date by 2D electrophoresis with 8767 resolved
spots and over 300 proteins identified by a combination of proteomic and genetic
methods, (Figure 1.2).
A number of brain region proteomes have been studied to investigate differences in
protein expression. Preliminary analysis of the mouse cerebellar proteome has
identified 30 proteins (Beranova-Giorgianni et al., 2002) and analysis of the porcine
cerebellum led to identification of 56 spots (Friso and Wikstrom, 1999). A
developmental proteomic study of the rat cerebellum resulted in resolution of over
3000 spots and identification of 67 of these (Taoka et al., 2000). Most proteins
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Figure 1.2 - Protein standard map of the mouse brain supernatant fraction
obtained by large-gel 2-D electrophoresis
(image from Gauss, C., Kalkum, M., Lowe, M., Lehrach, H. & Klose, J. Analysis of the
mouse proteome. (I) Brain proteins: separation by two- dimensional electrophoresis
and identification by mass spectrometry and genetic variation. Electrophoresis 20, 575-
600. (1999))
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showed an increase in abundance as the cerebellum matured, however, 42 spots
appeared to be exclusively expressed in the immature cerebellum. Some of the latter
were identified by MS and included proteins with defined roles in nervous system
development. Although, the approach of using 2D gels in conjunction with MS
techniques is a classical proteomic approach, it is evident that it falls short as a sole
platform for global proteomics. The range of biochemically different proteins, co-
migration of proteins and difficulty of resolution of low abundance molecules has
hampered the use of this technology to comprehensively analyse highly complex
mixtures of proteins present in brain preparations. Problems associated with 2D gel
resolution of membrane proteins have been overcome to some extent (Santoni et al.,
2000), however gel-free proteomic solutions such as multidimensional protein
identification technology (MudPIT) (Wu et al., 2003) allow greatly increased
coverage of the membrane proteome. However, 2D-electrophoresis will remain a
useful tool in proteomics, due to sophisticated image analysis, software and
fluorescent dyes, which now permit more sensitive and accurate comparative
proteome analysis.
1.2.2 Subcellular proteomics
The observation of cells under an electron microscope for the first time in the 1940's
revealed a previously unexpected level of complexity (Palade, 1966). Extensive
compartmentalisation was observed and was found to be achieved by intracellular
membranes. This realisation prompted intensive investigation of sub-cellular
organelles and in the following decades led to the development of a number of
methodologies to physically isolate cellular organelles. The identification of the
protein composition of sub-cellular organelles has been a significant challenge for
many years and is only now becoming routine with sophisticated mass
spectrometry-based platforms (Table 1.1). Most sub-cellular organelles are isolated
using density gradient centrifugation, in which a gradient of sucrose solutions is
used to partition different organelles according to their density. A limitation of this
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approach is the difficulty in assessment of the degree of purity of the isolated
fractions. Usually, the presence and absence of sub-cellular markers is used to






(Houde et al., 2003), (Garin et al., 2001), (Gagnon et
al., 2002), (Dermine et al., 2001)
Nucleolus 489 (Andersen et al., 2005)
Spliceosome 292 (Neubauer et al., 1998), (Rappsilber et al., 2002)
Exosome 295 (Pisitkun et al., 2004)
Lysosome 215 (Bagshaw et al., 2005)
Centrosome 64 (Andersen et al., 2003)
Mitochondria 847 (Cotter et al., 2004)
Clathrin-coated
vesicles 209 (Blondeau et al., 2004)
Lipid raft 241 (Foster et al., 2003)
Golgi 136 (Bell et al., 2001), (Wu et al., 2000), (Wu et al., 2000)
Nuclear pore 174 (Rout et al., 2000)
Neutrophil granules 286 (Lominadze et al., 2005)
Table 1.1 - Summary of organellar proteomic studies
Recently, with the advent of quantitative mass spectrometry-based approaches, it is
possible to asses the relative amounts of each protein present in a fraction compared
to the starting material of the isolation. This approach was successfully applied to
the identification of proteins in the centrosome (Andersen et al., 2003). In this study,
they quantitatively profiled hundreds of proteins across several centrifugation
fractions and identified proteins which were quantitatively enriched in centrosomes
(Andersen et al., 2003).
Traditionally, the protein content of purified organelles are separated by either ID
or 2D SDS-PAGE and protein containing bands or spots are excised, digested and
subjected to analysis by mass spectrometry. ID SDS-PAGE has the advantage of
being particularly well suited for separation of membrane proteins, while 2D SDS-
PAGE provides better separation of protein species. However, both of these
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approaches require band or spot excision, which is very labour intensive, not very
reproducible and causes significant sample loss due to incomplete peptide
extraction from the gel slices/spots. These difficulties have been overcome, in part,
by gel-free separations of peptides such as MudPIT (multidimensional protein
identification technology) pioneered by John Yates, in which the protein sample is
denatured, digested in solution and the resultant peptides separated in the first
dimension by ion-exchange chromatography and in the second dimension, by
reverse-phase chromatography (Washburn et al., 2001). The first application of this
methodology was the profiling of the yeast proteome and this facilitated
identification of 1484 proteins (Washburn et al., 2001), far exceeding the numbers of
protein identifications from traditional methods.
Complete characterisation of the protein inhabitants of every organelle in a cell type
would provide valuable information on protein localisation, provide annotation for
the large numbers of proteins of unknown function and would provide a starting
point for large-scale functional investigation of the biology of each organelle. Such
data would be invaluable for neuroscience research and application of this approach
to synapses, which are specific to neurons, would certainly provide an
unprecedented parts list and platform for the study of synaptic biology.
1.2.3 Multiprotein complex proteomics
1.2.3.1 NMDA receptor-adhesion protein signalling complex
Protein-protein interactions are the basis on which cellular structure and function
are built and interaction partners are an immediate lead into biological function that
can be exploited for therapeutic purposes. Proteomics has been shown to make a
crucial contribution to the study of protein-protein interactions (Neubauer et al.,
1997). Proteomic approaches to tackle multiprotein complexes usually involve
purification of the entire complex by a variety of affinity methods, and protein
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identification by western blotting or mass spectrometry based approaches. The first
proteomic analysis of multiprotein complexes relevant to the brain was the
purification and identification of the molecular constituents of the NMDA receptor-
adhesion protein signalling complexes (NRC) (Husi et al., 2000), (Husi and Grant,
2001).
1.2.3.1.1 Methodology
Similar to most neurotransmitter receptors, the NMDAR has a low abundance in
neurons compared with the overall protein content. Therefore, it is important to
generate highly enriched samples containing the target molecule. This can be
achieved by a variety of methods, generally involving affinity chromatography
steps. These can range from ligand affinity (drugs, substrates or co-factors) to the
more widely used approach of immunoprecipitation, involving specific antibodies
to the molecule of interest. A major drawback in using antibody-based approaches
for proteomic analysis is the introduction of the IgG itself, which interferes with the
analysis by overshadowing proteins of interest that co-migrate during the gel-
separation. This same problem arises with protein-affinity based methods, in which
a recombinant protein carries one or several affinity-tags (e.g. poly-histidines), or is
expressed as a GST-fusion protein. This problem can be eliminated using either the
tandem affinity purification (TAP) method (Rigaut et al., 1999) or with the use of
non-protein based methods, which exploit substrate or ligand affinities, such as
peptide-based isolation procedures (Husi and Grant, 2001). All of these ligands,
groups or proteins are then coupled to a resin either irreversibly (usually in the case
of small molecules), or through a secondary affinity linkage specific for the bait-
molecule. Neuronal extracts are then incubated with the resins bearing the bait and
bound proteins separated from each other as well as from the matrix by
conventional gel analysis.
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Identification of isolated proteins can be readily achieved using western blotting or
mass spectrometry. Western blotting (also known as immunoblotting) utilises
specific antibodies to detect a protein that has been transferred from a gel onto a
membrane. A major advantage of western blotting is its sensitivity and ability to
detect amounts of protein beyond the range of current sequencing-based or mass
spectrometry methodologies. It is obvious that this approach is biased by the
assumption that a given molecule might be present, and cannot be used to identify
unknown or unsuspected proteins. However, there is a large amount of
neurobiological evidence concerning the putative involvement of molecules that
influence many target proteins and such proteins pose ideal targets for western
blotting approaches. Additionally, changes in protein levels, as a result of
modulation or modification in the receptor's environment, can easily be visualised
using specific antibodies against the proteins under investigation. A disadvantage of
this method is its labour intensive nature and thus difficulty in performing on a
large scale.
The main approaches to protein identification are peptide-mass fingerprinting using
matrix-assisted laser desorption/ionisation (MALDI) (Henzel et al., 1993),
(Shevchenko et al., 1996) and electrospray ionisation using a tandem mass
spectrometer (Shevchenko et al., 1997) or a combination of both (Shevchenko et al.,
2000). Recent developments led to new methodologies using direct liquid
chromatography/tandem mass spectrometry (LC/MS-MS) techniques, which allow
fast and reliable mapping of very low amounts of peptides in an almost completely
automated fashion (Shevchenko et al., 2000). Furthermore, using this method, it is
also possible to determine if a protein or peptide carries any post-translational
modifications, such as glycosylation or phosphorylation (Pandey et al., 2000).
The sample is usually separated on a gel and the bands of interest excised and
treated with trypsin in order to generate fragments of proteins that can
subsequently be extracted from the gel slice. There are several reasons for analysing
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peptides rather than proteins. The peptide's mass can be measured at much greater
precision than the mass of intact proteins. Peptides give rise to a library of molecular
masses that are directly derived from the proteins, which can be identified using
computational techniques.
Using the approaches described above the NRC was shown in 2000, to comprise 77
proteins organised into receptor, adaptor, signalling, cytoskeletal and novel
proteins, of which 30 are implicated from binding studies and another 19 participate
in NMDAR signalling (Figure 1.3) (Flusi et al., 2000).
NMDAR and metabotropic glutamate receptor subtypes were linked to cadherins
and LI cell-adhesion molecules in complexes lacking AMPA receptors. These
neurotransmitter-adhesion receptor complexes were bound to kinases,
phosphatases, GTPase-activating proteins and Ras with effectors including MAPK
pathway components. A striking feature of the composition is that there appears to
be 'modules' or sets of signalling proteins that are known to comprise key
components of signal transduction pathways that can be distinctly regulated. For
example, all of the molecules necessary to induce the phosphorylation of mitogen-
activated protein kinase (MAPK) following NMDAR stimulation are present in the
NRC (including CaMKII, SynGAP, Ras, MEK and ERK) (Figure 1.5). There modules
may allow the NMDAR and mGluR to integrate signals within the complex and
then couple to down-stream cellular effector mechanisms, such as trafficking of
AMPA receptors and cytoskeletal changes that mediate structural and physiological
plasticity. Furthermore, at least 18 NRC constituents are regulated by synaptic
activity indicating that the composition of the complex is dynamic. In the
hippocampus, these activity-dependent genes are known to undergo specific
temporal changes following the induction of plasticity.
Chapter 1 - Introduction 22
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
Figure 1.3 - Schematic representation of the NMDA receptor complex (NRC). Proteins
depicted here (except for those in grey, which were found in the literature) were found in the
NRC by proteomic screens. Protein-protein interactions were mined from the literature and
can be found in PPID (www.PPID.org).
Adapted from "Proteomics of the nervous system" Husi H, Grant SG. Trends Neurosci. 2001
24(5):259-66.
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1.2.3.2 Other membrane receptor complexes
Since characterisation of the NRC, two other receptor complexes have been
reported. P2X receptors are ATP-gated ion channels in the plasma membrane, and
activation of the P2X7 receptor also leads to rapid cytoskeletal re-arrangements such
as membrane blebbing. 11 proteins in human embryonic kidney cells that interact
with the rat P2X7 receptor were identified by affinity purification followed by mass
spectroscopy and immunoblotting (Kim et al., 2001). Also using a proteomic
approach based on peptide affinity chromatography followed by mass spectrometry
and immunoblotting, another study identified 15 proteins that interact with the C-
terminal tail of the 5-hydroxytryptamine 2C (5-HT (2C)) receptor, a GPCR (Becamel
et al., 2002). These proteins include several synaptic multidomain proteins
containing one or several PDZ domains (PSD95 and the proteins of the tripartite
complex Veli3-CASK-Mintl), proteins of the actin/spectrin cytoskeleton and
signalling proteins. Co-immunoprecipitation experiments showed that 5-HT (2C)
receptors interact with PSD-95 and the Veli3-CASK- Mintl complex in vivo.
Electron microscopy also indicated a synaptic enrichment of Veli3 and 5-HT (2C)
receptors and their co-localisation in microvilli of choroidal cells. These results
indicate that the 5-HT (2C) receptor is associated with protein networks that are
important for its synaptic localisation and its coupling to the signalling machinery
(Becamel et al., 2002).
It is now emerging that multiprotein signalling complexes or "signalling machines",
of which the NRC is prototypic, are responsible for orchestrating the complex
signalling events at ionotrophic glutamate receptors (Husi et al., 2000), ATP
receptors (Kim et al., 2001) and G-protein coupled receptors (Becamel et al., 2002).
They seem to share a common organisation of receptor, protein scaffold, (in which
the signalling molecules are localised) and membrane to cytoskeletal interactions.
Therefore, study of individual receptor multiprotein complexes such as the NRC
will most likely provide a mechanistic basis that will be very useful and applicable
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for the systematic identification and study of membrane receptor complexes
associated with the estimated 100 other receptor types believed to exist in the brain.
1.3 One hundred years of protein phosphorylation
Phosphorylation was first detected in the protein Vitellin, in 1906 (Alsberg, 1906)
and phosphoserine was detected in Vitellin nearly thirty years later (Levene, 1933).
It took another 20 years to discover that this phenomenon was actively catalysed by
enzymes (Burnett and Kennedy, 1954). It was in the 1950's when phosphorylation
became of interest to the fields of metabolism and hormone action, in which
phosphorylase A was intensively studied. The effects of epinephrine and glucagon
on phosphorylase activity were investigated and it was found that these hormones
stimulate cAMP (3', 5'-cyclic-adenosine monophosphate), which regulates
phosphorylase activity (Rail and Sutherland, 1958). This regulation was
subsequently shown to be mediated by incorporation of phosphate into
phosphorylase A, converting the enzyme to phosphorylase B, the active form
(Fischer and Krebs, 1955). The necessity for cAMP for phosphorylase activation
promped speculation that there was a cAMP-dependent kinase that was responsible
for phosphorylase A activation and it was the first time a signalling cascade was
proposed. In 1968, this cAMP-dependent kinase (PKA) was purified (Walsh et al.,
1968) and subsequently, intensive study of the first protein kinase revealed that is
was a tetramer composed of regulatory and catalytic subunits (Taylor et al., 1990).
The significance of phosphorylation was realised through the 1970's and the early
1980's. Important studies by Paul Greengard in the field of synaptic
phosphorylation paved the way for the countless studies on synaptic
phosphorylation ever since. These studies were the first to report phosphorylation
of synaptic membrane proteins in response to cAMP stimulation (Ueda et al., 1973),
(Ueda and Greengard, 1977). The first calmodulin-dependent kinase was identified
Chapter 1 - Introduction 25
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
1906 j | Identification of phosphate in the protein Vitellin (Alsberg, 1906)
1933 Detection of phospho-serine in Vitellin (Levene, 1933)
1954 | First protein kinase activity observed (Burnett and Kennedy, 1954)
1955 Characterisation of Phosphorylase A phosphorylation (Fischer and Krebs, 1955)
1968 Discovery of cAMP-dependent protein kinase A and the first example of a
signalling cascade (Walsh et al., 1968)
1978 Identification of the first calmodulin-dependent kinases
(Dabrowska et al., 1978), (Cohen et al., 1978), (Schulman and Greengard,
1978)
1979 Determination of the amino-acid sequence of the first protein kinase (PKA)
(Shoji et al., 1981)
1979 LTP induces phosphorylation of a synaptic protein (Browning et al., 1979)
1980 Discovery of tyrosine phosphorylation (Hunter and Sefton, 1980)
1982 Characterisation of calcineurin, a serine/threonine specific phosphatase
(Stewart et al., 1982)
1987 Identification of the MAP kinase cascade (Ray and Sturgill, 1987)
1988 Purification of the first tyrosine phosphatase (Tonks et al., 1988)
1988 Identification of PI3-kinase activity (Whitman et al., 1988)
1989 Creation of the first kinase knockout mouse (Schwartzberg et al., 1989)
1991
1
Cloning of JAK kinases, a new family of tyrosine kinases
■ (Wilksetal., 1991)
1996 I 1 Demonstration of phosphorylation-dependent binding of 14-3-3 proteins
1 (Muslin et al., 1996)
1997 1 1 Engineered unnatural nucleotide specificity for SRC (Shah et al., 1997)
2002 | I First large-scale analysis of phosphorylation sites, the yeast phospho-
proteome (Ficarro et al., 2002)
2002 | Classification of the human kinome (Manning et al., 2002)
2005 First quantitative phosphoproteomic analysis: the yeast pheromone pathway
(Gruhler et al., 2005)
Figure 1.4 - One hundred years of protein phosphorylation
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in late 1970's which included CaMKI, CaMKII (Schulman and Greengard, 1978),
phosphorylase kinase (Cohen et al., 1978) and myosin light-chain kinase
(Dabrowska et al., 1978). In 1979, the amino-acid sequence of the first kinase (PKA)
was determined (Shoji et al., 1981). In the same year, an exciting report that showed
that LTP (Long-term potentiation) induced phosphorylation of a synaptic protein
(Browning et al., 1979), a key finding which provided a link between
electrophysiological phenomena with protein phosphorylation.
The next major finding occurred in 1980, when Tony Hunter discovered tyrosine
phosphorylation (Hunter and Sefton, 1980), which is now recognised as a very
important and specific type of phosphorylation. A number of important
serine/threonine protein kinases were characterised in the 1980's providing insight
into how the process of reversible phosphorylation is controlled (Ingebritsen and
Cohen, 1983) (See Ingebritsen and Cohen, 1983 for review). The late eighties and
nineties were characterised by the signalling cascade, with much attraction focused
on the MAP kinase cascade. In addition, this period saw the identification of the
first protein tyrosine phosphatase (Tonks et al., 1988), PI3-kinase (Whitman et al.,
1988), and JAK kinases (Wilks et al., 1991). One of the major landmarks of the late
1980's was the creation of the first protein kinase knockout in mouse (Schwartzberg
et al., 1989), this was closely followed by a Fyn knockout, the first kinase knockout
mouse relevant to neuroscience. Analysis of this Fyn tyrosine-kinase mutant
revealed defects in LTP, spatial learning and hippocampal development and thus,
established for the first time, the importance of a specific kinase in synapse function
(Grant et al., 1992).
The 1990's brought many studies focused on specific kinases and phosphorylation
sites and also the demonstration of phospho-dependent binding of adapter proteins
such as 14-3-3 proteins (Muslin et al., 1996). In 1997, the sophisticated use of genetic
engineering allowed manipulation of the residues in Src tyrosine kinase responsible
for nucleotide specificity (Shah et al., 1997). These residues were altered to allow the
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use of unnatural nucleotides which the kinase would use to specifically label its
substrates. The new millennium brought phosphorylation research into proteomics
and the new field of phosphoproteomics begun. This new approach to study
phosphorylation was exemplified by the work of Ficarro et al. in 2002. This reported
identification of hundreds of phosphopeptides and phosphorylation sites from S.
cerevisiae by using a combination of phosphopeptide enrichment and tandem mass
spectrometry (Ficarro et al., 2002) and set the standard for phosphoproteomic
experiments to follow. In the same year, the portion of the genome encoding protein
kinases was analysed and for the first time a complete set of kinase sequences were
assembled and classified (Manning et al., 2002). The result, the human kinome,
which contains 518 protein kinases, is a useful data resource and profiling of
kinomes is becoming relevant to therapeutics (Vieth et al., 2005).
The assembly of the human kinome as well as the possibility of identification of
hundreds of phosphorylation sites started to reveal the complexity of the
phosphoproteome and prompted researchers to ask how to understand and address
this complexity. This has been addressed in part by using quantitative mass
spectrometry to monitor protein phosphorylation in response to specific conditions
and stimuli, e.g. the yeast pheromone pathway (Gruhler et al., 2005). In addition,
attempts to integrate phosphoproteomic data have been made, using systems
biology type approaches such as network analysis to derive understanding of
complex signalling pathways. This has been applied to derive network and pathway
maps of EGF (epidermal growth factor) receptor signalling (Oda et al., 2005), one of
the best characterised signalling systems to date.
1.4 Phosphorylation in neuronal signalling
In the 1894, Ramon y Cajal proposed a theory that changes in synaptic strength
(synaptic plasticity) maybe involved in memory formation (Ramon y Cajal, 1894)
and this basic mechanism is now the most widely accepted theory of memory
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storage on a cellular level. The phenomena of long-term potentiation (LTP) and
long-term depression (LTD), the enduring increase or decrease in the amplitude of
excitatory-postsynaptic potentials as a result of high or low frequency stimulation of
afferent pathways, are considered to be the electrophysiological manifestations of
synaptic plasticity.
Since the discovery of cAMP-dependent phosphorylation of proteins in the synaptic
membrane in the early 1970's by Paul Greengard and co-workers (Ueda et al., 1973),
(Ueda and Greengard, 1977), the field of synaptic phosphorylation has become an
essential part of the study of synaptic physiology. It was realised in the late 1970's
that repetitive stimulation of the of the Schafer collateral-commissural system of the
rat hippocampus induced LTP and resulted in phosphorylation of a 40 kDa protein
(Browning et al., 1979), which was later identified as alpha subunit of pyruvate
dehydrogenase (Browning et al., 1981). This was the first demonstration of the link
between the electrophysiological phenomenon of LTP and the biochemical
manifestation of LTP; synaptic protein phosphorylation. Since these initial insights
into synaptic signalling, much attention has been focused on phosphorylation and
its role in synapse function (Figure 1.5 for overview), a number of these key findings
in glutamatergic synaptic signalling will be reviewed here.
1.4.1 Overview of glutamatergic signals
Glutamatergic synapses contain ionotropic (N-methyl-D-aspartate (NMDA) and -
amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)) receptors and
metabotropic glutamate receptors (mGluRs), which exist as multiple subtypes
(mGluRl-8). All of these receptors are activated by glutamate release from the
presynaptic membrane; NMDA receptors allow influx of calcium ions, an important
the second messenger, AMPA receptors are permeable to potassium and sodium
ions, while metabotropic glutamate receptors are coupled to G-proteins and
participate in regulation of intracellular stores of calcium. LTP is triggered by
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Figure 1.5 - An overview of signalling at the synapse. Activation of postsynaptic glutamate
receptors causes increases in the level of intracellular calcium and other second messengers
such as cAMP. A complex regulatory mechanism mediated by kinases, phosphatases and
signalling molecules modulate channel function and signalling pathways which control processes
such as transcription, cell survival and actin reorganisation.
Adapted from "Proteomics of the nervous system" Husi H, Grant SG. Trends Neurosci. 2001
24(5):259-66.
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transient activation of NMDA receptors and is expressed as a persistent increase in
synaptic transmission through AMPA receptors. High frequency synaptic
stimulation causes calcium ion influx through the NMDA receptor and activation of
CaM kinase II (CaMKII) and induction of LTP. On the other hand, low frequency
stimulation causes moderate but prolonged increases in calcium levels which
activate protein phosphatases and induction of LTD.
Analysis of the modulation of these receptors and associated proteins by
phosphorylation, mediated by kinases and phosphatases, is essential to understand
how signals are propagated and resolved by synapses.
1.4.2 NMDA receptor phosphorylation
The NMDA receptor NR1 and NR2 subunits are extensively phosphorylated, which
permits modulation of NMDAR activity (see (Yamauchi, 2002) and (Salter and
Kalia, 2004) for review), localisation (Trngley et al., 1997) and trafficking (Chung et
al., 2004). The NR1 subunit is phosphorylated by PKA and PKC, which regulates its
intracellular localisation (Tingley et al., 1997). Yotiao is a NRl-binding protein that
also binds PKA and the constitutively active protein phosphatase PP1. Association
of PP1 with this complex limits the channel activity but is opposed by the effects of
PKA, which rapidly enhances NMDAR activity (Westphal et al., 1999). This is a
classic example of how adapter proteins such as Yotiao can facilitate the localisation
of a kinase and a phosphatase proximal to their substrate, in this case NR1.
The NR2 subunits have long C-terminal tails which contain multiple protein
interaction sites that nucleate the complex of proteins attached to the receptor. The
NR2B subunit is bound to and phosphorylated by CaMKII (Omkumar et al., 1996).
CaMKII is activated by NMDAR receptor-mediated calcium influx and activated
CaMKII binds to NR2B and results in sustained Ca2+/calmodulin (CaM)-
independent (autonomous) kinase activity (Bayer et al., 2001). This activated
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CaMKII-NR2B complex is also regulated by PP1 which causes dissociation of
CaMKII from the PSD (Yoshimura et al., 1999). PSD-95, which is an important
synaptic scaffolding protein involved in many synaptic processes (Kim and Sheng,
2004), binds to the C-terminal tail of NR2B. Recently, it was shown that
phosphorylation of this binding site on NR2B by Casein Kinase 2 (CK2) disrupts the
PSD-95-NR2B interaction (Chung et al., 2004). Phosphorylation of this site is
regulated by NMDAR activity and Ca2++/CaMKII and results in decreased surface
expression of NMDA receptors (Chung et al., 2004).
The NR2 subunits are heavily tyrosine phosphorylated by Src (Yang and Leonard,
2001) and Fyn (Nakazawa et al., 2001) tyrosine kinases. Fyn phosphorylation of
NR2B is significantly increased after induction of LTP in the CA1 region of the
hippocampus and is reduced in Fyn mutant mice (Nakazawa et al., 2001). Src
phosphorylates tyrosine residues in NR2A responsible for zinc binding and
phosphorylation of these sites results in potentiation of the NMDA receptor by
reducing tonic zinc inhibition (Zheng et al., 1998).
1.4.3 AMPA receptor phosphorylation
The AMPA receptor subunits are also heavily regulated by phosphorylation. Similar
to the NMDA receptor, phosphorylation of the AMPA receptor modulates receptor
function as well as protein interactions with the receptor. There are two major sites
of phosphorylation on the GluRl subunit, S831 and S845 that are phosphorylated by
CaMKII and PKA, respectively (Lee et al., 2000). CAMKII phosphorylation of GluRl
is correlated with an increase in the single-channel current of the AMPA receptor
and this phosphorylation occurs during LTP in the CA1 region of the hippocampus
(Barria et al., 1997). Investigation of the modulation of GluRl by PKA
phosphorylation of Ser-845 has suggested that phosphorylation of this residue may
underlie the PKA-induced potentiation of AMPA receptors in neurons (Roche et al.,
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1996). Induction of chemical LTP results in the dephosphorylation of GluRl at serine
845, (PKA substrate), but not at serine 831 (PKC and CaMKII substrate) (Lee et al.,
1998). In fact, LTP activates CaMKII, which phosphorylates S845, whereas LTP
activates protein phosphatases such as PP1/PP2A, which dephosphorylate S845. It
would therefore seem that regulation of these sites would contribute to the change
in the efficacy of synaptic transmission that occurs during LTP and LTD.
Phosphorylation of the GluR2 subunit modulates its interaction with PDZ-
containing binding proteins. S880, which is phosphorylated by PKC, is located in
the C-terminus of GluR2 and occurs in a binding site for PICK-1 and GRIP-1.
Phosphorylation of S880 decreases GRIP-1, but not PICK-1 binding (Chung et al.,
2000). It has been demonstrated that PKC activation in neurons increases the S880
phosphorylation and recruits PICK1 to excitatory synapses. This correlates with fast
internalisation of surface GluR2 suggesting that phosphorylation of S880 in GluR2 is
important in the regulation of the AMPA receptor internalisation during synaptic
plasticity (Chung et al., 2000). In addition, induction of LTD in hippocampal slices
increases phosphorylation of S880 suggesting that the modulation of GluR2
interaction with GRIP1 and PICK1 may regulate AMPA receptor internalisation
during LTD (Kim et al., 2001). The use of a peptide that disrupts the GluR2-PICKl
interaction was shown to inhibit LTD in the hippocampus, further supporting the
importance of PKC phosphorylation in synaptic plasticity (Kim et al., 2001).
1.4.4 Modulation of the postsynaptic scaffold
As discussed for both the NMDA and AMPA receptors, phosphorylation is
employed to modulate channel function as well as to modulate protein interactions.
Dynamic modulation of protein interactions is emerging as a theme common among
postsynaptic proteins and is of particular interest as the postsynaptic scaffold is
thought to harbour many signalling proteins. If the postsynaptic scaffold is
dynamically modulated then it would be possible that it plays a significant role in
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orchestrating signalling pathways from the postsynaptic membrane. A selected
number of examples of this will be introduced to discuss this theme further.
One of the first examples of regulation of a kinase by a scaffolding protein was that
of AKAP79 (A Kinase Anchor Protein). AKAP79 forms a ternary complex with PKA
and the calcium-dependent phosphatase, Protein phosphatase 2B (PP2B) (Coghlan
et al., 1995) and regulates the action of this kinase-phosphatase pair by
compartmentalisation with preferred substrates. AKAP79 targeting to the plasma
membrane is regulated by PKC phosphorylation and calmodulin binding (Gomez et
al., 2002). AKAP79 localisation is regulated by NMDA receptors through CaN
activation and F-actin remodelling (Gomez et al., 2002). NMDA receptor activation
also regulates dendritic spine localisation of PKA and CaN and association of the
AKAP79-PKA complex with PSD-95 family members (MAGUKs) (Gomez et al.,
2002). Glutamate receptors and PKA are recruited into a macromolecular signalling
complex through direct interaction between the MAGUK proteins, PSD-95 and
SAP97, and AKAP79 and phosphorylation of AMPA receptors is enhanced by a
SAP97-AKAP79 complex that directs PKA to GluRl (Colledge et al., 2000). This
AKAP79 signalling complex is able couple intracellular calcium levels (through
PP2B) to the PKA phosphorylation state of GluRl. This integration of intracellular
signals can be transduced to GluRl by the AKAP79 signalling complex and,
regulation of AKAP79/150 postsynaptic targeting may be important for synaptic
plasticity.
PSD-95 is a member of the membrane-associated guanylate kinase protein family
(MAGUK) and is the best characterised of the group of scaffolding proteins at the
synapse. It contains three PDZ domains, an SH3 domain and a GK domain, which
together mediate interactions with at least 54 proteins. PSD-95 binds to the NMDA
receptor (Niethammer et al., 1996) and is a crucial component of the NMDA
receptor complex (Husi et al., 2000). PSD-95 also forms oligomers and is thought to
exist as a scaffold in association with the postsynaptic membrane (McGee and Bredt,
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1999), (Topinka and Bredt, 1998). The protein-tyrosine kinase Fyn has been shown to
phosphorylate the NR2A subunit of the NMDA receptor in vivo (Tezuka et al.,
1999). PSD-95 binds Fyn as well as the NMDA receptor subunits and promotes Fyn-
mediated phosphorylation of NR2A (Tezuka et al., 1999). Different regions of PSD-
95 interact with Fyn and the NMDA receptor subunits and therefore can recruit Fyn
and other members of the protein-tyrosine kinases family to the NMDA receptor to
regulate channel activity (Tezuka et al., 1999). In fact, PSD-95 and SAP102 (another
MAGUK), can recruit PYK2, (protein-tyrosine kinase) to the NMDA receptor
(Seabold et al., 2003). Induction of LTP requires the Pyk2/Src signalling pathway,
which up-regulates the activity of NMDA receptors, so this recruitment of tyrosine
kinases is an important regulatory mechamism at the synapse (Seabold et al., 2003).
SAP97 is also a MAGUK and is involved in the trafficking and clustering of
glutamate ionotropic receptors to the postsynaptic membrane (Mauceri et al., 2004).
It directly interacts with the NR2A subunit of NMDA receptor and CaMKII
phosphorylation of S232 on SAP97 prevents binding to NR2A (Gardoni et al., 2003).
CaMKII phosphorylation of an additional site (S39) drives SAP97 into spines and
regulates the association of SAP97 with the postsynaptic scaffold (Mauceri et al.,
2004).
It can be seen that from these examples of glutamate receptors and synaptic
scaffolders that phosphorylation, both tyrosine and serine/threonine, is extensively
used for modulation of function, protein interaction and localisation. Two
particularly interesting points concerning phosphorylation at the synapse are that
firstly, adaptor/scaffold proteins regulate kinases and phosphatases by specific
recruitment to their substrates and secondly, phosphorylation of these
adaptor/scaffold proteins regulates their association with other proteins and their
localisation. This system of regulation does not have a clear hierarchy; the mediators
of phosphorylation (kinases and phosphatases) regulate, and are regulated by their
substrates, in this case scaffolding proteins. This process, in turn, regulates
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receptor/channel activity as do signals (e.g. intracellular calcium) coming from
receptors/channels regulate this system of kinases, phosphatases and scaffolding
proteins.
Although, we have enough data concerning synaptic phosphorylation to draw
broad conclusions such as these, the exact mechanisms and organisation of this
complex regulatory system are unknown. Systematic analysis of these components
by proteomic approaches will enable identification of the proteins at the synapse,
identification of sites of phosphorylation of these proteins and with further
developments in the field of kinomics/phosphoproteomics, annotation of kinases
and phosphatases to their cognate substrates. This will provide a comprehensive
platform for tackling synaptic signalling as a whole. However, functional
characterisation of phosphorylation sites such as that described above is still very
labour intensive and technological advances are necessary to functionally
characterise phosphorylation sites on a proteome-wide scale.
1.5 Approaches to probe the phosphoproteome
1.5.1 Technology
Traditional biochemical approaches to analyse phosphorylation usually involve
focused study of one phosphoprotein and often of one particular phosphorylation
site. Antibodies that specifically recognise the phosphorylated epitope can be made
and used to purify the phosphoprotein, detect the phosphoprotein in western blots
or for imunohistochemistry or immunocytochemisty analyses. Generation and
validation of such phospho-specific antibodies is a time consuming process taking
up to one year to have an antibody that can be used confidently. The use of 32P
labelled y-ATP for in vitro kinase reactions has been used widely and separation of
labelled phosphorylated peptides by TLC (Thin layer chromatography) provides
information about the number phosphopeptides and the intensity of
phosphorylation. Analysis of these phosphopeptides from TLC plates has been
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performed using mass spectrometry (MALDI-ToF (Matrix-associated laser
desorption ionisation-time of flight)) and Edman sequencing. However, this
methodology is suited for single phosphoprotein studies and the use of 32P is
hazardous.
1.5.1.1 Phosphoproteome enrichment strategies
Development of mass spectrometry and in particular liquid-chromatography-
coupled mass spectrometry (LC-MS/MS) in the late 1990's permitted identification
of large numbers of peptides in proteome-scale experiments (Gygi and Aebersold,
2000). The use of mass spectrometry for characterisation of phosphorylation on a
proteome-scale was hampered by characteristics of phosphorylation itself. It has
been estimated that one-third of any given proteome is phosphorylated and the
stoichiometry of phosphorylation is often low, so to study phosphorylation on a
global level, phospho-enrichment is a prerequisite.
Digestion of a proteome or even a portion of a proteome can result in generation of
tens of thousands of tryptic fragments. This number of peptides is overwhelming in
an LC-MS-MS experiment and as the mass spectrometer is usually operated in a
mode which only selects the most intense ions for sequencing, only the most
abundant portion of the proteome is sampled. Many signalling proteins are present
at low abundance in cells and the portion of these proteins that are phosphorylated
at any one time may also be quite low. Therefore in a standard LC-MS/MS
experiment, the chance of detecting and sequencing a phosphopeptide is very low
indeed. A number of strategies to overcome these problems were developed, which
involve either physically enriching for phosphorylated species or isolating phospho¬
peptide specific signals in the mass spectrometer (Figure 1.6).
A number of chemical modification strategies have been developed in which the
phosphate group has been replaced with a moiety that is chemically more stable
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Figure 1.6 - Overview of techniques used to detect and map phosphorylation sites
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A. Phosphopeptide enrichment by Gallium IMAC resin














































Figure 1.7 - Principle of immobilized metal affinity chromatography.
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than phosphate. One such method employs p-elimination of the phosphate from
phospho-threonine or serine and results in the formation of dehydroaminobutyric
acid or dehydroalanine, respectively (Jaffe et al., 1998). The product can be detected
using tandem mass spectrometry or in another method Michael addition is used to
add a reactive thiol group after p-elimination to provide a linker for attachment of
an affinity tag (Oda et al., 2001). This affinity tag is usually biotin and it permits
purification of the chemically-modified (previously phosphorylated) peptides. This
type of chemical modification of phosphate is not applicable to phospho-tyrosine
residues and suffers from side-chain reactions in which cysteine and methionine can
be modified. Other chemical modification protocols which are applicable to all
phosphorylated residues have been developed (Zhou et al., 2001) but it involves
many chemical reactions and have not been used successfully on real proteomic
samples.
These chemical modification-based strategies were superseded in 2002 with the
modification of the traditional IMAC (Immobilised metal-affinity chromatography
methodology (Ficarro et al., 2002). IMAC purification of phosphopeptides is based
on the attraction of negatively charged phosphate groups to positively charged
immobilised (on a resin) metals (Figure 1.7). The main problem associated with this
protocol is that acidic groups of aspartic and glutamic acid and electron donors
(histidine) can bind to the positively charged metal, thereby contaminating the
eluted sample. Ficarro et al. addressed this non-specific binding by chemical-
esterification of acidic residues before IMAC enrichment. Application of this
modified procedure to the yeast proteome permitted characterisation of 216
phosphopeptides (Ficarro et al., 2002).
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Figure 1.8 - Novel phosphorylation sites determined by mass spectrometry. The
numbers of novel phosphorylation sites that have been identified by mass spectrometry as
determined by literature mining are shown by year for the years 1992-2003. Contributions
to the total number of sites per year of pSer (blue), pThr (red), and pTyr (yellow) are shown.
Adapted from "Mass spectrometric contributions to the practice of phosphorylation site
mapping through 2003: a literature review." Loyet KM, Stults JT, Arnott D. Mol Cell
Proteomics. 2005 Mar;4(3):235-45
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Figure 1.9 - Workflow of an LC-MS/MS experiment. A mixture of peptides from a protein
sample digest is separated by reversed-phase chromatography on a nano-flow HPLC. The
peptides elute from the RP column and are ionized by an electrospray source. In the first stage
of mass spectrometry, m/z values and charge states for each precursor ion are determined and
the most abundant precursor ions are selected for analysis in the second stage. The ions are
then fragmented with by collision-induced dissociation (CID) with a gas to produce fragment
ions which are detected. Using the mass (from MS-1) and sequence information (from MS-2)
protein sequence databases are searched to provide peptide identifications and protein
matches. Analysis of phosphopeptides is similar but specific scanning approaches are used in
the mass spectrometer to detect the loss of phosphate during CID. Assignment of the exact
position of phosphorylation is accomplished by manual interpretation of the mass spectra.
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1.5.1.2 MS-based strategies for phosphorylation analysis
The use of mass spectrometry for phosphorylation site identification has increased
greatly over the last decade superseding traditional approaches of 2D
phosphopeptide mapping and Edman sequencing. In the period from 1992 to 2003
1281 phosphorylation sites were characterised by mass spectrometry in 203
publications (Loyet et alv 2005) (Figure 1.8). In the latter years of this period,
advances in sample preparation have enabled hundreds of phosphorylation sites to
be determined and reported in a single publication. In addition, the concomitant
advances in technology of mass spectrometers have also facilitated the transition
from single phosphoprotein analysis to analysis of phosphoproteomes.
A mass spectrometer consists of an ion source, a mass analyser that measures the
mass to charge ratio (m/z) of peptides and a detector that counts the numbers of
ions at each m/z value (Figure 1.9). ESI mass spectrometers use a heated capillary
needle through which the peptide solution elutes and are subsequently ionised and
introduced into the mass spectrometer. This type of ion source is readily compatible
with liquid chromatographic separations resulting in an LC-MS/MS setup that was
used in the analyses described in this thesis. In a typical LC-MS/MS experiment a
peptide mixture is separated by analytical reversed-phase chromatography on a
HPLC (High pressure liquid chromatography) and are introduced into the mass
spectrometer via the ESI source. Multiply protonated peptides give rise to the first
mass spectrum (MSI) and then the computer generates a prioritised list of the most
intense precursor ions detected and are subsequently subjected to fragmentation by
energetic collision with gas (CID (collision induced dissociation)) in the collision
cell. This MS/MS spectrum contains data relating to the amino acid composition of
the peptides and the pattern of fragmentation that occurred. This process of tandem
mass spectrometry provides m/z values of the peptides and fragmentation data for
each peptide. This data is then used by sequence database searching programs such
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as MASCOT (Perkins et al., 1999) or SEQUEST (Ducret et al., 1998) and provides
probability-based peptide matches and therefore protein identifications.
Identification of phosphopeptides and characterisation of phosphorylation sites by
LC-MS/MS analysis is more difficult than standard protein identification
experiments and can be achieved by special phospho-scanning functions in the mass
spectrometer. Neutral loss scanning is a popular approach to detect
phosphopeptides and it involves monitoring for the loss of ions characteristic to
phosphorylated residues. When peptides containing phosphoserine or
phosphothreonine are subjected to CID they usually undergo gas-phase p-
elimination resulting in a neutral loss of phosphoric acid (-98 Da) or are
dephosphorylated (-80 Da). The resultant mass spectrum indicates the position of
the loss of phosphate by a spacing of 69 Da (dehydroalanine) or 83 Da
(dehydroaminobutyric acid). This type of analysis requires prior knowledge of the
charge state of the precursor ion before CID and thus is highly compatible with Q-
Tof mass spectrometers operated in data-dependent acquisition mode. This
approach is not as efficient for detecting phosphotyrosine as phosphotyrosine is
more resistant to neutral loss. However, another scanning approach is suitable for
detection of phosphotyrosine and is based on the production of reporter ions
characteristic for the loss of phosphotyrosine. Immonium ions of phosphotyrosine
have an m/z value of 216.043 and are generated by double cleavage of the peptide
backbone. These can be detected with good sensitivity with detection possible from
sub-picomole amounts of gel-separated proteins (Steen et al., 2001).
Additionally, when phospho-Ser/Thr/Tyr containing peptides are fragmented by
collision-induced dissociation (CID) in the negative ion mode, a characteristic PO3-
ion (m/z = -79) can be detected by precursor ion scanning. Once this ion is detected,
the mass spectrometer can be set to automatically switch to positive ion mode to
conduct MS/MS for sequencing.
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1.5.2 Challenges
The main challenge for phosphoproteome analysis is enrichment of phosphorylated
proteins and peptides to sufficient quantities so that they can be characterised by
mass spectrometry. Preservation of phosphorylation during enrichment is essential,
as any loss of phosphorylation due to phosphatase activity or by chemical
dephosphorylation would significantly reduce the likelihood of detection of low
abundance phosphorylation. Phosphoproteome enrichment methods should also be
as straightforward as possible to minimise sample losses and to enhance
reproducibility of the protocol. Another important challenge of proteomic or
phosphoproteomic experiments is analysis of large volumes of data that can be
produced. After identification of phosphorylation sites, comprehensive
bioinformatic analysis is necessary to annotate phosphorylation sites. Extensive
literature mining for functional information pertaining to phosphoproteins,
phosphorylation sites and also to the sequence surrounding the phosphorylation
sites should be performed. The use of prediction algorithms to annotate domains,
amino acid sequence characteristics and potential kinases and binding sites is
necessary. Without this kind of post-analysis annotation lists of phosphopeptides
are of limited initial value. In a similar manner, generation of long lists of protein
identifications in proteome profiling experiments presents the problem of data
analysis. It is necessary to systematically annotate such lists with as much relevant
data as possible to extract the value and biological significance of the data.
The strength of proteomics is that its can generate vast amounts of unbiased data
and can allow the rapid characterisation of proteomes and phosphoproteomes,
which would not be possible using conventional techniques.
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1.6 Aims of the project
The synapse is a specialised cell-cell contact that contains presynaptic and
postsynaptic membranes that can transduce electrical information into long-lasting
molecular changes that constitute synaptic plasticity. It is now apparent that
complex mechanisms of trafficking, signalling and reorganisation occur on both
sides of the synaptic cleft and that these processes must be highly organised and
regulated.
The aim of this project was to study the phosphorylation and the organisation of
proteins at the synapse. To achieve this, novel and robust methodologies for
phosphoproteome enrichment and analysis were developed and the application to
synaptic and cytosolic phosphoproteomes is described in this thesis. In addition, the
identification and integration of data from postsynaptic proteomes is described as
well as analysis of this data to reveal trends of molecular organisation that may exist
in the postsynaptic proteome.
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CHAPTER 2
ROBUST ENRICHMENT OF PHOSPHORYLATED SPECIES IN COMPLEX
MIXTURES BY SEQUENTIAL PROTEIN AND PEPTIDE METAL-AFFINITY
CHROMATOGRAPHY AND ANALYSIS BY TANDEM MASS
SPECTROMETRY
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2. Robust enrichment of phosphorvlated species in complex mixtures
by sequential protein and peptide metal-affinity chromatography and
analysis by tandem mass spectrometry
2.1 ABSTRACT
Reversible protein phosphorylation mediated by kinases, phosphatases and
regulatory molecules, is an essential mechanism of signal transduction in living
cells. Although phosphorylation is the most intensively studied of the several
hundred known post-translational modifications on proteins, until recently the rate
of identification of phosphorylation sites has remained low. The use of tandem mass
spectrometry has greatly accelerated the identification of phosphorylation sites
although this progress was limited by difficulties in phosphoresidue enrichment
techniques. We have developed upon existing immobilised metal-affinity
chromatography (IMAC) techniques for capturing phosphopeptides, to selectively
purify phosphoproteins from complex mixtures. Combinations of phosphoprotein
and phosphopeptide enrichment were more effective than current single
phosphopeptide purification approaches. We have also implemented iterative MS-
based scanning techniques to improve detection of phosphorylated peptides in
these enriched samples. Here, we provide detailed instructions for implementing
and validating these methods together with analysis by tandem mass spectrometry
for the study of phosphorylation at the mammalian synapse. This strategy should be
widely applicable to the characterisation of protein phosphorylation in diverse
tissues, organelles and in cell culture.
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2.2 INTRODUCTION
Protein phosphorylation is an essential regulator of protein function and signalling
pathways in the cell. Phosphorylation is primarily used as a reversible tag of
activity, by which information can be transduced from one protein to another in
response to an appropriate stimulus. This process of signal transduction is
fundamentally important to many cellular processes and as a consequence, is a
highly complex and regulated system. It is now known that such signalling
pathways are often mediated by multi-protein complexes which translate a stimulus
(e.g. receptor stimulation) to downstream effectors. Multiprotein signalling
complexes or "signalling machines" are responsible for orchestrating the complex
signalling events at glutamate receptors (Husi et al., 2000), (Farr et al., 2004), ATP
receptors (Kim et al., 2001), cytokine receptors (Bouwmeester et al., 2004), growth
factor receptors (Blagoev et al., 2004) and G-protein coupled receptors (Becamel et
al., 2002). They seem to share a common organisation of receptor, protein scaffold,
(in which the signalling molecules are localised) and membrane to cytoskeletal
interactions. The propagation of an appropriate response to receptor stimulation is
highly regulated by phosphorylation cascades. This is exemplified by the
intensively studied MAP kinase pathway, which ultimately leads to activation of
transcription factors and modulation of gene expression. Phosphorylation is
employed to modulate protein function and stability and to mediate
phosphorylation dependent protein-protein interactions (e.g. SH2 binding of PI 3-
kinase to NR2B) (Hisatsune et al., 1999) conferring a higher order level of regulation
in such protein complexes.
Historically, synapse phosphorylation and its importance in regulating signal
transduction and protein function has been studied at the level of single molecules
(Greengard et al., 1993), (Sweatt and Kandel, 1989), but new proteomic strategies
lend themselves to the global characterisation of the signalling properties of the
proteome. Systematic characterisation of kinase and phosphatase substrates is
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essential to extend current knowledge of known signalling pathways and will
inevitably reveal many more. It is now apparent that the extent of phosphorylation
in a proteome far exceeds original estimates, with the majority of proteins capable of
being phosphorylated at multiple sites with a recent reports of 20-30
phosphoresidues in a single protein (Collins et al., 2005), (Zhang et al., 2004). A
recent estimate of a possible 100,000 phosphorylation sites in the human proteome
and a current knowledge of 3-4% of these, highlights the daunting task ahead
(Zhang et al., 2002). The use of mass spectrometry to characterise phosphorylation
has rapidly increased in recent years with a 5000% increase in phosphorylation sites
defined by this approach from 1992 to 2002 (Loyet et al., 2005). Although MS-based
strategies for phosphorylation site identification have clear advantages over
traditional techniques (for review, see Mann et al. 2002) it is not yet routine to
analyse complex phosphoprotein samples. Analysis of phosphoproteins is not
straightforward for a number of reasons. First, the stoichiometry of phosphorylation
is generally low. Second, the phosphorylated sites on proteins might vary, implying
that any given phosphoprotein is heterogeneous. Third, many classes of proteins are
present at low abundance within cells and, in these cases; enrichment is essential
before analysis. Fourth, most analytical techniques used for studying protein
phosphorylation have a limited dynamic range meaning that minor sites might be
difficult to identify. Finally, endogenous phosphatases could dephosphorylate
proteins/peptides unless their activity is inhibited during sample preparation.
Sample preparation is crucial for the success of any MS-based phosphoproteomic
analysis and numerous approaches have been developed to overcome its associated
problems. These include phosphoresidue enrichment strategies such as
phosphospecific antibodies and IMAC (Immobilised metal affinity
chromatography), and labelling strategies such as 32P-ATP and chemical
modification with subsequent biotin tagging (for review, see Mann et al. 2002).
IMAC enrichment, which is based on the affinity of metals (usually Fe(III) or Ga(III)
to negatively charged phosphate groups, has become the most common approach
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for in vivo phosphorylation site identification (Loyet et al., 2005). This is largely due
to improvements made in the specificity of IMAC brought about by chemical
derivatisation of carboxylic acid groups to methyl esters, which decreases non¬
specific binding of acidic peptides (Ficarro et al., 2002). Recent phosphoproteomic
studies have utilised peptide IMAC protocols together with methyl esterification to
enrich for phosphopeptides prior to mass spectrometry. This has been used
successfully to study phosphorylation in yeast (Ficarro et al., 2002), arabidopsis
(Nuhse et al., 2003), and cell lines (Shu et al., 2004) however, the use of these IMAC
approaches on complex mammalian sub-cellular organelles has not proved as
successful (DeGiorgis et al., 2005), (Trinidad et al., 2005).
The MS strategy employed for phosphorylation analysis is mass spectrometer type-
dependent and the most commonly used are ESI (electrospray ionisation) mass
spectrometers (usually nanoelectrospray) in conjunction with 1 or 2D liquid
chromatography separation (Loyet et al., 2005). Historically, triple quadrupole mass
spectrometers were the first to be widely used for phosphorylation studies,
particularly with the nano-electrospray source (Wilm and Mann, 1996). This
instrument was particularly suited to linked scanning modes: neutral loss and
precursor ion scanning were useful for detecting phosphopeptides in the presence
of much larger amounts of unmodified peptide. The triple quadrupole for
proteomics work was largely superseded by the more sensitive quadrupole time-of-
flight (Q-Tof) geometry, which could not perform linked scans in hardware by the
very nature of the geometry. Post-processing of the data could extract
phosphopeptide information (and indeed information on many other types of post-
translational modification), and the increased sensitivity of the Q-Tof made this
trade-off acceptable. Recently, a new generation of instruments based on linear traps
offer new scanning possibilities for phosphopeptides similar to those originally
available from triple quadrupoles. It should be noted that no one mass spectrometer
type will cover all cases. In particular, we point out that matrix assisted laser
desorption ionisation (MALDI) still has a very useful role in studying
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phosphopeptides, and with enrichment methods may be better-suited to the
detection of multi-phosphorylated peptides (Larsen et al., 2005). The work described
here was carried out on either a Q-ToF Ultima (Waters) or a 4000 Q-Trap (AB).
Specific MS scanning modes such as neutral loss and precursor ion scanning have
been developed to improve the detection of phosphorylation in highly complex
peptide mixtures. Gas phase p elimination of phosphorylated serine and threonine
residues produce a loss of phosphate that can be monitored in neutral loss mode
and sequence information can be obtained in the same experiment. When phospho
Ser/Thr/Tyr containing peptides are fragmented by collision-induced dissociation
(CID) in the negative ion mode, a characteristic PO3- ion (m/z = -79) can be detected
by precursor ion scanning. Once this ion is detected the mass spectrometer can be
set to automatically switch to positive ion mode to conduct MS/MS for sequencing.
In this protocol we describe how we have improved traditional IMAC and LC-
MS/MS based strategies to study the synapse phosphoproteome by implementing
multistage proteome fractionation and phosphoproteome enrichment and iterative
MS-based scanning approaches (Figure 2.1). This protocol should be useful for
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ECL Plus Western Blotting detection reagents (Amersham Bioscience, RPN2132)
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Urea-ultra grade (Sigma, U0631)
2.3.2 Enzymes/proteins
Trypsin Gold, Mass Spectrometry Grade (Promega) V5280
PeppermintStick phosphoprotein molecular weight standards (Molecular Probes, P-
33350)
2.3.3 Plastics
38 ml polycarbonate centrifuge tubes (Nalgene, 306/0258/08)
1.5 ml Microcentrifuge tubes
2.3.4 Columns and Resins
Fast-flow chelating sepharose with iminodiacetic acid (IDA) (Amersham
Biosciences, 17-0575-01)
Self Pack POROS 20 MC Media (Applied Biosystems, 1-5428-02)
Bio-Spin Chromatography Columns (BioRad, 732-6025)
Trap column:
PepMap C18 3 pm 100A, 300 pm i.d. x 5mm (LC Packings)
BetaMax Neutral 5pm, 180 pm i.d. x 30mm (Thermo Hypersil-Keystone,
95005-030215)
Analytical column:
PepMap C18 3 pm 100A, 75 pm i.d. x 15 cm (LC Packings, 160321)
Note: other type columns at similar performance may also be used.
C 10/10 chromatography column (Amersham Bioscience, 19-5001-01)
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RESOURCE 15RPC 1ml Reversed Phase chromatography column (Amersham
Bioscience, 17-1181-01)
Vivaspin 20 PES membrane 5000 MWCO (Vivascience, VS2011)
2.3.5 Equipment
Dounce Homogeniser (VWR, 406/0315/10)
Peristaltic Pump (Amersham Bioscience, 18-1110-91)
AKTA FPLC (Amersham Bioscience, 18-1900-256)
Mini-PROTEAN II Multiscreen apparatus (BioRad, 170-4017)
X-ray film developer
Microcentrifuge




Sorvall Discovery™ 100SE ultracentrifuge with swinging bucket rotor AH-
629(36ml) or equivalent
Savant SpeedVac (Thermo)
Typhoon™ Scanner (Amersham Bioscience, 9410-PC)
Nano flow HPLC system with an autosampler and a valve switch unit, such as
• Ultimate™ gradient pump equipped with FAMOS autosampler and
Switchos II (LC Packings), or
• CapLC with nano stream selected module (Waters)
Mass spectrometer: Q-Tof Ultima API with nanospray source (Micromass)
Note: Other type Q-Tof API or tandem mass spectrometers which give
similar performance can also be used.
4000 Q TRAP (Applied Biosystems).
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Other
Hyperfilm™ ECL™ (Amersham Bioscience, RPN2103K)
2.4 RECIPES
Recipe 1: Synaptosome preparation buffer A
50 mM Tris-acetate pH 7.4 (0.5 M stock)
10% (w/w) sucrose
5 mM EDTA (0.5 M stock)
1 mM PMSF
2 pg/ml Aprotinin (2 mg/ml stock)
2 gg/ml Leupeptin (2 mg/ml stock)
1 mM sodium ortho-vanadate
Add H2O to 50 ml
Combine components in a 50 ml tube, rotate to dissolve sucrose and chill at 4°C
Recipe 2: Synaptosome preparation buffer B
5 mM Tris-acetate pH 8.1 (0.5 M stock)
1 mM PMSF
2 gg/ml Aprotinin (2 mg/ml stock)
2 pg/ml Leupeptin (2 mg/ml stock)
1 mM sodium ortho-vanadate
Add H2O to 50 ml
Combine components in a 50 ml tube and chill at 4°C
Recipe 3: Synaptosome preparation buffer C
50 mM Tris-acetate pH 7.4 (0.5 M stock)
28.5% (w/w) sucrose
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Combine components in a 50 ml tube, rotate to dissolve sucrose and chill at 4°C
Recipe 4: Synaptosome preparation buffer D
50 mM Tris-acetate pH 7.4 (0.5 M stock)
10% (w/w) sucrose
Combine components in a 50 ml tube, rotate to dissolve sucrose and chill at 4°C
Recipe 5: 100 mM GaCI3 Solution
Carefully break off the glass seal of the vial of GaCk powder (5 g) and immerse in
284 ml of distilled H2O in a glass beaker. Once dissolved store in at 4°C protected
from light.
Note: Caution must be exercised when dissolving GaCI3 in water, as it is an
exothermic reaction, which sputters and evolves HCI gas; wear protective clothing
and perform in a fume hood.
Recipe 6: Protein IMAC wash buffer
6 M Urea
50 mM Tris-acetate pH 7.4
Make up to 1 L and pass through a 0.2 micron filter
Recipe 7: Protein IMAC elution buffer
6 M Urea
50 mM Tris-acetate pH 7.4
100 mM EDTA
100 mM EGTA
Make up to 1 L and pass through a 0.2 micron filter
Recipe 8: SDS-PAGE (Laemmli) 5 X reducing sample buffer
4 ml H2O
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1 ml 0.5 M Tris pH 6.8
1 ml glycerol
1.6 ml 10% SDS
0.4 ml p-ME or 20 mM DTT (0.32 ml 0.5 M)
0.2 ml 0.1% bromophenol blue
Recipe 9: SDS-PAGE (Laemmli) gel solutions
Acrylamide/Bis 146 g acrylamide
4 g Bis-acrylamide
H2O to 500 ml, store at 4°C or at RT
1.5 M Tris pH 8.8 90.75 g Tris-Base
H2O to 400 ml, set pH to 8.8, H2O to 500 ml, store at RT
0.5 M Tris pH 6.8 30 g Tris-Base
H2O to 450 ml, set pH to 6.8, H2O to 500 ml, store at RT
10% SDS (w/v) 10 g SDS (Sodium salt)/ 100 ml H2O, store at RT
10% APS (w/v) 0.1 g ammoniumpersulfate / 1 ml H2O
Store at RT, do not keep for more than 1 week
TEMED TEMED, store at 4°C
Iso-butanol Water saturated iso-butanol
Recipe 10: SDS-PAGE (Laemmli) running buffer
10 x Running buffer 30 g Tris-Base
144 g glycine
10 g SDS
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H2O to 11, check pH (should be self-adjusting) and set to 8.3
Recipe 11: Pro-Q Diamond Phosphoprotein gel fixing solution
Prepare a solution of 50% methanol and 10% acetic acid.
Recipe 12: Pro-Q Diamond Phosphoprotein gel destain solution
1 L of destain solution:
50 mL of 1 M sodium acetate, pH 4.0
750 mL of ultrapure water
200 mL of acetonitrile
Combine and mix thoroughly.
Recipe 13: Wash solution for SYPRO Ruby gel staining
Prepare a 100 ml solution of 10% methanol and 7% acetic acid.
Recipe 14: Transfer solution
10 mM CAPS pHll.O at 4°C
10% (v/v) MeOH
Recipe 15: 20 x PBS
160 g NaCl
4 g KC1
12.2 g Na2HP04 (anhydrous)
4 g KH2PO4
H2O to 1 L
Store at 4°C or RT (might precipitate at lower temperature)
PBS/Tween PBS + 0.1% Tween20
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Recipe 16: Chemiluminescence solution A
Stocks
250 mM Luminol (44.3 g/1) in DMSO, keep at -20°C
90 mM p-coumaric acid (14.8 g/1) in DMSO, keep at -20°C
Solution A
5 ml Luminol
5 ml p-coumaric acid
12.5 ml 1.5 M Tris pH 8.8
12.5 ml 0.5 M Tris pH 6.8
215 ml H2O
Store at 4°C in the dark
Recipe 17: Chemiluminescence solution B
250 pi 30% H2O2
250 ml H2O
Store at 4°C in the dark
Mix solutions A and B 1:1 just prior to blot development
Recipe 18: Tryptic digestion buffer
Dilute the sample to
1 M urea
0.125 M thiourea
25 mM NH4HCO3 (pH 8)
Trypsin was reconstituted with 50 mM acetic acid and was added to this solution
Recipe 19: Mobile phase A for reversed phase desalting of phosphoprotein
digest
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Recipe 21: 2 M Methanolic HCL
Add 160 jj.1 of acetyl chloride with stirring to 1 ml of methanol slowly in a
dropwise fashion.
Note: Caution must be exercised during this addition as this reaction generates
heat. Perform operation in fume hood using safety glasses and gloves
Recipe 22: High organic peptide solubilisation/loading buffer
1:1:1 of acetonitrile, methanol and H2O, pH 2.5-3
Recipe 23: Aqueous peptide solubilisation/loading buffer
0.3 % acetic acid, pH 2.5-3




Recipe 25: Mobile phase B for LC-MS/MS of tryptic digest of phosphoproteins
95% CHsCN
4.9% H2O
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0.1% formic acid
Recipe 26: Mobile phase C for LC-MS/MS of tryptic digest of phosphoproteins
99.9% H2O
0.1% formic acid
Recipe 27: Mobile phase A for LC-MS/MS of IMAC enriched phosphopeptides
99.9% H2O
0.1% formic acid




Recipe 29: Mobile phase B for LC-MS/MS of IMAC enriched phosphopeptides
99.5% H2O
0.5% formic acid
Both CH3CN and H2O are at HPLC gradient grade in recipes 19 - 24.
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Figure 2.1 - Schematic overview of methodology.
The target proteome, in this case a sub-cellular fraction, is phase-partitioned by its differential
solubility in 6 M urea. The soluble fraction can be processed in two ways. Traditionally this
fraction is digested in solution, desalted and applied to a peptide IMAC column (green arrows)
with or without methyl-esterification and analysed by LC-MS/MS. In addition we have
developed top-down enrichment step where the soluble proteins are applied to a protein IMAC
column (blue arrows) and the eluted phosphoproteins are digested and also analysed by LC-
MS/MS. A novel combination of these two approaches (red arrow) in which a two-step
enrichment of phosphoproteins and phosphopeptides and analysis by LC-MS/MS results in
improved identification of phosphorylation sites. The urea-insoluble fraction which represents
tightly bound or integral membrane proteins can be analysed by direct digestion in 2 M urea to
release peptides from cytoplasmic domains of these proteins, which can be applied to a
peptide IMAC column to isolate phosphopeptides. These combined strategies when applied to
the synapse phosphoproteome yielded identification of over 650 phosphorylation events
corresponding to 331 phosphorylation sites. This combined strategy of phase-partitioning and
sequential enrichment of phosphoresidues allows comprehensive analysis of a complex
sample.
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2.5 INSTRUCTIONS
An overview of the purification strategies is shown in Figure 2.1. In this section the
application of our protocols to the synapse phosphoproteome will be described but
these should be readably applicable to other tissues, cells and organelles.
2.5.1 Purification of Synaptosomes by Sub-cellular Fractionation
This section briefly describes purification synaptosomes from mouse forebrains, this
protocol has been well documented (Carlin et al., 1980) but the original protocol has
a number of variations.
1. Mouse forebrains should be rapidly dissected, frozen immediately in liquid
nitrogen and stored at -80°C.
2. Cool all buffers and the Homogeniser to 4°C.
3. Collect 16 forebrains and add to homogenisation buffer (Recipe 1) (9 ml/g of
buffer) in a 50 ml Dounce Homogeniser.
4. Homogenise with 15 strokes.
5. Collect the extract and centrifuge at 800 x g for 20 min (all centrifugation
steps performed at 4°C).
6. Centrifuge the supernatant at 16,000 x g for 30 min.
7. Re-suspend the pellet in Recipe 2 (5 ml/g of buffer).
8. Homogenise with 3 strokes.
9. Incubate the extract in the Homogeniser at 4°C for 45 min.
10. Homogenise with 10 strokes.
11. Add sucrose to 34% (w/w).
12. Prepare sucrose gradients by addition of 10 ml of Recipe 4 (10% sucrose
(w/w) to 38 ml polycarbonate centrifuge tubes, followed by careful
introduction of 10 ml of recipe 3 (28.5% sucrose (w/w) from the bottom of the
tube.
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13. Add 10 ml of extract (irt 34% sucrose (w/w)) to the bottom of the tube, such
that the gradients are 10, 28.5 and 34% sucrose (w/w) from the top to the
bottom.
14. Centrifuge at 60,000 x g for 120 mins.
15. Collect the protein-containing band that forms between the 34% and 28.5%
sucrose gradients and dilute with 50 mM Tris-acetate pH 7.4 to 10% sucrose.
16. Centrifuge at 48,000 x g for 30 min, remove supernatant and re-suspend this
synaptosome pellet in 50 mM Tris-acetate pH 7.4.
17. Store at -80°C.
2.5.2 Protein IMAC Sample Preparation
In our protein IMAC protocol, a cell lysate or sub-cellular fraction is solubilised in 6
M urea and incubated with a metal-charged sepharose-based resin. Specific elution
is achieved by a stopped-flow elution with chelating buffer and eluted
phosphoproteins can be concentrated and washed. This method when performed
with an FPLC system permits large scale purification which is necessary for
subsequent phosphopeptide analysis by mass spectrometry (Figure 2.2). Batch
purification in microcentrifuge tubes can also be formed which can be useful for
rapid purification of smaller quantities of phosphoprotein for gel or western blot
analysis.
1. Strip the Fast-flow chelating sepharose (IDA) of any bound metal by
incubation with 100 mM EDTA and 100 mM EGTA for 1 hour with gentle
agitation.
2. Clamp a C 10/10 chromatography column to a retort stand and connect to a
Peristaltic Pump.
3. Add 5 ml (bed volume) of chelating resin to the column.
4. Wash the resin with 10 column volumes of H2O using the pump at a flow
rate of 1 ml/min.
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5. Remove the resin and add to 50 ml of Recipe 5 (100 mM GaCh Solution) and
incubate at room temperature on a roller-mixer over night and protected
from sunlight.
6. Wash the charged resin with 10 resin volumes of H2O using the pump at a
flow rate of 1 ml/min.
7. Store the charged resin (50% H2O) at 4°C, protected from sunlight and use
within 1 week.
8. Solubilise the protein sample (Synaptosomal proteins) (12.5 mg/10 ml) in 6 M
urea for 20 min with mixing, centrifuge at 13,000 rpm for 5 min and retain
the supernatant.
9. Equilibrate 1 ml of gallium charged resin with Recipe 6 (protein IMAC wash
buffer) by a 5 resin volume in-column wash.
10. Incubate the urea-soluble supernatant (~ 9.5 ml) with 1 ml of resin for 1 hour
at room temperature on a roller shaker and protect from light.
11. Equilibrate an FPLC (AKTA) system with elution buffer (Recipe 7) and then
wash buffer (Recipe 6) at room temperature.
12. Pack the resin/protein mixture into a C 10/10 column and attach to the
FPLC, avoiding introduction of air bubbles into the system.
13. Wash unbound protein from the column with 20 column volumes of wash
buffer (100% A) at a flow rate of 1 ml/min until the A280 > 0.25 mAU.
14. Switch the flow to 100% buffer B (recipe 7 (elution buffer)) and run at 0.5
ml/min and start to collect 1 ml fractions.
15. Once the A280 reaches ~ 10 mAU, change to 0% B for 10 min to allow a
stopped flow elution which results in a discrete elution peak, see Figure 2.2.
16. Pool 4-5 fractions surrounding the phosphoprotein peak and wash with
buffer B (4 times dilution of the sample) in a Vivaspin 6 PES membrane spin
column and concentrate the sample to 200 pi.
Chapter 2 - Robust enrichment of phosphorylated species in complex mixtures by sequential protein and 66
peptide metal-affinity chromatography and analysis by tandem mass spectrometry
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
Figure 2.2 - FPLC chromatogram of a protein IMAC purification
Un-bound protein is washed off the IMAC column with 20 column volumes of wash buffer
(100% A) at a flow rate of 1 ml/min until the A280 > 0.25 mAU. Then the flow is switched
to 100% buffer B (elution buffer) and run at 0.5 ml/min. A stopped-flow elution with a
chelating buffer is performed to elute the phosphoproteins in a discrete peak (P).
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2.5.3 Validation of Phosphoprotein Purification
This section describes validation of the protein IMAC enrichment which is advisable
before further purification or analysis by mass spectrometry. Validation can be
achieved by phosphoprotein staining of protein IMAC purified phosphoproteins on
an SDS-PAGE gel (Figure 2.3). Alternatively western blotting with phosphospecific
antibodies or antibodies to known phosphoproteins should show clear enrichment
in the protein IMAC purified sample (Figure 3.3). As elements of these two
techniques are routine they will be described briefly.
2.5.3.1 Electrophoresis and Phosphoprotein Staining of SDS-PAGE gels
1. Boil 10% of the eluted phosphoprotein and molecular weight marker in
tightly closed micro-centrifuge tubes in 5x Sample (Laemmli) Buffer (Recipe
8).
2. Separate on an SDS-PAGE (Recipe 9,10) mini-gel for 50 min at 200 V.
3. All incubation steps are performed at room temperature with gentle
agitation.
4. Fix the gel in 100 ml of fixing solution (Recipe 11) and incubate for 30 min
and repeat this step again to remove all SDS.
5. Wash the gel three times in 100 ml H2O for 10 min each.
6. Stain the gel with 50 ml of Pro-Q Diamond phosphoprotein gel stain in the
dark for 90 min.
7. Destain the gel three times with 100 ml of Destain solution (Recipe 12) for 30
min.
8. Wash the gel twice with H2O for 5 min each.
9. Scan the gel with a Typhoon scanner using excitation maximum at -555 nm
and an emission maximum at -580 nm.
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Figure 2.3 - Validation of IMAC phosphoprotein isolation strategy
A. Overlay of Pro-Q diamond phosphoprotein/ Ruby total protein stains of an SDS-
PAGE gel for different resin/metal IMAC combinations used to selectively isolate
phosphoproteins from urea-soluble synaptosomal extract. The corresponding unbound
fractions are included for comparison. 20% of eluted protein from each purification was
separated on a 12% SDS-PAGE gel and stained and imaged sequentially.
Phosphorylated protein appears pink to black, whereas unphosphorylated protein
appears green. Lane 1 shows Peppermint Stick molecular weight markers in which
proteins of molecular weight 23 and 45 kDa are phosphorylated and those of 55 and
116 kDa are not phosphorylated, thus serving as an internal control for selective
staining of phosphorylated proteins. A 25 kDa band (see arrow) was shown to consist
of ribosomal proteins, which were retained on the IMAC resins due to ion-exchange
effects, and therefore removed from the dataset.B. Western blots of equal amounts of
IMAC enriched (I) versus synaptosomal (S) protein for 8 synaptic phosphoproteins. A
significant enrichment for all phosphoproteins was observed in the protein IMAC
sample, and a specific enrichment for the phosphorylated form of MEK was seen using
a phospho-specific antibody.
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10. Rinse the gel twice with H2O for 5 min each.
11. Incubate the gel in 50 ml SYPRO Ruby gel stain solution overnight.
12. Wash in Recipe 13 for 30 min and then twice with H2O for 5 min each.
13. Scan the gel with a Typhoon scanner using excitation maximum at -280/450
nm and an emission maximum at -610 nm.
14. Overlay the phosphoprotein and total protein images of the gel using
Totallab software (Nonlinear Dynamics).
2.5.3.2 Western Blotting
Western blotting of protein IMAC enriched and whole synaptosome samples for
a selected set of phosphoproteins was carried out using a Mini-PROTEAN II
Multiscreen apparatus (Figure 3.3). This apparatus allows screening of up to 40
different antibodies on a single membrane and requires much less of each
individual antibody compared to traditional western blotting. This offers a high-
throughput approach for validating a set of proteins but a conventional western
blotting apparatus will suffice in its absence.
1. Adapt an SDS-PAGE gel-casting comb to cast a single well across the gel.
2. Separate the samples on a 12% SDS-PAGE mini-gel and transfer to PVDF
membrane at 4°C for 90 min at 75 V in transfer solution (Recipe 14).
3. Block the membrane with 1% BSA in PBS/Tween (Recipe 15) overnight.
4. Wash the membrane with 3 x 20 ml of 1 x PBS/Tween for 5 min each.
5. Place the membrane onto the base of the Multiscreen apparatus, tighten
screws to clamp.
6. Use optimal dilutions of primary antibodies in PBS/Tween, 550 #1 per well
and incubate for 2 hours with gentle agitation at room temperature.
7. Wash each well with 3x 0.5 ml of 1 x PBS/Tween for 5 min each.
8. Add 0.6ml of 1/5000 dilution of peroxidase-linked secondary antibody (in 1%
BSA/PBS/Tween and incubate for 2 hours at room temperature.
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9. Wash each well with 3x 0.5 ml of 1 x PBS/Tween for 5, 10 arid 15 min each.
10. Signals were detected using enhanced chemiluminescence using Recipes 16
and 17, or alternatively with ECL Plus Western Blotting detection reagents
(Amersham Bioscience).
2.5.4 In Solution Protein Digestion
1. Dilute the sample to 1 M urea, 0.125 M thiourea, 25 mM NH4HCO3 (pH 8) to
a final volume of 400 pi (Recipe 18).
2. Add Trypsin Gold, mass spectrometry grade (Promega) in a ratio of 1:20 in
50 mM acetic acid.
3. Incubate at 37°C for 3 hours.
Note: We recommend Trypsin Gold, mass spectrometry grade as it has high
activity and good specificity. Trypsin, sequence grade (Roche) can also be used
but an overnight incubation is necessary for complete proteolysis. We have also
used Sequencing grade modified porcine trypsin (Promega) but in our
experience it produces semi-tryptic ends but this can be accommodated by
specifying "semi-trypsin" in Mascot's search parameters.
4. Terminate the reaction by freezing in liquid nitrogen and lyophilise.
Note: 6 M Urea insoluble membranes can be digested by increasing the urea
concentration in the digestion buffer to 2 M. This will result in reduced activity of
trypsin but will allow better solubility and thus digestion of these proteins.
2.5.5 Reversed Phase Desalting of Protein Digests
Protein samples, whole lysate or protein IMAC enriched, for further processing
(peptide IMAC) are desalted on a 1 ml bed volume RESOURCE 15RPC Reversed
Phase chromatography column. Peptides for analysis by mass spectrometry are
desalted on-line as described in the LC-MS/MS section to follow.
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1. Wash and equilibrate the column with Buffer A (99.9% H2O/0.1% FA, Recipe
19) and Buffer B (95% Acetonitrile/4.9 % H2O/0.1% FA, Recipe 20).
2. Load the trypic digest into the injection loop and introduce to the column at
0.5 ml/min.
3. Wash with Buffer A until baseline is reached, ~ 10 column volumes.
4. Elute desalted peptides with a 0-95% gradient of Buffer B over 5 min.
5. Collect fractions, pool and lyophilise.
2.5.6 Peptide IMAC Sample Preparation
Peptide IMAC was carried out as described (Ficarro et al., 2002) with some
modifications. There are a number of conditions in this protocol which can affect the
yield and population of phosphopeptides obtained. Firstly, the choice of metal used
to perform peptide IMAC can affect specificity and recovery. The most commonly
used metals are Fe3+ and Ga3+ (Haydon et al., 2003), (Ficarro et al., 2002), (Posewitz
and Tempst, 1999) and display different efficiencies of capture and release of
phosphopeptides (Haydon et al., 2003). However, we found that Ga3+ performed the
best in protein IMAC experiments (Collins et al., 2005), so we recommend to also
use Ga3+ in the peptide IMAC step of a sequential phosphoprotein and
phosphopeptide purification to minimise losses due to differences in specificity. It
has been stated many times that acidic peptides affect the specificity of peptide
IMAC purifications and methyl-esterification of peptide side chains has been
reported to improve the specificity (Ficarro et al., 2002). In agreement with this we
have observed a 30% reduction in the number of acidic amino acids in
phosphopeptides which have been detected in peptide IMAC of methyl-esterified
samples compared to unmodified samples. However, other studies have found that
contaminating peptides do not have any different physiochemical properties than
phosphopeptides in the sample but were actually from highly abundant proteins in
the sample (Haydon et al., 2003).
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In addition, peptide chemical modification reactions do not go to completion and
we have observed that methyl-esterification in particular never occurs on 100% of
peptides. This have the effect of diluting any particular sample into populations of
modified and unmodified peptides which effectively reduces the amount of any
given peptide and increases the sample complexity overall. It is recommended to
perform peptide IMAC on methyl-esterified and unmodified versions of a sample to
increase overall phosphopeptide coverage.
Next, the buffer in which peptides are solubilised and applied to the column affects
the population of phosphopeptides observed. In sequential protein and peptide
IMAC experiments we used a high organic (equal volumes of acetonitrile, methanol
and water pH 2.5-3) and an aqueous (0.3 % acetic acid, pH 2.5-3) buffer to Solubilise
and load peptides to the peptide IMAC column. Phosphopeptides found in both
experiments represented a small fraction of the total phosphopeptides detected,
with 37 and 60% of the double IMAC dataset found in the high organic and aqueous
experiments respectively. The reason for this differential appearance based of the
solvent used can be explained by looking at the GRAVY (Kyte and Doolittle, 1982)
(Grand Average of Hydropathy) values of these peptides (Figure 2.4).
Phosphopeptides found in the aqueous solubilised samples are overall less
hydrophobic than those found in the high organic solvent solubilised samples. This
would indicate that in previous studies such as that of the yeast phosphoproteome
(Ficarro et al., 2002), in which only a high organic loading buffer was used, a
significant sub-population of phosphopeptides may have been lost at this step. It is
clear that in any complex sample there are populations of peptides which favour
different solubilisation conditions depending on their hydrophobicity, so it is
recommended to use different conditions to achieve greater coverage of the peptide
population.
1. For methyl-esterification, desalt and lyophilise peptide digest and
reconstitute with 0.5 mg/ml 2 M Methanolic HCL (Recipe 21).
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2. Incubate with gentle agitation for 2 hours at room temperature.
3. Quench with 2 volumes of H2O and lyophilise.
4. Take 0.5 ml (bed volume) of POROS MC and incubate with 100 mM EDTA
and 100 mM EGTA on a roller mixer overnight to remove any trace metals
from the resin.
5. Transfer the resin to a C 10/10 column and wash with 10 volumes of H2O.
6. Incubate with 5 ml of Recipe 5 (100 mM GaCh Solution) at room temperature
on a roller mixer over night and protect from sunlight.
7. Wash the charged resin with 10 resin volumes of H2O. Store the charged
resin (50% H2O) at 4°C, protect from sunlight and use within 1 week.
8. Reconstitute the peptide sample (methyl-esterified/unmodified) in either a
high organic loading (equal volumes of acetonitrile, methanol and water pH
2.5-3, Recipe 22) or an aqueous loading buffer (0.3 % acetic acid, pH 2.5-3,
Recipe 23).
Note: For phosphoprotein digests, 3 mg of digested phosphoprotein was
applied in 1 ml of loading buffer to a 100 pi bed volume of gallium charged
POROS MC. A higher concentration of whole cell lysate may be applied to a
similar resin volume as the percentage phosphopeptide content will be lower,
for example 6 mg of digested whole synaptosomes was also applied in 1 ml
of loading buffer to a 100 pi bed volume of gallium charged POROS MC.
9. Centrifuge the peptide solution for 10 min at 13, 000 rpm to remove any un-
solubilised material.
10. Incubate the solubilised peptides with 200 pi of pre-equilibrated gallium
charged POROS MC slurry (100 pi bed volume) at room temperature for 1
hour with gentle agitation.
11. Load the peptide/resin slurry into a pre-equilibrated spin column and
centrifuge briefly to elute the unbound peptides.
12. Wash by addition and removal (by centrifugation) with 10 resin volumes of
the loading buffer.
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Figure 2.4 - Comparison of peptide IMAC solubilisation/loading buffers
GRAVY (Grand Average of Hydrophobicity) versus isoelectric point for phosphopeptides found in
2 peptide IMAC experiments are plotted. In one double IMAC experiment peptides were
solubilized and loaded onto the peptide IMAC column in a high organic buffer (1:1:1 of
acetonitrile/methanol/H20) and in the other peptides were solubilised and loaded in an aqueous
buffer (0.3% acetic acid). These two buffers enable identification of two populations of
phosphopeptides differing in their hydrophobicity.
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13. Add 100 pi of 200 mM Na2HP04 and incubate for 5 min, spin and collect
eluted phosphopeptides, repeat this elution again.
Note: The concentration of Na2HP04 used to elute phosphopeptides from the
peptide IMAC column may be reduced to 50 mM, if volume reduction by partial
lyophilisation is necessary.
14. Rapidly freeze at -80°C.
2.5.7 Double IMAC Sample Preparation
This protocol is a combination of protein and peptide IMAC steps described above
and provides the obvious advantage of two rounds of enrichment for
phosphorylated molecules. The application of a single protein IMAC strategy to the
synaptic phosphoproteome resulted in the detection of 105 phosphorylation events
but selective enrichment of the phosphopeptides derived from these purified
phosphoproteins improved the detection of phosphorylation three fold, with the
detection of 308 phosphorylation events.
1. Digest 3 mg of protein IMAC purified phosphoprotein with 1:20 ratio of
Trypsin Gold, mass spectrometry grade for 3 hours in Recipe 18.
2. Desalt the digest as described in the Reversed Phase Desalting of Protein
Digests section.
3. Perform methyl-esterification if required (see Peptide IMAC Section).
4. Reconstitute in loading buffer (high organic or aqueous).
5. Incubate 1 ml of this peptide mixture with 200 pi of pre-equilibrated POROS-
Ga slurry (100 pi bed volume) for 1 hour at RT.
6. Load the resin into a spin-column and wash with 10 volumes of loading
buffer.
7. Elute phosphopeptides with 2 x 100 pi of 200 mM Na2HP04.
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2.5.8 LC-MS/MS Analysis
For LC-MS/MS analysis, a nano flow HPLC system with valve switch unit is
needed, so that the trap column can be placed for loading and desalting sample
efficiently. This is particularly true for desalting phosphopeptide samples in high
salt (0.2 M Na2HP04) with a large volume size (100-200 pi). Using a flow at 10
pL/min, we found it took up to 1 hour to desalt the sample. In our lab, we used
Ultimate™ nano flow gradient pump equipped with FAMOS autosampler and
Switchos II (LC Packings), or CapLC with nano stream selected module (Waters)
coupled to Q-Tof hybrid tandem mass spectrometer. We found it is very helpful to
have good mass accuracy in MS/MS spectra in assigning the phosphorylation sites.
Before sample analysis on LC-MS/MS, a systematic check is always performed in
our lab and we would like to recommend the following:
1. Optimise the nanospray position and instrument parameters with 500 fmol/pL
(for Q-Tof) or 100 fmol/pL (for Q-Tof Ultima) of [Gluip-fibrinopeptide B in 25%
CHsCN, 74.9% H2O, 0.1% formic acid.
2. Calibrate the instrument with the [GlulJ'-fibrinopeptide B solution in step 1.
3. Systematically perform LC-MS/MS system checks with a tryptic digest of BSA,
such as chromatographic resolution, mass accuracy and sequence coverage of
BSA. For Q-Tof, use either 100 or 200 fmol BSA; for Q-Tof Ultima, 100 fmol.
Note: If the analytical sample is at a low quantity, then the system should be
tested using BSA at 10 fmol or lower.
2.5.9 LC-MS/MS analyses of a tryptic digest of IMAC purified phosphoproteins
on a Q-Tof Ultima.
1. Loaded the protein digest via the autosampler to the trap column on the
valve switch unit then and desalt with 0.1% formic acid (Recipe 26) at a flow
rate of 10-20 pl/minute.
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Note: When using a PepMap C18 3 pm 100A, 300 pm i.d. x 5mm (LC
Packings) trap column, the flow rate can be at 20 pi/minute. If the trap is
BetaMax Neutral 5pm, 180 pm i.d. x 30mm (Thermo Hypersil-Keystone), the
flow rate should be set at 10 pi/minute.
2. Switch valve after 3 minutes to connect the trap column on-line with
analytical column.
3. Run a gradient as show in Table 2.1 to reverse elute peptides from the trap
and separate on the analytical column using mobile phases (Recipes 24 and
25). The flow rate through the columns should be 250 - 300 nl/min.
MS acquisition starts at t = 3.0 min when desalting is finished. The instrument is
operated in automated Data Dependent Acquisition (DDA) acquisition mode using
MassLynx. In DDA mode, the instrument continues to scan at Tof-MS survey and
only switches to Tof-MS/MS scan when multiply charged ions (precursor ions) in
the Tof-MS survey spectrum meet the criterion for fragmentation. The majority of
ions generated from tryptic peptides are at a charge status of at least 2. Details for








0.1 94 6 Trap and analytical column off-line;
sample loading and desalting3.0 94 6
180.0 70 30
Trap and analytical column on-line;
gradient separation;




248.0 94 6 Trap and analytical column off-line to
equilibrated separately300.0 94 6
Table 2.1 - Liquid chromatography conditions for analysis of a phosphoprotein digest.
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1. Acquire Tof-MS survey over the mass range m/z 400-1500 at 1 sec per scan.
2. The switching criterion from Tof-MS to Tof-MS/MS is dependent on
precursor ion intensity and charge state (+2 and +3 selected), each for 5 sec.
3. The collision energy used to perform Tof-MS/MS is varied according to the
m/z and the charge state of the precursor ion.
4. Acquire data for Tof-MS/MS over the mass range m/z 50-2000.
5. Perform Tof-MS/MS on up to three multiply charged ions of the highest
intensity with a dynamic exclusion time of 120 sec.
Note: depending on the complexity of the sample, more precursor ions can
be selected from Tof-MS survey spectrum to subject to Tof-MS/MS.
6. For a highly complex sample, two LC-MS/MS runs with the same LC
gradient may be used.
7. After the first standard LC-MS/MS run is finished (Run 1), examine the
survey data.
8. Select up to 5 multiply charged ions above the intensity threshold from each
survey spectrum that had not been subjected to MS/MS in Run 1 and
incorporate into an inclusion list for the second run (Run 2).
9. Perform the Run 2 analysis using the same conditions as Run 1 except that
the MS switching to MS/MS should be directed to analyse only multiply
charged ions from the "including list".
Note: We term this LC-MS/MS approach, incorporating a primary analysis
followed by a repeat experiment based on an inclusion list, Targeted Repeat
Analysis (TRA).
10. Process both LC-MS/MS data to pkl files using Proteinlynx in Masslynx and
then merge to a single mgf file with the software (merge) provided by Matrix
Science and submitted to Mascot search.
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2.5.10 LC-MS/MS analyses of a tryptic digest of IMAC purified phospho-
proteins on a 4000 Q TRAP
Although we have found that the majority of proteins in protein IMAC samples are
phosphorylated, the molar ratio of phosphorylated to non-phosphorylated species is
reduced upon trypic digestion. An alternative to performing a second round of
enrichment of phosphopeptides is to selectively monitor phosphopeptides in the
mass spectrometer. The specific behaviour of phosphopeptides in a mass
spectrometer can be exploited in a number of ways for analysis of very complex
peptide mixtures with a low abundance of phosphorylated peptides.
• Neutral loss of 98 in MS/MS for those phosphopeptides containing
phosphoserine and phosphothreonine in positive electrospray ionisation
mode.
• 216 fragment ion for phosphopeptides containing phosphotyrosine in
positive electrospray ionisation mode.
• 79 fragment ion for phosphopeptides in negative electrospray ionisation
mode.
By setting the mass spectrometer to specifically monitor precursor ions of the
fragment ions, phosphopeptides can be selectively identified. In our experience, we
found that monitoring the precursor of 79 fragment ion in the negative mode was
the most efficient approach and the use of the 4000 Q TRAP which is capable of fast
auto-switching between negative and positive ionisation mode is well suited for
this.
Two precursor-scanning approaches based on monitoring the precursor of 79
fragment ion can be adopted on the 4000 Q TRAP to selectively analyse
phosphopeptides. The LC conditions are the same as that used for IMAC purified
phosphoprotein digest, described above.
i
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Approach 1: Conventional precursor of 79 fragment ion scanning
1. The instrument is set in negative ion mode (-ESI) to scan for the precursors
of m/z 79 (POr);
2. When detected precursor ions for 79, the instrument is automatically
switched to positive mode (+ESI) then MS/MS fragmentation the detected
precursors.
3. The steps are repeated.
Approach 2: TRA precursor of 79 fragment ion scanning
1. Analyse one-third of the sample in negative mode for detecting precursors of
m/z 79.
2. Examine data to generate the inclusion list for the second run in positive ion
mode (+ESI).
3. Analyse the remaining two-thirds of the sample in Information Dependent
Acquisition (IDA) mode with the above inclusion list.
2.5.11 LC-MS/MS analyses of IMAC enriched phosphopeptides.
This is performed in a similar way to that described above for digested IMAC
purified phosphoproteins, with the following exceptions.
1. Load phosphopeptides to the trap column and desalt with 0.5% formic acid
(Recipe 29) at a flow rate of 10 pl/minute for 30-60 min depending on salt
amount in the sample.
Note: We suggest the trap column here is BetaMax Neutral 5 pm, 180 pm
i.d. x 30 mm (Thermo Hypersil-Keystone).
>
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161 99 1 Trap and analytical column off¬
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Table 2.2 - Liquid chromatography conditions for analysis of a phosphopeptide
mixture isolated by a peptide IMAC step.
2. Separate phosphopeptides with the gradient shown in Table 2.2, using
mobile phases described in Recipes 27 and 28 (A as 99.9% H2O-0.1% formic,
B as 70% CH3CN-29.9% H2O-0.1% formic acid). The flow rate is 150 nl/min
Note: This is due to the high pressure when the trap and analytical columns
are setup on-line.
The majority of phosphopeptides elute at very low organic percentage. A
comparison of liquid chromatography separations of a phosphoprotein digest and
an IMAC enriched phosphopeptide mixture is shown in Figure 2.5.
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2.6 Data Analysis
We recommend a Mascot V2.0 (Matrix Science) server for iterative searching of a
custom, non-identical, combined human, mouse and rat IPI database (EBI).
1. Select trypsin with a maximum of 2 miscleavage sites when using Trypsin
Gold from Promega or sequence grade trypsin from Roche; Select semi-
trypsin with maximum 2 miscleavage sites for sequence grade modified
trypsin from Promega as this trypsin produce some semi-tryptic fragments.
2. Select correct database with the appropriate taxonomy.
3. Set following variable modifications:
Carbamyl (N-term)
Carbamyl (K)
Methyl ester (C-term) - when peptides are methyl esterified




4. Select monoisotopic mass
5. Set peptide tolerance at 0.4 Da and MS/MS tolerance at 0.3 Da though
majority MW errors will be less than 0.2 Da if calibration is correct.
6. Select Data format as Micromass (.pkl) file when data file is generated by
Proteinlynx in Masslynx; for merged file as described previously select
"Mascot generic".
7. Protein identifications with peptides matching details will be given by
Mascot as well as the possible phosphorylation sites.
Verify the phosphorylation sites by manually checking the spectra using PEAKS
software. An example of a mass spectrum of a methyl-esterified di-phosphorylated
peptide is shown in Figure 2.6.
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2.7 Troubleshooting
We have found the protein IMAC protocol to be very reproducible, but in case of
problems there are a number of parameters which should be checked. The most
likely reason for failure or low yields in protein IMAC purifications is sample or
buffer contamination. Small amounts of chelating chemicals such as EDTA or EGTA
will strip the metal from the resin and contamination of the buffer with the metal
used as the affinity reagent will result in reduced or no phosphoprotein yield. In the
event of a failed IMAC purification, we recommend that in the first instance, that all
buffers should be replaced and the efficiency monitored by western blotting or
phosphoprotein staining. We recommend a working concentration of approximately
1 mg/ml for the protein extract and a ratio of 10:1 of extract to resin to ensure
specific binding of phosphoproteins. Reduction of the protein extract concentration
or extract to resin ratio may result in non-specific binding. The applicability of
protein IMAC to integral membrane or membrane associated proteins is limited by
their solubility in 6 M urea. We recommend that partial proteolysis with trypsin or
endoproteinase Lys-C be carried out to release cytoplasmic domains of such
proteins for subsequent protein and or peptide IMAC purification. Phosphoproteins
may be eluted from the resin by boiling in at 97°C for 5 min in 5 X reducing sample
buffer for subsequent SDS-PAGE separation but it should be noted that after
specific chelating elution, low levels of non specific binding proteins are retained
and would thus contaminate the sample prepared by a boiling elution. The peptide
IMAC protocol is also subject to similar effects from contaminating chelators and
metals and the same precautions should be taken to avoid this. There are two main
problems associated with purification of phosphopeptides by IMAC: specificity of
binding and elution efficiency. Traditional peptide IMAC suffers to varying
degrees, from non specific binding of acidic non-phosphorylated peptides. This has
been improved by the conversion of peptides to corresponding methyl-esters, but as
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Figure 2.5 - Liquid chromatography desalting and separation of peptides
BPI (base peak intensity) chromatographs of Run 1 for the protein IMAC digest (A) and for
the peptide IMAC purified phosphopeptides (B). The red dashed line represents the
gradient plot in each chromatogram. A standard gradient was used for the protein IMAC
digest (A) with the majority of peptides eluted by 30 % buffer B (32% organic). As most
phosphopeptides isolated in a peptide IMAC step are multi-phosphorylated and hence
quite hydrophilic, a shallow gradient of buffer B is used (B). It can be seen that the
majority of phosphopeptides are eluted before 5% B (3.5% organic).
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this reaction does not usually go to completion, this introduces other problems such
as dilution of a peptide species into modified and unmodified forms.
Phosphoproteins may be eluted from the resin by boiling in at 97°C for 5 min in 5 X
reducing sample buffer for subsequent SDS-PAGE separation but it should be noted
Non-specific interactions due to hydrophobic and ionic effects can be reduced by
performing IMAC at pH 2.5-3, at which most glutamic and aspartic acid residues
are protonated and by including up to 30% acetonitrile in the loading buffer. We
recommend these later conditions in conjunction with and without methyl-
esterification for greatest coverage of a phosphopeptide population in a sample.
2.8 Notes and remarks
It is generally accepted that currently no one approach for enrichment and analysis
of phosphoproteins or phosphopeptides will enable identification of all
phosphorylation sites (Steen et al., 2002). We support the idea that a multi-faceted
approach such as that we have described in this protocol is necessary to achieve
higher phosphoproteome coverage. It is also clear that a portion of the
phosphoproteome is hidden from analysis in basal state conditions and those
phosphoproteomic approaches which have been developed in the last number of
years, should be applied to numerous activation/treatment states in a given system
to reveal more of the low-abundance and transient phosphoproteome.
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Figure 2.6 - Mass spectrum of a methyl-esterified phosphopeptide derived from
Bassoon protein (Swiss-Prot accession 088737) showing phosphorylated serine
residues 2860 and 2866. Phosphorylation of serine 2860 was identified by the mass
difference between the b(2) and b(3) ions caused by neutral loss of phosphate in the mass
spectrometer. 167 daltons (phosphoserine) minus 98 daltons (H3P04) results in a mass
difference of 69 daltons, which is characteristic of dehydroalanine, and therefore
phosphoserine prior to neutral loss. Similarly, phosphorylation of serine 2866 was identified
by the mass difference between the y(10) and y(11) ions that was caused by neutral loss of
phosphate, resulting in a mass difference of 69 daltons.
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CHAPTER 3
PROTEOMIC ANALYSIS OF IN VIVO PHOSPHORYLATED SYNAPTIC
PROTEINS
Chapter 3- Proteomic Analysis of in Vivo Phosphorylated Synaptic Proteins 88
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
3. Proteomic Analysis of in Vivo Phosphorvlated Synaptic Proteins
3.1 ABSTRACT
In the nervous system, protein phosphorylation is an essential feature of synaptic
function. Although protein phosphorylation is known to be important for many
synaptic processes and in disease, little is known about global phosphorylation of
synaptic proteins. Heterogeneity and low abundance make protein phosphorylation
analysis difficult, particularly for mammalian tissue samples. Using a new
approach, combining both protein and peptide Immobilised metal-affinity
chromatography (IMAC) and mass spectrometry (MS) data acquisition strategies;
we have produced the first large-scale map of the mouse synapse
phosphoproteome. We report over 650 phosphorylation events corresponding to
331 sites (289 have been unambiguously assigned), 92% of which are novel. These
represent 79 proteins, half of which are novel phosphoproteins, and include several
highly phosphorylated proteins such as MAP1B (33 sites) and Bassoon (30 sites). An
additional 149 candidate phospho-proteins were identified by profiling the
composition of the protein IMAC enrichment. All major synaptic protein classes
were observed, including components of important pre- and post-synaptic
complexes as well as low abundance signalling proteins. Bioinformatic and in vitro
phosphorylation assays of peptide arrays suggest a small number of kinases
phosphorylate many proteins and each substrate is phosphorylated by many
kinases. These data substantially increase existing knowledge of synapse protein
phosphorylation and support a model where the synapse phosphoproteome is
functionally organised into a highly interconnected signalling network.
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3.2 INTRODUCTION
The molecular architecture of the synaptic junction has been studied intensely for
many years yielding information on its composition and function based on studies
of individual receptors or small groups of proteins (Sheng, 2001). In recent years
with the advent of proteomic technologies a coherent map of the mammalian
synapse proteome is emerging. Mass spectrometry (MS) based analysis of the
postsynaptic density (PSD) has established for the first time a detailed list of its
molecular components (Yoshimura et al., 2004), (Peng et al., 2004), (Li et al., 2004).
Systematic analysis of functional multiprotein complexes embedded in the PSD
(Husi et al., 2000) has also added to our knowledge of the overall organisation of the
postsynaptic proteome.
Central to the functioning of signalling complexes and indeed the most basic
signalling pathways is the process of reversible phosphorylation. The propagation
of an appropriate synaptic response to receptor stimulation is highly regulated by
phosphorylation cascades. This is exemplified by the process of synaptic plasticity, a
process whereby glutamate receptor activation results in diverse signalling cascades
which, ultimately lead to activation of transcription factors and modulation of gene
expression. Phosphorylation is also employed to modulate protein function and
stability and to mediate phosphorylation dependent protein-protein interactions
(e.g. SH2 binding of PI 3-kinase to NR2B) (Hisatsune et al., 1999) conferring a higher
order level of regulation in such protein complexes.
Historically, synapse phosphorylation and its importance in regulating neuronal
signal transduction and brain function has been studied at the level of single
molecules (Greengard et al., 1993), (Sweatt and Kandel, 1989), but new proteomic
strategies lend themselves to the global characterisation of the signalling properties
of the synapse proteome. Phosphopeptides can be purified from complex protein
mixtures using immobilised metal affinity chromatography (IMAC) (Andersson and
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Porath, 1986) and identified using MS (Ficarro et al., 2002). Recent
phosphoproteomic studies have utilised various peptide IMAC approaches,
sometimes with methyl-esterification, to enrich and improve specificity for
phosphopeptides prior to MS. This approach has been successfully used to study
phosphorylation in yeast (Ficarro et al., 2002), arabidopsis (Nuhse et al., 2003), and
cell lines (Shu et al., 2004). However, the application of these approaches to
complex mammalian sub-cellular organelles such as the synapse has yet to be
established.
MS, although a powerful tool for analysis of phosphorylation analysis, has several
on-going technical challenges. In particular these result from heterogeneity arising
from dynamic site occupancy, multiple phosphorylation sites in the same low-
abundance peptide as well as inherently poor fragmentation of phosphopeptides.
Continued improvements in three critical areas: unbiased sample enrichment
methods, high sensitivity MS and data analysis methods are required to fully
harness the potential of MS. The field is in a phase of rapid development and
various strategies for protein or modification centric analyses are being explored
(Beausoleil et al., 2004), (Chang et al., 2004).
Here, we describe the use of a combination of cellular fractionation procedures with
large-scale IMAC phosphoprotein and phosphopeptide enrichment protocols and
complementary MS analytical strategies to characterise mouse forebrain
synaptosomes. This has resulted in the unambiguous identification of 331 sites of
phosphorylation in 79 synaptic proteins involved in important pre- and
postsynaptic multiprotein complexes and signalling pathways. Large-scale in vitro
phosphorylation screening on peptide arrays for 95 sites with 7 kinases identified 28
phosphorylated sites and a total of 52 phosphorylation events. The simultaneous
identification of large numbers of sites of phosphorylation and identification of
responsible kinases, as exemplified by this study, is a powerful approach to expand
the current knowledge of cell signalling in a particular system.
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3.3 MATERIALS AND METHODS
3.3.1 Isolation of Synaptosomes
See section 2.5.1: Purification of Synaptosomes by Sub-cellular Fractionation.
3.3.2 Phosphoprotein/peptide purification
3.3.2.1 Protein IMAC of urea soluble synaptosomal fraction
Fast-flow chelating sepharose with iminodiacetic acid (IDA) (Amersham
Biosciences) or nitrilotriacetic acid (NTA) (Qiagen) chelating groups were charged
with GaC13 or FeC13. Synaptosomal proteins (12.5 mg) were solubilised in 6 M urea
and the supernatant was removed and incubated with 2 ml of the metal charged
resin with mixing for 1 hour at room temperature (RT). The unbound protein was
washed with buffer A (6 M urea/50 mM tris-acetate) to baseline and the
phosphoproteins were specifically eluted with buffer B (6 M urea, 50 mM tris-
acetate, 100 mM EDTA, 100 mM EGTA). The fractions were collected, concentrated
and washed with buffer B in a Vivaspin 6 PES membrane spin column
(Vivascience). 13.4 pg protein was diluted with buffer C (1 M urea, 0.125 M thiourea,
5% (v/v) CF13CN and 0.1 M NH4HC03) to a final volume of 400 pi. Trypsin
(sequence grade, Roche) was added to the sample in a ratio of 1:20 and the mixture
was incubated at 37°C for 2 hours and then dried in a SpeedVac (Thermo Life
Science). The sample was reconstituted in 50 mM NH4HC03 and 1/4 was injected
for each on-line LC-MS/MS analysis.
3.3.2.2 Double IMAC of urea soluble synaptosomal fraction
3 mg of protein IMAC purified sample was digested with modified porcine or gold
trypsin (Promega) in a ratio of 1:20 in buffer D (1 M urea and 25 mM NH4HC03) at
37°C for 4 hours. The resultant digest was desalted and dried and methyl
esterification was performed with 2 M methanolic HC1, (10), when needed. Self Pack
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POROS® 20 MC Media (Applied Biosystems) for phosphopeptide purification was
charged with GaC13 as described above for the IDA/NTA resins. Peptide digests
(with and without methyl esterification) were reconstituted in buffer E (equal
volumes of acetonitrile, methanol and water pH 2.5-3). 1 ml of this peptide mixture
was incubated with 200 pi of POROS-Ga slurry for 1 hour at RT. The resin was then
loaded into a spin-column and washed with 10 volumes of buffer E.
Phosphopeptides were eluted with 2 x 100 pi of 200 mM Na2HP04.
3.3.2.3 Peptide IMAC of whole and urea insoluble synaptosomal fractions
2.5 mg of the 6 M urea insoluble pellet left after removal of the supernatant was
digested with trypsin in buffer F (2 M urea and 25 mM NH4HC03). The resultant
digest was desalted, methyl-esterified and subjected to peptide IMAC step as
described previously. Similarly, 6 mg of whole synaptosomal proteins were
digested in buffer F, desalted, methyl-esterified and subjected to peptide IMAC
step.
3.3.3 Phosphoprotein staining and image analysis
IMAC enriched phosphoprotein samples were separated on a 12 % SDS-PAGE gel
and sequentially stained with Pro-Q diamond (phosphoprotein) and SYPRO Ruby
(total protein) stains (Molecular Probes). Peppermint Stick phosphoprotein
molecular weight standards (Molecular Probes) served as a molecular weight
marker and internal control. Images were captured with a Typhoon scanner
(Amersham Biosciences) and overlaid using TotaLab software (Nonlinear
Dynamics).
3.3.4 Mass spectrometry
Mass spectrometry was performed by Lu Yu (The Wellcome Trust Sanger Institute)
3.2.4.1 Online nano LC-MS/MS
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On-line nano LC-MS/MSA nanoflow HPLC system, Ultimate™ (LC Packings) or
CapLC (Waters), was coupled to a Q-Tof 1, Q-Tof Ultima (Waters/Micromass) or
4000 QTRAP (Applied Biosystems). Tryptic peptides from the phosphoprotein
digest were loaded in 0.1% aqueous formic acid (FA) and desalted on PepMap C18
trapping cartridge (LC Packings). BetaMax Neutral (Thermo Hypersil-Keystone)
was used to trap the IMAC enriched phosphopeptides in 0.5% aqueous FA. Peptides
on the trap were back-flushed to, and separated on the analytical column (PepMap
C18, 75 pm id x 15 cm, LC Packings). The gradients are shown Table 3.1.
Chapter 3- Proteomic Analysis of in Vivo Phosphorylated Synaptic Proteins 94
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
3.2.4.2 Analysis of IMAC enriched phosphoprotein digests
In the LC-MS/MS analysis of the phosphoprotein digest, the Q-Tof Ultima was
operated in automated Data Dependent Acquisition (DDA) mode. Each cycle had a
1 sec MS survey (m/z 400-1500) and up to three of the highest intensity multiply-
charged ions (+2 and +3) were selected for MS/MS (m/z 50-2000), each for 5 sec. The
collision energy in MS/MS was varied according to the m/z and the charge state of
the precursor ion. Due to the high complexity of the sample, there were two LC-
MS/MS runs with the same LC gradient. After the first standard run (Run 1), survey
data were examined and multiply charged ions above the intensity threshold that
had not been subjected to MS/MS in Run 1 were incorporated into the inclusion list
for the second run (Run 2). We term this latter LC-MS/MS approach, incorporating a
primary analysis followed by a repeat experiment based on an inclusion list,
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Table 3.1. Liquid chromatography gradients
A. LC gradient for separation of phosphoprotein digest. Solvent A was 95% H20-5%
AC N/0.1% FA, solvent B was 95% ACN-5% H20 / 0.1% FA. Flow rate through the
columns in the separation was 200-250 nL/min.
B. LC gradient for IMAC enriched phosphopeptides analysis. Solvent A was 100%
H2O/0.1% FA, solvent B was 70% ACN-30% H2O/0.1% FA. Flow rate through the
columns in the separation was 150 nL/min.
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3.2.4.3 Analysis of IMAC enriched phosphopeptides
Analysis of IMAC enriched phosphopeptides was performed on the Q-ToF using
similar acquisition parameters to those for the Q-ToF Ultima. Two different
precursor-scanning approaches were adopted on the 4000 QTRAP to selectively
analyse phosphopeptides. In the first approach the instrument was used in negative
ion mode (-ESI) to scan for the precursors of m/z 79 (P03-) with automatic switching
to positive mode (+ESI) for MS/MS for the detected precursors. In the second
approach, we applied TRA strategy. First, one-third of the sample was analysed in
negative mode for detecting precursors of m/z 79. Data were examined to generate
the inclusion list for the second run in positive ion mode (+ESI) using the remaining
two-thirds of the sample in Information Dependent Acquisition (IDA) mode. Raw
data was processed to give a peak list file and submitted to a local Mascot V2.0
(Matrix Science) server for iterative searching on a custom, non-identical, combined
human and mouse IPI database (EBI). Assignment of phosphorylation sites was
verified manually with the aid of PEAK Studio (Bioinformatics Solutions) software.
3.3.5 Peptide array phosphorylation assays
Peptide array data was generated by Marcelo Coba (The Wellcome Trust Sanger
Institute)
Jerini Phosphosite detectorTM peptide arrays (Jerini Peptide Technologies, Gmbh,
Germany) were used to determine which of the MS identified phosphorylation sites
(selected 95 sites) could be phosphorylated by 7 kinases in an in vitro assay. 15
amino acid long peptides which encompassed the selected sites were synthesised on
cellulose membranes in a parallel manner using SPOT technology (Wenschuh et al.,
2000) deposited to glass slides and were covalently Immobilised to the glass slide
surface. Each peptide was present in triplicate on the chip, and 7 full length proteins
which are capable of being phosphorylated were also included. Negative control
peptides for each phosphorylation site were included, replacing serine or threonine
Chapter 3- Proteomic Analysis of in Vivo Phosphorylated Synaptic Proteins 96
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
with alanine or valine, respectively and positive control peptide sequences for each
kinase were present.
3.2.5.1 Kinase reactions
Peptide arrays were sealed with Gene-Frame TM incubation chambers (Abgene
house, Surrey, UK) the chambers were filled with 330 pi of kinase buffer (20 mM
MOPS, pH 7.2, 25 mM P glycerol phosphate, 5 mM, EGTA, 1 mM sodium
orthovanadate, 1 mM DTT, 100 pM ATP, 15 mM MgC12 and 10 pM [y-32] ATP).
Recombinant active kinases (Upstate), (3 pg of PKA catalytic subunit (with 2 pM
cAMP), 2 pg of Aktl (delta PH, S473D), 2 pg of Erkl, 3 pg of p38a, 3 pg of CKII, 3 pg
of Cdk5/p35 and 1.5 pg of PKC (a, p, y)), were included in the appropriate kinase
assays. In the case of PKC, a modified kinase buffer was used (10 mM MOPS, pH
7.2, 12.5 mM P glycerol phosphate, 2.5 mM EGTA, 0.5 mM sodium orthovanadate,
0.5 mM DTT, 0.5 mM CaC12, 0.1 mg/ml phosphatidylserine, 25 pg/ml
diacylglycerol).
After a 45 minute incubation at 32 °C the peptide microarrays were washed 6 times,
alternating between 0.1 M phosphoric acid and distilled water.
3.2.5.2 Peptide array image analysis
y-32 P incorporation in the Immobilised peptide spots was detected on a Typhoon
8600 Phosphor imager (50 pm resolution), (Amersham Biosciences). Image analysis
and signal quantification was carried out using ImageQuant TL (Amersham
Biosciences) and positive signals were defined after background subtraction.
3.3.6 Bioinformatic analysis
All proteins detected in this study were classified according to Swiss-Prot keywords
(http://ca.expasy.org/sprot/). Known phosphoproteins in Supplementary Table 1
were annotated by extensive literature mining of PubMed. Scansite
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(http://scansite.mit.edu/) was used in high stringency mode to predict if proteins in
Supplementary Table 1 were likely to be phosphorylated and responsible kinases
are indicated. TMHMM Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/)
was used to predict the occurrence of transmembrane helices. Scansite and
NetPhosK (http://www.cbs.dtu.dk/services/NetPhos/) were both used for predicting
phosphorylation sites by cognate kinases, and on those peptides where the
phosphorylation sites could not be unambiguously assigned by MS data
(Supplementary Table 3). Scansite was also used to check the presence of
phosphorylation sites in Pfam protein domains and to predict if phosphorylation
sites were localised in phospho-dependent interaction domains (Supplementary
Table 3). Graphical illustrations of the location of identified sites in relation to
protein domain structure, 3D structure and information on homologs and paralogs
of identified phosphorylation sites can be found at
http://www.ppo4.org/phospho/synaptosome.html. Network construction: Protein-
protein interactions for NMDA receptor complex proteins were obtained from PPID
(www.PPID.org). Each protein (node) which had interaction (edge) information was
used to plot a network graph using InterViewer, a network graphing program.




Several approaches capable of identifying large numbers of in vivo phosphorylated
proteins have been used to functionally annotate the mouse synaptic proteome. A
summary of this is shown in Figure 1A. In the first approach, a mouse synaptosomal
preparation was digested with trypsin and phosphopeptides captured by peptide
IMAC. The enriched sample was analysed by nano-flow LC-MS/MS. Despite the
enrichment, the majority of identifications corresponded to unphosphorylated
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peptides. In the second approach, the synaptosomes were first divided into urea
soluble and insoluble fractions, the latter containing mostly membrane bound
components. Peptide IMAC and MS was performed on the insoluble fraction in a
comparable manner to the first approach. For the urea soluble fraction a new
strategy was adopted, entailing an additional stage of enrichment by capture of the
phosphoproteins. A two-pronged route was taken for subsequent analysis of the
trypsin digest of this enriched fraction. The first route is based on rigorous MS using
a) LC-MS/MS peptide identification based on a targeted repeat analysis (TRA)
approach described in the methods section, and b) precursor ion scanning to
identify phosphopeptides prior to sequencing. The second route used a further
peptide IMAC followed by LC-MS/MS. Using these combined approaches, and
implementing a previously unreported strategy of sequential protein and peptide
IMAC, we have identified 228 potential synaptic phosphoproteins (Supplementary
Table 1) and characterised over 350 phosphopeptides containing 331 sites of
phosphorylation (Supplementary Table 2, 3).
3.4.2 Synaptic phosphoprotein analysis
3.4.2.1 Protein IMAC protocol
Unlike peptide IMAC that is widely used for phosphoproteomic analysis, to our
knowledge protein IMAC approaches have not been reported. In order to develop a
protein IMAC protocol, we tested two resins: sepharose IDA (a tridentate ligand)
and agarose NTA (a quadradentate ligand) and two metal ions, FeC13 and GaC13
(Figure 3.2A), to isolate phosphoproteins from urea soluble preparations. The IDA
resin with both metal ions showed marked enrichment indicated by specific
phosphoprotein staining on SDS-PAGE gels. The Ga3+ resin showed more effective
depletion of phosphoprotein from the unbound fraction together with stronger
phospho-staining of the purified sample (Figure 3.2B), and therefore was used in all
subsequent protein IMAC experiments.
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Figure 3.1 - Schematic representation of protein and peptide purification
strategies.
Alternative starting material was derived from the differential solubility of
synaptosomes in 6 M urea. Large-scale protein identification was achieved by
TRA LC-MS/MS analysis of the IMAC purified phosphoproteins from the urea
soluble fraction with some of the most abundant phosphopeptides characterized
at this step. Further phosphopeptide identification was achieved by sequential
protein and peptide IMAC purification, with esterification and single peptide
IMAC with esterification of the urea insoluble fraction and of whole
synaptosomal digests.
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Analysis of tryptic peptides from the protein IMAC enrichment by LC-MS/MS
identified 152 proteins and 19 phosphopeptides (Supplementary Tables 1, 2). TRA
extended this by an additional 30 protein identifications and 21 phosphopeptides. A
further 28 different phosphopeptides from these samples were identified using the
precursor-scanning approach, applied in the routine as well as the targeted manner
as described in the methods section. Clearly, the TRA strategy is effective in both
standard LC-MS/MS and precursor scanning modes for extending both protein and
phosphorylation mapping from complex peptide mixtures. 186 proteins have been
identified in the protein IMAC sample. 105 of these have been confirmed as
phosphoproteins in the literature and by phosphorylation sites identified in this
study (Figure 3.3). This suggests that whilst a small proportion may represent
contaminating proteins, the majority are likely phosphoproteins.
The identified components represent a diverse range of protein classes (Figure 3.3B,
Supplementary Table 1) and low abundance protein classes, such as kinases,
phosphatases and small G-proteins and modulators, are well represented even in
the presence of very abundant cytoskeletal proteins.
The protein IMAC approach presents important benefits for phosphorylation
analysis. It offers the opportunity to use basic protein identification to identify
many candidate phosphoproteins, which are of low abundance and would not have
been in the dynamic range required for direct phosphorylation analysis. The
majority of phosphopeptides characterised MS analysis of the phosphoprotein
mixture cover single phosphorylation events (Figure 3.4), and thus is
complementary to measurements made from the peptide IMAC approach that
represents highly phosphorylated peptides better. A further important benefit is
that it provides scope for two stages of sample enrichment, at the protein and
subsequently at the peptide level.
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Figure 3.2 - Development of IMAC phosphoprotein isolation strategy.
A. Overlay of Pro-Q diamond phosphoprotein/ Ruby total protein stains of resin/metal
IMAC combinations used to selectively isolate phosphoproteins from urea soluble
synaptosomal extract. The corresponding unbound fractions are included for
comparison. 20% of eluted protein from each purification was separated on a 12%
SDS-PAGE gel and stained and imaged sequentially. Phosphorylated protein appears
pink to black, whereas unphosphorylated protein appears green. Lane 1 shows
Peppermint Stick molecular weight markers in which proteins of molecular weight 23
and 45 kDa are phosphorylated and those of 55 and 116 kDa are not phosphorylated,
thus serving as an internal control for selective staining of phosphorylated proteins. A
25 kDa band (see arrow) was shown to consist of ribosomal proteins, which were
retained on the IMAC resins due to ion-exchange effects, and therefore removed from
the dataset. B. Relative signal intensities of the Pro-Q diamond phosphoprotein stained
image used in the overlay in Figure 3.2A. Phosphoprotein signals for lanes 2-5 in A
are shown and plotted versus molecular weight. IDA-Ga has the highest overall signal
intensity and thus the most enriched in phosphoprotein.
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3.4.2.2 Double IMAC protocol
LC-MS/MS analysis of phosphopeptide from double IMAC yielded identification
and characterisation of 176 phosphopeptides (Figure 3.3A, Supplementary Table 2)
derived from 41 phosphoproteins. The results from the double IMAC protocol
significantly extended those from the Protein IMAC protocol on several levels. First,
of the 25 validated phosphoproteins found in the protein IMAC experiments, we
found an additional 115 phosphopeptides on 16 proteins, indicating greater depth of
analysis. We also identified a further 14 phosphopeptides corresponding to 7
proteins detected in the protein IMAC sample. Second, 19 phosphoproteins
containing 37 phosphopeptides that were not characterised in the protein IMAC
were observed in the double IMAC protocol. Third, the increased depth of
phosphorylation coverage through overlapping peptides reflects variability in site
occupation that can occur on a protein and a level of heterogeneity associated with
this type of modification. This is well illustrated in Bassoon, for which we found 15
phosphorylation sites (10 peptides) in the protein IMAC protocol and 16 new sites
(16 peptides) in the double IMAC protocol (Supplementary Table 3). It is evident
that combination of protein and double IMAC strategies enables identification and
characterisation of phosphoproteins across a wider range of protein abundance and
phosphorylation states.
3.4.3 Synaptic membrane phosphoprotein analysis
Integral membrane proteins are usually difficult to analyse since detergent based
extraction methods are not readily compatible with subsequent purification
strategies and LC-MS/MS analysis. However, for a phospho-proteomic analysis,
cytoplasmic domains of integral membrane proteins are sufficient, since they
contain the phosphorylation sites involved in intracellular signalling.
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Figure 3.3 Summary of Datasets
A. Venn diagram of phosphoproteins detected in the protein, double and peptide IMAC
protocols. Data from peptide IMAC experiments on whole synaptosomal digests and urea
insoluble synaptosomal digests were combined to simplify the comparison. Values in
brackets indicate the number of phosphoproteins in each set for which evidence of their
phosphorylation was found in the literature.
B. Class distribution of phosphoproteins identified. Phosphoproteins were cross-referenced
with 6 MS based studies of the postsynaptic density and with the NMDA-receptor complex
(NRC). Proteins in which we found phosphorylation sites (Experimental) and known
phosphoproteins (Literature) are indicated.
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Number of phosphates per phosphopeptide
Figure 3.4 Distribution of the number of phosphates per phosphopeptide identified.
The values are representative of all phosphopeptides detected by each approach and
therefore contain some peptides covering overlapping sequences in proteins but with
differing numbers of phosphates attached.
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Therefore we digested 6 M urea insoluble fractions of synaptosomes: the
supernatant was desalted and esterified as described above and was subjected to a
single peptide IMAC and LC-MS/MS analysis (Figure 3.1) This approach allowed
identification and characterisation of 60 phosphopeptides from 31 proteins
(Supplementary Table 2), of which 12 are predicted to be integral membrane
proteins, and many others such as PSD-95 and Adapter-related protein complex-2
alpha-1 are known to be membrane associated. 10 of the identified membrane
proteins were not previously known to be phosphoproteins. Of these 31
phosphoproteins, 18 were not detected in either protein or double IMAC protocols
(Figure 3.3A).
3.4.4 Complementarity of analytical approaches
Inspection of the summariseddata (Figure 3.3A, 3.4) shows that the combination of
sub-cellular fractionation and IMAC protocols with MS analyses are
complementary, both in terms of the protein identification, as well as
phosphorylation site characterisation. Overall, we sequenced 350 phosphopeptides
covering 653 phosphorylation events. These correspond to a total of 331
phosphorylation sites of which 289 were localised unambiguously (Figure 3.1). The
phosphorylation sites were found in 79 synaptic proteins and we identified a further
149 candidate phosphoproteins. Interestingly, the large numbers of phosphorylation
events characterised by the double IMAC approach mainly correspond to greater
coverage of a small set of proteins. The phosphopeptide-based methods in contrast,
cover a proportionately larger number of proteins but with fewer representative
sites.
Further complementarity is observed in the frequency of phosphorylation of
peptides detected using the different protocols (Figure 3.4). Peptide IMAC
approaches have been reported to enrich for multi- phosphorylated peptides (10),
(11) and we have also observed this. In contrast, protein IMAC shows a shift in
specificity favouring detection of mono-phosphorylated peptides. The combination
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of protein and peptide IMAC results in more representative coverage, with very
similar preferences for mono- and di-phosphorylated peptides together with
improved detection of higher phosphorylated states. Another approach using
strong cation exchange and exploiting the net charge on phosphopeptides at low
pH, has a bias toward singly phosphorylated peptides (Ballif et al., 2004). This
approach yielded peptides with an average of 1.15 phosphates per peptide,
compared to our 1.85 per peptide. It is likely that our combination of protein and
peptide protocols is more representative of the distribution of phosphorylation sites
in vivo.
Interestingly, the peptide-based approach on the membrane fraction shows more
multiple phosphorylated peptides (up to 6 sites) than the other methods. Moreover,
the average number of phosphorylation sites per peptide detected in the direct
peptide IMAC (2.53) on the membrane fraction is higher than that of whole
synaptosomes (2.05) and are greater that that observed for the protein IMAC (1.44)
and double IMAC (1.75) analysis of the urea soluble fraction (Figure 4.3). The
enrichment of multi-phosphorylated peptides in the urea insoluble fraction may
reflect clusters of phosphorylation sites, often found on the intracellular domains of
membrane proteins.
Of the total 331 sites defined, 281 correspond to phosphoserine phosphorylation
events, 43 and 8 can be attributed to phosphothreonine and phosphotyrosine
respectively. Tyrosine phosphorylation is usually associated with a higher gain in
signals because it is less abundant and more tightly regulated. We have observed
more tyrosine phosphorylation sites than would be expected from previously
reports in other large-scale studies (11), (12), (13). Since most of the phospho-
tyrosines we characterised are on multi-phosphorylated peptides that were
identified by the protein or double IMAC approach, this increased coverage can be
attributed to increased phosphoprotein enrichment, together with the
improvements in analysis of multi-phosphorylated peptides.
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3.4.5 Literature mining and bioinformatic assessment
Literature mining and bioinformatic analysis of the 228 proteins that we have
identified in this study clearly indicate an enrichment of phosphoproteins (Figure
3.3 and Supplementary Table 1). Systematic PubMed searching on the identified
components revealed that 110 have been described in the literature as
phosphoproteins (Supplementary Table 1 and Figure 3.3). Of the 79 synaptic
phosphoproteins characterised here, only 41 were previously reported as
phosphorylated, the present work representing a 2-fold increase to the published
literature. We also report an additional 149 putative phosphoproteins, which we
have characterised based on protein identifications in the protein IMAC samples. 69
(46%) of these components have been reported as phosphorylated in the literature,
thereby strongly indicating further mapping of these proteins will produce
confirmation of their phosphorylation (Figure 3.3A) and further validation of this
approach. Within our data set we have also identified phosphorylation sites in 14
novel or uncharacterised proteins, adding functional annotation in an unbiased
manner not possible in single protein focused studies.
To further explore the putative phosphoproteins as well as phosphopeptides with
ambiguous site assignment we utilised phosphorylation prediction software that
provides information on sites and cognate kinases. We found that prediction
programs were particularly useful for assigning specific sites to phosphopeptides
with multiple potential phosphorylation sites. For example, the peptide 44-
IG(S)(T)(T)NPFLDIPHDPNAAVYK-64 from mKIAA0942 protein was detected in
the protein IMAC analysis and contained 1 p(S/T) phosphorylation site. Scansite
predicted that the most likely site to be phosphorylated in this sequence (by PKC
delta) was S46 and this site was subsequently confirmed when it was detected again
in the double IMAC analysis. We have observed accurate predictions in many
similar cases, which support the use of in silico localisation of the remaining 43
ambiguous phosphorylation sites (Supplementary Table 3).
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Based on bioinformatic prediction and in a few cases data from the literature, we
identified the kinases that were most likely to phosphorylate 289 defined sites
(Supplementary Table 3). All sites could be accounted for by a minimum set of 23
kinases (Figure 3.5) and 14 of these are shown in the literature to phosphorylate
proteins in our dataset. The predicted kinases emerged as two groups; those that
phosphorylate multiple sites on proteins (phosphate/substrate ratio > 1 (9 kinases))
(left of dashed line, Figure 3.5) and those that phosphorylate a single site per protein
(phosphate/substrate ratio = 1 (14 kinases)). 9 kinases could each phosphorylate 10
or more sites on multiple substrates and together could account for 258 of the
observed sites and 8 kinases could phosphorylate ten or more distinct synaptic
substrates. In agreement with another report, we noted that the majority of sites
cluster outside characterised protein domains (Nuhse et al., 2004) (Supplementary
Table 3). 25 phosphorylation sites corresponded to residues predicted to mediate
phosphorylation-dependent protein-protein interactions such as 14-3-3 and SH2
domains.
3.4.6 In vitro phosphorylation assays
Peptide array technology was employed to evaluate kinase specificity and
multiplicity inferred from bioinformatic analysis of the synaptic phosphorylation
dataset. 190 peptides were synthesised that encompassed 95 phosphorylation sites
from the described MS analyses. Control peptides were used to confirm enzymatic
activity for each kinase and analytical spot signals were only considered positive
when they were positive after background subtraction and when serine/threonine
substitutions on control peptides eliminated or significantly reduced the resultant
signal. 7 kinases (PKA, Akt, PKC (a, P, y), CK2, p38 MAPK, ERK1, Cdk5) were used
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Figure 3.5 - Predicted kinase multiplicity for 289 defined synaptic phosphorylation
sites. Scansite and NetPhosK kinase predictions and in a few cases data from the literature
were used to evaluate the number of phosphorylation sites and distinct substrates for 23
kinases on 289 sites in synapse proteins. The total number of predicted sites (blue) and
substrate proteins (red) are shown on the Y-axis for a given kinase (X-axis). The dashed
vertical line between CamKII and ERK divides the kinases into two groups; the left-hand set
has kinase/substrate ratio of >1 and the right-hand set has a kinase/substrate ration of 1.
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to screen for positive signals across 190 peptides, arrayed in triplicate. Robust
positive signals for 28 unique phosphorylation sites were detected resulting in 52
kinase substrate-site identifications (Figure 3.6) with an observed kinase/substrate-
site ratio of 1.9. To evaluate the agreement of this in vitro data with the in silico
kinase predictions by Scansite and NetPhosK, predictions were made with both
programs for the 7 kinases used on the 28 positive sites in the peptide array
experiments. Scansite and NetPhosK predicted 58 % and 63 % of sites, respectively
(Supplementary Figure IB). The overlap of positive predictions by Scansite and
NetPhosK for this set of phosphorylation sites was 26 %, strongly indicating that
neither algorithm is sufficient and that both must be used to obtain good coverage
of a dataset.
Accession Phosphoprotein Residue Cognate kinases determined by the peptide arrays
PKA Aktl PKC CK2 p38 ERK1 Cdk5
Q9Z2H5 Band 4.1 -like protein 1 T650 X
088737 Bassoon S2122 X
088737 Bassoon T2908 X X
088737 Bassoon S3213 X
088737 Bassoon S3217 X X X
P28652 Calcium/calmodulin-dependent protein kinase type II beta S315 X
Q9R196 Calcium-activated potassium channel alpha subunit 1 S711 X X
Q8K1M3 cAMP-dependent protein kinase type II-alpha rep chain S77 X
035927 Delta catenin-2 S531 X X
Q8BJ42 DISKS large-associated protein 2 S440 X X X
Q8BJ42 DISKS large-associated protein 2 S450 X X
AA089219 DISKS large-associated protein 3 S58 X X X
Q8BJY3 Glutamate receptor, metabotropic 5 S135 X X X
Q8BJY3 Glutamate receptor, metabotropic 5 S137 X X X
P20357 Microtubule-associated protein 2 SI 800 X
P14873 Microtubule-associated protein IB SI 775 X X X
P10637 Microtubule-associated protein Tau S493 X
BAC65687 mKIAA0942 protein S46 X X
P04370 Myelin basic protein (generic) S144 X X
035413 nArgbp2 S844 X
Q9Z0P4 Paralemmin T141 X X X
O9Z0P4 Paralemmin T145 X
Q9Z0P4 Paralemmin S157 X X X
099569 Plakophilin 4 S510 X
P70207 Plexin 2 SI 620 X X
091XM9 PSD-93/Chapsyn-110 S414 X
Q62108 PSD-95/SAP90 S418 X
Q9JIR4 Rab3 effector, RIM-1 S895 X X
Table 3.2. MS-identified phosphorylation sites with their cognate kinases as assessed by
in vitro phosphorylation assays on immobilized peptide arrays. Detected signals which
were positive after background subtraction are indicated with "X". Cognate kinase predictions
for these selected phosphorylation sites were carried out using Scansite and with NetPhosK,
and are indicated by yellow and green boxes respectively. Blue boxes indicate when both
programs predicted the same kinase for a given site.
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I Scansite and NetPhosK predicted
I Peptide array positive signals
Figure 3.6 - Comparison of cognate kinase identifications for 28 phosphorylation
sites screened by peptide arrays
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The number of kinases and binding sites with known consensus sequences
constrains global predictions, however in combination with datasets of defined in
vivo phosphorylation sites and in vitro phosphorylation data, they point to the fact
that multiple synaptic substrates may exist for each kinase and a complex
regulatory network may arise.
3.5 DISCUSSION
3.5.1 The synapse phosphoproteome
The aim of this study was to establish an in vivo map of the synaptic
phosphoproteome. We therefore examined the representation of phosphorylation
data across synaptic proteins and important synaptic subcomponents and
organelles. Our dataset contained postsynaptic components including the
postsynaptic density (134 proteins) and NMDA-receptor associated proteins (44
proteins) (Figure 3.3) and presynaptic components, of which the most striking
examples were Piccolo-Bassoon transport vesicles.
3.4.1.1 Presynaptic multiprotein complexes
A number of protein complexes have been identified at the presynaptic active zone,
a region where synaptic vesicles dock, fuse and release their neurotransmitters into
the synaptic cleft (Sudhof, 2004). It is well known that phosphorylation is critical to
the regulation of calcium regulated synaptic vesicle exocytosis (Turner et al., 1999)
and we have identified a number of phosphoproteins known to play a role in this
process (Figure 3.7). Piccolo-Bassoon transport vesicles (PVT) have been shown to
be putative precursor vesicles in the active zone (Shapira et al., 2003), and contain a
number of proteins functionally coupled to synaptic vesicle exocytosis. Bassoon, a
presynaptic protein with homology to Piccolo, has is intimately involved in vesicle
release (Shapira et al., 2003) and together with Piccolo and Rim-1/2, constitute half
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of the protein content of PTVs. We have detected 30 phosphorylation sites on
Bassoon and a further 16 sites on Piccolo.
We have identified a number of phosphorylation sites on Rim-1, a Rab3 effector
involved in the regulation of synaptic vesicle fusion which is associated with PTVs
(Shapira et al.; 2003). PKA phosphorylation of an isoform of Riml regulates
presynaptic LTP (Lonart et alv 2003) highlighting the regulatory importance of such
presynaptic molecules. In addition to the main constituents of PVTs, we mapped 10
phosphorylation sites on Munc-18 (Figure 3.9). Phosphorylation of Munc-18 by PKC
has been shown to disassemble Munc-18-syntaxinlA complexes and may have a
regulatory role in presynaptic plasticity (Craig et alv 2003). We have identified a
number of phosphorylation sites in components of other presynaptic multiprotein
complexes such as Cysteine string protein, SNAP25 interacting protein and the
Rabll interacting protein, Ripll (Figure 3.7).
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3.4.1.2 Postsynaptic multiprotein complexes and pathways
The neurotransmitter glutamate activates synaptic plasticity primarily via the
ionotropic N-methyl-D-aspartate (NMDA) receptor and metabotropic (mGluR)
receptors. This leads to Ca2+ elevation in the dendritic spine and signal transduction
to AMPA (alpha-amino-3-hydroxy-5-methylisoxa-zole-4-propionate) receptors and
other effector mechanisms. Proteomic analysis of proteins associated with the
NMDA receptor revealed that a multiprotein complex of over 180 proteins is
embedded in the postsynaptic density (Husi et al., 2000), (Grant, 2003).
We have identified 115 phosphopeptides derived from 17 NMDA receptor complex
(NRC) proteins, most of which have been also identified as PSD proteins and an
additional 142 phosphopeptides from another 29 PSD proteins (Figures 2, 4).
Phosphopeptides derived from three PDZ domain-containing proteins (Shankl, and
PSD-93/ChapsynllO and PSD-95) were detected in this study. PDZ domain-
containing are important components of the NRC and the postsynaptic density and
form protein scaffolds which support and regulate many essential synaptic
signalling processes (Nourry et al., 2003). We found a phosphorylation site in PSD-
93 (S414) which was also found in MS analyses of purified NRC complexes
(unpublished results). As this site was detected in the NRC with no specific
enrichment for phosphoproteins, it must be highly phosphorylated and enriched in
this complex, in agreement with another study of PSD-93 phosphorylation in the
NRC (Nada et al., 2003). Three phosphorylation sites were mapped in PSD-95
within a 20 amino acid stretch, 2 pSer just before its SH3 domain and a pTyr (Y432)
located at the start of its SH3 domain in the pi sheet (Figures 3.10, 3.11). Structural
analysis of the SH3 and Guanylate kinase (GK) domains of PSD-95 (McGee et al.,
2001), (Tavares et al., 2001) showed that there is an intermolecular interaction
between the SH3 and GK domains involving the formation of a P-sheet including
residues N- and C- terminal to the SH3 domain.
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Figure 3.9 - Predicted 3D structure of Munc-18-1. The structure of Munc-18-1 was
predicted by SwissModel, a Comparative Protein Modelling Server using 5 known template
structures chosen by primary sequence homology. The location of 6 defined phosphorylation
sites and 4 phosphorylation sites which were not exactly defined are indicated on the
structure. It can be seen that all of these phosphorylation sites are in accessible regions of
low complexity.
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Figure 3.10 - Known partial 3D structure of PSD-95. 3D structure of the SH3 and
GK domains of PSD-95 (UXO.pdb) showing the identified phospho-tyrosine-432 and
its neighbouring residues tryptophan-717 and histidine-461, all of which have been
implicated in the proposed mechanism of oligomerization of PSD-95 (Tavares, G. A.,
Panepucci, E. H. & Brunger, A. T. (2001) Mol Cell 8, 1313-25.)
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Figure 3.11 - Protein domain structure of PSD-95. The location of 3 phosphorylation sites
and the phosphopeptides they were found in are indicated. Scansite was used to predict the
most likely kinases to phosphorylate these sites.
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Y432 is located in this hydrophobic core mediating this interaction and is itself,
interacting with H461. Introduction of a negative charge by phosphorylation of
Y432 could disturb this interaction and may have a regulatory role in the formation
of an SH3 and GK intermolecular interaction and also affect the interaction of other
proteins such as AKAP79 which bind to this region (Colledge et al., 2000) (Figure
3.10). It has been proposed that this intermolecular interaction is a conserved feature
of MAGUK (Membrane-associated guanylate kinase) superfamily based on
mutational data available for different MAGUK proteins (McGee et al., 2001). These
phosphorylated sequences in PSD-95 are also present in two paralogous proteins;
SAP97 and SAP102, representing a possible conservation of regulatory functions
(Table 3.3).
Mouse Human Rat Name Phosphopeptide sequences Residues
Q62108 PSD-95 EQLMNSpSLGpSGTASLRSNPKRGFpYIR 409-434
P31016 PSD-95 EQLMNS SLG SGTASLRSNPKRGF YIR 409-434
P78352 PSD-95 EQLMNS SLG SGTASLRSNPKRGF YIR 452-477
Q62936 SAP102 EQMMNS SMS SGSGSLRTSEKRSL YVR 500-525
P70175 SAP102 EQMMNS SMS SGSGSLRTSEKRSL YVR 500-525
Q92796 SAPI02 EQMMNS SMS SGSGSLRTSEKRSL YVR 482-507
Q12959 SAP97 EQMMNS SIS SGSGSLRTSQKRSL YVR 562-587
Q8CGN7 SAP97 EQMMNS SVS SGSGSLRTSQKRSL YVR 529-554
Q62696 SAP97 ETMMNS SVS SGSGSLRTSQKRSL YVR 561-586
Table 3.3- Paralogous phosphorylation sites in MAGUK proteins. Two phospho-serines
and one phospho-tyrosine residue found just before and at the start of the SH3 domain in
PSD-95 are completely conserved in two other paralogous proteins; SAP102 and SAP97
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There is a growing body of evidence that scaffold proteins are regulated by
phosphorylation (Gardoni et al., 2003), which is consistent with the number of
identified scaffold phosphoproteins identified in this study. In fact, we have
identified two phosphorylation sites on PKA-RII alpha, which map to a defined 15
amino acid sequence, which has been shown to interact with MAP2 (Figure 3.12)
(Scott et al., 1990). This interaction is believed to influence cytoskeletal localisation
of the PKA holoenzyme (Scott et al., 1990) and phosphorylation of the binding site
could modulate this interaction and ultimately localisation of PKA.
The usefulness of a differential urea extraction strategy is shown by identification of
phosphorylation sites in a number of integral membrane or membrane-associated
proteins. We have found sites in cell adhesion molecules such as NCAM and
Neurofascin, potassium channels and a number of other known membrane proteins.
However, the value of such a targeted extraction procedure is exemplified by the
identification of components of a plasma membrane to intracellular membrane
signalling complex associated with mGluR5 (Farr et al., 2004) (Figure 3.7). We have
identified phosphorylation sites in mGluR5 (group I metabotropic glutamate
receptor) and IRBIT (membrane associated IP3 (inositol triphosphate receptor)
binding protein)) in the urea insoluble synaptosomal fraction and PLC-(3 in the urea
soluble fraction. Activation of mGluR5 results in the hydrolysis of membrane
phosphatidyl-inositol bisphosphate (PIP2) to diacylglycerol (DAG), which activates
PKC, and inositol triphosphate (IP3), which in turn activates the IP3 receptor to
release intracellular calcium (33). IRBIT binds to the IP3 receptor via its N-terminus
and is released from the IP3 receptor upon IP3 binding. The N-terminal region of
IRBIT responsible for this interaction contains 3 novel phosphorylation sites, and
phosphorylation in this region has been postulated to regulate this interaction
(Ando et al., 2003). mGluR5, G-proteins and PLC-(3 form a multiprotein complex
with the IP3 receptor and IRBIT via the scaffolding properties of Homer (Tu et al.,
1998). This complex seems to facilitate a signalling pathway from mGluR5 to
modulation
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Figure 3.12 - Novel phosphorylation sites in the type two alpha regulatory subunit
of cAMP-dependent kinase. Discovery of 2 phosphorylation sites in a region of PKA-R2A
which was previously identified as important for binding MAP2. Introduction of negatively
charged phosphate groups may regulate this interaction and thereby the localisation of
PKA-R2A by MAP2. Top schematic adapted from Scott JD, 1990.
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There is a growing body of evidence that scaffold proteins are regulated by
phosphorylation (Gardoni et al., 2003), which is consistent with the number of
identified scaffold phosphoproteins identified in this study. In fact, we have
identified two phosphorylation sites on PKA-RII alpha, which map to a defined 15
amino acid sequence, which has been shown to interact with MAP2 (Figure 3.12)
(Scott et al., 1990). This interaction is believed to influence cytoskeletal localisation
of the PKA holoenzyme (Scott et al., 1990) and phosphorylation of the binding site
could modulate this interaction and ultimately localisation of PKA.
The usefulness of a differential urea extraction strategy is shown by identification of
phosphorylation sites in a number of integral membrane or membrane-associated
proteins. We have found sites in cell adhesion molecules such as NCAM and
Neurofascin, potassium channels and a number of other known membrane proteins.
However, the value of such a targeted extraction procedure is exemplified by the
identification of components of a plasma membrane to intracellular membrane
signalling complex associated with mGluR5 (Farr et al., 2004) (Figure 3.7). We have
identified phosphorylation sites in mGluR5 (group I metabotropic glutamate
receptor) and IRBIT (membrane associated IP3 (inositol triphosphate receptor)
binding protein)) in the urea insoluble synaptosomal fraction and PLC-(3 in the urea
soluble fraction. Activation of mGluR5 results in the hydrolysis of membrane
phosphatidyl-inositol bisphosphate (PIP2) to diacylglycerol (DAG), which activates
PKC, and inositol triphosphate (IP3), which in turn activates the IP3 receptor to
release intracellular calcium (33). IRBIT binds to the IP3 receptor via its N-terminus
and is released from the IP3 receptor upon IP3 binding. The N-terminal region of
IRBIT responsible for this interaction contains 3 novel phosphorylation sites, and
phosphorylation in this region has been postulated to regulate this interaction
(Ando et al., 2003). mGluR5, G-proteins and PLC-|3 form a multiprotein complex
with the IP3 receptor and IRBIT via the scaffolding properties of Homer (Tu et al.,
1998). This complex seems to facilitate a signalling pathway from mGluR5 to
modulation
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Figure 3.12 - Novel phosphorylation sites in the type two alpha regulatory subunit
of cAMP-dependent kinase. Discovery of 2 phosphorylation sites in a region of PKA-R2A
which was previously identified as important for binding MAP2. Introduction of negatively
charged phosphate groups may regulate this interaction and thereby the localisation of
PKA-R2A by MAP2. Top schematic adapted from Scott JD, 1990.
Chapter 3- Proteomic Analysis of in Vivo Phosphorylated Synaptic Proteins 122



























Figure 3.13 - Identification of phosphorylation sites in a membrane to membrane
signalling pathway. A. Activation of mGluR5 results in the hydrolysis of membrane
phosphatidyl-inositol bisphosphate (PIP2) to diacylglycerol (DAG), which activates PKC, and
inositol triphosphate (IP3), which in turn activates the IP3 receptor to release intracellular
calcium (33). We have identified novel phosphorylation sites in proteins marked with are red
star. B. Domain map of IRBIT with N-terminal phosphorylation sites. IRBIT binds to the IP3
receptor via its N-terminus and is released from the IP3 receptor upon IP3 binding. The N-
terminal region of IRBIT responsible for this interaction contains 3 novel phosphorylation
sites, and phosphorylation in this region has been postulated to regulate this interaction.
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of intracellular calcium, which is known to regulate a myriad of intercellular
signalling activities.
mGluR5 has a critical role in NMDAR dependent forms of synaptic plasticity and
excitotoxicity. Co-activation of mGluR5 and NMDA receptors is required for
potentiation of excitatory synaptic transmission in hippocampal neurons (Kotecha et
al., 2003) and this process requires IP3R-mediated mobilisation of intracellular
calcium and activation of PKC for maintenance of potentiation. As well as being
functionally coupled, there is evidence to suggest that these receptors are physically
associated; mGluR5 is a component of the NMDA receptor complex (Husi et al.,
2000), NR2A (an NMDA receptor subunit) is present in the mGluR5 receptor
complex (Farr et al., 2004) and 20 other proteins are common to these complexes.
Function analysis of novel phosphorylation sites on mGluR5 and other components
of the associated pathway to calcium release and PKC activation may provide novel
insights into the functional interaction of these two important glutamate receptors.
3.5.2 Peptide array-based kinase screen
Oriented peptide libraries were first used in the study of protein phosphorylation to
map target specificity of kinases. This approach has contributed much of the kinase
consensus information currently known and constitutes the basis of a widely used
phosphorylation prediction algorithm (Obenauer et al., 2003). It is thought that
many phosphorylation sites tend to occur in accessible and flexible regions in three
dimensional protein structures and in agreement with another study (Nuhse et al.,
2004), the majority of phosphorylation sites (65 %) we identified are predicted to be
outside structural domains. This would indicate that phosphorylation of linear
peptide sequences in vitro should be similar to phosphorylation of the intact protein
for the majority of sites. Data derived from Immobilised peptide array experiments
is consistent with known kinase consensus sequences, (Lizcano et al., 2002),
(Rychlewski et al., 2004) and is therefore a useful tool for studying phosphorylation.
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Peptide array screening of a limited set of phosphorylation sites with seven kinases
resulted in the identification of 52 kinase-phosphorylation site sets. Kinase data for 2
phosphorylation sites screened on peptide arrays was available in the literature.
Microtubule-associated protein Tau was shown to be phosphorylated at Ser-493 by
Cdk5 (Cruz et al., 2003). This site was identified and was hyper-phosphorylated
only in p25 over expressing mice (increased activation of Cdk5) and along with
other hyper-phosphorylated residues contributed to neurodegeneration and
formation of neurofibrillary tangles (Cruz et alv 2003). We identified this site in vivo
in wild type mice and have shown that it can be phosphorylated by Cdk5 on a
peptide array. Also, Myelin basic protein is phosphorylated at Ser-144 by PKA and
PKC (Kishimoto et al., 1985), in agreement with our peptide array observations for
this site. The reported validation and use of peptide arrays in the literature and
confirmation of cognate kinases for these two sites supports the value of using
peptide array technology as a screening tool for in vivo identified phosphorylation
sites. We recognise that this in vitro data is not sufficient on its own to definitively
prove that a kinase may phosphorylate a given site in vivo, however because these
phosphorylation sites were identified from in vivo preparations it is reasonable to
use this peptide array technology as a first approach to screen for possible
substrates.
Large-scale screening of kinase substrates, directly in a protein complex is currently
not feasible due to technical limitations. However, an alternative strategy would be
to firstly, assign kinases to phosphorylation sites using peptide array screening,
which is a very scalable, and then for example, phospho-specific antibodies or
specific MS-based approaches could be used to assess the relevance of a substrate
phosphorylation in a particular complex or organelle. As phosphoproteomic
approaches are beginning to yield unprecedented numbers of phosphorylation site
identifications, peptide array based screening of cognate kinases may prove to be
very useful for selecting and prioritising phosphorylation sites or phosphoproteins
for further functional investigation.
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3.5.3 Kinase association
An important issue in assigning kinases to specific phosphorylation sites on
substrates is one of kinase proximity. The potential of a substrate to be
phosphorylated by a kinase depends on the presence of the appropriate consensus
sequence as well as the presence of the kinase in the micro-environment of the
substrate. Kinases can be targeted to their substrates via adapter proteins, for
example, a MAGUK-AKAP79 complex recruits PKA to the postsynaptic membrane
to phosphorylate the AMPA receptor subunit GluRl (Colledge et al., 2000).
Furthermore, it is probable that a given phosphorylation site can be phosphorylated
by multiple kinases in an in vitro assay but either the site is specific for a given
kinase in a given complex, or in some cases, the substrate would not usually be in
proximity that kinase in physiological circumstances.
We addressed this issue of proximity by focusing on protein-protein interactions in
the NRC. A network of interacting NRC proteins was constructed and kinase-
substrate data from MS and peptide array experiments was superimposed onto this
network (Figure 3.13). Six kinases were shown to phosphorylate 9 NRC components
on the peptide array. It should be noted that three of these kinases (AKT1, p38
MAPK and Cdk5) were not found in the NRC, perhaps these kinases are transiently
associated with the NRC, (thus beyond detection limits), or they phosphorylate
NRC components in a different physiological context. Certain substrates such as
SAPAP1/2 act as phosphorylation hubs, being phosphorylated on various sites by
all six kinases, whereas others are phosphorylated by a single kinase. It is apparent
that some kinases such as PKA act on sets of interacting proteins (Figure 3.13B).
PKA is linked to four interacting substrates (PSD-95, PSD-93, SAPAP1 & 2) via
AKAP79, a kinase anchor protein which recruits PKA to the postsynaptic membrane
in proximity to its physiological substrates. The layering of kinase-substrate data
onto protein-protein interaction networks such as this can result in the identification
of interacting substrates, which are more likely to be physiologically important and
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therefore should be prioritised for further functional annotation. A prerequisite for
this kind of approach is a well defined and functionally relevant interactome such as
the NRC and layering dynamic aspects of phosphorylation such as phosphorylation
time courses, in response to stimuli, will certainly advance the dissection of complex
synaptic signalling pathways
3.5.4 Synaptic plasticity and disease
In addition to identifying and characterising phosphoprotein components in
important synaptic multiprotein complexes, we have found phosphorylation sites in
a number of proteins, which are directly implicated in synaptic plasticity and
disease (Supplementary Table 4). It is generally accepted that phosphorylation is
important in the regulation of synaptic plasticity, a process, which is believed to be
involved in learning and memory (Tokuda and Hatase, 1998), drug addiction (Yao
et al., 2004) and pain (Garry et al., 2003). Functional studies have shown that 7
phosphoproteins we identified are involved in synaptic plasticity and perturbation
of 5 in rodents, show impairments in learning and memory. Also, 7 out of the top
11 kinases predicted to phosphorylate our total phosphoprotein dataset are known
to be intimately involved in synaptic plasticity. We have identified 8
phosphoproteins, which have been linked to Schizophrenia and other mental
disorders. Finally, we have detected at least 7 known phosphorylation sites on
Microtubule-associated protein tau (and one novel site), many of which have been
shown to be involved in neurodegeneration and the development of neurofibrillary
pathology (Cruz et al., 2003).
3.5.5 Conclusions
We have described large-scale analysis of phosphorylation of synaptic proteins
using multiple complementary approaches at the levels of protein extraction,
phosphoprotein and phosphopeptide enrichment, analysis by MS, in vitro
phosphorylation assays and network analysis. This integrated large-scale approach
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has several advantages over more traditional methods, where a single protein or site
is characterised, and in particular it can be used to derive a picture of the global
organisation of the synapse phosphoproteome. The establishment of
phosphorylation maps will provide the basis for numerous functional studies,
which will aid the understanding of complex signalling pathways at the synapse. In
addition to enhancing this map of the synapse phosphoproteome with further
studies, there is an important need to develop novel functional assays to monitor
the regulation of multiple phosphorylation events in a physiological context.
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CHAPTER 4
PHOSPHOPROTEOMIC ANALYSIS OF THE MOUSE FOREBRAIN:
INVESTIGATION OF THE RELATIONSHIP BETWEEN INTRINSIC
PROTEIN DISORDER AND PHOSPHORYLATION IN THE BRAIN.
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4. Phosphoproteomic analysis of the mouse forebrain: Investigation of
the relationship between intrinsic protein disorder and phosphorylation
in the brain.
4.1 ABSTRACT
We have analysed the mouse forebrain cytosolic phosphoproteome by using a
tandem (protein and peptide) immobilised gallium affinity chromatography
purification strategy and analysis by tandem mass spectrometry. This resulted in
identification of 485 phosphorylation events corresponding to 321 unique
phosphorylation sites on 67 cytosolic proteins. We found that in a single 4-hour
reversed-phase LC run with a PepMap column we could identify 401
phosphorylation events on 173 phosphopeptides, highlighting the efficiency of our
approach. Intrinsic protein disorder, which is characterised by lack of any regular
structure and enrichment of specific disorder promoting amino acids, is becoming
increasingly recognised as important for protein function. We have investigated the
role of protein disorder and its relationship with protein phosphorylation in the
brain. We found that the cytosolic phosphoproteome dataset presented here is rich
in sequence disorder and contains many putatively disordered proteins. The
majority of these have RNA or tubulin binding functions and the combination of
disorder and phosphorylation is likely to be essential for their function. We have
observed that the majority of phosphorylation sites occur in regions of sequence
disorder and that disordered proteins may produce more tryptic fragments than
ordered regions, with implications for phosphoproteomic analyses. We identified 37
phosphorylation sites on nine protein kinases, the majority of which are novel and
are not located in kinase domains indicating secondary regulatory functions.
Finally, in our global study of cytosolic phosphorylation we have characterised a
number of phosphoproteins with disease-associations, which may have related roles
in the pathogenesis of neurodegenerative disease.
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4.2 INTRODUCTION
Protein phosphorylation is an essential regulator of cellular function and the
complement of phosphorylation sites in a proteome (phosphoproteome) is dynamic
and highly complex. Recent phosphoproteomic analyses of numerous biological
samples have together identified thousands of phosphorylation sites (Loyet et al.,
2005), indicating that the phosphoproteome is much larger and complex than
original estimates. Annotation of large numbers of phosphorylation sites is a
difficult task as the amount of associated biological information is usually low in
large-scale experiments. Phosphorylation sites can be mapped to functional protein
domains, assigned putative kinases by prediction programs such as Scansite
(Obenauer et al., 2003), assigned as putative binding sites, for example for 14-3-3
proteins, by using the ELM server (Puntervoll et al., 2003). Phosphorylation sites can
also be assigned putative functions by retrospective annotation from the literature,
for example, deletion studies that map a binding, catalytic or regulatory function to
a portion of a protein sequence. In the absence of direct functional data relating to
datasets of phosphorylation sites, such sequence- or literature-based annotation is
important to identify potentially important phosphorylation sites for more focused
study.
As phosphorylation can affect the conformation of a protein (Johansen and
Ingebritsen, 1987), it occurs on accessible regions in the three dimensional structure
(Ridsdale et al., 1997) and is thought to occur mostly in flexible regions in a protein
structure (Shen et al., 2005) annotation of phosphorylation sites with structural
information may be useful. The three-dimensional structure of a protein is encoded
in its amino acid sequence and can take a number of forms along a continuum of
increasing content of stable tertiary structure. Figure 4.1 shows examples of types of
protein structure from completely unstructured proteins, molten globules, linked-
folded domains to mostly folded proteins. The extent of folding upon target binding
reduces with
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Increasing content of stable three-dimensional structure
Unstructured
(conformational ensemblei
For example. ACTR (no NCBO)
ACTR-NC80 complex
Molten globule Linked folded domains
(conformational ensemble) (beads on a string)
Mostly folded, local disorder
For example. NC8D (no ACTR)
Folding on target binding
For example, anc fingers (no UNA)
Zinc-finger-1 -3-DNA complex elF4E-elF4G complex
For example. elF4E (N terminus
«s unfolded)
Figure 4.1 - Types of protein structure. Examples of the types of protein structure from
completely unstructured proteins, molten globules, linked-folded domains to mostly folded
proteins. The extent of folding upon target binding reduces with increasing content of stable
three-dimensional structure. Adapted from "Intrinsically unstructured proteins and their
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Figure 4.2 - Propensities for amino acids to be disordered.
Three different definitions of protein sequence disorder were used to define the propensities
of amino acids to be in disordered sequence. Adapted from "Protein disorder prediction:
implications for structural proteomics". Linding Retal. Structure. 2003 Nov;11(11):1453-9.
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increasing content of stable three-dimensional structure. The of structure or lack of
protein structure can be observed indirectly by X-ray crystallography, NMR-,
Raman and CD-spectroscopy and by hydrodynamic measurements (Linding et al.,
2003). The extent of disorder in a protein sequence will affect the likelihood of
protein crystallisation and the success of subsequent X-ray structure determination.
Therefore, disorder prediction algorithms have been developed to improve the
success of structural proteomic studies by providing a way of screening proteins
that are not likely to be amenable to such analysis. One such disorder prediction
server is DisEMBL, which uses three different definitions of proteins disorder;
presence of Loops/coils, Hot loops which are loops with a high degree of mobility as
determined from temperature factors (B factors) and finally missing co-ordinates in
X-ray structure that are defined as remark465 entries in PDB (Linding et al., 2003).
The hot loop definition is probably the most reliable as an indication of protein
disorder as the missing co-ordinates in PDB definition can be misleading as missing
co-ordinates can be caused by protein truncations which result in abnormally
disordered sequence.
Figure 4.2 shows the amino acid propensities determined from the definitions of
protein disorder. It can be seen that generally hydrophobic residues promote order
according to all three definitions and disorder-promoting residues include lysine,
proline, arginine, serine, threonine and methionine. As serine and threonine are
enriched in disordered sequence and it is known that phosphorylation sites tend to
be located in flexible regions of proteins, it is likely that intrinsic protein disorder
and protein phosphorylation are intimately linked. In fact, DISPHOS, which is a
phosphorylation site predictor, uses protein disorder information to improve
discrimination between phosphorylated and non-phosphorylated sites.
In recent years, mass spectrometry has been applied to biological samples to
identify phosphorylation sites, usually in combination with a phospho-enrichment
step. We have developed a tandem Immobilised gallium-affinity (IMAC) protocol in
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which phosphoproteins are specifically purified from a biological sample,
tryptically digested and the resultant peptide mixture applied to another IMAC
column to specifically enrich for phosphopeptides (Collins et al., 2005), (Collins et
al., 2005). This tandem-affinity protocol and single protein and peptide IMAC
protocols were used to identify phosphorylation sites in urea-soluble synaptic
proteins. In, total 650 phosphorylation events, corresponding to 331 unique
phosphorylation sites were identified, with the largest portion (308 phosphorylation
events) identified in the tandem-IMAC experiment.
Here we describe application of this tandem-IMAC approach to the mouse forebrain
cytosolic phosphoproteome. In a single four-hour LC run we could identify up to
401 phosphorylation events on 173 phosphopeptides. In total, we identified 485
phosphorylation events corresponding to 321 unique phosphorylation sites on 67
phosphoproteins. We have investigated the relationship between protein disorder,
proteolytic cleavage and phosphorylation in the cytosolic phosphoproteome. The
cytosolic extraction procedure was enriched for very soluble proteins i.e.
hydrophilic proteins, which tend to be disordered. Phosphoproteomic analysis of
this fraction identified at least 16 putative intrinsically disordered phosphoproteins,
which have mainly RNA- or Tubulin-binding function. The majority of identified
phosphorylation sites in the total dataset are located in regions of sequence disorder
indicating a function associated with phosphorylation-dependent binding or
regulation of conformational state. We suggest that protein phosphorylation is
heavily employed in intrinsically disordered regions to regulate the increased
number protein interactions (Wright and Dyson, 1999) mediated by intrinsically
disordered proteins. In addition, the use of hyperphosphorylation as a means of
creating local negative charge to regulate, for example, protein-RNA/DNA
backbone interactions, may explain the high stoichiometry of phosphorylation
observed for some proteins. Finally, we have characterised a number of
phosphoproteins with disease-associations, which may have related roles in the
pathogenesis of neurodegenerative disease.
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4.3 MATERIALS AND METHODS
4.3.1 Protein extraction
Mouse forebrairts were rapidly dissected, frozen immediately in liquid nitrogen and
stored at -80°C. Cool all buffers and the Homogeniser to 4°C. 10 forbrains were
Homogenised with 25 stokes in a dounce Homogeniser in homogenisation buffer
(50 mM tris pH 9, 50 mM sodium fluoride, 20 gM zinc chloride, 1 mM sodium
ortho-vanadate, 0.5 mM PMSF, 2 pg/ml aprotinin, 2 pg/ml lepteptin) at a ratio of
0.379g tissue/7ml buffer. The extract was subjected to centrifugation at 50,000 x g for
30 min and was concentrated in a Vivaspin 10 kDa MWCO and stored at -80°C.
4.3.2 Protein IMAC of forebrain cytosolic fraction
Fast-flow chelating sepharose with iminodiacetic acid (IDA) (Amersham
Biosciences) chelating groups was charged with GaC13. Cytosolic protein (50 mg)
was brought to 6 M urea and incubated with 2 ml of the metal charged resin with
mixing for 1 hour at room temperature (RT). The unbound protein was washed with
buffer A (6 M urea/50 mM tris-acetate) to baseline and the phosphoproteins were
specifically eluted with buffer B (6 M urea, 50 mM tris-acetate, 100 mM EDTA, 100
mM EGTA). Two of these purifications were carried out, eluted phosphoproteins
pooled, concentrated and washed with buffer B in a Vivaspin 6 PES membrane spin
column (Vivascience), resulting in a final yield of 3 mg of purified phosphoproteins.
4.3.3 Double IMAC of forebrain cytosolic fraction
3 mg of the protein IMAC purified sample was digested with modified porcine
trypsin (Promega) in a ratio of 1:20 in digestion buffer (pH 8) (1 M urea and 25 mM
NH4HC03) at 37°C for 4 hours. The resultant digest was desalted and dried and
methyl esterification was performed with 2 M methanolic HC1 (10). Self Pack
POROS® 20 MC Media (Applied Biosystems) for phosphopeptide purification was
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charged with GaC13 as described above for the IDA/NTA resirts. Peptide digests
were reconstituted in loading buffer (equal volumes of acetonitrile, methanol and
water pH 2.5-3). 1 ml of this peptide mixture was incubated with 200 pi of POROS-
Ga slurry for 1 hour at RT. The resin was then loaded into a spin-column and
washed with 10 volumes of buffer E. Phosphopeptides were eluted with 2 x 100 pi
of 200 mM Na2HP04.
4.3.4 On-line nano LC-MS/MS
Mass spectrometry was performed by Lu Yu (The Wellcome Trust Sanger Institute)
A nanoflow HPLC system, Ultimate™ (LC Packings) was coupled to a, Q-Tof Ultima
(Waters/Micromass). Tryptic peptides from the phosphoprotein digest were loaded
in 0.1% aqueous formic acid (FA) and desalted on PepMap C18 trapping cartridge
(LC Packings) or a BetaMax Neutral (Thermo Hypersil-Keystone) was used to trap
the IMAC enriched phosphopeptides in 0.5% aqueous FA. Peptides on the trap were
back-flushed to, and separated on the analytical column (PepMap C18, 75 pm id x
15 cm, LC Packings). The Q-Tof Ultima was operated in automated Data Dependent
Acquisition (DDA) mode. Each cycle had a 1 sec MS survey (m/z 400-1500) and up
to three of the highest intensity multiply-charged ions (+2 and +3) were selected for
MS/MS (m/z 50-2000), each for 5 sec. The collision energy in MS/MS was varied
according to the m/z and the charge state of the precursor ion.
4.3.5 Data Analysis
4.3.5.1 Database searching
Raw data was processed to give a peak list file and submitted to a local Mascot V2.0
(Matrix Science) server for iterative searching on a custom, non-identical, combined
human and mouse IPI database (EBI). Assignment of phosphorylation sites was
verified manually with the aid of PEAK Studio (Bioinformatics Solutions) software.
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4.3.5.2 Sequence-based analysis
ProtParam (http://us.expasy.org/cgi-bin/protparam) was used to compute pi values
and GRAVY (Grand average of hydropathicity index) scores for all
phosphopeptides. All phosphoproteins proteins detected in this study were
classified according to Swiss-Prot keywords (http://ca.expasy.org/sprot/). Known
phosphorylation sites in Supplementary Table 2 were annotated by extensive
literature mining of PubMed. Scansite (http://scansite.mit.edu/) and was used for
predicting the most likely kinases responsible for the phosphorylation sites
characterised in this study. In addition for ambiguously defined phosphorylation
sites Scansite was used to predict the most likely site of phosphorylation when a
number of possibilities were present on a phosphopeptide. Scansite was also used to
check the presence of phosphorylation sites in Pfam protein domains and to predict
if phosphorylation sites were localised in phospho-dependent interaction domains
(Supplementary Table 2). DisEMBL, Intrinsic Protein Disorder Prediction 1.4
(http://dis.embl.de/) was used to predict phosphoprotein sequence disorder and in
these predictions, the "hotloop" definition was used. PeptideCutter
(http://us.expasy.org/tools/peptidecutter/) and Phospho-pepsort7
(http://acrux.igh.cnrs.fr/gs/phospepsort7.html) were used for in silico tryptic
digestion of phosphoproteins. BCM search launcher in combination with
BOXSHADE 3.21 (http://www.ch.embnet.org/software/BOX_form.html) were used
for construction of multiple sequence alignments. Members of protein kinases
families were downloaded from The Protein Kinase Resource (http://www.
kinasenet.org/pkr/). Three-dimensional protein structure data was visualised with
the Deep View Swiss-PdbViewer 3.7 (http://swissmodel.expasy.org/spdbv/).
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4.4 RESULTS
4.4.1 Distribution of characterised phosphorylation sites
The phosphoproteomic strategy employed here to study cytosolic phosphoproteiris
in the mouse forebrain resulted in the identification of 485 phosphorylation events
on 218 phosphopeptides, corresponding to 321 unique phosphorylation sites (Table
4.1, Figure 4.3). Eighty-six percent of these phosphorylation events were
unambiguously assigned exact sites in peptide sequences with the remaining 44
(14%) phosphorylation events mapped to a few possible serine, threonine or
tyrosine residues in peptide sequences. The distribution of phosphorylation sites
was 81, 9.5 and 0.6% for phosphoserine, phosphothreonine and phosphotyrosine
respectively. These numbers include some ambiguously assigned sites for which
the type of phosphorylation site could be deduced, for example, the only possibility
of phosphorylation in a peptide sequence was on serine residues. Of the
ambiguously assigned phosphorylation sites with ambiguous phosphorylation type,
24 were phosphoserine or phosphothreonine and 4 were phosphoserine,
phosphothreonine or phosphotyrosine.
4.4.2 Analytical comparison
We performed two parallel analyses of phosphopeptides derived from a tandem
protein and peptide gallium-affinity purification from forebrain cytosolic extract.
Equal quantities of these peptides were applied to different on-line reversed-phase
(RV) chromatographic separations. In the first experiment a PepMap (details)
column was used as the analytical column and in the second a BetaMax neutral
column was used. Reverse-phase separation is essential for on-line LC-MS/MS and
the type of RV column influences the efficiency of peptide separation and the
population of peptides that are retained and eluted from the RV column. Two
identical LC-MS/MS experiments with RV separations of 4 hours were performed to
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350
Figure 4.3 Distribution of phosphorylation sites in the cytosolic phosphoproteome.
Numbers of phosphopeptides, phosphorylation evens and a breakdown of the types of
phosphorylation sites found are shown.
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assess the selectivity of these two columns in terms of the phosphopeptides detected
in the mass spectrometer.
Phosphopeptides and particularly multi-phosphorylated peptides are more
hydrophilic than their un-phosphorylated counterparts. This results in earlier
elution of phosphopeptides in a chromatography run and can prevent binding of
very hydrophilic phosphopeptides to the RV column and are thus not analysed in
the mass spectrometer.
A
RV Number of Phosphorylation Phosphates per
Column phosphopeptides events phosphopeptide
PM 173 401 2.31
BM 110 224 2.03
B
GRAVY Pi P/phosphopeptide
PM + BM -0.815 6.89 2.1
PM only -0.943 7.75 2.55
BM only -0.762 7.4 1.92
Table 4.1 - Performance of PepMap (PM) and BetaMax neutral (BM) columns
A. The numbers of phosphopeptides, phosphorylation events and stoichiometry of
phosphorylation in the datasets from the PM and BM 4 hour gradients are
shown.
B. To evaluate the differences in peptide binding between these to column types,
GRAVY (Grand average of hydropathicity index) scores, isoelectric points and
stoichiometry of phosphorylation of phosphopeptides detected in both analyses
(PM + BM), of phosphopeptides specific to the PM analysis and of
phosphopeptides specific to the BM analysis are shown.
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These LC-MS/MS analyses permitted characterisation of 199 phosphopeptides with
451 phosphorylation events. The use of a PepMap column appears to allow
identification of more phosphopeptides than the BetaMax column (173 versus 110,
respectively (Table 4.1A). In addition the number of phosphorylation events
detected in the PepMap experiment was also greater (401 versus 224, respectively)
with a peptide stoichiometry of phosphorylation of 2.31 compared to 2.03 for the
BetaMax experiment. These differences likely reflect the underlying binding
characteristics of the two RV columns.
Firstly, phosphopeptide distribution in terms of stoichiometry of phosphorylation is
different (Figure 4.4A). The PepMap column exhibits a preference for multiply
phosphorylated peptides as opposed to the BetaMax column which is more efficient
at binding mono and di-phosphorylated peptides. Secondly, the hydrophobicity
score and isoelectric point calculated for the peptide sequences highlight a
preference for hydrophilic peptides by the PepMap column. It can be seen in Figure
4.4B that peptides specific to the PepMap experiment are generally more
hydrophilic than those found in the BetaMax experiment. On average the GRAVY
score for PepMap-specific phosphopeptides is -0.943 compared to BetaMax-specific
phosphopeptides with an average GRAVY score of -0.762 (Table 4.IB).
The combination of higher gravy scores (hydrophilic) and preference for multi-
phosphorylated peptides (phosphate moiety increases the hydrophilicity of a
peptide) bound by the PepMap column both indicate that it better suited for capture
of hydrophilic peptides. This data would indicate that the use of the PepMap
column is preferable for phosphoproteomic analysis as it enabled binding of
hydrophilic phosphopeptides that were not bound by the BetaMax column and
allowed characterisation of a greater number of phosphopeptides.
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Figure 4.4 - Comparison of PepMap and BetaMax neutral reversed phase columns
for analytical separation of phosphopeptides
A. Bar chart comparing the stoichiometry of phosphorylation of phosphopeptides
characterized in the PepMap and BetaMax LC-MS/MS experiments.
B. Scatter-plot of GRAVY versus pi of phosphopeptides found in both PepMap and
BetaMax experiments and those specific to each experiment.
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In addition, to these two 4 hour LC-MS/MS runs that compared the RV columns, a
number of 2 hour LC-MS/MS experiments were performed with the PepMap
column. The first PepMap 2 hour run resulted in identification of 23
phosphopeptides, of which 18 were found in the 4 hour PepMap run with an
additional 5 phosphopeptides not detected previously. The same sample was
analysed again but with further tryptic digestion to reduce missed cleavages. This
allowed identification of 28 phosphopeptides of which, 16 were found in the
previous 2 hour LC-MS/MS experiment, 7 were found in the 4 hour PepMap
experiment and 5 were not previously found. Next the endopeptidase Asp-N was
used to cleave the same phosphopeptide sample further (cleaves N-terminal to
aspartate) and resulted in identification of 17 phosphopeptides, all of which were
identified previously in one or more of the 4 or 2 hour LC-MS/MS analyses.
4.4.3 Classification of cytosolic phosphoproteins
The combination of LC-MS/MS approaches described in the previous section
resulted in the identification of 321 unique phosphorylation sites on 67 cytosolic
phosphoproteins. These proteins were classified according to annotated information
in UniProt as well as from literature mining. The largest class of phosphoproteins
have no known function and the fact that they represent 20% of the observable
cytosolic phosphoproteome in our experiments highlights the lack of
comprehensive functional annotation of the mouse proteome. The next most
significant class of proteins are involved in splicing and /or are RNA binding
proteins and represent 19% of the dataset. Other classes observed include
Cytoskeletal proteins (17%), Kinases (13%), Scaffolding proteins (6%), Signalling
proteins (6%), Development/neuronal differentiation (4%), DNA binding proteins
(4%), Synaptic vesicle proteins (4%) and G-protein modulators (3%). This broad
range of protein classes is not surprising as the cytosolic purification protocol is
based on protein solubility rather than protein localisation within the cell.
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Figure 4.5 - Classes of phosphoproteins characterised from forebrain cytosolic
fraction
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Protein Accession Protein Name Number of Phospho
Class Number Sites
Kinases
Q5RJI5 Serine/threonine kinase SADB (BRSK1) 12
Q6DMN7 BR serine/threonine-protein kinase 2 (BRSK2) 4
Q68EG2 CaMKII beta 2
Q5SQZ3 CaMKII gamma 3
Q9WV60 Glycogen synthase kinase-3 beta 1
Q9JLM8 Serine/threonine-protein kinase DCAMKL1 7
Q61136 Serine/threonine-protein kinase PRP4 homolog 4
Q9R1L5 Syntrophin-associated serine-threonine protein 1 2
Q9UKE5 TRAF2 and NCK interacting kinase 2
Cytoskeletal proteins
Q9QYB8 Beta adducin 6
Q9WV69 Dematin 3
P78559 Microtubule-associated protein 1A 13
P14873 Microtubule-associated protein 1B 11
P20357 Microtubule-associated protein 2 35
P27546 Microtubule-associated protein 4 1
P10637 Microtubule-associated protein Tau 19
Q9QYX7 Piccolo protein 3
Q9QWI6 SNAP-25-interacting protein (SNIP) 1








Q68FF6 G protein-coupled receptor kinase-interactor 1 6
Q5RIT9 Similar to PITPNM family member 3 2
Q8VCD2 SR-related CTD associated factor 6 3
Q7TQD2 Tubulin polymerization-promoting protein 2
Splicing/RNA binding proteins
Q9JIX8 Apoptotic chromatin condensation inducer in the 2
P62996 Arginine/serine-rich splicing factor 10 (SfrslO) 7
070305 Ataxin-2 (Spinocerebellar ataxia type 2 homolog 2
Q13427 Cyclophilin G 2
Q9CYC6 mRNA decapping enzyme 2 3
Q9R0U0 Neural specific sr protein NSSR 1 3
070495 Plenty-of-prolines-101 (Srrml) 19
Q8R4E7 Pur-gamma 3
Q96MU7 Putative splicing factor YT521 1
Q8BTI8 RNA binding protein homolog (Srrm2) 33
Q8VE97 Splicing factor, arginine/serine-rich 4 3
Q99J36 THUMP domain containing protein 1 2
Development/neuronal differentiation
P97427 Dihydropyrimidinase related protein-1 4
008553 Dihydropyrimidinase related protein-2 7
Q9QZS3 Numb 3
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Q8K019 Bcl-2-associated transcription factor 1 [Bclaf 1 ] 5
094894 Prp5-like DEAD-box protein 2
Q9CTM9 RNA Helicase-related protein homolog Ddx42 2
Synaptic vesicle
P17426 Adapter-related protein complex 2 alpha 1 subui 3
Q5J8K4 Rab3 effector, RIM-1 9
Q9EQZ7 Rab3-interacting molecule 2 (RIM-2) 2
Ribosomal/associated proteins
P62754 40S ribosomal protein S6 (RPS6) 1
Q7Z417 FMRP (fragile X mental retardation protein) inter 1
Unknown function
Q8VDP4 2610301G19Rik protein 3
Q9CXN5 3110050K21Rik protein 2
Q7TQF8 Camsapl 2
Q80TK8 CamsapM (MKIAA1078 protein) 1
Q80UZ7 D430018P08 protein 3
Q80YT1 Glucocorticoid induced transcript 1 (Glccil) 1
Q6NXJ5 Gm1568 2
Q6PG39 HSHIN1 protein 2




Q5M7V8 Thyroid hormone receptor associated protein 3 5
Table 4.2 - Phosphoproteins and numbers of phosphorylation sites characterised in the
cytosolic phosphoproteome
Chapter 4- Phosphoproteomic analysis of the mouse forebrain: Investigation of the relationship between 147
intrinsic protein disorder and phosphorylation in the brain
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
4.4.4 Intrinsic protein disorder and phosphorylation
4.4.4.1 Putative intrinsically-disordered phosphoproteins in the brain
We investigated the relationship between intrinsic protein disorder and protein
phosphorylation in the cytosolic phosphoproteome dataset. The DisEMBL Intrinsic
Protein Disorder Prediction server was used to identify intrinsically disordered
regions or "hotloops" in each of the cytosolic phosphoproteins characterised in this
study. To evaluate this distribution of intrinsic disorder in this dataset, we
compared it to a dataset of experimentally verified wholly disordered proteins (52
proteins) (Oldfield et al., 2005) and a dataset of wholly ordered proteins (100
proteins) (Proteins in PDB with X-ray structure data) (Oldfield et alv 2005). Figure
4.6 shows the comparison of these 3 datasets in terms of percentage-disordered
sequence for each protein versus log of molecular weight. The percentage intrinsic
disorder in cytosolic phosphoproteins ranges from 5.4 to 88.7 % of total sequence
lengths, with an average of 46% sequence disorder. The average intrinsic disorder in
the experimentally verified wholly disordered dataset predicted by DisEMBL was
63% and 14 cytosolic phosphoproteins have a percentage disorder of 62% or higher.
TPPP, Microtubule-associated protein Tau and Beta-adducin, which are known
intrinsically disordered proteins, are indicated on the graph in Figure 4.6.
These 14 predicted intrinsically disordered phosphoproteins (including TPPP
(which is a known IDP) and 2 other known IDP's (Tau and Beta-adducin) are
described in Table 4.3. The majority of these putative IDP's are RNA/DNA binding
proteins, a class of proteins that are generally unstructured until bound to their
target molecule. The 3 known IDP's (TPPP, Tau and Beta-adducin) are cytoskeletal
proteins highly expressed in the brain and are implicated in neurodegenerative
diseases where protein aggregation is a prominent pathological feature.
Chapter 4- Phosphoproteomic analysis of the mouse forebrain: Investigation of the relationship between 148
intrinsic protein disorder and phosphorylation in the brain




























■ * . ®
^-TPPP ■
# ♦ 1 ♦ "^4 ^
♦ ■ ■k' '♦
j6-adducin
■ ■ i. ':
u i,1'.- . -
,jT » ♦ ■




Figure 4.6 - Comparison of the distribution of hotloops in datasets of wholly
disordered, wholly disordered and cytosolic phosphoproteins (characterised in this
study). The percentage of disordered sequence (hotloops) was calculated for each of these
datasets and was plotted against log of protein sequence length. The horizontal blue and
green lines represent the average percentage of disorder in the "Wholly disordered" and
"Wholly disordered" datasets respectively. Cytosolic phosphoproteins with a percentage
disorder equal to or greater than that of the "Wholly disordered" dataset are circled and are
therefore putative intrinsically (natively) unstructured phosphoproteins. TPPP, Microtubule-
associated protein Tau and Beta-adducin which are known intrinsically disordered proteins
are indicated on the graph
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UniProt Name % disorder P sites P sites in disorder
Q9CXN5 3110050K21Rik protein 88.7 2 2
P62996 Arqinine/serine-rich splicing factor 10 (SfrslO) 87.2 7 7
070495 Plenty-of-prolines-101 (Srrml) 86.3 19 16
Q9R0U0 Neural specific sr protein NSSR 1 84.7 3 3
Q8VE97 Splicing factor, arginine/serine-rich 4 (Sfrs4) 83.0 3 3
Q13427 Peptidyl-prolyl cis-trans isomerase G (Cyclophilin G) 82.5 2 2
Q5M7V8 Thyroid hormone receptor associated protein 3 [Thrap31 81.1 5 5
Q8K019 Bcl-2-associated transcription factor 1 TBclafll 77.3 5 3
Q8BTI8 RNA binding protein homolog (Srrm2) 74.0 33 31
P62754 40S ribosomal protein S6 (RPS6) 72.7 1 1
Q96MU7 Putative splicing factor YT521 70.7 1 1
Q7TQD2 Tubulin polymerization-promotinq protein (p25 alpha)** 64.2 4 2
Q9JIX8 Apoptotic chromatin condensation inducer in the nucleus (Acini) 62.9 2 1
Q9UQ09 KARP-l-binding protein 1 61.8 5 4
P10637 Microtubule-associated protein Tau** 57.4 19 14
Q9QYB8 Beta adducin** 41.7 6 6
Table 4.3 - Putative intrinsically disordered cytosolic phosphoproteins in
mouse forebrain. The percentage disorder, number of phosphorylation (P) sites and
the number of phosphorylation sites in disordered regions are presented. ** indicates
experimentally verified intrinsically disordered proteins. The entries highlighted in blue
have % disorder values substantially lower than the average for the control disordered
dataset but they have been experimentally verified as natively disordered proteins.
4.4.4.2 Phosphorylation in regions of intrinsic protein disorder.
It has been observed that the attributes surrounding phosphorylation sites such as
amino acid composition, hydrophobicity and sequence complexity are quite similar
to those of intrinsically disordered regions in proteins. In fact, a phosphorylation
prediction algorithm (DISPHOS) uses such attributes of IDP's to predict
phosphorylation sites. In the cytosolic phosphoproteome dataset, 231
phosphorylation sites (72%) are predicted to lie in intrinsically disordered regions.
In addition, of the remaining 90 phosphorylation sites that are predicted to occur in
ordered regions, only 5 (1.5%) can be mapped to Pfam protein domains; a tyrosine
phosphorylation site (Y216) in GSK3B is present in its kinase domain, 3 pS/T sites in
Numb are located in its Numbf domain and phosphoserine 495 in Similar to
PITPNM family member 3 is located in a DDHD domain. As few of the
phosphorylation sites predicted to be present in ordered regions are actually located
in known protein domains, either the algorithm for predicting hotloops
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% of phosphorylated residues per protein
Figure 4.7 - Investigation of the relationship between intrinsic protein disorder and
protein phosphorylation. The percentage disorder of each cytosolic phosphoprotein was
plotted against the percentage of phosphorylated residues per protein. The best fitting trend
line indicates a possible positive relationship between disorder and phosphorylation,
although this result is not statistically significant.
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underestimates protein disorder or these phosphorylation sites are located in other
types of low complexity regions.
Are IDP's phosphorylated to a greater extent than structured proteins? As IDP's
contain a greater proportion of protein sequence with attributes similar to that
surrounding phosphorylation sites and have more accessible loops for kinases to
phosphorylate, we wanted to assess whether IDP's are indeed more likely to be
phosphorylated. Figure 4.7 shows the relationship between percentage disorder (of
protein sequence) and the percentage of phosphorylated residues per protein. The
best fitting trend line to the data points indicates a positive relationship between
disorder and extent of phosphorylation. The data used for this analysis is most
likely biased towards what appear to be lesser-phosphorylated proteins but this is
probably because many of these proteins may be phosphorylated on other sites that
were not detected in our experiments. It would seem likely that if this dataset was
complete that a stronger correlation would be apparent. Microtubule-associated
protein Tau is an IDP is well known to be highly phosphorylated with at least 35
known phosphorylated sites (19 identified in this study). Four phosphorylation sites
in Tau are located in tubulin-binding domains, two of which are in disordered
sequence (Figure 4.8).
4.4.4.3 Mapping phosphopeptides to regions of intrinsic disorder
Phosphopeptides characterised in this study were mapped to disorder plots and
sequences of protein disorder (Figure 4.9). CaMKIIy is very structured with only
21% disordered sequence and a large protein kinase domain that constitutes more
than half of the protein sequence. A phosphopeptide in CaMKIIy and another in
CaMKIip (homologous sequence) map to the main disordered region outside the
protein kinase domain. The occurrence of these phosphopeptides in a small window
of disordered sequence would seem to suggest that there is a link between
phosphorylation and disorder.
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Figure 4.8 - Phosphorylation sites and disorder plot of Microtubule-associated protein
Tau. A. Schematic illustration of the domain profile of Tau with all known phosphorylation
sites and phosphorylation sites characterized in this study (red). B. Disorder plot of Tau
showing three measures of protein disorder. The blue line represents coiled regions, the red
line represents coiled regions with high B factors (high degree of mobility as determined from
Ca temperature factors) and green line, which represents missing, coordinates in X-ray
structure as defined by remark465 entries in PDB. The dashed horizontal lines correspond to
the random expectation level for each predictor. 57% of the sequence of this known
intrinsically disordered protein is predicted to be disordered. The best measure of disorder is
high B factors (red line) and it can be seen that there is more disorder, as measured by high
B factors, in the N-terminal part of the sequence, where the majority of phosphorylation
occurs.
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Caloum/calmodulin-deperident protein kinase (CaM kinase) H gamma.
Residue
>Q5SQZ3_HOTLOOPS 1-16, 33-55, 341-395, 486-503
MATTATCTRF TDDYQLfeel gkgafswrr cvKKTSTQEY AAKIXNTKKL SARDHqkler earicrllkh
pnivrlhdsi seegfhylvf dlvtggelfe divareyyse adashcihqi lesvnhihqh divhrdlkpe
nlllaskckg aavkladfgl aievqgeqqa wfgfagtpgy lspevlrkdp ygkpvdiwac gvilyillvg
yppfwdedqh klyqqikaga ydfpspewdt vtpeaknlin qmltinpakr itadqalkhp wvcqrstvas
mmhrqetvec lrkfnarrkl kgailttmlv srnfsvgrqs sapaspaasa aglagqaaks LLNKKSDGGV
KKRKSSSSVH LMEPQTTWH NATDGIKGST ESCNTTTEDE DLKVRkqeii kiteqlieai nngdfeaytk
icdpgltsfe pealgnlveg mdfhkfyfen llsknskpih ttilnphvhv igedaaciay irltqYIDGQ
GRPRTSQSEE TRVwhrrdgk wlnvhyhcsg apaaplq
Figure 4.9 - Disorder and phosphorylation of CaMKIIy
Disorder plot of CaMKIIy showing three measures of protein disorder. The blue line
represents coiled regions, the red line represents coiled regions with high B factors (high
degree of mobility as determined from Ca temperature factors) and green line which
represents missing coordinates in X-ray structure as defined by remark465 entries in PDB.
The dashed horizontal lines correspond to the random expectation level for each predictor.
The protein kinase domain is indicated by a black rectangle and a phosphopeptides CaMKIIy
and CaMKIIp (homologous sequence) in blue and green respectively. Unambiguously
assigned phosphorylation sites are coloured in red and ambiguously assigned sites are
coloured in gold. Although, CaMKIIy contains only 21% disordered sequence the
phosphopeptides from CaMKIIy and CaMKIIp map to a clearly disordered segment of the
sequence (red box).
Chapter 4- Phosphoproteomic analysis of the mouse forebrain: Investigation of the relationship between 154
intrinsic protein disorder and phosphorylation in the brain
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
4.4.4.4 Effect of intrinsic disorder on tryptic cleavage and analysis by MS
Analysis of datasets of experimentally verified intrinsically disordered proteins
have identified amino acid propensities in disordered sequences that are used by
DisEMBL to predict disorder in proteins (Lending et al., 2003). We noticed that
lysine and arginine were among the significantly enriched amino acids in
disordered sequences and that because trypsin cleaves at these residues, we
reasoned that there may be a relationship between the frequency of tryptic cleavage
and protein disorder. To investigate this we calculated the percentage intrinsic
disorder and number of tryptic peptides (by in silico digestion) for all proteins in the
cytosolic phosphoproteome dataset (Figure 4.10). This in silico digestion did not
include the single amino acid peptides R and K. We observed that disordered
proteins tend to be cleaved into more tryptic fragments compared to less disordered
proteins. The shortest average peptide length was 3.9 amino acids for Splicing
factor, Arg/Ser rich 4 (83 % disorder) and the longest peptide length was 11.5 amino
acids for SR-related CTD associated factor 6 (15.9% disorder).
If indeed disordered proteins are more likely to be highly phosphorylated then
complete mapping of these phosphorylation sites by tryptic digestion and tandem
mass spectrometry may prove difficult as many of the resultant tryptic peptides
would be outside the mass window for analysis. Next the monoisotopic masses and
isoelectric points from an in silico tryptic digest of Srrml (86.3% disorder, average
peptide length 5.4 AA's) and Synapsin I (5.4% disorder, average peptide length of
10.8 AA's) were calculated and plotted with experimentally determined Mr values
(and calculated isoelectric points) for phosphopeptides characterised in the cytosolic
phosphoproteome dataset (Figure 4.11). We observed that there are substantially
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Percentage intrinsic disorder
Figure 4.10 - Relationship between intrinsic disorder and frequency of tryptic
cleavage. The percentage intrinsic disorder and number of tryptic peptides (in silico
digestion) was calculated for all proteins in the cytosolic phosphoproteome dataset.
Disordered proteins tend to be cleaved into more tryptic fragments compared to less
disordered proteins. Argine and lysine residues are positively enriched in regions of protein
disorder and therefore these sequences are more likely to be cleaved by trypsin (cleaves at
arg and lys residues). If indeed disordered proteins are more likely to be highly
phosphorylated then complete mapping of these phosphorylation sites by tryptic digestion
and tandem mass spectrometry may prove difficult as many of the resultant tryptic peptides
would outside the mass window for analysis.
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Figure 4.11 - Compatibility of tryptic digestion with phosphoproteomic analysis of
disordered and ordered proteins. The monoisotopic masses and isoelectric points from
an in silico tryptic digest of Srrml (86.3% disorder, average peptide length 5.4 AA's) and
Synapsin I (5.4% disorder, average peptide length of 10.8 AA's) were calculated and
plotted with experimentally determined Mr values (and calculated pi's) for
phosphopeptides characterised in the cytosolic phosphoproteome dataset. Peptides with
Ser/Thr or Tyr residues are marked in dark blue to allow comparison with the
experimentally verified phosphopeptides. It can be seen that there are substantially more
phosphorylatable peptides in Srrml outside the mass range of detection (blue box) than
for Synapsin I
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more phosphorylatable peptides in Srrml outside the mass range of detection (blue
box) than for Synapsin I. 62 out of a total of 97 phosphorylatable peptides in Srrml
were below 800 Da meaning that 64% of peptides potentially carrying a
phosphorylated serine/threonine or tyrosine were not amenable to analysis by MS.
In contrast, only 9 out of 37 phosphorylatable peptides in Synapsin I were below 800
Da meaning that 24% of putative phosphopeptides were not suitable for analysis by
MS.
The frequency of tryptic cleavage is not only increased between ordered and
disordered proteins but between ordered and disordered regions in the same
protein sequence. A tryptic cleavage map of MAP4, which is 53% disordered is
shown in Figure 4.12. There are 87 unstructured peptides covering 676 amino acids
with an average peptide length of 7.7 compared to 28 structured peptides covering
449 amino acids, resulting in an average peptide length of 16 amino acids. There are
more than double the number of peptides arising from disordered compared to
ordered sequence when adjusted for relative sequence coverage. This would
indicate that even within a single protein, disorder affects the sequence coverage
obtained by mass spectrometry when tryptic digestion is used. Also, as
phosphorylation is more likely to occur in disordered sequence, the coverage of
phosphorylation sites is expected to be influenced by disorder too.
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dvappmeEEIVPGNDTTSPK ETETTLPIK MDLAPpedvlltk etelapak gmvslseieealak
ndvr saeiPVAQETWSETew 1 aTEWLPSDPITTLTK DVTLPLEAER
PLVTDMTPSLETEMTLGK ETAPPTetnlgmak dmsplpesevtlgk dwiLPETK
VAEFNNVTPLSEEEVTSVK DMSPsaeteaplak nadlhsgtelivdnsmapasdlalPLETK
■TVP* DK GTVQTEEK PR EDSQLASMQHK GQSTVPPCtaspepvk
aaeqmstlpidapsplenleqk etPGSQPSEPCSGVSr qeeak aaVGVTGNDITTPPNK
EPPPSPEK | AK PLATTQPAK TSTSK AK TQPTSLPK QPAPTTSGGLNk k
pmslasgsvpaaphk r paAATATAR PSTLPAR DVK PK PITEAK VABX | TSPSjj
PSSAPALK PGPK TTPTVSK ATSPSTLVSTGPSSR SPATTLPKt R PTSIK TEGK |ADV|J |
MTAK SASADLSR SK TTSASSVK R JSTTTPTGAAPPAGMTSTR VK PMSAPSR SSGALSVDK K
PSSSAPR VSR LATTVSAPDLK SVR SK VGSTENIK HQPGGGR AK VEK K
TEAATTAGK PEPNAvtk aagSIASAQK PPAGK vqivsk k vsyshiqsk CVSK DNIK
HVPGCGNVOIQNK K VDISK VSSK CGSK ANIK HK PGGGDVK iesqk lnfk ek aqak
vgsldnvghfpaggavk tegggsealpcpgppageepvipeaapdr
gaptsasglsghtTLSGGGDQR EPQTLDSQIQETSI
Figure 4.12 - In silico digestion of Microtubule-associated protein 4. The predicted tryptic
cleavage pattern for MAP4 is shown. This protein contains 53% disordered sequence, which is
indicated by capitals and tryptic peptides containing mostly disordered sequence are
highlighted in blue. There are 87 unstructured peptides covering 676 amino acids with an
average peptide length of 7.7 amino acids and 33 of these peptides contain 4 or less amino
acids. The structured sequence is indicated by lowercase sequence and mostly ordered
peptides are highlighted in yellow. There are 28 structured peptides covering 449 amino acids,
resulting in an average peptide length of 16 amino acids and 7 of these peptides contain 4 or
less amino acids. The phosphopeptide found in MAP4 is underlined.
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4.4.5 Identification of novel phosphorylation sites in protein kinases
We have identified 37 phosphorylation sites in nine protein kinases from analysis of
the forebrain cytosolic phosphoproteome. These kinases are mapped to the human
kinome tree in Figure 4.13. The major family of protein kinases in our dataset is the
CAMK family with 5 members (CaMKII p, CaMKIIy, DCAMKL1, BRSK1 and
BRSK2), next the CMGC family with 2 members (GSK3P and PRP4) and finally the
AGC and STE families with one member each (MAST1 and TNIK respectively). We
found 5 pS/T in the variable region of CaMKII p and CaMKIIy (Figure 4.14).
The phosphopeptide found in CaMKII y contains 3 consecutive phosphorylation
sites which are located in the variable domain in a region present only in CaMKII a
and y. The CaMKII P phosphopeptide is also in the variable domain, located C-
terminally and contains 2 pS/T (ambiguously assigned) sites which are in a
relatively conserved portion of the variable domain. To help assign the exact sites of
phosphorylation in this phosphopeptide sequence we carried out a multiple
sequence alignment of sequences from the variable domains of members of the
CAMK protein kinase family (Figure 4.15). The phosphopeptide found in the
variable domain of CaMKII p is well conserved across all CAMKII family members
from different species. The 2 pS/T were located to 4 possible sites in the
phosphopeptide sequence. Analysis of this evolutionary alignment of CAMKII
family members revealed that the first and third serine residues (S354, S357) are
completely conserved and thus are more likely to be the actual sites of
phosphorylation.
One of the six known phosphorylation sites out of the 37 characterised on protein
kinases was pY216 on GSK3p. This site is completely conserved in many members
of the GSK3 kinase family and across 13 species as shown in Figure 4.16. This is an
important regulatory site on this kinase and is located in the protein kinase domain,
which is also a predicted region of sequence order that has enabled X-ray structure
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Figure 4.13 - Human kinome tree showing the evolutionary relationship between
members of the protein kinase family. Phosphorylation sites on nine protein kinases were
characterised in this study and are mapped to the human kinome tree shown.
Adapted from "The protein kinase complement of the human genome." Manning G, Whyte
DB, Martinez R, Hunter T, Sudarsanam S. 2002. Science 298:1912-1934.
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Figure 4.14 - Multiple sequence alignment of CaMKII a, p, y and 5.
The phosphopeptide found in CaMKII y (Blue line) contains 3 consecutive phosphorylation
sites which are located in the variable domain in a region present only in CaMKII a and y. The
CaMKII p phosphopeptide is also in the variable domain, located C-terminally and contains 2
pS/T (ambiguously assigned) sites which are in a relatively conserved portion of the variable
domain.
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PKR id Name Description Organism Class
1430 KCCB RAT Calcium/calmodulin-dependent protein kinase type II beta chain Rattus norveqicus CAMK
6193 Q8BL41 Calcium/calmodulin-dependent protein kinase type II beta chain Mus musculus CAMK
1429 CAM KM B Calcium/calmodulin-dependent protein kinase type II beta chain Mus musculus CAMK
1428 CaMK2beta Calcium/calmodulin-dependent protein kinase type II beta chain Homo sapiens CAMK
3637 093560 Calcium/calmodulin-dependent kinase type II beta subunit Gallus qallus CAMK
4080 Q91549 Calmodulin dependent protein kinase II beta subunit Xenopus laevis CAMK
4088 Q91587 Calcium/calmodulin-dependent kinase type II beta'-subunit Xenopus laevis CAMK
1434 KCCG MOUSE Calcium/calmodulin-dependent protein kinase type II qamma chain Mus musculus CAMK
13647 Q8WMW7 CaM kinase II qamma C-2 Mustela putorius furo CAMK
12912 077706 Calmodulin-dependent protein kinase ll-gamma dashl Oryctolagus cuniculus CAMK
1435 CAMKIIG Calcium/calmodulin-dependent protein kinase type II gamma chain Rattus norveqicus CAMK
16711 Q8NIA4 Calcium/calmodulin-dependent protein kinase II qamma Homo sapiens CAMK
1433 CAMK2gamma Calcium/calmodulin-dependent protein kinase type II qamma chain Homo sapiens CAMK
1431 CaMK2delta Calcium/calmodulin-dependent protein kinase type II delta chain Homo sapiens CAMK
1432 CAM KM D Calcium/calmodulin-dependent protein kinase type II delta chain Rattus norveqicus CAMK
12879 Q95266 Calcium/calmodulin-dependent protein kinase II delta 2-subunit Sus scrofa CAMK
16765 Q9Y2H4 KIAA0968 protein Homo sapiens CAMK
17638 Q8IWE0 Calcium/calmodulin-dependent protein kinase IIA; isoform 2 Homo sapiens CAMK
1424 CAMK2alpha Calcium/calmodulin-dependent protein kinase type II alpha chain Homo sapiens CAMK
1425 KCCA MOUSE Calcium/calmodulin-dependent protein kinase type II alpha chain Mus musculus CAMK
1427 CAMKIIA Calcium/calmodulin-dependent protein kinase type II alpha chain Rattus norvegicus CAMK
Figure 4.15 - Multiple sequence alignment of sequences from the variable domains of
members of the CAMK protein kinase family. The phosphopeptide found in the variable
domain of CaMKII (3 is well conserved across all CAMKII family members from different species.
The 2 pS/T were located to 4 possible sites in the phosphopeptide sequence and analysis of
this evolutionary alignment of CAMKII family members, we found that the first and third serine
residues (S354, S357) are completely conserved and thus are more likely to be the actual sites
of phosphorylation.
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PKR id Name Description Organism Class
875 GSK3 SCHPO Protein kinase gsk3 Schizosaccharomyces pombe CMGC
18585 Q9HE92 Probable glycogen synthase kinase 3 alpha Neurospora crassa CMGC
4341 Q9YH61 Glycogen synthase kinase 3 alpha Danio rerio CMGC
1642 GSK3a Glycogen synthase kinase-3 alpha Homo sapiens CMGC
1646 KG3B RAT Glycogen synthase kinase-3 beta Rattus norvegicus CMGC
1644 GSK3b Glycogen synthase kinase-3 beta Homo sapiens CMGC
4091 Q91627 Glycogen synthase kinase 3 beta Xenopus laevis CMGC
16370 Q9GTK0 Serine/threonine kinase GSK3 Hydra vulgaris CMGC
1311 KSG6 ARATH Shaggy-related protein kinase dzeta Arabidopsis thaliana CMGC
1313 KSG8 ARATH Shaggy-related protein kinase theta Arabidopsis thaliana CMGC
1307 KSG2 ARATH Shaggy-related protein kinase beta Arabidopsis thaliana CMGC
11943 082038 Shaggy kinase 6 Petunia x hybrida CMGC
11889 024139 Shaggy-like kinase 6 Nicotiana tabaoum CMGC
9503 Q9FSG4 Wound-induced GSK-3-like protein Medioago sativa CMGC
1149 MSK1 MEDSA Glycogen synthase kinase-3 homolog MsK-1 Medicago sativa CMGC
1305 KSG1 ARATH Shaggy-related protein kinase alpha Arabidopsis thaliana CMGC
1310 KSG5 ARATH Shaggy-related protein kinase epsilon Arabidopsis thaliana CMGC
10558 Q94IZ2 Putative shaggy-related protein kinase Oryza sativa (japonica cultivar-group) CMGC
1309 KSG4 ARATH Shaggy-related protein kinase delta Arabidopsis thaliana CMGC
1648 KG3H DROME Putative glycogen synthase kinase-3 homolog Drosophila melanogaster CMGC
18538 P78772 Schizosaccharomyces pombe Schizosaccharomyces pombe CMGC
Figure 4.16 - Multiple sequence alignment of sequences from protein kinase domain of
GSK3 family members. Phospho-tyrosine 216 is an important regulatory site in GSK3B and is
well conserved across GSK3 family members.
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Figure 4.17 - X-ray crystal structure of a Glycogen Synthase Kinase-3 p dimer. This 3D
model (1GNG) shows amino acids 36-384 of GSK3P that encompasses the protein kinase
domain of the kinase dimer. The dashed white line indicates the dimer interface. Phospho-
tyrosine 216 which is indicated on both molecules is not essential for kinase activity but does
have a regulatory effect on activity. It is proposed to be involved in docking of GSK3P
substrates for phosphorylation.
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determination (Dajani et al., 2001). (Figure 4.17). GSK3© exists as a dimer with
pY216 freely accessible on both monomers and is proposed to interact with residues
on the substrate thereby facilitating substrate docking prior to phosphorylation
(Dajani et al., 2001).
Brain selective kinase 1 and 2 (BRSK1/2) are 2 closely related kinases (Identities =
337/399 (84%), Positives = 365/399 (91%)) in which we have characterised 16
phosphorylation events. Figure 4.18 shows a multiple sequence alignment of BRSK1
and 2 protein sequences from mouse and human and the potential conservation of
these phosphorylation sites is summarised in Table 4.5. Of the 12 phosphorylation
sites mapped in BRSK1 6 of the unambiguously assigned sites are completely
conserved, three are conserved with a serine/threonine substitution. Four potential
sites (2 pS/T) were also found in BRSK1 and of these one (S527) was completely
conserved (potentially a good candidate for the real phosphorylation site) and the
other three possibilities were only present in BRSK1.
Kinase Phosphopeptide sequence Mod Site Conserved Conserved S/T BRSK1 only








BRSK1 SSGGTPLHpSPLHTPR I 1 pS + 1 pS S511 ✓
S512 ✓
S519 ✓
BRSK1 ASPXGTPGTpXPPPSPGGGVGGAAWR 1 pS/T + 1 pT S527 ✓
T529 ✓
T535 ✓
BRSK2 pSMEVL SVTDGGpfiPVPAR 2 pS S383 V
S394 V
BRSK2 SRSISGAS£GL£Tp£PLSSPR 1 pS + 1 pS S419 ✓
S422 V
S424 ✓
Table 4.5 - Identification and conservation of phosphorylation sites in BRSK 1 and 2.
Unambiguously assigned phosphorylation sites are indicated in red and ambiguously
assigned sites in blue. Phosphorylation sites conserved in BRSK1 and 2 in the mouse and
human proteins are indicated in the "conserved" field. Phosphorylation sites partly conserved
(serine or threonine) in BRSK1 and 2 in the mouse and human proteins are indicated in the
"conserved S/T" field. Finally, 4 phosphorylation sites were found in BRSK1 only as
indicated.
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Figure 4.18 - Multiple sequence alignment of BRSK1 and 2 protein sequences from
mouse and human. The human ortholog of BRSK1 is SAD1A. Phosphopeptides found in
BRSK1 are indicated by the green lines and those found in BRSK2 are indicated by blue
lines. Unambiguously assigned phosphorylation sites are indicated in red and ambiguously
assigned sites in gold. All of the phosphopeptides are located N-terminal to the kinase and
UBA domain.
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Four phosphorylation sites were found in BRSK2, three were unambiguously
assigned with two being completely conserved and one being an S/T substitution.
One out of the two possibilities for the remaining ambiguous site is completely
conserved (S442) which makes it the likely phosphorylation site. Only one of the 16
phosphorylation sites found on these two kinases is definitely specific (S450, in
BRSK1 only) and may be important in functions specific to BRSK1.
4.4.6 Putative 14-3-3 binding motifs in cytosolic phosphoproteins
One function of phosphorylation is to provide a regulated binding site on proteins.
There are many different types of such phosphorylation-dependent protein
interactions but the motifs for prediction of most these interactions are not complete.
However, 14-3-3 proteins which bind to phosphorylated serine or threonine
residues have been intensively studied and their optimal binding motifs have been
characterised. We investigated the potential of the phosphorylation sites identified
in this study to be sites for 14-3-3 binding by screening each site using Scansite, a
short sequence motif prediction server. 40 out of the 321 (12.5%) of the
phosphorylation sites on we characterised by mass spectrometry are predicted by
Scansite to be sites for 14-3-3 binding. When compared to our previous analysis of
the mouse forebrain synapse phosphoproteome, in which 18 out of the 331
phosphorylation sites (5.4%) were predicted by Scansite to be sites for 14-3-3
binding, there is an apparent enrichment for this motif in this dataset. This may be
accounted for by the differences in intrinsic disorder between these datasets (46%
sequence disorder for cytosolic compared to 34% for synapse phosphoproteome,
Figure 4.19)), as such phosphorylation-dependent binding motifs occur more
frequently in disordered regions (ref). Indeed, 95% of the 14-3-3 binding sites
predicted by Scansite occur in intrinsically disordered sequences.
All 14-3-3 binding sites predicted by scansite fall into three consensus motifs,
Rxx[pS/T]xP, Rxx[pS/T]x[G/D/E/S/T] and Kxx[pS/T]x[P/G/D/E/S/T], except for 5
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which are omitted from Table 4.6. Seven sites conform to the minimal motif
Rxx[pS/T]xP while the majority of sites (66%) conform to the Rxx[pS/T]x[G/D/E/S/T]
A Rxx[pS/T]xP
Acc Name Binding site 14-3-3 ml Kinase 1 Kinase 2 Kinase 3
P10637 Tau RSRTP[S]LPTPP 0.2656 Akt (0.2979)
070495 Srrml KRRTA[S]PPPPP 0.109 Akt (0.3493)
Q8BTI8 Srrm2 RARSR[T]PPSAP 0.0631
Q8CIL3 Parcel PSRRS[S]QPSPT 0.3768 PKA (0.4574)
Q9WV48 Shankl QGRSM[S]VPDDA 0.2317 Akt (0.4455)
Q80TS1 nArgBP2 GLRSP[S]PPPRS 0.3321 Cdk5 (0.4697) Cdc2 (0.5182)
Q8VCD2 CHERP SSRSP[T]PPSAA 0.3246 Akt (0.4835)
B Rxx[pS/T]x[G/D/E/S/T]
Acc Name Binding site 14-3-3 ml Kinase 1 Kinase 2 Kinase 3
P10637 Tau GSRSR[T]PSLPT 0.1093 CaMKII (0.3087)
P62996 SFRS10 YRRRH[S]HSHSP 0.5876 PKA (0.4018) Clk2 (0.5341)
Q5SQZ3 CaMK2G KKRKS[S]SSVHL 0.53 PKA (0.5185) CaMKII (0.5543) Akt (0.6614)
Q8VE97 SFRS4 EPRAR[S]RSTSK 0.4017
Q8VE97 SFRS4 RARSR[S]TSKSK 0.3151
Q9R0U0 NSSR1 YERRR[S]RSRSF 0.4404 Clk2 (0.4194) PKA (0.3803)
Q9R0U0 NSSR1 RRRSR[S]RSFDY 0.3403 Clk2 (0.4233) Akt (0.4451)
070495 Srrml ARRRR[S]PSPAP 0.1428 PKA (0.0398)
070495 Srrml IQRRY[S]PSPPP 0.1158 Akt (0.3761) Cdc2 (0.2619) ERK1 (0.415)
070495 Srrml VRRGA[S]ASPQG 0.1193
P62995 SFRS10 IYRRR[S]PSPYY 0.4961 PKA (0.3333)
Q6PDH0 Phldbl GRRTR[S]PSPTL 0.5055 Akt (0.4869)
Q8BTI8 Srrm2 HSRSR[S]SSPDS 0.3365
Q8BTT8 Srrm2 RERSS[S]ASPEL 0.0768 Akt (0.19)
Q8BTI8 Srrm2 RKRSR[S]RSPLA 0.0896
Q8VCD2 CHERP RRRSR[S]RSPTP 0.315 Clk2 (0.4208) Akt (0.4276)
Q9R0U0 NSSR1 RSRSR[S]FDYNY 0.4602 Akt (0.2830) Clk2 (0.4154) PKCzeta (0.4174)
Q9WV69 Dematin LERHL[S]AEDFS 0.5774 ATM (0.4350) Clk2 (0.6472) PKC mu (0.5141)
Q6NXJ5 Gml568 TARSF[S]LGDLS 0.2867 Akt (0.4244) PKA (0.5261)
Q7Z417 82-FIP LERND[S]WGSFD 0.4725 PKC mu (0.5283) PKA (0.5788) Akt (0.5301)
Q80YT1 Glccil HQRSA[S]WGSAD 0.3003 Akt (0.5009) Clk2 (0.6182)
Q6PDH0 Phldbl RTRSP[S]PTLGE 0.4794 PKA (0.5115)
Q8VCD2 CHERP RSRSR[S]PTPPS 0.3855 Clk2 (0.4799) Akt (0.4409)
C Kxx[pS/T]x[P/G/D/E/S/T]
Acc Name Binding site 14-3-3 ml Kinase 1 Kinase 2 Kinase 3
070495 Srrml PPKRR[T]ASPPP 0.1477
P14873 MAPlb PAKSP[S]LSPSP 0.1446 GSK3 (0.6423)
Q80UZ7 D430018P( LKKSH[S]SPSLN 0.0952
Q9WV69 Dematin SPKST[S]PPPSP 0.4978 ERK1 ( 0.4387 ) GSK3 (0.5211) Cdk5 (0.5760)
Q5SQZ3 CaMK2G VKKRK[S]SSSVH 0.5985 PKA (0.4521) PKC mu (0.5985) CaMKII (0.5667)
Table 4.6 - Cytosolic phosphoproteome phosphorylation sites predicted to be 14-3-3
binding sites. 35 out of the 40 Scansite predicted 14-3-3 binding sites conformed to the three
consensus sequences shown. The prediction score for the presence of 14-3-3 binding sites
and phosphorylation of sites by kinases are shown.
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Figure 4.19 - Comparison of intrinsic protein disorder in cytosolic and synapse
phosphoproteomes. The percentage of disordered sequence (hotloops) was calculated for
each of these datasets and was plotted against log of protein sequence length. The average
percentage disorder in the synapse phosphoproteome (34%) is 12% lower than that of the
cytosolic phosphoproteome (46) indicating the presence of more structural proteins at the
synapse. In addition, there are 11 proteins with more than 70% sequence disorder in the
cytosolic phosphoproteome, whereas the synaptic phosphoproteome does not contain any
proteins with 70% sequence disorder. The increased disorder in the cytosolic
phosphoproteome may account for the 2-fold increase in predicted 14-3-3 binding sites in
the cytosolic phosphoproteome compared to synapse phosphoproteome.
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Figure 4.20 - Kinases predicted to phosphorylate putative 14-3-3 binding sites.
Analysis of the 35 putative 14-3-3 binding sites in Table 4.6 by Scansite revealed that over
30% of these sites are predicted to be phosphorylated by Akt kinase. The substrate
selection of Akt and PKA kinases are similar to the motif recognized by 14-3-3 proteins.
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motif. Figure 4.20 shows the kinases predicted (by Scansite) to phosphorylate the
putative 14-3-3 binding sites. It is known that basophilic kinases such as Akt, PKA




We have applied our previously developed tandem metal affinity purification
approach (Collins et al., 2005), (Collins et al., 2005) in combination with two
different reversed-phase separations and analysis by tandem mass spectrometry to
study phosphorylation in the brain. We have identified 485 phosphorylation events
corresponding to 321 unique phosphorylation sites on 67 cytosolic phosphoproteins
in the mouse forebrain. In our previous analyses of the synapse phosphoproteome
we used a number of analytical approaches including single protein and single
peptide IMAC as well as tandem IMAC, to identify phosphorylation sites. The most
efficient approach was the combination of protein and peptide IMAC (tandem
IMAC) and this resulted in identification of 308 phosphorylation events on 41
synaptic phosphoproteins.
To further refine this tandem IMAC methodology we sought to determine the
optimal analytical reversed-phase separation for phosphopeptides. Efficient capture
and separation of phosphopeptides is crucial for efficient tandem MS analysis and
high phosphoproteome coverage. The chromatographic conditions used for
reversed-phase (RP) separation of phosphopeptides are quite different from those
used for cell-lysate digests for basic protein identification. The majority of
phosphopeptides elute at 3.5% organic solvent compared to 32% for standard
digests because phosphopeptides are more hydrophilic than non-phosphorylated
peptides (Figure 2.5, (Collins et al., 2005)). Therefore a long shallow gradient of
organic solvent is used for efficient phosphopeptide separation. However, the
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hydrophilicity of phosphopeptides can cause them to elute from the RV too early for
analysis by the mass spectrometer and therefore the binding properties of the RP
column media may be important in such phosphoproteomic analyses.
We compared two different RP columns; PepMap C18 3 mm 100A, 300 pm i.d. x
5mm and a BetaMax neutral 5pm, 180 pm i.d. x 30mm. The phosphopeptides
purified from tandem IMAC purification were subjected to two identical
experiments. This involved two 4-hour RP separations of the phosphopeptides on a
BetaMax neutral (BM) column and a PepMap (PM) column with a hypercarb
column as a trapping column in both experiments. The phosphopeptides separated
in these two experiments were analysed on a Q-Tof Ultima with identical
acquisition parameters. The PM experiment yielded greater coverage of the sample,
with identification 401 phosphorylation events on 173 phosphopeptides compared
to the BM experiment in which we identified 224 phosphorylation events on 110
phosphopeptides (Table 4.1). The identification of so many phosphorylation events
in a single experiment indicated that the Tandem IMAC purification and MS
acquisition settings were performing very well but that the subtle differences in the
RP media were having a significant effect on the overall performance of the
approach.
To investigate these RP media differences we compared the physiochemical
properties of phosphopeptides characterised in both analyses. We found that the
hydrophilicity of the phosphopeptides differed between the analyses in two ways.
Firstly, GRAVY scores (hydrophobicity score) calculated for phosphopeptide
sequences (effect of phosphate not calculated) indicated that the PM column was
capturing more hydrophilic peptides compared to the BM column (GRAVY score of
-0.943 compared to -0.762 for PM and BM specific phosphopeptides, respectively).
Secondly, the PM column captured more highly phosphorylated peptides (and
therefore, more hydrophilic) than the BM column, with an average stoichiometry of
phosphorylation of 2.31 compared to 2.03 phosphates per phosphopeptides for the
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PM and BM experiments, respectively (Table 4.1, Figure 4.4). The combination of
these two calculations clearly indicate that the PM column is more applicable to
separation of complex mixtures of phosphopeptides because it can capture many
more phosphopeptides with a higher sequence hydrophilicity as well as more
highly phosphorylated peptides.
4.5.2 Intrinsic protein disorder and its relevance to protein phosphorylation.
We investigated the relationship between protein phosphorylation and protein
disorder in the cytosolic phosphoproteome by using DisEMBL to predict the
percentage disordered sequence (hotloops) of each cytosolic phosphoprotein. These
were then compared with a dataset of experimentally verified ordered proteins and
disordered proteins (Figure 4.6). This resulted in the identification of 16 putative
natively disordered proteins, which included three experimentally verified natively
disordered proteins. The cytosolic phosphoproteome contained a range of proteins:
some with very low sequence disorder (structured proteins), those that had regions
of sequence disorder (linked-folded domains) to those which had high sequence
disorder and are thus putatively unstructured proteins.
Next, we looked at the location of phosphorylation sites in terms of local regions of
intrinsic disorder. 72% (231 phosphorylation sites) of the phosphorylation sites
characterised in the cytosolic phosphoproteome are located in regions of sequence
disorder. Only 5 out of the remaining 90 phosphorylation sites could be mapped to
Pfam domains (structured regions), indicating that either DisEMBL under predicts
unstructured sequence or there are tertiary structural types which have not yet been
mapped to Pfam domains. Since serine and threonine residues are enriched in
disordered sequence we asked whether intrinsically disordered proteins are
phosphorylated to a greater extent than structured proteins. We compared the
extent of phosphorylation with the extent of protein disorder in the cytosolic
phosphoproteome dataset. We found a potentially positive relationship between
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stoichiometry of phosphorylation and protein disorder; however this dataset is
probably biased toward lower phosphoprotein stoichiometry due to difficulties in
mapping all phosphorylation sites present in a given protein. A phosphoproteomic
experiment targeted to the study of a small number of proteins with differing
amounts of sequence disorder would be necessary to define this relationship
further. Top-down mass spectrometry-based approaches using for example an LTQ-
FTICR (linear ion trap fourier transform ion cyclotron resonance) mass spectrometer
would allow measurement of the total number of phosphorylated residues in an
intact protein, thereby permitting direct comparison of the total phosphorylation
state of a number of proteins with varying intrinsic disorder.
We observed that in proteins with low sequence disorder that phosphopeptides
tend to be located in the short regions of disorder that are present. For example,
CamKIIy has only 21% disordered sequence but the phosphopeptide we found for
this kinase and another phosphopeptide in a homologous kinase are located
consecutively in a region of intrinsic disorder and constitute 43 out of the 55 amino
acids of this disordered region (Figure 4.9). The identification of 2 phosphopeptides
from this discrete region of a mostly structured protein led us to ask if there were
was something specific to disordered sequences which make them more amenable
to our analytical approaches.
4.5.3 Enzymatic accessibility of intrinsically disordered regions.
In addition to the enrichment of phosphorylatable residues in disordered sequence,
we noticed that arginine and lysine residues are also enriched. As trypsin is the
enzyme of choice to digest protein samples for analysis by mass spectrometry, we
investigated the frequencies of proteolytic cleavage by trypsin (in silico digestion) of
proteins in the cytosolic phosphoproteome dataset. Figure 4.10 demonstrates that
proteins with a higher percentage of intrinsic disorder produce shorter tryptic
fragments. As disordered sequences are enriched for argine and lysine there are
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more potential sites of cleavage for trypsin than in structured regions which have
lower frequencies of these amino acids. It can be seen in Figure 4.11 that structured
peptides in an in silico digest of MAP4 tend to be longer than unstructured
peptides. In fact, a structured tryptic peptide of 57 amino acids long could be
produced from tryptic digestion of MAP4 and thus mapping of potential
phosphorylation sites on this peptide is very unlikely using current shotgun
proteomic approaches.
On one hand we have observed and it is generally accepted, that the majority of
phosphorylation sites occur in regions of intrinsic disorder and not very often in
structural domains. However, on the other hand, proteolytic cleavage of structural
domains is more difficult and produces longer tryptic fragments that may be too
large for analysis by traditional MS approaches. Is it possible that due to this uneven
distribution of cleavage sites in proteins, that we are under-sampling the extent of
phosphorylation of structural domains? A systematic study of sequence motifs
associated with phosphorylation sites has suggested that they occur predominantly
within intrinsically disordered regions (Iakoucheva et al., 2004). This analysis led to
predictions that only 1% of ordered serine and threonine residues compared to 6%
of ordered tyrosine residues may be phosphorylated. Thus it would seem that
tyrosine residues may be phosphorylated in intrinsically disordered and surface
exposed ordered states. Of the 2 unambiguously assigned tyrosine phosphorylation
sites found in the cytosolic phosphoproteome, one was located in a disordered
region in SFRS10 and the other was in the ordered kinase domain of GSK3p. It is
known that regions of intrinsic disorder are strongly favoured as sites of protease
digestion (Iakoucheva et al., 2004) as ordered regions (in non denaturing conditions)
cannot fit into the active site of proteases without disordering at lease 12 residues. In
a similar manner intrinsic disorder seems to be necessary for most kinase substrates
as hydrogen bonding with kinase partners, which is necessary for phosphorylation,
is not possible if the substrate is in a state of disorder (McDonald and Thornton,
1994). Furthermore, the lack of enrichment of tyrosine residues in disordered
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sequence (Linding et al., 2003) and the increased likelihood of ordered tyrosine
phosphorylation may be explained by the decreased requirement of tyrosine kinases
for docking interactions with the substrate that are separate to the site of
phosphorylation (Holland and Cooper, 1999). The majority of such docking
interactions are associated with serine/threonine kinases, which according to
intrinsic disorder predictions, phosphorylate mostly disordered sequences that are
in a conformation suitable for docking interactions. Thus, it is possible that tyrosine
phosphorylation may occur on partly ordered surface-exposed loops or regions that
undergo an order to disorder transition just prior to association with the kinase. In
these situations, backbone hydrogen bonding potential is sufficient for interaction
with the active site but a secondary docking interaction with the substrate would
not be required.
As regions of intrinsic disorder are strongly favoured as sites of protease digestion
in native conditions because of accessibility and under denaturing conditions
because of more cleavage sites for trypsin, these regions will produce more
proteolytic fragments than ordered regions. Production of smaller tryptic fragments
is problematic for analysis by traditional MS approaches and it appears that this
may occur in disordered sequence. We compared the molecular weight of tryptic
peptides from an in silico digest of Srrml (86.3% disorder) to that of Synapsin I
(5.4% disorder) (Figure 4.11). We found that there are many more phosphorylatable
(containing serine/threonine/tyrosine) peptides in Srrml outside the mass range of
detection than for Synapsin I. 64% of phosphorylatable peptides from Srrml
compared to only 24% of phosphorylatable peptides from Synapsin I were below
800 Da and thus not amenable to analysis by traditional shotgun MS approaches. It
appears that intrinsic protein disorder may have a significant influence on protein
sequence coverage and mapping of post-translational modifications using current
tryptic digestion and subsequent shotgun MS-based analysis. We suggest that this
should be investigated by using proteases with cleavage sites that differ to trypsin
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or by analysis of whole proteins or protein domains by the top-down MS-based
approaches described above.
4.5.4 Intrinsic protein disorder and phosphoprotein function
Intrinsically disordered proteins or regions of intrinsic disorder in proteins are
associated with many cellular functions, including regulation of transcription and
translation, signal transduction and protein phosphorylation and assemble of multi-
protein complexes such as the ribosome (Dyson and Wright, 2005). Intrinsic protein
disorder has evolved from relatively low levels in bacteria (2%) and viruses (7%) to
between 18 and 32% in C. elegans and D. melanogaster, respectively (Iakoucheva et
al., 2004)). It has been suggested that intrinsically unstructured proteins evolve by
repeat expansion and two of the putatively unstructured phosphoproteins
identified in this study (MAP2 and Tau) have statistically significant satellite
regions (Tompa, 2003). The reason for positive evolutionary selection appears to be
that unstructured proteins are capable of more versatile molecular functions
compared to structured proteins. Their unstructured or flexible conformation may
permit interaction with multiple binding partners at once and have many more
accessible sites for post-translational modifications (Linding et al., 2003).
Unstructured proteins have little or no hydrophobic core and as a consequence
more of the sequence can form binding interfaces compared to structured proteins,
which are limited by their reduced surface area. It has been suggested that they
allow large intermolecular interfaces while keeping the sizes of proteins, cells and
genomes small (Gunasekaran et al., 2003) (Figure 4.21).
4.5.4.1 Disordered phosphorylation in the splicesome.
The majority of putative phosphorylated IDP's found in this study (Table 4.3) are
involved in RNA binding and RNA splicing. Alternative mRNA splicing plays an
important role in development and differentiation allowing many polypeptide
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products, with potentially different functions, to be produced from a single gene.
Alternative splicing occurs on spliceosomes, which are complex particles composed
of small nuclear ribonucleoproteins (snRNPs) and non-snRNP proteins (Figure
4.22). Five of the most disordered phosphoproteins found in the cytosolic
phosphoproteome belong to the SR family of non-snRNP splicing factors (SRRRM1,
SRRM2, NSSR1, SFRS4 and SFRS10) and we have mapped 65 phosphorylation sites
on these proteins. These proteins are characterised by the presence of arginine- and
serine-rich (RS) domain and an RNA recognition motif. The RS domain acts as a
splicing-activation domain and it can enhance splicing when tethers to a pre-mRNA
via a heterologous RNA-brnding domain (Graveley and Maniatis, 1998).
In addition, to a protein binding function, the RS domain appears to be capable of
binding directly to double-stranded RNA (Valcarcel et al., 1996). It has also been
suggested that the positively charged arginine residues in the RS domain interact
with, and neutralise the negatively charged phosphate backbone of mRNA
(Valcarcel et al., 1996), enabling interaction with a wide variety of mRNA sequences.
A characteristic feature of SR proteins is extensive serine phosphorylation , which is
essential to their function in early stages of spliceosome assembly (Cao and Garcia-
Blanco, 1998), (Xiao and Manley, 1997). Structural analysis of an SR protein kinase
(Skylp) revealed that it phosphorylates SR proteins constitutively and in particular
phosphorylates Arg-Ser repeats sequentially, resulting in high stoichiometry of
phosphorylation (Nolen et al., 2001). Such widespread phosphorylation of serine
residues in SR proteins is necessary to complete spliceosome assembly and RS-
domain phosphorylation can regulate the activity of SR proteins (Cao et al., 1997),
(Graveley, 2000).
The exact mechanism of this regulation is unknown but two hypotheses have been
put forward; one that involves regulation of RS domain-protein interactions and
another that involves regulation of RS domain-mRNA interactions, both of which
are compatible with each other. Hypophosphorylated RS domains are more likely to
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Figure 4.21 - Schematic representation of protein dimers. A represents interaction of
disordered monomers and B represents interaction of 2 ordered monomers. The
intermolecular interface is the same in both examples but the size of the ordered monomers
is much larger than the disordered monomers. This represents the current view of why
disordered proteins have been positively selected by evolution.
Adapted from Gunasekaran K, Tsai CJ, Kumar S, Zanuy D, Nussinov R. 2003. Extended
disordered proteins: targeting function with less scaffold. Trends Biochem Sci 28:81-85.
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interact with RNA, due to charge considerations, whereas phosphorylated RS
domains might participate in protein interactions with other RS domains via
electrostatic interactions between positively charged argine residues and negatively
charged phosopho-serines.
SRRM1 (SRml60) and SRRM2 (SRM300) are two SR proteins and we characterised
19 and 33 phosphorylation sites on these proteins respectively. In addition, we
found that they are predicted to be highly disordered, with 86.3 and 74.0%
disordered sequence, respectively. The two proteins form the splicing coactivator,
which functions in splicing by promoting critical interactions between splicing
factors bound to pre-mRNA (Blencowe et al., 2000). SRRM1 is a component of the
exon junction complex (EJC) that is involved in RNA export and has an (ATP)-
dependent mobility (Wagner et al., 2004).
It has been reported that SRRMl-containing RNA export, but not splicing,
complexes have an ATP-dependent mobility and that these RNA export complexes
have an ATP-regulated mechanism for release from binding sites at splicing
speckled domains (Wagner et al., 2004). It is likely that this ATP-dependent mobility
is actually a dependency for extensive phosphorylation of the RS domain, which is
proposed to promote proteins interactions, perhaps recruiting proteins associated
with RNA export function. Thus, SRRM1 phosphorylation could be responsible for
the regulated export of bound mRNA transcripts, as well as functioning in
spliceosome assembly. SRRM2 is present in spliceosomes, bound to SRRM1, but is
not part of the exon junction complex and was not found in the ATP-dependent
RNA export complexes (Wagner et al., 2004). SR-cyp (Cyclophilin G) is another
phosphoprotein which we have characterised and it is also highly disordered, with
82.5% predicted sequence disorder.
SR-cyp interacts with Clkl, a SR protein kinase which hyperphosphorylates SR
proteins causing their localisation to change from nuclear speckles (zones of
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Figure 4.22 - Multiple Roles of SR Proteins in mRNA processing.
Hyperphosphorylated SR proteins are recruited to pre-mRNA molecules, where they
participate in splicing. SR proteins bind to the branch site and 5' splice site of the
intron during spliceosome assembly and splicing results in the dephosphorylation of
bound SR proteins and in the deposition of exon junction complexes (EJC) upstream
of exon-exon boundaries in the spliced RNA. Hypophosphorylated forms of the
shuttling SR proteins then help to recruit the export adapter NXF1, which
orchestrates passage of the mRNP through the nuclear pore. Translation is
accompanied by RNP remodeling, leading to the release and reimport of
rephosphorylated SR proteins and some EJC components into the nucleus.
Adapted from "Sorting out the complexity of SR protein functions." Graveley BR.
RNA. 2000 Sep;6(9):1197-211.
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accumulation of transcriptional and mRNA splicing factors) to a diffuse
nucleoplasm^ localisation (Colwill et al., 1996). Similarly, SR-cyp regulates the
localisation of SR proteins, including SRRM2, re-distributing them from nuclear
speckles to a diffuse nucleoplasms localisation (Lin et al., 2004). SR-Cyp contains a
PPPIase domain, which could catalyse the conversion of czs-proline to tnms-proline
in a polypeptide chain, thereby regulating protein folding and/or the
conformational state of SR proteins. Another member of the SR protein family
(pinin) interacts with SR-cyp via its RS domain, indicating that this may be a
common mechanism of SR-cyp binding to SR proteins.
We have also characterised phosphorylation sites on another SR protein kinase,
PRP4 (56.5% disorder). Clkl has been shown to bind to PRP4 and phosphorylate it
at its N-terminus, possibly at N-termrnal sites which we have mapped (S143, S145)
(Kojima et al., 2001). Overexpression of Clkl causes re-distribution of PRP4 from
nuclear speckles to a diffuse nucleoplasm^ localisation, again in a similar manner as
that described for other SR proteins (Kojima et al., 2001). There is evidence to
suggest that Clkl is not a direct regulator of SR proteins and that PRP4 is more
active than Clkl in phosphorylating SR-proteins (Kojima et al., 2001).
Neural specific SR protein NSSR 1 (SRp38) was found in the cytosolic
phosphoproteome and is also highly disordered with 84.7% sequence disorder. This
SR protein appears to be important in neuronal differentiation, possibly via
regulating the neural-specific alternative splicing of genes (Liu et al., 2003). Unlike
other SR proteins, SRp38 does not copurify with other SR proteins using a classical
purification protocol (Zahler et al., 1992). Also, unlike other SR proteins, SRp38
cannot activate splicing in extracts lacking other SR proteins. However,
dephosphorylation of SRp38 converts it into a potent, general repressor that inhibits
splicing at an early step (Shin and Manley, 2002). Furthermore, this
dephosphorylation occurs specifically in mitotic cells, presumably to ensure that
inappropriate gene expression does not occur during mitosis (Shin and Manley,
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2002). Upon heat shock treatment, SRp38 is rapidly dephosphorylated and therefore
activated to repress splicing to ensure that inaccurate spicing does not occur until
the heat-damaged splicing apparatus is restored (Shin et al., 2004).
Two other SR proteins, SFRS4 (SRp75) and SFRS10 (Tra2B) are highly disordered
phosphoproteins with 83.0 and 87.2% sequence disorder, respectively. SFRS4
interacts with SRRM2 and forms a multiprotein complex which may be involved in
pre-mRNA processing (Zimowska et al., 2003). SFRS10 can autoregulate its own
protein concentration by autoregulating alternative splicing of its own pre-mRNA
(Stoilov et al., 2004). As with other SR proteins, hyperphosphorylation of SFRS10
strongly reduces its binding to RNA and as a consequence is under the regulatory
control of SR kinases. SFRS10, like SRp38 is involved in neuronal differentiation and
it regulates the splicing of FGF-2R and GluR-B minigenes.
It should be noted that the SR proteins and other splicing-associated
phosphoproteins characterised in this study were isolated from the cytosolic
fraction, supporting a function in RNA export, where they would shuffle from the
nucleus to the cytoplasm. In addition, as these proteins were found in their
phosphorylated state, their presence in RNA export complexes or their cytoplasmic
shuttling is likely to be regulated by phosphorylation. It has been shown that
dephosphorylation of SR proteins is critical for determining the selectivity and
efficiency of TAP (an export receptor)-dependent mRNA export (Fluang et al., 2004).
In fact, RS domain phosphorylation stimulates the nuclear import of mammalian SR
proteins (Lai et al., 2000) after release from mRNA export complexes. Thus, the
phosphorylation state of SR proteins found in this study can be temporally mapped
to just prior to nuclear import, either after their translation or after release from
mRNA export complexes.
The current evidence seems to suggest that SR-proteins such as SRRM2 are
extensively regulated by phosphorylation by SR kinases such as Clk and PRP4 and
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by binding or folding by chaperones such as SR-cyp, both of which function to
regulate the function and localisation of splicing factors. SRRM1 is also regulated by
phosphorylation, which is necessary for spliceosome assembly and RNA export,
and it interacts with RNA as well as proteins in its function as a splicing factor. The
demands placed on SR proteins in terms of molecular binding capabilities and
extensive regulation by phosphorylation would not be satisfied by ordered proteins.
These examples of highly disordered and phosphorylated proteins provide insight
into how intrinsic disorder can facilitate both protein and RNA binding and in
conjunction with extensive phosphorylation and interaction with other disordered
chaperones such as SR-cyp, participate in highly regulated processes such as RNA
splicing and export. SR proteins are essential splicing factors present in all
metazoans but interestingly are completely absent in lower eukaryotes such as S.
cerevisiae (Graveley, 2000). It is tempting to speculate that the appearance of SR
proteins in higher eukaryotes is related to the parallel positive evolutionary
selection for intrinsic protein disorder, a likely requirement for SR protein function.
4.5.4.2 Phosphoprotein disorder in the regulation of the cytoskeleton
Three phosphorylated components of the cytoskeleton which are known to be
disordered or contain disordered sequences, were found in the cytosolic
phosphoproteome; TPPP (Tubulin polymerisation promoting protein) (64.2%
disorder), Tau (Microtubule-associated protein Tau) (57.4% disorder) and Beta-
adducin (41.7% disorder) (Figure 4.6, Table 4.3). Beta-adducin binds to spectrin-
actin complexes and promotes the association of actin with spectrin (Hughes and
Bennett, 1995). The C-terminal tail of beta-adducin is intrinsically disordered and
was identified as the site for binding to spectrin-actin complexes (Hughes and
Bennett, 1995). We have identified 6 phosphorylation sites on 2 consecutive
phosphopeptides spanning 53 amino acids of this unstructured C-terminal tail. This
multi-site phosphorylation cluster is well placed to regulate interaction with
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spectrin-actin complexes, N-terminal to PKC phosphorylation sites that inhibit beta-
adducin's activity in promoting spectrin-actrn complexes (Matsuoka et alv 1998).
TPPP was originally identified as a natively unfolded protein (Orosz et al., 2004) but
has subsequently been found to be partially ordered with an extended structure
(Otzen et al., 2005). TPPP stimulates aberrant tubulin polymerisation which gives
rise to microtubule assemblies in inclusion bodies of human pathological brain
tissues such as Alzheimer's and Parkinson's disease. We have characterised four
phosphorylation sites in TPPP, two of which are located in the unstructured N-
terminus, which is missing in shorter forms of TPPP encoded by two separate genes
in mammals (Tirian et al., 2003). A phosphorylation sites motif (TPPKSP) within this
region is present in Tau and is phosphorylated by Cdk5 (Takahashi et al., 1991). We
found both phosphorylation sites in the motif (pTPPKpS) in Tau and also in TPPP
and this shared motif may have a similar function in TPPP as it does in Tau.
Tau is a highly phosphorylated protein, with 17 out of a total of 35 phosphorylation
sites characterised in this study (Figure 4.8). Phosphorylated Tau has been
implicated by many studies in the pathology of Alzheimer's disease (AD), a
neurodegenerative disease characterised by deposits of amyloid A-beta peptides in
plaques and by Tau deposits in the form of paired helical filaments (PHF's). Most
neurodegenerative disorders are disorders of protein folding and the consequences
of protein folding, and are therefore classified as foldopathies. Tau interacts with
alpha and beta tubulin, as well as other microtubule-associated protein tau isoforms
to promote microtubule assembly and stability (Lee et al., 1989). Mutations in exon
10 of the Tau gene are associated with FTDP-17, an autosomal dominant hereditary
neurodegenerative disorder (Jiang et al., 2003). These mutations lie in an enhancer
region, which SFRS10 (an intrinsically disordered SR protein characterised in this
study) binds and regulates the alternative splicing of exon 10 (Jiang et al., 2003).
Exon 10 encodes one of four microtubule-binding motifs and aberrant splicing of
this exon and has implicated SRFS10 and the increased affinity of Tau for
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microtubules in the pathogenesis of tauopathies (Kondo et al., 2004), (Jiang et al.,
2003).
The region surrounding the microtubule-binding repeats is highly phosphorylated
by multiple kinases and is thought to regulate microtubule binding (Goode et al.,
1997). Hyperphosphorylated Tau shows defective microtubule binding and fails to
promote microtubule assembly. (Mandelkow, 1999). Tau is natively disordered
(Barghorn et al., 2004), especially either side of the microtubule-binding repeats,
where most phosphorylation is concentrated (Figure 4.6). Hyperphosphorylated
Tau is thought to cause aggregation and the formation of PHF's and it has been
shown that Tau displays an increased level of beta-structure in PHF's (Barghorn et
al., 2004). It therefore seems likely that the combination of disorder and
phosphorylation surrounding the microtubule-binding repeats is important in PHF
formation. The folding or conformation of Tau is regulated in a manner analogous
to that described for SRRM2, in which a chaperone (SR cyp) regulates SRRM2
conformation by peptidyl-prolyl cisttrans isomerisation of the polypeptide chain.
Pinl, a PPIase, specifically regulates the conformation of proline-directed
phosphorylation sites (Lim and Lu, 2005). Pinl targets phosphorylated Tau on a
Thr321-proline motif and restores its biological function after Tau is inactivated by
hyperphosphorylation (Lim and Lu, 2005). Pinl allows Tau dephosphorylation by
PP2A and restoration of normal function. This pathway is characterised by a
combination of protein disorder and phosphorylation, which is necessary for
normal regulation of Tau function, and is regulated by a specific chaperone which
can modify Tau protein conformation and allow restoration of Tau function by
dephosphorylation by PP2A. It highlights the importance of regulation of protein
disorder and phosphorylation in protein function and how their deregulation may
be involved in foldopathies.
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4.5.4 Phosphorylation and human brain disorders
The dysregulation of cellular signalling pathways is fundamental to many
pathologies and especially in neurodegenerative diseases where aberrant
phosphorylation of key proteins such as Tau has been implicated in disease
formation and progression. The identification of sites of phosphorylation or
mapping of the normal phosphorylation state of a phosphoproteome is necessary to
understand how changes in the phosphorylation state of proteins can lead to
disease. In addition to mapping many phosphorylation sites on Tau and TPPP,
which are implicated in AD, we have also identified phosphorylation sites on other
neurodegenerative disorder-associated proteins. Figure 4.23 shows a portion of the
AD protein interaction network illustrated in Figure 5.16, highlighting
phosphoproteins found in the cytosolic phosphoproteome.
GIT1, a G protein coupled receptor kinase-interacting protein has numerous cellular
functions from acting as a scaffold for the kinases ERK1/2 and MEK1 in focal
adhesions (Yin et al., 2005) to being part of a signalling complex which includes PIX,
Rac and PAK, that plays an essential role in the regulation of dendritic spine and
synapse formation (Zhang et al., 2005). Interestingly, when a protein-protein
interaction network for Huntington's disease (HD) was constructed from a yeast
two-hybrid screen it was discovered that GITI directly interacted with huntington
protein (HTT) (Goehler et al., 2004). In addition, GITI is localised to neuronal
inclusions and is selectively cleaved in HD brains, indicating a role in HD
pathogenesis (Goehler et al., 2004). GITI also interacts with CRMP1 (Collapsin
response mediator protein 1) (Goehler et al., 2004), which directly interacts with
HTT (Goehler et al., 2004). CRMP1 in turn interacts with CRMP2 (Collapsin
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Figure 4.23 - Phosphoproteins involved in neurodegenerative disease. A selected set of
proteins involved in AD or HD are shown with arrows representing protein interactions (red
arrow indicates phosphorylation interaction). Red-filled boxes indicate phosphoproteins
characterised in this study. Protein interaction data was mined from the literature and the
following PMIDs describe the interactions shown above: 12942088, 12011466, 12942088,
15383276,15923189, 10515232,9689133, 12093283, 15676027
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response mediator protein 2), both of which we characterised in the cytosolic
phosphoproteome. Increased GSK3© activity is associated with AD and CRMP2 has
been found to be a physiological substrate for GSK3#©(Cole et al., 2004). A
hyperphosphorylated region of CRMP2 is an Alzheimer epitope and is physically
associated with neurofibrillary tangles (Cole et alv 2004), (Gu et al., 2000). We have
characterised this phosphorylated AD epitope and found that it contained 7
phosphorylated residues in a stretch of 16 amino acids, three of which are novel. It
appears that phosphorylation of this epitope regulates CRMP2 binding to tubulin
and that GSK3@©is at least partly responsible for this regulation (Uchida et al., 2005).
Also, GSK3@®phosphorylation of CRMP2 regulates axon elongation in primary
neurons, possibly by promoting microtubule assembly (Cole et al., 2004).
Numb, a phosphotyrosine-binding domain-containing protein was originally
identified as a Notch signalling antagonist in Drosophila, where is determines cell
fate during nervous system development (Nishimura et al., 2003). Numb interacts
with CRMP2 and ©-adaptin (both in cytosolic phosphoproteome) with a role in
endocytosis (Nishimura et al., 2003). CRMP2, in addition to regulating microtubule
assembly, regulates Numb-mediated endocytosis for axon growth (Nishimura et al.,
2003). In fact, isoforms of Numb have the ability to increase vulnerability of cells to
the amyloid beta peptide, possibly by affecting notch-mediated cell fate. Whether
the interaction of CRMP2 with Numb has a role in Numb-mediated cell death in
response to amyloid beta peptide has yet to be determined, but with CRMP2 also
regulating cell fate decisions it would seem likely that they are involved in a
common pathway.
The Ataxin-2 gene contains a trinucleotide repeat that encodes a polyglutamine
stretch, which when expanded causes spinocerebellar ataxia type 2 (SCA2) (Raiser et
al., 2005). SCA2 belongs to the family of polyglutamine disorders, which includes
HD, and there is evidence to show that HTT and Ataxin-2 are functionally linked.
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They both interact with Endophilin A complexes and are involved in pathways
regulation actin organisation (Raiser et al., 2005).
As well as characterisation of phosphoproteins implicated in neurodegenerative
disorders we have found phosphorylation sites on 82-FIP, a FMRP (Fragile X Mental
Retardation Protein) interacting protein. The absence of FMRP causes fragile-X
syndrome, the most common monogenic form of mental retardation. FMRP is an
RNA-binding protein and was observed to involved in translational control (mRNA
trafficking) at a postsynaptic level (Weiler et al., 1997), (Mazroui et al., 2002). 82-FIP
binds specifically to FMRP and is associated with polyribosomes (Bardoni et al.,
2003). The distribution of 82-FIP is cell-cycle dependent, being cytoplasmic in the
G2/M phase and nuclear in the G1 phase (Bardoni et al., 2003). It has been proposed
that this cell-cycle dependent localisation of 82-FIP is regulated by phosphorylation
in an analogous manner to dFMRP in drosophila (Bardoni et al., 2003), (Siomi et al.,
2002). We have characterised a phosphorylation site on 82-FIP at serine 652 that is
predicted to be a site for 14-3-3 binding and may be involved in the observed
regulated localisation of this protein.
4.5.6 Conclusions
We have applied our previously developed tandem IMAC purification strategy and
analysis by mass spectrometry to study the mouse forebrain cytosolic
phosphoproteome. This led to identification of 485 phosphorylation events
corresponding to 321 unique phosphorylation sites on 67 cytosolic proteins. We
compared the suitability of two reversed-phased columns for the analytical
separation of phosphopeptides and found that in a single 4 hour LC run with a
PepMap column we could identify 401 phosphorylation events on 173
phosphopeptides. This data yield from a single MS analysis highlighted the
efficiency of our approach and application of this approach to a fractionated (e.g.
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ion-exchange) phosphoproteome with multiple MS analyses would certainly yield
increased coverage.
Analysis of the types of phosphoproteins characterised in this study led to a number
of interesting findings. Firstly, as this dataset is derived from a very soluble fraction
of the mouse brain proteome, we reasoned that it was likely that these proteins were
quite hydrophilic and therefore more likely to be unstructured proteins. Intrinsic
disorder predictions confirmed this and allowed identification of a set of putative
natively unstructured or intrinsically disordered phosphoproteins. These proteins
were mostly RNA or tubulin-binding proteins and further investigation revealed
that a combination of disorder and phosphorylation is very likely essential for their
function. Secondly, it is known that phosphorylation is more likely to occur in
regions of disorder and we investigated the distribution of phosphorylation sites in
each of the identified phosphoproteins. We found that proteins with higher
sequence disorder seem to be phosphorylated to a greater extent and that in
structured proteins and phosphorylation sites usually occur in local regions of
disorder. Thirdly, disordered proteins are more susceptible to proteolytic cleavage
and we found that a clear relationship between sequence disorder and frequency of
tryptic digestion exists, which may impact on the coverage of certain smaller
phosphopeptides in phosphoproteomic analyses. Fourthly, we identified 37
phosphorylation sites on nine protein kinases, the majority of which are novel and
were not in kinase domains indicating secondary regulatory functions. In addition,
35 phosphorylation sites in the cytosolic phosphoproteome are predicted to be 14-3-
3 binding sites, more than a two-fold increase compared to that predicted for the
synapse phosphoproteome. This increase in predicted 14-3-3 binding sites was
accompanied by increased sequence disorder in the cytosolic phosphoproteome
supporting the argument that disorder confers increased molecular regulation.
Finally, we have discussed the relationship between phosphorylation and disorder
in brain disease and how in a global study of phosphorylation we have
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characterised a number of phosphoproteins with disease-associations, which may
have related roles in the pathogenesis of neurodegenerative disease.
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CHAPTER 5
MOLECULAR ORGANISATION OF THE POSTSYNAPTIC PROTEOME
REVEALED BY INTEGRATIVE BIOINFORMATIC ANALYSIS
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5. Molecular organisation of the postsynaptic proteome revealed by
integrative bioinformatic analysis
5.1 ABSTRACT
Identification of the composition of the synapse proteome provides a framework for
understanding the overall organisation, development, evolutionary origins and
function of the synapse in normal and pathological conditions. In addition,
proteome data allows the derivation of proteome-wide molecular network maps at
the level of gene regulation, protein interaction and protein phosphorylation that
can be merged with functional or phenotype data from individual molecule studies
to derive new models of synapse function. Proteomic analysis has facilitated
identification of the components of the postsynaptic density, AMPAR complex and
MASC (MAGUK-associated signalling complexes) (Collins MO. J. Neurochem
2005). We have extracted data from six other synapse proteome experiments and
combined these with our data to provide a consensus on the composition of the
post-synaptic proteome (PSP). In total, 1124 proteins are present in the PSP with 466
of these validated by their detection in two or more studies, forming what we have
designated the "Consensus PSD" (cPSD). We have performed bioinformatic analysis
of each level of complexity in the PSP; gene evolution, mRNA expression, protein
annotation, phosphorylation, protein complexes and protein networks. We have
linked these data types and have observed molecular organisation at every level of
complexity from the evolutionary origins of the PSP to the proposed model of
MASC assembly of in developing neurons. These synapse proteome datasets and
the analysis described in this study offer a basis for future research in synaptic
biology and will provide useful information in brain disease and mental disorder
studies.
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5.2 INTRODUCTION
An important goal of cognitive science is to identify neural mechanisms for
processing information. The synapse both transmits information between cells and
processes it by detecting specific patterns of neural activity and converting this
electrical activity into intracellular biochemical events changing the properties of the
neuron (Greengard, 2001);(Kandel/ 2001) . In recent years it has become clear that
synapses, like other cell-cell interactions in metazoans, utilise signal transduction
complexes and pathways with a high degree of molecular complexity and cross talk
(Pawson and Nash, 2003);(Sheng and Kim, 2002). A major challenge for biology is to
devise strategies that extract emergent physiological properties and simple
biological principles from highly complex genomic and proteomic datasets, and
shed light on both mechanisms and disease processes. The synapse proteome is a
suitable prototype to explore these general issues because; i) it contains a highly
localised set of proteins found in dendritic spines; ii) an important role for signalling
complexes and pathways has been established, iii) signalling can be exquisitely
studied using patterns of action potentials, iv) genetic and pharmacological
perturbations result in behavioural changes. However, the molecular complexity
and global organisation is not well understood.
The post-synaptic density (PSD) is a structural component of the synapse that can be
observed under the electron microscope, beneath the postsynaptic membrane
(Cotman et al., 1974). Recent proteomic efforts have given an insight into the
complexity of the PSD and its subcomponents (Husi and Grant, 2001), (Walikonis et
al., 2000), (Yamauchi, 2002), (Yoshimura et al., 2004), (Jordan et al., 2004), (Peng et
al., 2004), (Li et al., 2004), (Collins et al., 2005). Advances in mass spectrometry
techniques have enabled large-scale investigations of the protein content of
organelles with similar complexity to the PSD (for reviews see (Jeong et al., 2000);
(Taylor et al., 2003)).
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The neurotransmitter glutamate activates synaptic plasticity primarily via
the ionotropic N-methyl-D-aspartate (NMDA) receptor and metabotropic (mGluR)
receptors. This leads to Ca2+ elevation in the dendritic spine and signal transduction
to AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptors and
other effector mechanisms. The cytoplasmic C-termini of NMDA receptor subunits
(NR2A/el, NR2B/s2) bind PDZ domains of PSD-95, a MAGUK (Membrane
Associated Guanylate Kinase) protein. Previous proteomic analysis of NMDAR-
PSD-95 complexes identified 77 proteins that include mGluR receptors, whilst
AMPA receptors were found in different complexes (Husi et al., 2000). These
complexes are embedded in the postsynaptic terminal of excitatory synapses with
other postsynaptic proteins.
Here we present a large-scale proteomic analysis of the postsynaptic
proteome (PSP) of the mouse brain. We have performed MS-based analysis of
MASC and AMPA receptor complexes, isolated postsynaptic densities and
validation of a set of MASC and PSD proteins by large-scale immunoblotting. In
addition to generating novel data, we have systematically compiled data from
publicly available sources to produce a comprehensive dataset of the composition of
the PSP. This includes data on the PSD and various sub-components, namely the
NMDA receptor complex (NRC), the AMPA receptor complex (AC), and the
MAGUK associated signalling complexes MASC). Functional information for these
PSP proteins was extracted from gene expression data derived from developing
hippocampal primary neurons in culture. Integration of this data with that of the
synapse proteome has resulted in a model of synapse assembly in which, the
sequential expression of sets of genes describe how a synapse may be formed. In
addition, inclusion of electrophysiological data from the same type of developing
neuronal culture provides a functional measure of synaptic outputs, the timing of
which is in agreement with that predicted by gene expression data. Extensive
analysis of these synapse proteome datasets revealed multiple levels of organisation
from gene expression, protein domain organisation, formation of multi-protein
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complexes to their evolution. This proteomic map can be considered as a first draft
of the synapse proteome and will be used to design experiments to dissect the
molecular complexity at the synapse
5.3 MATERIALS AND METHODS
5.3.1 Biochemistry
PSD and complex purifications were performed by Holger Husi (University of
Edinburgh)
MASCs were isolated using a peptide affinity method modelled on the PDZ binding
domain of NR2 subunits and was reported elsewhere (Husi and Grant, 2001).
AMPA receptor complexes (AC) were isolated using immunoprecipitation of
AMPA subunits with an anti-GluR2 antibody (BD Biosciences). PSD fractions were
prepared as described (Carlin et al., 1980). Protein samples were separated by SDS-
PAGE and stained by Collodial Coomassie blue. The entire gel lane was excised into
42 individual protein bands, reduced, alkylated and digested with trypsin
5.3.2 Mass spectrometry
Mass spectrometry was performed by Lu Yu (The Wellcome Trust Sanger Institute).
The resultant peptide mixtures were analysed by on-line Liquid Chromatography
Tandem Mass spectrometry (LC-MS/MS) to generate peptide sequence information
(Link et al., 1999). Chromatographic separations of the peptide mixture were
performed on a 180 pm (intensely stained bands) and 75pm (weakly stained bands)
PepMap column using an Ultimate LC system (LC Packings, The Netherlands)
delivering a gradient of formic acid (0.05%) and acetonitrile. The LC column was
connected directly to a micro-electrospray interface on a Q-TOF mass spectrometer
(Micromass Ltd., U.K.). The mass spectrometer operated in automated function
switching mode, selecting precursor ions based on intensity for peptide sequencing
by tandem MS. Several hundred MS/MS spectra could be generated per run
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allowing the analysis of complex mixtures without any prior interpretation. The
search engine used in this work was Mascot (http://www.matrixscience.com/). Mass
spectrometry data were reduced to MassLynx 'PKL' format peak lists prior to
searching. Proteins were identified based on matching the MS/MS data with mass
values calculated for selected ion series of a peptide. The searches on in-house non-
identical protein database were performed without applying any constraints on
molecular weight or species of origin. Most proteins were identified with several
peptide matches although a few proteins were assigned based on a single peptide
provided near complete peptide sequence had been obtained.
5.3.3 Immunoblotting
Immunoblotting was performed by Holger Husi (University of Edinburgh) and by
Julia Brandon (The Wellcome Trust Sanger Institute).
Protein samples were subjected to reducing SDS-PAGE and transferred to
polyvinyldifluoride (PVDF) membrane (BioRad) at 4°C for 90 min at 75 V in 10%
(v/v) Methanol, 10 mm CAPS pH 11.0. Dilution of primary antibodies was between
1 : 100 and 1 : 1000, depending on the quality of the IgGs. Detection of signals was
done using peroxidase-linked secondary IgGs and enhanced chemiluminescence.
5.3.4 Primary Neuronal culture
Primary neuronal cultures were performed by Lawrence Humphreys and Paul
Charlesworth (The Wellcome Trust Sanger Institute).
Primary hippocampal neurons were prepared from embryonic day 17.5 El7.5) C57
B16 (c-/c- coat colour mutant - required?) mice using standard techniques. Embryos
were chilled and decapitated and hippocampi dissected in cold PBS. Hippocampi
(from 4-8 embryos) were pooled and placed in papain solution (Worthington, 10
Units/ml, reconstituted in Neurobasal) and incubated for 22 min at 37QC and 5%
CO2. Enzyme solution was then removed and replaced with 2mls DMEM/F12 + 10%
FCS in which the tissue was disaggregated by drawing up and down a fire polished
Pasteur pipette. Dissociated cells were centrifuged twice (3.5 min, 400g) in this
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medium after which the pellet was re-suspended in Neurobasal / B27 medium with
0.5 mM glutamine. Cells were counted, diluted and plated in this medium. For RNA
extraction cells were plated at 4-5 x 104 cells/cm2 in 6 well plates coated with Poly-D-
Lysine and laminin (1-2 pg/ cm2). Multielectrode arrays were coated with
polyethyleneimine and laminin. Initially, 105 cells in 150 pi were placed on the
array. After 1 hr this medium was removed and 800 pi of fresh Neurobasal / B27
was placed on the MEA dish. Final cell density was approx. 1500/mm2. MEA dishes
were sealed with Teflon lids (see Potter and DeMarse 2001) to maintain osmolarity
and sterility.
For total RNA extraction, typically 1 ml of TRIzol reagent (Invitrogen) per well was
used, scraping the cells by pipetting and then following the manufacturer protocol.
An additional clean up was made using the RNeasy Mini Kit (Qiagen) and
subsequent ethanol and NaOAc precipitation, or alternatively using the MinElute
kit (Qiagen). RNA integrity was checked in a 1% agarose-formaldehyde gel.
5.3.5 Gene expression profiling
Gene expression analysis was performed by Luis Valour (The Wellcome Trust
Sanger Institute).
1.5 pg of total RNA were retrotranscribed, labeled and hybridised on MG-430 2.0
array (Affymetrix), one array per sample. We followed the manufacturer
instructions, including the washing (Fluidics Stations 450, Affymetrix), scanning
(GeneChip Scanner, Affymetrix) and image treatment (GCOS software, Affymetrix).
Once verified quality and control report after each experiment, GeneSpring software
(Silicon Genetics) was used to normalise and analyse the data, including the
clustering method based on the K-means algorithms.
5.3.6 Analysis of PSP protein classes
Triplicate data for PSP probe sets were averaged and normalised ((X-
m)/8)). Hierarchical clustering of datasets was performed using average group
linkage with the Pearson correlation coefficient distance measure. Normalisation
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and clustering were performed using HCE3 (http://www.cs.umd.edu/hcil/multi-
cluster/). A minimum similarity threshold of 0.8 was used to filter the normalised
data and the resultant clustering was used to remove probe set outliers and
facilitated averaging of data from probe sets to unique genes. Time course series for
protein classes were plotted using normalised expression values >0 to indicate up-
regulation of expression at a given time point. PSP protein classes were defined by
Swiss Prot keywords and can be found in supplementary table 2. The functional
class of genes termed as "Neurogenesis" was also defined by Swiss Prot keywords
and the class "activity dependent genes" was defined by literature searching (supp
table act dep genes). PSP targets of the transcription factor creb were extracted from
a recent screen of PC12 cells (Impey et al., 2004). Neural specific transcription factors
present in the PSP were extracted from a recent genome wide screen (Gray et al.,
2004).
5.3.7 Tissue specific expression
The Gene expression atlas (http://expression.gnf.org) was mined to extract
expression data for genes in the PSP. 635 probe sets corresponding to 464 unique
PSP genes were obtained and expression data were normalised and clustered as
described previously for the culture time course experiments. Significantly enriched
(P <0.01) Gene Ontology terms were determined for genes in each cluster using
GoTree (Zhang et al., 2004).
5.3.8 Electrophysiology with MEAs
Elextrophysiology was performed by Lawrence Humphreys and Paul Charlesworth
(The Wellcome Trust Sanger Institute).
Multielectrode arrays (MEAs) (Multi Channel Systems (MCS), Reutlingen) were
used to record the electrical activity of developing E17.5 hippocampal neurons,
grown directly on a square grid of 60 titanium nitride electrodes (electrode diam 30
pm, spacing 200 pm). Signals were amplified (HOOx), sampled at 25 KHz and
recorded using MC Rack software (MCS). Spikes were detected on-line using a fixed
Chapter 5 - Molecular organisation of the postsynaptic proteome revealed by integrative bioinformatic analysis 202
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
level detection of -24 pV, which was approx 8 x SD of baseline noise. Off line
analysis of spike data was performed with Neuroexplorer (NEX Technologies).
Prior to recording, culture medium was removed and retained and recording
solution (NaCl 140, KC1 3, CaCk 2.5, HEPES 15, glucose 10, pH 7.4 with NaOH, Mg
free) placed in the array well (1 rinse). 30 min recordings were made in this solution.
The original culture medium was then replaced in the well for further culture in the
TC incubator.
5.3.9 Integration of proteomic datasets
A number of different sequence databases were used in these studies for MS mining
and as a result, we decided to use UniProt as our standard protein identifier. In a
few cases protein identifiers could not be mapped to UniProt, so their original
identifiers were retained. UniProt accession numbers were mapped to Unigene via
EMBL and Locuslink to cluster the merged total PSD dataset to remove redundancy.
5.3.10 Network construction and gene expression analysis
Cytoscape version 2.1 (www.cytoscape.org) was used as a platform to construct
networks onto which gene expression data was visualised. Cytoscape allows
construction of network graphs, with genes, proteins, and molecules represented as
nodes and interactions represented as links, i.e. edges, between nodes. Protein
interaction data from PPID (www.PPID.org) was loaded into Cytoscape as a SIF file,
which specifies nodes and interactions only. Once loaded, normalised time-course
expression levels from the primary neuronal gene expression experiments were
loaded as PVAL files and were visually superimposed on the network.
5.3.11 Ortholog mapping and analysis
PSP gene identifiers were mapped to Ensembl predicted genes for Human NCBI
Build 34 using the EnsMart data retrieval system. Orthologs of the Human genes
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were identified in 8 eukaryote species using the Ensembl Compara database.
Species studied and corresponding genome builds were; Mus musculus (Mouse,
NCBI m32), Danio rerio (Zebrafish, WTSI Zv3), Rattus norvegicus (Rat, RGSC 3.1),
Gallus gallus (Chicken, WASHUC1), Anopheles gambiae (Mosquito, MOZ 2),
Drosophila melanogaster (Fruitfly, BGDP 3.1) and Caenorhabditis elegans (WS 116). In
addition, homologues of the proteins were identified in the bakers yeast
Saccharomyces cerevisiae using the Inparanoid database (http://inparanoid.cgb.ki.se/).
An ortholog grid was constructed where "1" corresponded to an ortholog present
and "0" to an absent ortholog. This data was used for hierarchical clustering to
identify evolutionary clusters. The distribution of PSP protein classes populated by
orthologs in each species was analysed and numbers of the top enriched protein
classes in each evolutionary cluster plotted as bar charts.
5.4 RESULTS
5.4.1 Composition of the Postsynaptic Proteome
We isolated MAGUK associated signalling complexes (MASCs) using a previously
described peptide affinity method (Husi and Grant, 2001). This involved using a
peptide corresponding to the six C-terminal residues of NR2B that binds MAGUK
proteins (including PSD-95), as a specific affinity ligand to isolate NMDA-MAGUK
containing complexes. Purified complexes were separated by SDS-PACE gel
electrophoresis, bands excised, digested, and analysed by mass spectrometry.
Western blotting of peptide-purified complexes for candidate proteins were also
performed. These complexes are similar in composition to NMDA receptor
complexes and MAGUK complexes isolated with antibodies (Husi and Grant,
2001),(Husi et al., 2000). Out of the previously identified 100 proteins identified in
the NRC by analysis of anti-NRl immuno- purifications, 84 of these were also found
by the peptide approach. In addition, 86 new proteins were identified by the
peptide approach, many of which were in the molecular weight range obscured by
the contaminating antibody chains in the immuno-purification strategy.
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Figure 5.1 - Distribution of peptide and protein identifications of PSD proteins by MS
analysis of gel-slices.
Coomassie-stained SDS-PAGE gel lane containing purified mouse forebrain postsynaptic
density proteins. The resulting numbers of peptides, proteins and transmembrane proteins
identified in each gel-slice by LC-MS/MS analysis are shown. 1D-SDS-PAGE separation
offers effective protein separation of complex mixtures with an average of 34 proteins
identified per gel-slice and an average of 12 peptides characterised for each protein. The
number of peptides detected per gel slice increases proportionally with molecular weight. 1D-
SDS-PAGE is very compatible with membrane samples and the distribution of proteins with
transmembrane (TM) regions is shown.
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We combined datasets of proteins found in both the NRC and the MAGUK-pep
under the term MAGUK associated signalling complexes (MASCs) due to the large
overlap. 95 MASC proteins were detected by western blotting of purified complexes
and 35 of these were also validated by MS data.
The MASC set represents a comprehensive account of NMDAR-MAGUK complexes
identified by large-scale western blotting and mass spectrometry based analyses of
both antibody and peptide affinity-based purifications. We performed
immunoprecipitation of the AMPA receptor complex with an antibody directed to
the GluR2 subunit and found a significantly smaller complex of 9 proteins by MS
analysis, which included all 4 AMPA subunits. In order to gain an overall view of
the postsynaptic proteome and to validate the components of the MASC and AMPA
complexes, we performed a systematic analysis of purified postsynaptic densities.
PSD proteins were separated on an SDS-PAGE gel (Figure 5.1), 37 gel slices were
analysed by LC-MS/MS. 7402 peptides were identified corresponding to 620 non-
non-redundant protein identifications, with an average of 16.7 proteins identified
per gel slice (Supplementary Table 1).
5.4.2 Integration of postsynaptic proteome datasets
To evaluate the coverage of our PSD data set (now referred to as G2C PSD) we
compiled data from seven published proteomic studies of the PSD and 119
individual papers reporting PSD localised proteins. A number of different sequence
databases were used in these studies for MS mining and as a result, we decided to
use UniProt as our standard protein identifier. In a few cases protein identifiers
could not be mapped to UniProt, so their original identifiers were retained. We
observed redundancy in datasets, with the same protein ID present numerous
times, as well as many IDs corresponding to the same gene product. All 1124
proteins were submitted for blast analysis to the Proteome Analyst (Szafron et al.,
2004) to obtain homologous sequences for human, rat and mouse. We then mapped
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UniProt accession numbers to Unigene via EMBL and Locuslink to cluster the
merged total PSD dataset to remove redundancy. This process enabled grouping of
numerous entries into Unigene clusters and resulted in reduction of the dataset to
1124 non-redundant entries (Supplementary Tables 2 and 4). An evaluation the
relative coverage of each component PSD dataset is presented in Table 4.1.
G2C % Yosh % Jordan Peng % Li % Literature Satoh % Walik % Method
G2C % 100 1D Gel + LC-MS/MS
Yosh % 45 100 2D-LC-MS/MS
Jordan 54 43 100 1D Gel + LC-MS/MS
Peng % 68 54 53 100 1D Gel + LC-MS/MS
Li % 57 54 50 45 100 2D Gel/ICAT + MALDI-TOF
Literature 66 51 54 50 31 100 Various
Satoh % 85 57 52 57 41 37 100 2D Gel + LC-MS/MS
Walik % 100 97 93 90 90 72 41 100 1D Gel + MALDI-TOF
Table 5.1 - Percentage overlap between PSD datasets. Each dataset is represented as a
percent coverage of each other dataset in this grid. The G2C dataset has the best coverage of
each other PSD dataset reported indicating that this set is the most complete. Also, it is clear
that the G2C PSD dataset is the most complete with 66% coverage of literature defined PSD
proteins.
This matrix of percentage coverage shows that the G2C PSD dataset has the highest
coverage of each dataset in the group, indicating that this set of proteins is the most
representative and complete single dataset.
The analytical approaches used in these 7 studies are varied from using ID and 2D
electrophoresis for protein separation, ICAT for sample simplification to a number
of peptide chromatographic methods (RV, 2D-LC) and MS methods (MALDI-ToF,
LC-MS/MS) (Table 4.1). We addressed the issue of bias arising from the use of
different methodologies by comparing the distribution of proteins identified in; our
dataset (ID SDS-PAGE and LC-MS/MS); the dataset of Yoshimura et al (Yoshimura
Chapter 5 - Molecular organisation of the postsynaptic proteome revealed by integrative bioinformatic analysis 207
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
et al., 2004) (2D-LC-MS/MS) and the dataset of Li et al (Li et alv 2004). (2D gel/ICAT
and MALDI-TOF, LC-MS/MS). A 2D scatter plot of Log Mr versus pi was plotted
(Figure 5.2) for these 3 datasets. It can be seen that the 2D-LC-MS/MS approach used
by Yoshimura et al. has the benefit of identifying many low molecular weight
proteins as this approach does not utilise any gel electrophoresis step in which these
proteins would be lost. Our dataset is biased towards integral membrane proteins,
with this class representing 24 % of our total dataset. Both 2D-LC and 2D gel
electrophoresis are poorer approaches for identifying membrane proteins with a
representation of 17 and 7 % transmembrane proteins respectively.
The distribution of protein identifications in the Total PSD dataset show that the
majority of proteins were detected only once (58%) (Figure 5.2A) and that 198 (18%)
proteins were detected twice. The number of proteins detected 5 times or more is
just 72 (6%), although this value is limited by the smaller datasets included in the
Total PSD dataset. In order to define a set of higher confidence proteins we grouped
proteins, which were identified two or more times (466 proteins) and termed it the
"Consensus PSD" (cPSD). We reasoned that the majority of this set of proteins are
abundant, which are more likely to be detected in multiple analyses and that the set
of proteins detected once are perhaps of lower abundance or may reflect differences
in sample preparation. The coverage of each individual dataset with respect to the
core and Total PSD datasets is illustrated in Figure 5.2B. 363 proteins in our dataset
have been validated by their presence in one or more other datasets, representing
78% coverage of the cPSD. In addition, our dataset contains 257 unique proteins
representing 39% of proteins detected once.
5.4.3 Verification of Postsynaptic density proteins
We sought to verify the sub-cellular location of a selected set of postsynaptic density
and MASC proteins by large-scale immunoblotting of whole extract, synaptosomes
and postsynaptic densities from mouse forebrains. 48 commercially available
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■ G2C (1D gel): 147 TM proteins (24 %)
Yoshimura et al (2D-LC): 73 TM proteins (17%)








Figure 5.2 - Comparison of analytical approaches by physiochemical properties.
The G2C approach which was based on 1D-SDS-PAGE separation of PSD proteins
followed by systematic LC-MS/MS analysis of each gel slice is very well suited to
identification of integral membrane proteins and resulted in the identification of 147
transmembrane proteins, 25% of our PSD dataset. Our approach identified less, low
molecular proteins than a gel-free MudPIT-type approach (Yoshimura et al.) as these
proteins are out of the molecular size range of the 1D gel used. Li et al., used a combination
of 2D gel separation as well as ICAT purification which resulted in poorer coverage of
transmembrane proteins (7%) and pl restricted protein identifications.
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Figure 5.3 - Definition of a "Consensus PSD" set of proteins by integration of
multiple synaptic datasets.
(A) Analysis of the distribution of protein identifications reveals that the majority of PSD
proteins were identified only once. Proteins identified in two or more studies may
represent a higher confidence and most likely, a high abundance cPSD dataset. (B)
Contributions of each PSD dataset to the cPSD (Red) and Total PSD (Blue) datasets. It
can be seen that the G2C PSD analysis has the highest coverage of the cPSD at 78 %
and also contributes the most unique proteins to the Total PSD dataset.
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antibodies were tested on these three fractions to demonstrate the presence and
enrichment of postsynaptic proteins (Supplementary Table 5). Overall, we found
that 21 proteins (44%) were clearly enriched, 8 (17%) showed similar abundance, 14
(29%) were present but not enriched and 5 (10%) were undetectable in isolated
postsynaptic densities compared to the other brain fractions (Figures 5.4 and 5.5).
33 of the 48 proteins tested are cPSD proteins and 15 of these displayed enrichment
in the PSD fraction. Proteins contained in the MASC dataset were identified in
purifications from whole brain extract and although 144 out of 186 have been
verified by their identification in the PSD fraction, the remainder of this dataset
requires validation. 15 antibodies to MASC proteins were used to confirm their
presence in the PSD, of these 8 have not been shown to be PSD proteins and 7 were
detected in the PSD by MS just once. We have confirmed the PSD localisation of 14
out of the 15 MASC proteins tested (Figures 5.4 and 5.5), indicating that the majority
of MASC proteins are likely bona fide postsynaptic density proteins.
In addition to verification by immunoblotting, we performed extensive searching in
PubMed for PSD localisation data for these 1124 proteins (Supplementary Table 2).
We found that 119 (10.6%) of these proteins have been previously reported to have
postsynaptic density localisation. As shown in Supplementary Table 3, we have
identified the largest number of known PSD proteins (66% of PSD proteins from the
literature) in our analysis of the PSD compared to other similar analyses, indicating
the high coverage of our dataset.
Chapter 5 - Molecular organisation of the postsynaptic proteome revealed by integrative bioinformatic analysis 211
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes























Figure 5.4 - immunoblotting of proteins enriched in the PSD fraction
Antibodies directed to PSD/MASC proteins were used in immunoblotting experiments to
validate their presence in the postsynaptic density fraction. 21 of these proteins shown
here exhibited enrichment in the PSD fraction, compared to whole extract and
synaptosomal fractions. 3 MASC components (FGD4, MKK7 and RACK1) have not been
found in the PSD by MS analyses and 3 (Desmoglein, ERK2 and PYK2) were detected
only once by MS analyses of PSD fractions. All six of these MASC components have been
validated by immunoblotting which revealed their presence and enrichment in the PSD.
MASC proteins are indicated by an asterix (*).
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Figure 5.5 - Immunoblotting of proteins present or absent in the PSD fraction
Antibodies directed to PSD/MASC proteins were used in immunoblotting experiments to
validate their presence in the postsynaptic density fraction. 8 proteins showed similar
expression levels in whole extract, synaptosome fractions and PSD fractions. 14 proteins
were present in the PSD but not enriched and 5 proteins were not detectable in the PSD.
MASC proteins are indicated by an asterix (*).
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5.4.4 Functional classification of PSP components
The initial approach to characterise the organisation of the postsynaptic proteome
was to classify the proteins into categories that describe their known functional
properties (Table 1). Within the overall postsynaptic proteome, representatives of
many classes of proteins representing a broad range of cell biological functions were
observed: membrane bound receptors, adhesion proteins and channels; a plethora
of signalling proteins and adaptors; and proteins involved with regulation of
transport, RNA metabolism, translation and transcription. The cPSD contains
similar numbers of proteins in most classes compared to our PSD dataset, with the







Channels and Receptors 80 60 39
MAGUKs / Adaptors / Scaffolders 54 31 33
Ser/Thr Kinases 46 23 20
Tyr Kinase 3 3 2
Protein Phosphatases 18 13 11
G-proteins and Modulators 77 40 34
Signalling molecules and Enzymes 278 167 98
Transcription and Translation 119 36 41
Cytoskeletal and Cell Adhesion Molecules 153 99 97
Synaptic Vesicles and Protein Transport 159 119 76
Novel 107 29 11
Other 30 0 4
Summary 1124 620 466
Table 5.2 - Summary of PSD protein classifications.
Proteins found in the Total PSD dataset, our PSD dataset and the cPSD dataset were
functionally classified to show protein class enrichment. The distribution of our PSD
dataset and cPSD protein classes are similar except for Signalling molecules and
Enzymes, which are particularly enriched in our PSD dataset. In addition, the main
contribution of low abundance proteins such as tyrosine kinases and phosphatases to the
Total PSD dataset was from our PSD dataset. In fact, our study was the only one to
identify tyrosine kinases in the PSD, further supporting the increased sensitivity of our
approach. Details for individual proteins and further sub-classifications are found in
Supplementary Table 2.
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This becomes evident when the cPSD is compared to the Total PSD, indicating that
the reduced presence of these protein classes in the cPSD is most probably due to
the lower abundance of these proteins, and thus the decreased likelihood of
detection. This supports the idea that the cPSD represents a consensus of protein
identifications which, on one hand, decreases individual dataset bias for
contaminating proteins (nuclear or mitochondrial) but on the other hand, has
limited coverage of some protein classes because of abundance issues. It is worth
noting that the G2C PSD dataset contributed all three tyrosine kinases found in the
PSD, an indication of the sensitivity of our approach as tyrosine kinases are of
relatively low abundance. The G2C PSD dataset also has greater coverage of most
protein classes compared to individual datasets, which comprise the Total PSD.
5.4.5 Analysis of protein domains in PSP proteins
Do synapse proteomes comprise particular functional subsets of proteins? We
examined their protein domain profiles using the InterPro resource
(http://www.ebi.ac.uk/interpro). All domains in three PSD datasets (G2C PSD (594
proteins with domains (1709 domains)), the Total PSD (1032 proteins with domains
(2786 domains), and cPSD (447 proteins with domains (1298 domains)) were
identified and ranked by frequency (percentage of proteins in each PSD dataset with
a specific domain) and compared with the UniProt mouse proteome
(http://www.ebi.ac.uk/integr8). The enrichment of the top 10 domains found in the
cPSD was compared to the Total and our PSD dataset (Figure 5.6). The greatest
enrichment in these datasets is for protein interaction domains and in particular, the
cPSD has a striking enrichment of PDZ and SH3 domains (7.7 and 7.2 fold
respectively). This is in agreement with the notion that the cPSD contains abundant
proteins such as synaptic scaffolders containing PDZ and SH3 domains. The most
common domains in all three datasets are associated with kinase function and the
enrichment profile for these domains is similar across these datasets.
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■ Total PSD/Mouse Proteome
■ Consensus PSD/Mouse Proteome
Figure 5.6 - Enrichment of protein domains in PSD datasets. Interpro protein domains
were extracted for all PSD datasets and expressed as a ratio of their frequency in PSD
datasets compared to the mouse proteome. The top 10 enriched domains in the
Consensus PSD are plotted, along with the Total and G2C PSD datasets for comparison.
The most highly enriched domains are associated with scaffolding proteins, namely PDZ
and SH3 domains which characterise MAGUK proteins, important postsynaptic density
scaffolders. Other enriched domains are associated with prominent postsynaptic processes
such as calcium signalling, phosphorylation and G-protein signalling.
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This enrichment in kinase domains correlates with enrichment in other domains
commonly found in protein kinases, which allow them to interact in networks (e.g.
SH3, PDZ interaction domains (Manning et al., 2002). Importantly, domains
involved with Ca2+-dependent signalling, a major feature of postsynaptic signal
transduction, were also highly abundant (C2, C2 calcium/lipid-binding). Similarly,
members of the Ras GTPase superfamily were enriched by over 5-fold in the Total
PSD dataset. Conversely, some domains that are highly abundant in the mouse
proteome were absent from all PSD datasets, such as olfactory receptor homeobox
domains (2nd and 19th most abundant domains respectively).
5.4.6 Protein domain organisation
To evaluate the differences in molecular organisation between the MASC (a protein
complex dataset) and the cPSD, we compared their domain organisation by
hierarchical protein domain clustering. Proteins in these datasets that contained
Interpro domains that were present more than once, and were present in more than
one protein were clustered and the resultant clusters were annotated according to
their protein classes (Supp table). MASC protein domains cluster into 14 discrete
sets of proteins (Figure 5.7) reflecting many of the structural and functional aspects
known about this set of proteins. This complex is centred on interactions with
glutamate receptors and PDZ-containing scaffolders, which provide a framework in
which a host of kinases, phosphatases and signalling molecules transduce
information to gene expression regulatory pathways and to cytoskeletal and
transport networks. A large proportion of the MASC (113 proteins) is represented in
the cPSD, so to compare these two datasets; we clustered domains from cPSD
proteins, which are not MASC proteins (Figure 5.8). This cPSD (minus MASC) set
forms 25 clusters that encompass all MASC clusters except for tyrosine kinases,
which are well-known low abundance proteins. There is an increase in the diversity
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Figure 5.7 - Hierarchical domain clustering of MASC proteins. Interpro domains in MASC
proteins occurring more than once in the MASC dataset were clustered. Discrete clusters (red
boxes) were annotated with the protein class of which the majority proteins belonged to.
Clusters are formed from co-occurrence of 2 or more domains characteristic of a protein class
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Figure 5.8 - Hierarchical domain clustering of cPSD minus MASC proteins. In order
to dissect the molecular differences between the cPSD and MASC, Interpro domains in
cPSD minus MASC proteins, occurring more than once in the MASC dataset were
clustered. Discrete clusters (red boxes) were annotated with the protein class of which the
majority proteins belonged to. Clusters are formed from co-occurrence of 2 or more
domains characteristic of a protein class
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of protein domains/protein classes represented in this subset of the cPSD and also a
clear enrichment of cytoskeletal/cell adhesion proteins representing 7 clusters. This
dataset also contains other receptors and channels and may represent abundant
parts of other multiprotein complexes yet to be characterised.
5.4.7 Multiprotein complexes in the postsynaptic density
Analysis of organelles and protein sub-fractions based on affinity purifications
presented in this study provides complimentary information. It provides
preliminary validation of proteins, sub-cellular localisation information on
components identified in protein complexes and vice versa. Organelle-like
structures such as the PSD, represent complex protein mixtures that contain
molecules across a large dynamic range of abundances and fractionation methods
are known to enhance protein identification. In most cases, this would have been
based on general physical properties of proteins such as molecular weight or charge
(Lubec et al., 2003), however we have used methods to isolate protein complexes,
the functional models within the organelles. Characterisation of protein complexes
from the PSD, such as MASC and AMPA has enabled identification of 78 proteins
that were not characterised in our G2C PSD analysis and increased our coverage of
the PSP by 12.5%.
Previous proteomic studies showed that NMDAR-PSD95 complexes were 2-3MDa
particles which included mGluR receptors, and that AMPA receptors were in
different complexes (Husi and Grant, 2001); (Garry et al., 2003). The mGluR5
receptor complex has recently been characterised in a similar fashion to the MASC
and was found to comprise of 76 proteins, including the NMDA receptor subunit
NR2A (Farr et al., 2004). The majority of proteins in all three glutamate receptor
complexes have been independently identified as PSD proteins (Figure 5.9). These
complexes also contain proteins, which have not yet been detected in PSD analyses,
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Figure 5.9 - Multiprotein complexes at the postsynaptic density.
Venn diagram illustrating the overlap of three glutamate receptor complexes with the
Total and cPSD datasets. It can be seen that the majority of overlap between
components of these complexes and the PSD occurs in the high confidence cPSD
dataset. Proteins detected in these multiprotein complexes, which were not found in any
of the PSD datasets, are generally of low abundance that are enriched in immuno-
purifications of complexes compared to whole PSD analyses.
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presumably due to abundance issues in analyses of PSD preparations compared to
enriched protein complexes. We have validated the presence of seven such proteins
in the PSD by immunoblotting and this has been taken into account in the numbers
shown in Figure 5.4. It is interesting to note that the majority of the components of
these complexes validated as PSD proteins and the overlap between these
complexes occur in the cPSD (Figure 5.9), supporting the notion that the cPSD is an
important subset of the Total PSD dataset. This is consistent with a postsynaptic
organisation where the MASC signalling complex is connected to multiple cell
biological effector mechanisms organised into their respective complexes. In
addition to MASC and AMPA complexes, components of other complexes such as
cell adhesion, growth factor, cytoskeletal, transport and ribosomal complexes were
detected.
5.4.8 Developmental assembly of PSP components
5.4.8.1 PSP expression profiles
Having established a map of the protein components of the PSP in adult brain, we
sought to investigate how these components are assembled in a temporal fashion
using a genome-wide approach provided by the Affymetrix microarray technology.
Triplicate mouse primary hippocampal cultures were grown and total RNA
extracted at 0.25, 1, 2, 4, 8, 12 and 16 days, corresponding to different stages in the
neural morphology of the cells (Figure 5.10A). We did not extend further to avoid
possible apoptotic processes that could modify the gene expression profile. Briefly,
the morphology of the culture could be described as follows: first, some incipient
neurites were observable at 0.25 day but the initial neuronal contacts were taking
place around 4 days. Since here, a profusion of branches and prolongations
appeared more and more dense, producing mesh and fibre-like structures at the
final points of the time course (12 and 16 days).
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PSP protein accession numbers (UniProt, Unigene and Entrez Gene) and gene
names were used to mine probe set ids on the Mouse 430_2.0 affymetrix array,
which was used for gene expression analysis of primary neuronal cultures. An
initial hierarchical clustering analysis with a minimum similarity of 0.8 was used to
remove outliers and to average data from multiple probe sets to provide single data
points corresponding to individual genes. This data was then re-clustered as shown
in Figure 5.10B. This analysis resulted in 26 gene expression clusters, of which there
were four main clusters with similar expression profiles. Gene ontology (GO)
analysis of each cluster was performed and significantly (P > 0.01) enriched GO
terms (compared to distribution of GO terms for all of the genes on the array) are
shown in Figure 5.10B. Cluster 1 represents a steady up-regulation of gene
expression with respect to time and corresponds to genes involved in signalling
complex formation and synaptic signalling processes. Cluster 2 represents a similar
steady up regulation of genes till 288 hours in culture but then a down-regulation
after this point. This cluster of genes are involved in the secretory pathway and
vesicle-mediated transport processes. Cluster 16 represents a steady down-
regulation of initially highly expressed genes, which correspond to genes involved
in protein biosynthesis and ribosome function. Finally, cluster 21 represents a
complex up regulation and subsequent down-regulation of genes and corresponds
to processes associated with cytoplasmic organisation and dendritic morphogenesis.
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Figure 5.10 - Profiling of developing hippocampal cultures
A - Hierarchical clustering of PSP gene expression time course data from developing
hippocampal primary neurons. PSP expression data from 7 time points (0, 24, 48, 96, 192,
286, 384 hrs) was obtained from Mouse 430_2.0 affymetrix array analysis of hippocampal
primary neurons. Hierarchical clustering of PSP expression data with a minimum similarity of
0.8 resulted in 4 significant clusters. The significantly (P <0.01) over-represented GO terms
associated with proteins (compared to the Mouse 430_2.0 affymetrix array) in each of these
clusters is indicated on the right of this figure.
B - Development of hippocampal neurons in culture. Representative contrast phase
pictures of neurons at the indicated times (with or without the electrodes of the multielectrode
arrays) showing normal development.
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5.4.8.2 Time course analysis of synapse assembly
In order to observe detailed temporal profiles, we focused in this case on specific
classes of proteins in the PSP. In total 12 PSP classes were analysed, of which
(ribosomal (55), protein transport (67), G-proteins and modulators (73), cell
adhesion (35), receptors and channels (76), scaffolders (50), kinases (51),
phosphatases (20) and cytoskeletal proteins (104)) were defined by Swiss Prot
keywords (Supp table 2). In addition, 54 proteins with the Swiss Prot keyword
neurogenesis (11 in PSP), Neural specific transcription factors (93), (Gray et al.,
2004), Creb targets (78) (Impey et al., 2004) and 29 activity dependent genes (supp
table adg) (8 in PSP) were analysed. Genes with a normalised expression value of >
0 at a given time point were considered to be up-regulated and the percentage of
genes up-regulated for each class are represented in Figure 5.11. Time course
analysis of these defined gene/protein classes revealed four distinct expression
phases in developing hippocampal neurons. Phase 1 is characterised by high
expression of neural specific transcription factor genes, which decreases to its
average expression at the end of this phase (2.5 days). Phase 2 is characterised by the
expression of genes involved in protein transport, followed by a plateau of the
steadily increasing expression of G-proteins and modulators. Phase 3 represents the
main phase of up-regulation of the core synaptic machinery including receptors and
channels, scaffolding proteins and cell adhesion molecules. Phase 4 shows that the
necessary molecular machinery is in place to produce electrical activity and for the
up-regulation of activity-dependent genes.
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Figure 5.11 - Phases of synapse assembly determined by analysis of time
course gene expression data for PSP protein classes. Normalised gene
expression data for classes of PSP proteins was used to define potential phases
of synapse assembly. The percentage of genes up-regulated at a given time point
is the % of genes with a normalised expression value of > 0 and at each time
point and represents the average up or down regulation of PSP protein classes.
The total mean frequency is the measure of electrical activity in the cultured
neurons at each time point. This analysis revealed 4 main time courses of gene
expression during neuronal development which correspond to stages of synapse
assembly and ultimately to formation of mature neurons with robust electrical
activity and up-regulation of activity regulated genes
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5.4.8.3 Co-expression and protein interactions
Interacting proteins are more likely to be involved in similar cellular functions and
processes and are more likely to be co-expressed and co-regulated by sets of
transcription factors. It has been shown that interacting proteins are more likely to
be present in the same expression clusters than random sets of proteins in yeast (Ge
et alv 2001). To investigate this phenomenon in the PSP, protein interaction data for
MASC was integrated with gene expression data extracted for MASC genes from
the primary neuronal gene expression experiments. This was achieved by using
Cytoscape (Shannon et al., 2003), which enables construction of protein interaction
networks and allows integration of processed gene expression data.
Normalised MASC gene expression data was colour-coded from -2 (low expression
(green)) to +2 (high expression (red)) and overlaid with the protein interaction
network for the entire time course of gene expression (Figure 5.12). The main trend
observable from this analysis is that there are two sub-groups of proteins in this
expression/interaction network. One group (~ 25 %) is highly expressed early in the
primary culture experiment and their expression decreases with neuronal
development. This does not preclude a function in MASC in mature neurons
because although the expression is low at the end of the time course they are not
absent. It is possible that these proteins have a developmental function at non-
synaptic sites and then an alternative role in MASC in mature neurons. The majority
of MASC genes in this network however, start with a low expression level but
increase in a similar profile to high expression levels at the end of the time course.
This does not prove that co-expressed synaptic proteins are more likely to interact
with one another but when compared to the time course analysis of PSP protein
classes (Figure 5.11) it can be seen that the majority of the components of the MASC
complex seem to be co-regulated.
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Figure 5.12 - Network of protein interactions and dynamic gene expression in MASC.
Protein-protein interaction data (www.PPID.ora) was used to construct this network onto
which gene expression data from hippocampal primary neuronal cultures was overlaid.
Normalised gene expression data was used and represented in colour from green (low
expression) to red (high expression) and white (no expression data). It can be seen in the
time course that the expression of most proteins is up-regulated over time, although the
expression profile of some proteins is inverse to this indicating possible developmental
requirements for these proteins.
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5.4.9 Tissue expression transcriptome profiling of synapse proteomes
To extend our gene expression analysis of the PSP we mined the gene expression
atlas and retrieved data for 464 unique PSP genes across 45 mouse tissues (13
brain/neuronal tissues). Hierarchical clustering analysis with a minimum similarity
of 0.5 produced three broad clusters (Figure 5.13). Significant enriched (p >0.01) GO
terms associated with genes in each cluster were determined and are summarised in
Figure 5.13. Cluster 1 contains genes whose expression is lower in the 13 neuronal
tissues than the other tissues included in this analysis. The majority of GO terms
enriched in this cluster correspond to biosynthesis processes especially translation
with a number of GO terms referring to ribosome or protein biosynthesis. Cluster 3
also contains genes whose expression is lower in the 13 neuronal tissues than the
other tissues included in this analysis and the majority of GO terms enriched in this
cluster correspond to catabolic and metabolic processes. In contrast to cluster 1 and
3, cluster 2 contains genes highly enriched in neuronal tissue and in particular a
sub-cluster (marked by a red box, Figure 5.13) in which the gene expression is not
only high in neuronal tissues but appears to be nearly exclusive to neuronal tissues.
The majority of GO terms enriched in this cluster correspond to classical synaptic
functions, from ion transport to a variety of signalling processes. The distribution of
cPSD and MASC genes were mapped to these gene expression clusters and it can be
seen that both the cPSD and MASC are more prominent in the highly
expressed/neuronal enriched cluster 2.
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Figure 5.13 - Hierarchical clustering of PSP gene expression from 45 tissues.
Gene expression data for PSP proteins from the Gene expression atlas was clustered to
identify neuronal tissue enriched gene expression. This resulted in identification of 3
clusters of expression and GO terms significantly enriched in these clusters are
summarized on the right of this figure. A sub-cluster of high gene expression over 13
nervous tissues (red box) can be seen in cluster 2 which is associated with a higher
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5.4.10 Evolutionary of analysis of PSP genes
The enrichment of signalling domains in PSP proteins compared to the whole
proteome (section 5.4.5) correlates with the expansion of these domains in the
genome, with the evolutionary step from single to multi-cellular organisms
(Manning et al., 2002). In addition, in the tissue expression transcriptome analysis
(section 5.4.9) we observed that one quarter of the PSP genes analysed appear to be
specific to nervous tissue. These two observations support a model where proteome
diversification was necessary for the evolution of neuronal function and synapses in
particular. In order to investigate this further, ortholog analysis for PSP genes was
performed using data available for 696 PSP genes, which included the G2C PSD and
MASC datasets. Hierarchical clustering of PSP gene orthologs from C. elegans, A.
gambiae, D. melanogaster, D. rerio, S. cerevisiae, G. gallus, R. norvegicus, M. musculus
and H. sapiens was performed to identify taxon specific genes (Figure 5.14).
This ortholog analysis resulted in the identification of five major clusters of PSP
genes. Cluster 1 is the largest group of genes and corresponds to PSP genes present
in vertebrates only and represents 34% (234 genes) of the total dataset. Cluster 2
corresponds to higher vertebrate specific PSP genes and represents 12% (85 genes)
of the total dataset. Cluster 3 corresponds to genes absent in C. elegans and S.
cerevisiae, which represents 8% (56 genes) of the total dataset. Cluster 4 corresponds
to genes absent in S. cerevisiae only and is a significant proportion (25% (174 genes))
of the total dataset. Interestingly cluster 5 corresponds to PSP genes conserved in all
phylogenetic classes analysed, which means that 9% (64 genes) of the PSP proteome
is composed of genes with yeast orthologs.
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Figure 5.14 - Hierarchical clustering of PSP gene orthologs. Orthologs from C.
elegans, A. gambiae (Mosquito), D. melanogaster, D. rerio (Zebrafish), S. cerevisiae, G.
gallus, R. norvegicus, M. musculus and H. sapiens were clustered to identify taxon
specific sets of genes. It can be seen that a small set of genes are conserved in all
species which comprise ancient components of the PSP. Clusters with genes absent in
yeast and absent in C. elegans and S. cerevisiae were found and in addition, vertebrate
and higher vertebrate specific genes were identified.
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Is there are relationship between these PSP evolutionary clusters and the genes
which comprise them? We again used proteomic data to extract functional
information from genetic data. In this case we analysed the distribution of PSP
protein classes in each evolutionary cluster (Figure 5.15). The most ancient class of
proteins found in this analysis was cytoskeletal proteins, being the most enriched
class in the conserved cluster (Cluster 5) (Figure 5.15A). This is expected because
even the simplest organisms utilise a cytoskeleton for cell support and transport.
Cluster 4 corresponds to orthologs present in all taxa studied except for yeast,
shows a clear enrichment (2 fold) for motor proteins (Figure 5.15B). Transport
mechanisms in unicellular eukaryotes such as yeast, expanded to meet the increased
demand for transport in multicellular organisms (Vale, 2003). Prokaryotes use
filamentous systems for various transport processes, whereas eukaryotes emerged
with an efficient system consisting of a number of molecular motors, each of which
was designed to carry different types of cargo. The distinguishing feature of
multicellular eukaryotes compared to unicellular ones with respect to these motors
appears to be the increased diversity and regulation of these processes (Vale, 2003).
Thus, the enrichment of motor proteins in cluster 4 seems not to reflect a newly
acquired process in multicellular eukaryotes but rather a reflection of the increased
complexity of regulation of this process to meet increased transport demands.
Cluster 3 is characterised by orthologs absent in C. elegans and S. cerevisiae and is
enriched for enzymes and channels and receptors probably indicating an expansion
of these types of proteins after C. elegans (Figure 5.15C). Cluster 2 corresponds to
orthologs present in higher vertebrates only and shows enrichment for G-proteins,
novel proteins, transporters and cell adhesion proteins (Figure 5.15E). Cluster 1
contains orthologs that are present in vertebrates only and there is enrichment for
synaptic vesicle proteins, enzymes and signalling proteins (Figure 5.15D). Several
synaptic vesicle genes have orthologs in yeast that are associated with the secretory
pathway (Bennett and Scheller, 1993) however, as opposed to constitutive secretory
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Figure 5.15 Evolution of PSP protein classes. Ortholog clusters generated as
shown in Figure 5.15 were used to analyse the enrichment of specific classes of
proteins in the PSP. The top enriched protein classes for each evolutionary
cluster are shown from panels A to E. The most conserved protein classes are
cytoskeletal and kinases and the most recently evolved classes include G-
proteins, glutamate receptors and PDZ-containing scaffolders.
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pathways neurosecretion is regulated by calcium. Neurons therefore contain
additional regulatory components for regulated secretion and these may be
contributing to the enrichment of vesicle proteins in this vertebrate specific
evolutionary cluster (Volknandt, 1995).
5.4.11 Protein-protein interactions in the PSP
To facilitate analysis of the organisation of the PSP at the level of protein-
interactions an in-house database called PPID (www.PPID.org) was used. This
database is a mammalian (mouse, rat, human) Protein-Protein Interaction Database
(PPID) describing approximately 8000 protein interactions for > 1700 proteins. 650
protein-protein interactions for 281 PSP proteins are shown in Figure 5.16. The
individual proteins in this network are represented by filled circles (nodes) and the
interactions are represented by connecting lines (edges). The distribution of PSP
interactions show a clear bias toward proteins in MASC that can be explained by the
fact the MASC set was the starting point for data mining. The majority of interaction
data for non-MASC proteins in the PSP are for cPSD proteins. This is because of the
large overlap between the MASC and cPSD datasets and also possibly due to the
fact the highly abundant proteins may be more likely to be studied than low
abundant proteins.
This interaction network was combined with phenotypic data in a manner
analogous to that for integration of MASC interaction and gene expression data
(section 5.4.8). An in-house database of mouse targeted mutations, in which a
change in LTP or LTD was observed for a given gene knockout was used. PSP genes
for which such mutant phenotypic data was available are coloured in green in
Figure 5.16. 19 MASC genes, 29 cPSD and 8 Total PSD (Not in MASC or cPSD)
display changes in LTP/LTD when mutated. Although, at present this PSP
interaction network is incomplete, it indicates a potential way of identifying
potentially interesting genes for mutagenesis and follows the observed strong
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relationship between number of interactors and phenotype in S. cerevisiae (Jeong et
al., 2001).
5.4.12 Construction of an Alzheimer's disease protein interaction network.
The postsynaptic proteome contains many prominent candidate proteins for
neurodegenerative diseases such as Alzheimer's disease (AD). We reasoned that
these proteins may have similar functions or are involved in sets of pathways that
cause or affect AD. To address this we investigated the relationship between these
AD-associated proteins by constructing a protein-protein interaction network. The
starting point for this was a dataset of proteins, which were up- or down-regulated
in mice transgenically overexpressing glycogen synthase kinase-3P (GSK-3p), a
kinase with a prominent role in neurodegenerative disease (Kaytor and Orr, 2002).
GSK-3p is a serine-threonine protein kinase capable of phosphorylating tau and
hyperphosphorylated tau is a principle component of neurofibrillary tangles, which
are characteristic of AD brains. It is regulated by serine (Inhibitory) and tyrosine
(stimulatory) phosphorylation and by protein complex formation and its
intracellular localisation (Figure 5.17). GSK-3P is a key regulator of neuronal
plasticity and gene expression controlling the function of many metabolic, signalling
and structural proteins. It also regulates cell survival, as it facilitates a variety of
pro-apoptotic mechanisms [Harwood, 2001 #30]. It has been linked to all primary
abnormalities associated with AD and was shown to interact with components of
the plaque producing amyloid system [Grimes, 2001 #31].
A comparison between GSK-3P transgenic mice and wild type revealed 51 proteins
whose expression differed significantly (Tilleman et al., 2002). Twenty-five of these
proteins are present in the postsynaptic proteome, 14 of which are components of
NMDAR-PSD-95 complexes that constitute MASC. There was a significant decrease
in the relative abundance of cytoskeletal and energy metabolism proteins and a
significant increase in proteins involved in signal transduction and oxidative stress
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Figure 5.17 - Regulation and functions of GSK3{3.
Adapted from "The multifaceted roles of glycogen synthase kinase 3beta in cellular
signaling." Grimes CA, Jope RS. Prog Neurobiol. 2001 Nov;65(4):391-426.
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in the GSK-3p transgenic mice. A similar study by the same group was performed
on mice over expressing human Tau (Tilleman et al., 2002). Proteins were resolved
by 2D-PAGE and 34 proteins whose expression levels in wild-type and tau
transgenic mice differed at least 1.5 fold were identified by ESI-MS [Tilleman, 2002
#27],
A comparison of the profile of proteins with altered expression in the Tau and GSK-
3p transgenic mice showed that there were a number of proteins with similar
changes consistent with the mutual involvement of these two proteins in the process
of neurodegeneration.
Using the data obtained from the study of GSK-3P and Tau constitutively active
mutant mice by Tilleman et al, we attempted to create a global map of AD disease
association. This was achieved by constructing a protein-protein interaction map
(Figure 5.18) of proteins implicated in AD pathology. Proteins found to have altered
expression in the GSK3-P constitutively active mutant mice were extensively
searched for interactors in PPID (Protein-Protein Interaction database (Husi, 2002)
and in Pubmed. In addition, these initial proteins as well as the accumulating
interactors were extensively mined in PubMed to ascertain whether they had
previously been implicated in AD. These proteins were deemed implicated from
reports of altered expression in post-mortem brains or proteins, which have been
shown to affect the basic process of amyloid deposition and NFT formation. GSK-
3[3 phosphorylation substrates relevant to the disease were also included. This data
mining was carried out until satisfactory interaction information for the initial set of
proteins was obtained. This yielded 118 proteins in the interaction map, of which 97
are implicated in AD and 27 proteins were included for completeness of the
interaction network. This global approach of analysing proteins implicated in AD
provides a platform to evaluate mouse models of disease. It can be clearly seen that
many of the proteins altered in GSK-3P constitutively active mutant mice are
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Figure 5.18 - Alzheimer's disease protein interaction network. This interaction network
was constructed from literature mining for AD candidate proteins and protein interaction
data from PPID. A. Interaction network showing the overlap between AD candidate proteins
and postsynaptic proteome datasets. B. Evaluation of GSK3p as a mouse model for AD.
Proteins with altered expression in GSK3P overexpressing mice are overlaid onto the AD
protein interaction network.
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implicated in AD, and interacting proteins which were not previously implicated
may be novel AD associated proteins. Key proteins responsible for the pathological
hallmarks of AD such as Tau, GSK-3p, P-catenin, amyloid-precursor protein,
presenilin are present and are highly connected. They are closely linked to
functional classes of proteins such as the cytoskeleton, membrane receptors,
modulators of oxidative stress and cell death and numerous signalling molecules.
Components of this network have roles in pathways, which may relate to functional
impairments seen in AD. These range from synaptic transmission, stress response,
lipid transport, glycolysis and cytoskeletal organisation. The number of proteins
implicated in AD is quite striking and the fact that so many of these proteins can
cluster together into an extensively connected network (over 280 interactions)
creates confidence in this network approach. This points to the possibility of the
presence of pathways and processes present in the network that are core to the
pathogenesis of the disease
Further analysis of this network in relation to functional complexes at the synapse
revealed that 54 out of the identified 97 proteins associated with AD are
components of the PSD, 32 are found in MASC and three are present in the AMPA
receptor complex (Figure 5.18). This also highlighted a large overlap of 30 proteins
common to the PSD and MASC that are implicated in AD. It is probable that there
are subsets of proteins within the large number of proteins associated with AD that
represent distinct mechanisms leading to the formation of amyloid plaques and
NFT's characteristic of AD.
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5.5 DISCUSSION
5.5.1 Proteomic analysis of the postsynaptic proteome
We have presented a comprehensive analysis of isolated postsynaptic densities and
embedded multi-protein complexes associated with NMDA and AMPA receptors.
We have combined existing synapse proteomic data with that reported here to
provide the most complete picture of the postsynaptic proteome to date. To our
knowledge, the postsynaptic proteome is one of the most complicated subcellular
structures analysed, but unlike other organelles, the PSP appears to hold a high
degree of cellular autonomy. The composition of the PSP in terms of functional
protein classes is diverse, with the necessary molecular machinery for not only
classical synaptic processes and a myriad of signalling pathways, but for a host of
supporting activities such as protein synthesis and degradation, transport and
metabolism. Moreover, 10% of PSP proteins are novel and may participate in
synaptic processes yet unknown.
The large number of proteins found at the PSD and the presence of many ribosomal,
mitochondrial and nuclear proteins has prompted speculation over the purity of
isolated PSD fractions used in proteomic analyses. There are numerous examples
where such proteins were validated as true PSD proteins. Some proteins such as
voltage-dependent anion channel 1 (VDAC1), which was originally found in the
outer mitochondrial membrane, is present in the PSD (Moon et al., 1999). Nuclear
proteins such as AIDA-1A, mKIAA0417 and hnRNP localise to both the nucleus and
the PSD (Jordan et ah, 2004). It is apparent that many proteins do not exist in
discrete locations or indeed posses the same functions in different cellular contexts.
The data presented and compiled in this study is a draft of an average isolated
postsynaptic density. The starting material for the analyses incorporated into our
draft PSP are from different species (mouse and rat) and from different brain
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regions (forebrain and whole brain) and encompass hundreds of neuronal cell
types. We are now at a point where it is becoming feasible to compare different
types of synapse proteomes. This could be achieved by correlation profiling
(Andersen et al., 2003), a quantitative proteomic approach where synaptosomes and
isolated PSD's are isotopically tagged ((ICAT or iTRAQ) and the resultant
quantitative MS data would show enrichment or depletion of proteins in the PSD
compared to synaptosomes. This type of analysis would provide confident
assignment of true PSD proteins, highlight contaminating proteins and would
validate the PSD localisation of proteins currently considered restricted to other
cellular compartments.
In addition, isolated PSD's or protein complexes from different brain regions or
cultured cell types could be quantitatively compared using isotopic labelling.
Alternatively, peptides derived from SILAC (Stable Isotope Labelling with Amino
acids in Cell culture) labelled cells could be used to quantitatively compare the
expression of proteins in many tissue samples (Ishihama et al., 2005). Using these
approaches, proteins enriched in a particular cell type or brain region would be
identified as being potentially more relevant to the physiology of that particular
cellular or tissue type. It is at this stage where systematic immuno-cytochemistry of
these enriched proteins would be feasible and would provide complementary
information regarding their specific protein localisation at the PSD and throughout
the cell type in question. Current projects such as Gene Expression Nervous System
Atlas (GENSAT) in which large-scale in-situ hybridisation and BAC transgenic
reporter genes are being used to map gene expression in neuronal cell types will
provide complimentary information to the proteomic experiments suggested here.
5.5.2 PSP organisation
Mass spectrometry-based analysis of proteomes is routinely producing long lists of
proteins that describe the composition of a particular proteome. The usual type of
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bioinformatic analysis carried out on this data involves categorising the protein
components according to functional class (using varied criteria) and by Gene
Ontology (GO) terms. The usefulness of this basic approach is limited, and the value
of such proteome lists is debatable without the appropriate analysis to extract
biologically meaningful information, which describes the proteome in question. We
believe that integration of diverse data types with proteome data and analysis of
this integrated data provides an appropriate way to address the complex biology of
a proteome. In this study, we used data from multiple levels of cellular complexity
and integrated it with our proteomic data to ask how the postsynaptic proteome is
organised?
5.5.2.1 Genes
The genes that code for proteins in the postsynaptic proteome are diverse and as the
synapse itself is a cell-cell contact that specialised through evolution, we
investigated the possible origins of these genes. We performed ortholog analysis for
PSP genes using data available for 696 PSP genes, which included the G2C PSD and
MASC datasets. Hierarchical clustering of PSP gene orthologs from C. elegans, A.
gambiae, D. melanogaster, D. rerio, S. cerevisiae, G. gallus, R. norvegicus, M. musculus
and H. sapiens was performed to identify taxon specific genes (Figure 5.14). Five
major evolutionary clusters were found, which included higher vertebrate specific,
vertebrate specific, absent in C. elegans and S. cerevisiae, absent in S. cerevisiae only
and finally genes conserved in all phyla analysed. This clustering result clearly
showed that components of the PSP evolved in stages. To gain more insight into
these evolutionary clusters we analysed the distribution of PSP protein classes in
each cluster. The most ancient class of proteins, the first building blocks of the
synapse is cytoskeletal proteins. Genes associated with protein transport are the
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Figure 5.19 - Scheme of PSP complexity and the analysis applied to each level
of organisation
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next acquisition in evolutionary time, allowing trafficking of newly synthesised
proteins out to the dendrite.
Next, in the cluster representing genes absent in C. elegans and S. cerevisiae, we see
enrichment for enzymes, channels and receptors indicating an expansion of these
types of proteins after C. elegans. In the vertebrate only cluster, there is an
enrichment for synaptic vesicle proteins, enzymes and signalling proteins,
presumably necessary to deal with the increasing complexity of synapse function. In
the higher vertebrate cluster, there is enrichment for G-proteins, novel proteins,
transporters and cell adhesion proteins; these novel proteins would be good
candidates for further characterisation. This analysis has provided insight into the
timing of the appearance of sets of synaptic genes and also the appearance of the
functions associated with these genes.
5.5.2.2 mRNA expression
The next level of complexity that was investigated is the transcription of PSP genes
into mRNA. Two data sources were used for this analysis; tissue gene expression in
adult mice from the Gene Expression Atlas, and a time-course of genes expression in
developing primary hippocampal neuronal culture generated in-house. First, we
asked are there PSP-specific genes. To address this, we mined the gene expression
atlas and retrieved data for 464 unique PSP genes across 45 mouse tissues (13
brain/neuronal tissues). This resulted in three broad gene expression clustered and
to assign general functions to the genes in these clusters we looked a significantly
enriched GO terms associated with genes in each cluster. The first cluster contained
genes whose expression was lower in neuronal tissues than the other tissues
analysed. This cluster was enriched for GO terms associated with biosynthesis
processes especially translation with a number of GO terms referring to ribosome or
protein biosynthesis. Similarly, cluster three contained genes whose expression is
lower in the 13 neuronal tissues than the other tissues included in this analysis and
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the majority of GO terms enriched in this cluster correspond to catabolic and
metabolic processes. However, cluster two showed strong expression in neuronal
compared to non-neuronal tissues and the majority of GO terms enriched in this
cluster correspond to classical synaptic functions, from ion transport to a variety of
signalling processes.
This tissue expression analysis of the PSP reveals yet another level of organisation
and hints at the evolutionary origins of the synapse. Of the PSP genes included in
this analysis it appears that approximately a quarter of these are candidate neuronal
specific genes or at least prominent neuronal genes with strong enrichment of
synapse-associated GO biological processes. The remainder of PSP genes in this
analysis are not specific to neuronal tissues and have generalised housekeeping
functions. This supports the view that the synapse is home to a wide variety of
cellular processes, from protein biosynthesis to metabolic pathways which, provide
a supporting role for the more specialised synaptic processes of ion transport and
receptor signalling.
The differentiation of neural precursor cells into synaptically connected neuronal
networks with electrical activity can be monitored using primary culture of
embryonic mouse hippocampus neurons. Therefore, we used mRNA levels to
indicate the timing of expression of PSP genes in developing neuronal cultures.
Phase 1 is characterised by high expression of neural specific transcription factor
genes, which decreases to its average expression at the end of this phase (2.5 days).
Phase 1 also displays dramatic expression of ribosomal genes culminating in 97 % of
these genes being expressed by day two and the highest expression of genes
associated with the process of neurogenesis (Figure 5.11A). The coordinated up-
regulation of components of transcriptional and translational machinery within the
first 2 days is expected and necessary for the massive growth of projections/spines
that starts at day 4 . After production of ribosomes, expression of genes involved in
transport of proteins from the cell body to the growing projections is essential and
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the peak expression of such genes characterises phase two of this developmental
time course (Figure 5.11B). This is closely followed by a plateau of the steadily
increasing expression of G-proteins and modulators in agreement with the notion
that G-protein regulated processes are required during neurogenesis as well as in
mature synapses (Luo, 2000).
Phase 3 represents the main phase of up-regulation of the core synaptic machinery
including receptors and channels, scaffolding proteins and cell adhesion molecules
(Figure 5.11C). These three classes of proteins along with the core PSD display a
similar profile of up-regulation over time. After the expression, trafficking and
assembly of these synaptic molecules by day 10, it can be seen that sufficient
synapses have formed and that the necessary molecular machinery are in place to
produce electrical activity. It is this synaptic functionality, as measured by electrical
activity and the increase thereof, which defines the last phase characterised by gene
expression data. The steady increase in activity is accompanied by a plateau in
expression of the classes of proteins thus far described. However, the expression of
cytoskeletal proteins, kinases and phosphatases that may be regulating the ongoing
activity are still increasing in phase four (Figure 5.11D). Activity-dependent genes,
i.e. genes that are regulated by NMDA receptor activity in the hippocampus or
cortex (supp table x) show a sustained up regulation in this phase and the increase
in expression shows a profile similar to that of the total mean frequency of electrical
activity (Figure 5.11E). This would indicate that the electrical activity, including the
NMDA receptor-mediated component, is controlling the expression of these genes,
which are known to be involved in synaptic plasticity.
5.5.2.3 Proteins
Next, the proteins that were characterised in our proteomic data and from other
studies were analysed in terms of functional classes and proteins domains. In the
PSP there are representatives of many classes of proteins representing a broad range
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of cell biological functions were observed: membrane bound receptors, adhesion
proteins and channels; a plethora of signalling proteins and adaptors; and proteins
involved with regulation of transport, RNA metabolism, translation and
transcription.
Protein domains are structured units within proteins and many of these domains
have associated functions, so analysis of the occurrence of different domains in a
proteome can provide functional insight. The enrichment of the top 10 domains
found in the cPSD was compared to the Total and our PSD dataset (Figure 5.6). The
greatest enrichment in these datasets is for protein interaction domains, in
agreement with the notion that the cPSD contains abundant proteins such as
synaptic scaffolders. Protein domains associated with kinase function were the most
common in the PSP correlating with enrichment in other domains commonly found
in protein kinases, which allow them to interact in networks (Manning et al., 2002).
In addition, domains involved with Ca2+-dependent signalling and members of the
Ras GTPase superfamily were also highly abundant. The same signalling domains
enriched at the synapse are known to have expanded in the genome with the
evolutionary step from single to multi-cellular organisms (Manning et al., 2002).
62% of domains found in proteins contained in the Total PSD are present in S.
cerevisiae, indicating that a large proportion of the basic building blocks of
mammalian synaptic proteins are conserved from before the metazoan expansion.
The complement of these domains increases after this expansion with C. elegans, D.
rerio and D. melanogaster having 85, 86 and 87% of Total PSD protein domains
respectively. This would indicate that after this expansion there was an increase in
the order of 20-30% in the appearance of new domains as well as domain shuffling
to produce new proteins.
5.5.2.4 Protein Phosphorylation
The next level of complexity in the postsynaptic proteome was addressed in chapter
3. Protein phosphorylation is an essential regulator of protein function and is
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particularly important in the postsynaptic proteome where very complex signalling
pathways are believed to occur. Identification of phosphorylation sites, their
cognate kinases and functional significance is critically important for the
understanding of the dynamic organisation of the PSP. We investigated
phosphorylation in the PSP by identification of phosphorylation sites, their cognate
kinases (for a selected set) and construction of a simple three-dimensional network
(Figure 3.13). This network consisted of protein interactions within MASC with
kinase-substrate interactions superimposed. This basic representation of how
phosphorylation can be considered as an extra dimension in protein organisation
hints at possible complexity of a complete kinase-substrate interaction map of the
PSP.
5.5.2.5 Protein complexes
NMDAR, AMPAR complex and mGluR5 receptor complexes are contained in the
postsynaptic proteome and although they were not purified directly from synaptic
preparations the majority of their components are in the PSP. In total, there are 80
channels and receptors in the PSP and although these are very unlikely to exist
together in a single synapse, it is clear that many of these are likely to be
components of other signalling complexes. The idea that a proteome is composed of
such functional units of multiprotein complexes is supported by systematic studies
in yeast (Ho et al., 2002), (Gavin et al., 2002). The co-operative action of groups of
proteins in multiprotein complexes has led to the idea that proteomes are composed
of molecular machines (Gavin and Superti-Furga, 2003). These molecular machines
have distinct functions but may be composed of many of the same proteins that are
present in other machines. We have observed this in the PSP where 21 proteins are
common to MASC and mGlur5 complexes. These two complexes may physically
coupled as there is data that shows that they are functionally linked (Kotecha et al.,
2003). We have addressed organisation within MASC in terms of evolution, gene
expression, phosphorylation and networks, as detailed in those sections.
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5.5.2.6 Protein networks
Protein interactions are essential to the functionality of proteomes because proteins
rarely act alone, but rather in complexes. Large-scale mapping of protein
interactions in the yeast proteome reveals highly complex networks of protein
interactions (Fromont-Racine et al., 1997), (Gavin et al., 2002). These networks have
not only been useful for clustering functionally related proteins, but were recently
subject to analysis with mathematical tools developed for non-molecular models
such as social networks and the World Wide Web (Han et al., 2004). Interacting
proteins are more likely to be involved in similar cellular functions and processes
and are more likely to be co-expressed and co-regulated by sets of transcription
factors. It has been shown that interacting proteins are more likely to be present in
the same expression clusters than random sets of proteins in yeast (Ge et al., 2001).
We investigated this by analysing the primary neuronal culture time-course gene
expression data in relation to the MASC protein-protein interaction network.
This analysis revealed that there were two classes of proteins in this
expression/interaction network. One group (~ 25 %) is highly expressed early in the
primary culture experiment and their expression decreases with neuronal
development. However, the majority of MASC genes in this network however, start
with a low expression level but increase in a similar profile to high expression levels
at the end of the time course. Although, this does not prove that co-expressed
synaptic proteins are more likely to interact with one another but when compared to
the time course analysis of PSP protein classes (Figure 5.11) it can be seen that the
majority of the components of the MASC complex seem to be co-regulated. This
apparent co-regulation of a set of highly interconnected proteins does seem to
support the functional link between the transcriptome and the interactome. Models
which exploit gene expression data to predict protein interactions are currently
emerging and the inclusion of expression data for orthologs seems to improve the
predictive capabilities of such models (Bhardwaj and Lu, 2005). A more detailed
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analysis of MASC in this setting, in conjunction with such ortholog data would be
interesting and potentially useful for completing interaction maps.
5.5.2.6.1 Network analysis of proteins implicated in Alzheimer's disease
The main approach to analyse proteome changes in caused by brain pathology is to
use comparative 2D-PAGE separation of constituent proteins in diseased versus
normal samples. This is usually followed by gel image analysis to identify
alterations in the intensity of specific spots compared to the normal state and
subsequent excision of the abnormal spots and identification by mass spectrometry
or peptide sequencing. The number of comparative proteomic studies of disease and
disease models has increased over the last number of years. This has led to the
accumulation of lists of proteins whose expression levels have been shown to be
altered in the particular system, but with little integration of these lists to provide a
global view. This is emerging problem in the study of complex diseases, not only at
the level of proteomics but also at the level of study of individual protein function in
relation to disease.
The pathogenesis of neurodegenerative diseases such as AD is likely to consist of a
number of initial pathways converging to form the distinctive pathology of amyloid
plaques and NFT's (neurofibrillary tangles) characteristic of AD. Proteins
implicated in this pathogenesis may also be characteristic of the stage of progression
of the disease and may be transiently altered. The components and formation of
amyloid plaques and NFT's are reasonably well understood but the many pathways
leading to this end point are still elusive. It is clear that there is a need to integrate
the large amount of data concerning proteins involved in the pathogenesis of AD
into a coherent global view of the disease. It may be quite likely that an
understanding of the fundamental components and mechanisms of the pathways
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leading to AD pathology will be gained from a holistic view that can be obtained by
using a proteomic strategy combined with bioinformatics and network analysis.
The large number of implicated proteins present in the MASC and AMPAR complex
indicates that altered signalling from these membrane receptors may be responsible
for the loss of synaptic function and cognitive decline associated with AD. Recently,
its has been shown that application of amyloid-beta promotes endocytosis of
NMDA receptors in cortical neurons, possibly explaining the reduced glutamatergic
transmission and inhibition of synaptic plasticity observed in transgenic mice
overexpressing amyloid precursor protein (APP). Elucidating the involvement of
particular pathways in a systematic way should begin to uncover these various
molecular routes to the diseased state. This approach of network integration of
components of a complex disease should provide a coherent view of the disease
process at the molecular level. Network analysis of AD as well as many other
complex diseases might indicate new leads into the mechanisms of pathology and
areas of therapeutic intervention.
5.5.3 Conclusions
We have performed comprehensive bioinformatic analysis of the PSP and found
elements of organisation at every level of complexity. This analysis and annotation
of the PSP has added substantial value to the dataset and has provided insights into
how the PSP is organised. This PSP dataset is a candidate gene list for the Genes to
Cognition research programme in which the function of a large number of these
genes is studied by systematic targeted mutations in mice (Grant, 2003).
Comprehensive phenotypic analysis of these mutants in terms of biochemistry,
electrophysiology, cell biology and behaviour is allowing functional annotation of
PSP components. This approach together with SNP (Single-Nucleotide
Polymorphism) screening in humans for all genes in the PSP will produce
systematic data relevant to synaptic physiology and disease. Establishment this PSP
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dataset (available at www.genes2cognition.org/ science/proteomics/synapse.html) is
essential for the progression of synapse proteomics and with new quantitative
proteomic strategies which may be applied to activated or diseased states of the
synapse, will also provide a benchmark for analysis of dynamic aspects of the
synapse proteome.
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6. Discussion and conclusions
The postsynaptic proteome, which encompasses the postsynaptic density and
embedded multi-protein complexes, is the fundamental functional unit of neuronal
cells. Many of its component proteins are involved in functions specific to the brain
and dysregulation of these components characterise numerous neurological
disorders, from metal retardation to neurodegeneration. Protein phosphorylation is
an essential regulator of synaptic function and dysregulation of phosphorylation in
signalling pathways has also been implicated in nervous system disorders.
Therefore, global characterisation of the components and phosphorylation of the
postsynaptic proteome will undoubtedly shed light on basic processes of synaptic
function as well as synaptic dysfunction in disease.
The objective of this project was to develop and apply current proteomic and
bioinformatic approaches to map and understand the molecular environment of
central nervous system synapses.
6.1 - Method development: new tools to tackle the phosphoproteome
In 2002, at the same time as the work described in this thesis began, the first
phosphoproteomic dataset was published. Ficarro and co-workers had modified the
standard IMAC protocol, which suffered from non-specific binding of non-
phosphorylated peptides, and introduced chemical methyl-esterification of peptide
to neutralise acidic side chains (Ficarro et al., 2002). They applied this methodology
to the yeast phosphoproteome and identified 383 phosphorylation sites. We
reasoned that a 2-step enrichment of proteins and phosphoproteins would increase
the likelihood of obtaining greater phosphoproteome coverage. We adapted the
principle of peptide metal affinity chromatography and used it to target
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phosphoproteins. A key element of our protein IMAC approach was to use high
urea concentrations to denature synaptosomal proteins. This allowed inactivation of
any residual phosphatase activity, protein denaturation that would allow greater
protein solubility and more efficient binding to the IMAC resin.
Many phosphorylation sites were identified directly from this protein IMAC
fraction using precursor ion scanning functions. However, there was significant gain
in phosphoproteome coverage when this was combined with a peptide IMAC step.
This tandem affinity isolation of phosphorylated species was superior to single
protein or single peptide IMAC isolations. Comparable single peptide IMAC
purifications from isolated PSD's only resulted in identification of approximately
one-third of that observed from tandem-IMAC purifications (Trinidad et al., 2005),
supporting the validity of our approach. Our optimised protocol has identified up
to 401 phosphorylation events on 173 phosphopeptides in a single 4-hour LC-
MS/MS analysis. This advance in technology compared to traditional approaches
such as 32"P ATP labelling and Edman sequencing, has significantly decreased the
time and the increased the sensitivity of phosphorylation site identification. Indeed,
the advent of such approaches has made global phospho-profiling experiments
feasible.
6.2 - Application of phosphoproteomic methods
6.2.2 - The synapse phosphoproteome
The complexity of the synapse in terms of its components and the processes it
carries out necessitates a complex and robust regulatory system. Phosphorylation at
the synapse has been studied for over 35 years and the identification of
phosphorylation sites has been an arduous process. The study of synaptic
phosphorylation on a protein-by-protein level was inherently biased with attention
focused on channels and receptors, which were the earliest class of proteins
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characterised at the synapse by pharmacological methods. Undoubtedly,
phosphorylation of this class of proteins is important, but identification of
phosphorylation sites in a global unbiased manner is necessary to expand our
understanding of synaptic signalling beyond local regulation of channel function.
The aim of this study was to establish an in vivo map of the synapse
phosphoproteome. We detected over 650 phosphorylation events corresponding to
331 sites (289 have been unambiguously assigned), 92% of which are novel. These
represent 79 proteins, half of which are novel phosphoproteins. An additional 149
candidate phospho-proteins were identified by profiling the composition of the
protein IMAC enrichment. This degree of novelty in terms of newly identified
phosphoproteins as well as phosphorylation sites highlights a previously
unrecognised complexity in synaptic phosphorylation.
To examine the significance of this complexity we examined the representation of
phosphorylation data across synaptic proteins and important synaptic sub¬
components and organelles. Our dataset contained postsynaptic components
including the postsynaptic density (134 proteins) and NMDA-receptor associated
proteins (44 proteins) and presynaptic components, of which the most striking
examples were Piccolo-Bassoon transport vesicles. A prominent feature of the
synapse phosphoproteome was the appearance of many phosphorylated
postsynaptic scaffold proteins. Major components of the NMDA receptor complex
such as PSD-95, Chapsyn-110 and SynGAP were all phosphorylated indicating that
the scaffolding functions of these proteins may be regulated by phosphorylation.
This would suggest that the PSD scaffold, which provides a molecular matrix to
support and connect synaptic membrane receptors with intercellular signalling
pathways, is itself subject to regulation.
Would such a dynamic synaptic scaffold be able to regulate signalling proteins in a
spatial manner? We investigated this by looking at the relationship between kinases
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and scaffolding proteins in a network model of the NRC. Using in vitro kinase data
from peptide arrays and protein interaction data, we observed that some kinases
such as PKA, act on sets of interacting proteins. PKA was linked to four interacting
substrates (PSD-95, PSD-93, SAPAP1, SAPAP2) via AKAP79, a kinase anchor
protein that recruits PKA to the postsynaptic membrane in proximity to its
physiological substrates. This novel approach of layering kinase-substrate data onto
protein-protein interaction networks in the third-dimension provided an insight
into how phosphorylation may regulate synaptic signalling by acting on the
synaptic scaffold.
Another theme that emerged from the study of the synapse phosphoproteome was
that of kinase multiplicity. Data derived from in silico predictions of cognate kinases
for identified phosphorylation sites and in vitro phosphorylation of peptide arrays
suggested that a small number of kinases can phosphorylate many proteins and
each substrate is phosphorylated by many kinases. This phenomenon may represent
signal integration, i.e. when signalling pathways converge and result in multi-site
phosphorylation of substrate. Another possibility that is not mutually exclusive is
that kinase multiplicity represents robustness in signalling networks. The existence
of a number of variant signalling pathways involving different kinases/
phosphatases or substrates, which have the same downstream target (e.g.
transcription factor activation), would ensure signal transduction robustness.
Finally, the complexity of synaptic signalling may require subtle fine tuning, which
may be mediated by combinations of different kinases working on the same
substrates, resulting in slightly altered activity or localisation of the substrate.
Interestingly, we were able to characterise signalling components of the mGluR5-IP3
receptor-signalling pathway from a global analysis of synaptic phosphorylation. We
found novel phosphorylation sites on well-characterised proteins such as mGluR5
and PLC-|3, which are functionally and physically linked. In addition, we found
potentially very interesting regulatory phosphorylation sites on IRBIT, a poorly
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characterised signalling protein that binds the IP3 receptor in an activity-dependent
manner. This complex seems to facilitate a signalling pathway from mGluR5 to
modulation of intracellular calcium, which is known to regulate a myriad of
intercellular signalling activities. Identification of these phosphorylation sites in
proteins along the signalling cascade should provide an excellent starting point for
the investigation of signal transduction in this pathway.
6.2.1 - The cytosolic phosphoproteome
We applied our optimised tandem metal-affinity purification approach to purify
phosphorylated species from cytosolic extract from mouse forebrains. This cytosolic
forebrain preparation was chosen to get an overview of phosphorylation of soluble
brain phosphoproteins. Compared to the synapse phosphoproteome dataset that
was derived from multiple analyses of single protein, single peptide and double
IMAC experiments, the cytosolic dataset was the result of just two experiments.
These two analyses focused on a tandem IMAC (double) purification from cytosolic
extract with different on-line RP separations. This comparison identified that a
PepMap column is best suited for LC-MS/MS analysis of phosphopeptides with a
47% increase in phosphorylation event identifications using the PepMap column
compared to the BetaMax neutral column.
As water-soluble cytosolic proteins are hydrophilic we reasoned that they might
contain intrinsically disordered sequence, which also tends to be hydrophilic. We
found that the cytosolic phosphoproteome dataset was rich in sequence disorder
and contains many putative natively disordered proteins. The majority of these had
RNA or tubulin binding functions and the combination of disorder and
phosphorylation is likely to be essential for their function. We identified 37
phosphorylation sites on nine protein kinases, the majority of which are novel and
are not located in kinase domains indicating secondary regulatory functions.
Finally, in our global study of cytosolic phosphorylation we have characterised a
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number of phosphoproteins with disease-associations, which may have related roles
in the pathogenesis of neurodegenerative disease.
6.3 The postsynaptic proteome
6.3.1 Profiling postsynaptic proteomes
The last five years has seen tremendous growth in knowledge of the protein
components of mammalian synapses. The first investigation of the synapse
proteome appeared in 2000, with the identification of the components of the NMDA
receptor complex (77 proteins) (Husi et al., 2000). The large number of proteins in
this complex was at first controversial, as this exceeded the total number of known
PSD proteins. This report was soon followed by the first MS-based characterisation
of the PSD, which revealed just 31 proteins in the PSD, most of which were already
known. Our analysis of the PSD and protein complexes and that of other PSD
proteomic studies has subsequently validated the components of the NRC. The data
integration performed on these PSD and protein complex datasets has resulted in a
confidence-ranked database of postsynaptic proteins which totals 1124. This 10-fold
increase in known postsynaptic components reflects the technological advances of
MS-based protein identification compared to traditional methods.
The most important and striking point to come out of theses analyses is that the PSP
is incredibly complex. The vast amount numbers of proteins in the PSP presents a
daunting challenge to systematically attribute synaptic function to each protein.
However, for the first time we are in a position where we actually know the identity
of the majority of proteins in the PSP and are able to ask questions concerning the
entire postsynaptic proteome, as opposed to discrete subsets of proteins in the past.
We are therefore well equipped to start taking a systems biologic approach to study
synapse function. In fact, this PSP database is a candidate gene list for the Genes to
Cognition research programme in which the function of a large number of these
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genes is studied by systematic targeted mutations in mice (Grant, 2003).
Comprehensive phenotypic analysis of these mutants in terms of biochemistry,
electrophysiology, cell biology and behaviour is allowing functional annotation of
PSP components. This approach together with SNP (Single-Nucleotide
Polymorphism) screening in humans for all genes in the PSP will produce
systematic data relevant to synaptic physiology and disease.
6.3.2 Molecular organisation of the postsynaptic proteome
The emerging field of systems biology has yet to be given a clear definition but at its
most basic, it aims to integrate biological data to facilitate global representation and
modelling of biological phenomena. In order to address some aspects of synaptic
biology we used our database of postsynaptic proteins as a common platform onto
which we layered and integrated multiple data types. This encompassed many
levels of the hierarchy of cellular complexity from gene evolution and expression,
protein classification and domain architecture, post-translation modifications and
multi-protein complexes. Protein-protein interaction networks were used to
integrate the proteomic data with gene expression, phosphorylation, phenotypic
data in knockout mice and AD-protein association data. Networks are central to
representation of systems biology data and although in this study we did not use
graph-theory modelling, some interesting trends were observed.
We observed a theme of organisation at each level of complexity. At the genetic
level this organisation was the acquisition of synaptic genes through evolution, a
significant proportion of which exhibit neuronal specific expression as seen in the
tissue transcriptome analysis. The integration of our PSP proteomic data with
developmental gene expression and electrophysiological data from cultured
neurons provided insights into how a synapse might be constructed as a neuron
develops. The timing of expression of key components of the synapse correlates
with the onset of electrical activity at around 10 days in culture. The concomitant
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up-regulation of activity-dependent genes with electrical activity and the overall
timing of expression of different protein classes are intuitive. This would indicate
that despite complete correlation of mRNA with protein expression, that the
temporal model of assembly is plausible. Such a model could be verified using
quantitative proteomic analysis of the same cultured neurons. The proteome
coverage would not be as complete as that obtainable for the transcriptome but
enough protein expression data for correlation analysis would be achievable.
Integration of phenotypic data with PSP proteomic data and representation in
protein interaction networks provides an interesting way to try to connect a very
specific electrophysiological phenotype in observed in a number of knockout mice.
There seems to be a relationship between phenotype and connectivity of the gene
knocked out. In systematic deletion studies in yeast, the most severe phenotypes
were observed for deleted proteins that had many protein interaction partners
(Jeong et al., 2001). Currently, neither the protein interaction data nor systematic
mutations in mouse are available for the MASC to comprehensively test this model.
However, both of these issues are being addressed and it is expected that within the
next five years that sufficient data will be available to explore these issues
comprehensively.
Complex disorders such as AD have implicated many genes/proteins in their
causation or pathology. It is likely that a number of cellular pathways are involved
in this disease process and integration of data on AD-implicated proteins and their
connections in a protein interaction network may allow identification of common
pathways. In addition, such an approach is useful for evaluation of animal models
of disease. We used protein expression change data observed in GSK3P
overexpressing mice and overlaid it onto an AD-associated protein interaction
network. Many proteins with altered expression in the mouse model were present
in the AD interaction network, indicating that the pathway disrupted in the mouse
model is involved in at least some of the pathology. Such analysis of mouse models
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in a systematic manner should highlight perturbations in pathways responsible for
the disease.
6.4 Neuroproteomics perspective
Now that the field of proteomics is coming to the end of its developmental phase,
the application of proteomic methodologies to biological problems should provide
even more leaps of knowledge in the next five years. Analysis of the
phosphoproteome is not currently routine, however phosphoproteomic
methodologies are maturing. It is anticipated that full phosphoproteome coverage is
not achievable from analyses of "basal states" in tissue because some
phosphorylation sites are of such low abundance in the absence of a specific
stimulation. Therefore, the real challenge is to move from a discovery phase of
phosphorylation site identification to a profiling phase of phosphorylation in
response to stimulation of cells or tissues with drugs and inhibitors etc. Similarly,
the recent advent of quantitative mass spectrometry will facilitate profiling of
dynamic proteome states. The use of bioinformatics in the analysis of this data will
be of the utmost importance and is an area that will need much attention if the value
of such data is to be fully appreciated. One can envisage that the application of these
new approaches using well defined chemical (NMDA) or electrical stimulation
paradigms (LTP) in cultured neurons or tissue slices, will undoubted reveal novel
and interesting aspects of the complexity of synaptic plasticity
6.5 Conclusions
The work detailed in this thesis has for the first time, described the constituents and
phosphorylation of multiple brain proteomes. 652 in vivo phosphorylation sites were
identified directly from brain purifications, more than that identified by traditional
approaches in the last 35 years of study of in the field of neuronal signalling. For the
first time a comprehensive database of the components of the postsynaptic
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proteome was assembled and systematic molecular organisation of the PSP was
revealed. Establishment of such maps of proteins and phosphorylation at the
synapse will provide a basis for future research of synaptic physiology and disease.
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Appendix 1 - Synaptic proteins identified in IMAC purifications identified by mass
spectrometry. Mr, relative molecular mass; Rel Abun Rank, rank of relative abundance
(number of peptides detected for each protein normalized to molecular weight: PSD,
postsynaptic density proteins; NRC, NMDA receptor-signaling complex. Peptides detected,
total number of matching peptides sequenced by MS/MS for a specific protein. Proteins
previously shown to be phosphorylated and known kinases responsible for this
phosphorylation were identified from the literature. Proteins identified in this dataset, which
have been shown to be present in the post-synaptic density and in NRC complexes, are
shown. Scansite (high stringency and a percentile score of greater than 0.2%) and NetphosK
kinase hits are included and are represented by a letter corresponding to the following
kinases: a, Akt Kinase; b, ATM Kinase; c, Calmodulin dependent Kinase 2; d, Casein Kinase
1; e, Casein Kinase 2; f, Cdc2 Kinase; g, Cdk5 Kinase; h, Clk2 Kinase; I, DNA PK; k, EGFR
Kinase; j, Erk1 Kinase; I, GSK3 Kinase; m, Insulin Receptor Kinase; n, Itk Kinase; o, p38
MAPK; p, PDGFR Kinase; q, Protein Kinase A; r, PKC alpha/beta/gamma; s, PKC delta; t,
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Appendix 3 - Non-redundant phosphopeptide list from the synapse
phosphoproteome with unique phosphorylation site assignation. Unambiguously
assigned sites of phosphorylation are denoted in the sequence as pS/T/Y (red) and
ambiguous sites are just coloured in red. Mod Id: number of phosphates detected. MS
identified Phospho-sites: unambiguous identification of sites by MS. Predicted Phospho-
sites: when sites could not be unambiguously assigned, Netphos and Scansite were used
to predict the most probable site of phosphorylation and are indicated in the sequence in
red. Predicted cognate kinase: Kinases predicted by Scansite and NetphosK are indicated
for all sites. Scansite was used as the default program to predict potential kinases for
phosphorylation sites. However, NetphosK was used in cases which Scansite did not
produce any predictions and its use is denoted by "np" in the Predicted cognate kinase
field. Prediction scores are included for both Scansite (0 = best prediction) and NetphosK
(1 = best prediction). Also, in some cases Scansite predicted some phosphorylation sites to
be involved in phosphorylation dependent protein interactions. Pfam Domains: when
phosphorylation sites were found in a Pfam protein domain, the domain name and location
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
305
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
306
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
307
 






j 1 §85 8 = 8 n\ s
I!
jl

































a 58 £ £ £ £ £ - s 5 8 -to R SC! 85 - S; S SSS8 8? 8 8 ss SgS Es s s * 5 8 8 338 R8 3 8 5 8 £ 8 z^ 28 8 82;^ s s !II Is; ' ;r 8 ■ I i
'I
~ ~ - " ~ ~ _ ~~~~ ~ ~ ~~ *" ~ ~ ~ ~
n"
~ ~~~
Si * - c 77
~
" " ' " 01 " S « <o (N " " ~ 5 ' " " " u no.cc3' * p; n ■* =
■
1 s arm £ S3 2 5-. 5 - uS ^ ;• ~ :•
1 1 II 11 ml-INF 1 HP illlliilHi ii IP Si B£ 1 1w mw I i illmII -j^ ||| m F -|£ 11 ii I ?1 i !!
u \JL
mlplipjl mi m #1im mmmm |IE 5MEM im mmm * 5 Kjpi|s mt mm a ■ f m a IE 1
JffliillTrliTll I liTrrrrI ITI rl iTlrll 1111111 rrlTlTlTlTlTrrlTrrlTrmriTiTiTiTiri iXmii: ii II: •;
15 Ii■■I1 111111
niiii
ilill■1■Ife 1 i|g[ill illIBH1111i ! i|illK i
■
■



























Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
310
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes






















































































































































































































































































Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
315
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
316
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
317
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
318
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
319
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
320




n 5E*s %n m »S8i §88 5 8888
I 52885
88
58 « ili 88i M n 8§s 555



















56 §66 nSSJ 66 56 556
588 88 588 68 58 5565 55 58588

















Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
323
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
324













































































































































































































































































































































Appendix7-IntegrationofPSPdatasets.Ourtafr mMSdimmunoblottinganalysesthD,A CAM Ar c ptorco lex wereintegratedi hdatafrom6th rMSanalys sfPSDfrac ion("Yos ",Yosh uratl.,2004);"J d n",P ng( g























Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
Appendix 8
Times detected in PSDs 18 I 7 I 6 |5|4|3 XL1 IComplexes
Protein Class UniProt PPID Acc Unigene OMIM Gene name Consensus PSD MA mG AM
Acc cluster 1
Channels and Receptors LU
Glutamate Receptors Q62683 A0001 Mm.278672 138249 Grinl xt
~
2*2
008948 A0002 Mm.2953 138253 Grin2a IxT^ x Xj
Q62684 A0003 Mm.322010 138252 Grin2b X. x
P23819 A0297 Mm.220224 138247 Gria2 1 ~X~
P23818 A0296 Mm.4920 138248 Grial X X
Q9Z2W9 A0299 Mm.327681 305915 Gria3 _Xj X
P19493 A0300 Mm.209263 138246 Gria4 "Xl X
Q9EPV6 A0103 Mm.370186 604473 Grm1 ; I x 1 I 12*2
Q9QYS2 A1353 Mm.318966 601115 Grm3 S
P39087 A0022 Mm.332838 138244 Grik2 X 1
_ _
P31424 A0327 Mm.235018 604102 Grm5 X I
_ _xj
P35400 A0453 Mm.240881 604101 Grm7 X 1
Q61625 A0328 Mm.321227 602368 Grid2 B
Q03391 A0005 Mm. 152584 602717 Grin2d
Other ligand receptors Q9WV18 A0603 Mm.32191 603540 Gabbrl T
088917 A0038 Mm.260733 - Lphnl _x
P18504 A0503 Mm.6834 602376 Gabral ~x
088871 A2000 Mm.101909 607340 Gpr51 _x_ ~
Q9Z173 A3463 Mm.273631 - Lphn3 XT
055022 A3464 Mm.9052 300435 Pqrmcl m
Ca2+-ATPases 055143 A3467 Mm.227583 108740 Atp2a2 ■
P11505 A3465 Mm. 166944 108731 Atp2b1 B ~x~
Q9R0K7 A0508 Mm.321755 108733 Atp2b2 B
Q64568 A3466 Mm.210095 300014 Atp2b3 B
Q64542 A0114 Mm.188617 108732 Atp2b4 ■ x
NA+/K+-ATPases Q9Z1G6 A0342 Mm.44101 182350 Atp1a3 x | x ~x~
P06685 A0340 Mm.280103 182310 Atp1a1 x 1 1 x X IX
P06686 A0341 Mm.207432 182340 Atp1a2 u X
Q9WV28 A0343 Mm.337950 607321 Atp1a4 B
P14094 A0344 Mm.4550 182330 Atp1b1 B T
Voltage- and Ligand-gated Ca2+-channel Q61290 A3471 Mm.298091 601013 Cacnale x
P54285 A3476 Mm.3544 601958 Cacnb3 x
P54282 A0593 Mm.334658 601011 Cacnala "x ~ IX
Q01815 A0770 Mm.236039 114205 Cacnalc X
008532 A3474 Mm. 173392 114204 Cacna2d1 X
Q7TPF2 - Mm.41252 114207 Cacnbl _x
055017 A0592 Mm.4424 601012 Cacnalb m
Q9EQG2 A3472 Mm.273084 607082 Cacna2d2 B
Q9Z1L5 A3473 Mm.370172 606399 Cacna2d3 B
Q9JJV5 - Mm.241121 606403 Cacng3 B
Voltage-gated K+-channel Q8VHF1 - Mm.343607 600150 Kcnmal X 1 1
P63142 A0764 Mm.56930 176262 Kcna2 xl
P52190 A1867 Mm. 140760 600504 Kcnj4 u
Q9Z343 A3477 Mm.40615 602235 Kcnq2 B
Q64284 A3478 Mm.302496 601142 Kcnab2
Voltage-dependent anion channels Q60932 A0425 Mm.3555 604492 Vdacl | X
Q60930 A0426 Mm.262327 193245 Vdac2 "x i X
Q60931 A3479 Mm.227704 - Vdac3 _x 1 1
Na+-channel P15390 - Mm.218743 603967 Scn4a X 1
Q99250 A0598 Hs.93485 601219 SCN2A
~
Ca2+-release channels P11881 A0154 Mm.227912 147265 Itprl xr1
Q9ERN6 A3480 Mm.239871 180902 Ryr2 u
Other Channels and Receptors Q03555 A0637 Mm.341742 603930 Gphn x
P12023 A1169 Mm.277585 104760 App 11
Q9Z1G4 A0414 Mm.340818 192130 Atp6v0a1 JL _
Q9UI12 A0409 Mm.27082 608861 ATP6V1H X
014514 A1017 Mm.43133 602682 BAI1 X
060242 - Mm.336569 602684 BAI3 X
P43006 A0422 Mm.267547 600300 Slc1a2 X
~
IX
Q08406 A3490 Mm.272210 118946 Cntfr
008530 A3491 Mm.982 601974 Edg1
Q80VZ2 _ Mm.3249 602188 Epha4
P54762 A0542 Mm.22897 600600 EPHB1
Q63645 _ Mm.1614 600933 F2rl1
Q920E0 - Rn.81079 - F2r13
035658 A1608 Mm.30049 601269 C1qbp
P60894 - Mm. 167625 605188 GPR85
088703 A3486 Mm. 12956 602781 Hcn2
Q9NZN1 _ Mm.267669 300206 IL1RAPL1
Q61291 A1175 Mm.271854 107770 Lrp1
P15209 A0506 Mm. 130054 600456 Ntrk2
P70206 A3482 Mm.3789 601055 Plxnal
P70207 A3483 Mm.2251 601054 Plxna2
Q63495 A1094 Mm,3383 600214 Ager
Q91V14 A3489 Mm.252987 606726 Slc12a5 Ix
Q62634 A4034 Mm.255631 605208 Slc17a7
Q9EST0 A3481 Mm.314497 605556 Slc4a10
P16283 A3488 Mm.5053 106195 Slc4a3
088343 A3485 Mm.41044 603345 Slc4a4 ~x~
P48768 A3484 Mm.241147 601901 Slc8a2
MAGUKs / Adaptors / Scaffolders




Q62108 A0013 Mm.27256 602887 Dlg4 X
Q63622 A0014 Mm.257035 603583 Dlg2 ~x X
P70175 A0016 Mm.4615 300189 Dlg3 X X
Q9WU13 A0075 Mm.358922 604999 Shankl X
_ jlX
Q9R093 A0137 Mm. 197074 - Cnksr2 x
Q62402 A0015 Mm.382 601014 Dlg1 x_ I ~x"
Q9JLU4 A0074 Mm. 146855 606230 Shank3 x In
Q9QYX6 A0568 Mm.332219 604918 Pclo ~x Hj
P39447 A0086 Mm.4342 601009 Tjpl x_ X
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Protein Class UniProt PPIDAcc Unigene OMIM Gene name Consensus PSD MA mG AM
Acc cluster
070589 A0125 Mm.327591 300172 Cask X |
Q9WV34 A0436 Mm.36242 600723 Mpp2 X I
~
ZK.
088910 A0435 Mm.20449 601114 Mpp3 X I x_
Q925T6 A0301 Mm. 196692 604597 Gripl X 1 YT
Q9C0E4 A0302 Mm.333264 - GRIP2 m
Q99JP6 ~ Mm. 10022 604800 Homer3 m
Q62083 A0449 Mm.259464 605926 Prkcabp m
Q9H0F6 A0602 Mm.41463 - DKFZp434N1923 ■
Q9WV37 A0793 Mm.41288 606959 Mpp6 B
P70625 A1881 Mm. 104744 607709 TiP2 B
non-PDZ-domain containg scaffolders Q60437 A1015 Mm.197534 605475 Baiap2 X
P97841 A0107 Mm.311840 605445 Dlqapl _x x_
Q9Y2A7 A0545 Mm.25203 604891 NCKAP1 3
P24587 A0143 Mm.311452 604688 Akap5 ~x~
~
ZK1
035413 A0109 Mm.211096 - Arqbp2 X
088881 A0228 Mm.342085 - BEGAIN H X
Q8VHK2 A3990 Mm.70989 - Caskinl X
008917 A3496 Mm.2931 606998 Flotl X
094938 A4033 Hs.511386 - KIAA0856 _2L
Q60803 A0862 Mm.27431 601896 Traf3 X
P97837 A0447 Mm.323861 605438 Dlqap2 ~x "
Q8R550 - Mm.286495 300374 Sh3kbp1 X
Q62417 A0100 Mm.210815 605264 Sorbsl X
P25304 A3494 Mm.273098 103320 Agm
054931 A0796 Mm.348266 604582 Akap2
070333 A0275 Mm. 109329 604594 1200020A08Rik
Q9Y2H0 _ Mm.22094 _ DLGAP4
Q60902 A3493 Mm.288894 - Eps15l1
Q60634 A3497 Mm. 130227 131560 Flot2
Q60760 A0270 Mm.273117 601523 Grb10
Q60631 A0126 Mm.6900 108355 Grb2 ~x~
Q9EQR5 A3495 Mm.272712 - 2810038K19Rik
Q9EPM9 A3492 Mm.256536 604889 Nbea i
P98083 A0171 Mm.86595 600560 Shc1
Q62245 A0159 Mm.60975 182530 Sos1
Q99ME2 - Mm. 193395 - Wdr6
Q99P24 A0009 Mm.46044 604001 Akap9 ~x"
Q8K3H0 A0188 Mm.202322 604299 AppM X
035145 A0162 Mm.2720 604641 Mapk8ip1 X
P68040 A0124 Mm.5305 176981 GNB2L1
_ _x_
14-3-3 P35213 A0467 Mm.34319 601289 Ywhab Y YT
P35215 A0361 Mm.332735 601288 Ywhaz _x
~
jT X
P62260 A0280 Mm.234700 605066 YWHAE
13
X
P68510 A0633 Mm.332314 113508 YWHAH X YT
P61982 A0362 Mm.233813 605356 YWHAG X X X
P35216 A0907 Mm 289630 - Ywhaq _x X
Q9JJ20 A0901 Mm.44482 601290 Sfn
Ser/Thr Kinases Gene name
P11798 A0011 Mm.131530 114078 Camk2a X X
P28652 A1851 Mm.4857 607707 Camk2b |j( X
P63319 A0259 Mm.7980 176980 Prkcq Y
_ _X_
P15791 A1853 Mm.255822 607708 Camk2d Y
P11730 A1852 Mm.235182 602123 Camk2q _x^
Q9JLM8 A3506 Mm.295263 604742 Dcamkll Y
P12369 A0306 Mm.25594 176912 Prkar2b X
~
ZK.
P04411 A0168 Mm.207496 176970 Prkcbl _x x_
Q05512 A3505 Mm.258986 600526 Mark2
OP26817 A0813 Mm.254144 109635 Adrbkl
Q0JM02 A3503 Mm.42067 Map4k6 X
P20444 A0307 Mm.222178 176960 Prkca r X
P16054 A0144 Mm.287660 176975 Prkce _x
~
ZK.
Q60737 A0753 Mm.23692 115440 Csnk2a1
—
X ~x~
Q99PS2 A4036 Mm.30199 600863 Csnkle X
Q63092 A3499 Mm.274540 - 1G5 X
P68181 A4037 Mm.16766 176892 PRKACB X Z ZK
P70336 A3501 Mm.276024 604002 Rock2 z X
Q9WUN2 A3507 Mm.34580 604834 Tbk1 X
Q9UKE5 - Mm.126193 - TNIK _x
Q9UPV4 A3502 Mm. 116833 - AAK1
Q60823 A0466 Mm.177194 164731 Akt2 YC
054875 A3504 Mm.27397 - Cdc42bpb
P49615 A0667 Mm.298798 123831 Cdk5
Q92772 - Mm.44963 603442 CDKL2
076039 - Mm.336310 300203 CDKL5
P97633 A0896 Mm.26908 600505 Csnk1a1
P67871 - Mm.7405 115441 CSNK2B
P63086 A0181 Mm. 196581 176948 Mapkl
—
~x~
Q9WV60 A0222 Mm.200770 605004 Gsk3b Z X
QG0700 A1730 Mm. 172097 600447 Map3k12
P97820 A0177 Mm. 19073 604666 Map4k4
P31938 A0266 Mm.248907 176872 Map2k1 Y~
P12367 A0305 Mm.253102 176910 Prkar2a
P31750 A0189 Mm.6645 164730 Akt1
Q9DBC7 A0304 Mm.30039 188830 Prkarla z
Q63433 A0871 Mm.213000 601032 Pkn1
Q61410 A3500 Mm.263002 601591 Prkg2
Q9CST0 A0337 Mm.374825 608938 Rps6kb1
P18654 A0268 Mm.328476 300075 Rps6ka3 YT
Q9Z1W9 A0166 Mm.198414 607648 Stk39 X
Q8TBQ5 A3529 Mm.260934 608128 DUET
Q91YW5 A0265 Mm.8385 601795 Mapk3 z
009110 A0491 Mm. 18494 602315 Map2k3 ZL
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Protein Class UniProt PPID Acc Unigene OMIM Gene name Consensus PSD I MA mG AM
Acc cluster
Q61831 A0489 Mm.39253 602897 Mapk10 5f
Q63932 A0267 Mm.275436 601263 Map2k2 X
035406 A0164 Mm.3906 603014 Map2k7 X
Q62767 A0287 Mm. 170276 602747 Dusp4 X
Q9Z2A0 A0260 Mm. 10504 605213 Pdpkl x_
Q99N57 A0138 Mm.184163 164760 Raf1 x_
Tyr Kinase
P39688 A0019 Mm.4848 137025 Fyn _x
P05480 A0018 Mm.22845 190090 Src _x
~~
m
P25911 A0522 Mm.317331 165120 Lyn BZZ
P06240 A0463 Mm.293753 153390 Lck
P16879 A3508 Mm.48757 190030 Fes
Q9QVP9 A0030 Mm.21613 601212 Ptk2b by
Q04736 A0553 Mm.4558 164880 Yes
Protein Phosphatases
Q9Z1G2 A0147 Mm.277629 176875 Ppplca X
035274 A0273 Mm.229087 603325 Ppp1r9b _x
P63088 A4042 Mm.280784 176914 Ppplcc _x Y
P62143 A4043 Mm.241931 600590 PPP1CB X
P63329 A0123 Mm.331389 114105 Ppp3ca I x I Y
Q96DH3 A0295 Mm.294138 605983 PPP2R1A X x_
Q9QW00 A2624 Mm.258771 601576 Ptpsiqma SET
035867 A0510 Mm.332901 602468 Ppp1r9a Ell
P13353 A0132 Mm.260288 176915 Ppp2ca 111 I x_
Q64487 A1198 Mm. 184021 601598 Ptprd ill I
Q9WUT8 A1202 Mm.41639 176891 Ptprzl Ml
Q9D7X3 _ Mm. 196295 600183 Dusp3
Q8R3L3 _ Mm.266191 608867 Dusp10
Q8VEL2 A4016 Mm.197816 _ 1110061004Rik
Q8CB81 _ Mm.341988 _ Ppmle
P35235 A0020 Mm.8681 176876 Ptpn11 BY
Q9EQ17 A0223 Mm.29855 179590 Ptprf
060228 A3509 Mm.35483 603560 SBF1 ■I
035299 A0289 Mm.3294 600658 Ppp5c X
P54830 A0118 Mm.4654 176879 Ptpn5 x_
G-proteins and Modulators
G-proteins Q9Z2Q6 A3518 Mm.20365 602724 SEPT5 Y Y
P18872 A0043 Mm.251445 139311 Gnaol Y X
055131 A3520 Mm.270259 603151 SEPT7 _x X X
Q9QWG8 A0069 Mm.2344 139380 Gnb1 X X
Q9R1T4 A3519 Mm.260036 - SEPT6 _x
P01118 _ Hs.505033 190070 KRAS X
P42208 A3515 Mm.242324 601506 SEPT2 X
Q9Z1S5 A3516 Mm.309707 608314 SEPT3 X
Q9ESF7 A3525 Mm.274399 608418 SEPT8 x_
P08752 A0055 Mm. 196464 139360 Gnai2 Ml
070443 A0052 Mm.32595 139160 Gnaz Ml
P62880 A0070 Mm.30141 139390 GNB2 Ml x_
P54314 A0073 Mm. 17604 604447 Gnb5 Ml
P63012 A0037 Mm.5083 179490 Rab3a Ml X Y
P05810 A0203 Mm.27348 179550 Rala Ml X
P84096 _ Mm.259795 179505 RHOG Ml
Q9NVA2 A3524 Mm.236587 - SEPT11 Ml
Q9QZR6 A3521 Mm. 38450 604061 SEPT9 Ml
Q91Z61 _ Mm.44995 607862 Dirasl
Q96HU8 A4017 Mm.25648 - DIRAS2
P21279 A0042 Mm.195898 600998 Gnaq Y
P63095 A0051 Mm.125770 139320 GNAS BY
Q61411 A0200 Mm.334313 190020 Hrasl BY
Q9NYS0 _ Mm.25648 604496 NKIRAS1
Q9H067 A3974 Mm.261491 - DKFZp586D0222
008989 A3512 Mm.2045 608435 Mras
P08556 A0199 Mm.256975 164790 Nras
088565 A0359 Mm.329123 179512 Rab5a
P55258 A0620 Mm.162811 165040 Rab8a
P61027 A0621 Mm.74596 - Rab10 B^Y
P35284 A3513 Mm.248313 - Rab12 By
P15154 A0194 Mm.292510 602048 RAC1 By
Q9TU25 _ Mm. 1972 602049 RAC2
P62835 A0323 Mm.333868 179520 RAP1A B]^
P28661 A3517 Mm.2214 603696 SEPT4 B|]^
P29387 A0072 Mm.139192 - Gnb4 X
P53994 A0363 Mm.240224 179509 Rab2 X
Q9JJD4 A0364 Mm.28650 179513 Rab6a X
Q9JKM7 A0365 Mm. 143789 - Rab37 X
P62826 A0152 Mm.297440 601179 RAN X
Q80ZJ1 A0033 Mm.261448 179540 5830461 H18Rik X
Modulators 088938 A0276 Mm.8321 605629 Cit X X Y
Q9ESK6 A0024 Mm.291291 603384 Syngapl X X
Q9JIF2 A0214 Mm.260934 604605 Kalirin X
Q9JHW8 A3514 Mm.336761 605476 Centgl Y
Q9Z1P0 A3528 Mm.196153 606058 Rapqef4 X
P06837 A0215 Mm. 1222 162060 Gap43 X X
Q9Z272 A3532 Mm.290182 608434 Git1 X
Q96D85 A2428 Mm. 196943 - IQSEC1 X
Q9C0H5 A3530 Mm.291713 _ KIAA1688 X
Q7L804 _ Mm.24167 608599 RAB11FIP2 X
Q9ESG7 A0843 Mm.239329 607560 Arhqef2 X
008757 A0646 Mm.244068 605477 ' Arhgef7 X
Q96P47 _ Mm.250703 - CENTG3 X
Q96JJ3 Mm.35064 606421 ELM02 X
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Protein Class UniProt PPID Acc Unigene OMIM Gene name MA mG AM
Acc cluster mmm ■
Q9NYI0 A2433 Mm.32525 - PSD3
Q04690 A0196 Mm.255596 162200 Nf1 xl X
Q9D8S3 - Mm.258910 - Arfgap3
Q9QX73 A0707 Mm.44841 300429 Arhgef9
075689 - Hs.135183 608114 CENTA1
Q9UPQ3 - Mm.291135 608651 CENTG2
Q8TDL2 - Mm.29629 - Dab2ip
Q8IZD9 Mm. 150259 603123 DOCK3
Q9ESQ7 A2431 Hs. 154658 602327 Psd
Q9JL26 A4046 Mm. 138913 604656 Fmnll
P97379 Mm.290530 - G3bp2
P50398 A0567 Mm.205830 300104 Gdi1 X
Q9DAS9 A0067 Mm.234342 - Gng12
Q921M4 A3209 Mm. 106376 602580 Golga2
035550 A0589 Mm.7087 603616 Rabepl
Q923H2 A1069 Mm.143717 605991 Ngef
Q8CHG7 A0034 Mm.31220 - Rapgef2
094764 A4047 Mm. 148781 603854 RANBP9
Q8K2L6 - Mm. 180763 600278 Rap1ga1
Q8BU92 - Hs.167371 606136 A330066M24Rik
P70392 - Mm.248630 606614 Rasgrf2
P49801 - Mm.153013 603894 Rgs6
054829 A0932 Mm.7956 602517 Rgs7
P49804 - Hs.458417 607189 Rgs8
Q9QZB0 - Mm.44606 607191 Rgs17
Q9Z0G0 A1159 Mm.20945 605072 Rgs19ip1
Q60992 - Mm.179011 600428 Vav2
Q91ZT5 A0470 Mm.256131 - Fgd4 X
Signalling molecules and Enzymes
Heat shock / Chaperones /Chaperonins P08109 A0146 Mm.290774 600816 Hspa8 X
P17879 A2007 Mm.6388 140550 Hspalb X X
P20029 A0451 Mm.330160 138120 Hspa5 X
Q9QYJ0 A3535 Mm.279692 - Dnaja2 X
P38647 A2010 Mm.209419 600548 Hspa9a x
P11499 A2003 Mm.2180 140572 Hspcb 1x1
054946 A1578 Mm.290110 - Dnajb6 X
P11983 A3541 Mm.32019 186980 Cct1 X
P80314 A3540 Mm.247788 605139 Cct2 X
P80315 A3538 Mm.296985 605142 Cct4 X
P80316 A3543 Mm.282158 - Cct5 X
P54102 A3536 Mm.27897 602837 Dnajal X
P19226 A3550 Mm. 1777 118190 Hspdl X
043301 A3534 Mm.39739 _ HSPA12A X
Q91YN9 - Hs.55220 603882 Bag2
P80318 A3544 Mm.256034 600114 Cct3
P80317 A3545 Mm.153159 104613 Cct6a
P80313 A3539 Mm.289900 605140 Cct7
P42932 A3542 Mm.328673 - Cct8
P23927 - Mm.178 123590 Cryab
Q99M87 - Mm.248337 - Dnaja3
Q9QYI5 - Mm.248776 604139 DnajblO
075061 A0685 Mm.76494 608375 DNAJC6
P08113 A2004 Mm.87773 191175 Tra1
Q61699 A3533 Mm.270681 - Hsphl
P04792 - Mm.13849 602195 HSPB1
Q9NVH1 A3537 Mm.21353 - DNAJC11
Q922R8 A3548 Mm.222825 - Txndc7
055042 A090G Mm. 17484 1C3090 Snca
Q9CY50 A3549 Mm. 138725 600868 Ssr1
Phosphodiesterases P16330 A3553 Mm.15711 123830 Cnp X
Q01062 A3551 Mm.247564 602658 Pde2a X 1 I
Q8VBU5 - Mm.20181 600127 Pde4b 1 ■
Q01063 - Mm.343333 600129 Pde4d I
Q9QYJ5 A3552 Mm.87161 - Pde10a 1 I
Q8VID8 - Mm.246613 604961 Pde11a v1 I
Adenylate/Guanylate cyclase Q9WVI4 A1979 Mm.371695 601244 Gucy1a2 1 I
Secreted /secretory / signalling Q61361 A3556 Mm.4598 - Bean X r 1
Q62059 A3555 Mm.158700 118661 Cspg2 X
088998 A3557 Mm.43278 605366 Olfml XLJ
035382 A1304 Mm.265512 608185 Sec8l1 1 ■ATP synthases P56480 A0378 Mm.238973 102910 Atp5b X
P50516 A0397 Mm.217787 607027 Atp6v1a X X
P62815 A0400 Mm.249096 606939 Atp6v1b2 X
Q03265 A0377 Mm.276137 164360 Atp5a1 X X
P51863 A0403 Mm. 17708 607028 Atp6v0d1 X X
P50518 A0404 Mm.29045 108746 Atp6v1e1 X
Q925I1 A3559 Mm.241152 - Atad3a X
P35435 A0379 Mm. 12677 100729 Atp5c1 ■x
A0383 Mm.251152 603270 I
Q9Z1G3 A0401 Mm.276618 603097 Atp6v1c1 I
P57746 A0402 Mm.311549 - Atp6v1d I
NADH-Ubiquinone Oxidoreductase Q16795 A3563 Mm.29939 603834 NDUFA9
P28331 A3561 Mm.290791 157655 NDUFS1 X
Q9DCT2 A3564 Mm.30113 603846 Ndufs3 X 1
Q9D6J6 A0431 Mm.2206 600532 Ndufv2 xl X
Q62425 - Mm.41926 603833 Ndufa4 1 ■
Q9DCJ5 - Mm. 19834 603359 Ndufa8 I
Q99LC3 A3560 Mm.248778 603835 NdufalO 1 ■
Q91WD5 A3562 Mm.21669 602985 Ndufs2 I
Polyubiquitin Q62317 A1257 Mm.331 191340 Rps27a X [J
P62986 - Mm.43005 191321 UBA52 1 ■
Q63446 A1256 Mm.282093 191339 Rps27a 1 ■
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Protein Class UniProt PPID Acc Unigene OMIM Gene name Consensus PSD |MA mG AM
Acc cluster 1
_
Proteases /protease inhibitors 088543 A3570 Mm.40 604665 Cops3
P46101 A3565 Mm.42078 126141 Dpp6
Q9EQF2 A3571 Mm.19958 110900 Kel
035593 A3566 Mm.218198 607173 Psmd14
Q9R1P0 A3567 Mm.30270 - Psma4
Q63569 - Mm.289832 186852 Psmc3
088761 A3568 Mm.280013 - Psmdl
Q13200 - Mm.243234 606223 PSMD2
Q99JB5 A3569 Mm.273152 - Psmd8
Q9Z2X3 _ Mm.17640 603480 PsrndlO
P48594 - Mm.283677 600518 SERPINB4
Q9JJI7 _ Mm.243926 606797 St14
088399 A1731 Mm.236068 - Synj2
Development 088558 A3579 Mm.37249 606322 Cyfipl 1 X | |
088741 A3576 Mm.18218 606598 Gdapl Ixl ±z
Q9D2N4 A3577 Mm.94371 601239 Dtna TTTZ
Q8VE33 A3980 Mm. 102080 _ GdaplH XL
Q05175 A3574 Mm.29586 605940 Baspl
_
P18572 A3573 Mm.726 109480 Bsg
Q9CYN5 A3575 Mm.86523 - 5730405l09Rik
Q9JIQ6 A3998 Mm.39388 607802 Cnnml
Q9CQQ2 A4001 Mm.87417 606626 Daaml
Q9QXL0 A3578 Mm.248788 602865 Dbccrl
Q03173 _ Mm.87759 _ Enah
Q9QZY2 A3581 Mm.41812 _ Gprinl
Q62813 A3572 Mm.310524 603241 Lsamp
Q8K377 - Mm.292568 - Lrrtml
043300 _ Mm.39900 _ LRRN2
Q86VH4 _ Mm.94135 _ LRRTM4
008919 A2635 Mm.255487 604018 Numbl
Q924Y6 - Mm.32831 605186 Wif1
~
Other signalling molecules Q61358 A0095 Mm.44736 602377 Dnm1 _X_ "x"
P62157 A0008 Mm.285993 114180 CaM _x _ _x_ X
P39052 A1927 Mm.39292 602378 Dnm2 X X
Q9NRX7 - Mm.335310 607815 Eb-1 JL
P04925 A4012 Mm.648 176640 Pmp _x_
Q9WV31 A0277 Mm.25405 _ Arc III 1
~
[X!
Q9NZT1 _ Mm.21075 605183 CALML5 Ml
P49621 _ Mm.242576 604070 Dqkb Ml
Q8R3T9 A1928 Mm.29567 - Dnm3 Ml
070465 A4013 Mm.254610 - Odz4 Ml
008957 _ Mm.232930 607409 Nrn1 Ml
088377 Mm.39700 603261 Pip5k2b Ml
094811 _ Mm.39752 608773 Tppp Ml
Q9WUD1 A3978 Mm.277599 607207 Stubl Ml
035639 - Mm.7214 106490 Anxa3
Q91VR9 - Mm.5061 - Arf2
035143 _ Mm.2171 - Atpifl
075498 A1114 Mm.9749 604515 BLNK
P63030 - Mm.288510 - Brp44l
008918 _ Mm.3527 603203 Ccng2
P27274 A1630 Mm.247265 107271 Cd59
Q99KW9 A4005 Mm.334685 - Tip
P61810 A0666 Mm.142275 603460 Cdk5r1
Q9JLH7 A4007 Mm.28297 608202 Cdk5rap3
Q9Z140 Mm.5249 605688 Cpne6
Q9Z0J4 A0262 Mm.44249 163731 Nos1 jf
Q9Z1B3 A0330 Mm.330607 607120 Plcbl X ~x~
Q9JHK5 A0919 Mm.98232 173570 Plek
Q9ES97 _ Mm.246990 604249 Rtn3
Q9JK11 _ Mm. 192580 604475 Rtn4
P05942 _ Mm.3925 114210 S100a4
P06702 A1551 Mm.2128 123886 S100A9
P50114 A1342 Mm.235998 176990 S100b
P07092 A1547 Mm.3093 177010 Serpine2
088602 A0473 Mm.277338 602911 Cacng2 ~x~
055106 A2120 Mm.311915 - Stm
P58404 _ Mm.21612 - Stm4
075962 A0739 Hs. 130031 601893 TRIO
P20156 A2164 Mm.297818 602186 Vgf
P61206 A0421 Mm.221298 103190 ARF3 IT
Q61337 A0476 Mm.4387 603167 Bad X
P47728 A0437 Mm.2755 114051 Calb2 X T
P47713 A0106 Mm.4186 600522 Pla2q4a X
Q00731 A0434 Mm.282184 192240 Veqf X
P35637 A0217 Mm.277680 137070 FUS X
P53762 A0488 Mm.250265 126110 Amt X
P35569 A0484 Mm.4952 147545 Irs1 X
Q12888 A0286 Mm.215389 605230 TP53BP1 X
Q62077 A0012 Mm.44463 172420 Plcgl
_ JL
Q9NQ38 A4014 Mm.35369 605010 SPINK5
_ _x_
Other enzymes P05064 A1923 Mm.275831 103850 Aldoa T ~x~
P15105 A0424 Mm.210745 138290 Glul _x I ir
P97427 A3605 Mm.290995 602462 Crmpl ~x
Q62167 A3653 Mm.289662 300160 Ddx3x X
Q9WUA3 A1926 Mm.273874 171840 Pfkp X
P05063 A0428 Mm.7729 103870 Aldoc IT 11n ~x~
P07335 A3693 Mm.16831 123280 Ckb X
Q9NQC7 _ Mm.24282 605018 CYLD X
Q91VR5 A3656 Mm.251255 601257 Ddx1 X
060275 A2429 Mm.33027 -- IQSEC2 X
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Protein Class UniProt PPID Acc Unigene OMIM Gene name Consensus PSD MA mG AM
Acc cluster 1
Q9CPU4 A1948 Mm.218286 604564 Mqst3 | XI 1
Q9DBJ1 _ Mm.315962 172250 Pqaml X
P42337 A0153 Mm.260521 171834 Pik3ca Ixl 1 :x
008662 A3658 Hs.529438 600286 Pik4ca
P10111 - Mm.5246 123840 Ppia
088541 _ Mm.325816 123841 Ppib u
P17751 A0433 Mm.4222 190450 Tpi1 13 x
Q00981 _ Mm.29807 191342 UchM il
Q91V92 A3586 Mm.282039 108728 Acly
054734 A3619 Mm.7236 602202 Ddost
"
i
Q61656 A0814 Mm.220038 180630 Ddx5
035098 A3606 Mm.250414 608407 Dpysl4
P17182 A3615 Mm.70666 172430 Eno1
Q63835 A3659 Mm.267478 604443 Acsl6
Q9EQR0 A3584 Mm.236443 600212 Fasn
Q9Z2W5 A3592 Mm.28188 601336 Gcs1
015294 _ Mm.259191 300255 OGT
P12382 A1925 Mm.269649 171860 Pfkl I 31
P47858 A0261 Mm.272582 232800 Pfkm
P35700 A0371 Mm.30929 176763 Prdxl
~
31
P50137 _ Mm.290692 606781 Tkt A
Q9R1T2 A1052 Mm.258530 - Ublela
Q925C4 A3582 Mm.31374 200350 Acac
P55266 - Mm.316628 601059 Adar
Q9D1E8 A3630 Mm.24117 - Agpat5
P51635 _ Mm.30085 103830 Akr1a1
P24549 A3585 Mm.250866 100640 Aldh1a1
P11274 A0902 Mm.333/22 151410 bCK
Q99PU5 A3593 Mm.20592 - Lpd
088738 _ Mm.290908 605638 Birc6
P24270 _ Mm.4215 115500 Cat
Q8VDP6 - Mm.28219 605893 Cdipt
P52825 _ Mm.307620 600650 Cpt2
Q9D5V5 _ Mm.218910 601741 Cul5
Q64678 _ Mm.214016 601771 Cyp1b1
P16381 A3652 Mm. 108054 - D1Pas1
008560 A1300 Mm.314923 601441 Dgkz
Q99J47 A3651 Mm.21475 - BC003479
Q9BQF9 A3641 Mm.29678 - DKFZp761F069
Q9WU83 A3638 Mm.201322 603503 DPMI
Q9JMG8 A3610 Mm.27732 608383 Dpysl5
P21550 A3617 Mm.251322 131370 Eno3
P17183 A3616 Mm.3913 131360 Eno2
P70428 _ Mm.4336 133701 Ext2
Q9ESW4 A3620 Mm.32840 _ 2610037M15Rik
Q8TE79 A3634 Mm.11827 - Comtdl
P28037 A3594 Mm.30035 600249 Aldhl 11
Q9Z148 A0444 Mm.35345 604599 Bat8 ~x~
Q9Z339 A1969 Mm.29457 605482 Gstol
054865 A1980 Mm.9445 139397 Gucy1b3
070351 _ Mm.6994 300256 Hadh2
Q9DD18 _ Mm.28109 _ Hars2
P97852 _ Mm.277857 601860 Hsd17b4
070503 A3633 Mm.22505 _ Hsd17b12
P97618 _ Mm. 183042 602064 Impal
Q62784 A3587 Mm. 150420 600916 Inpp4a
075043 A3640 Mm.140138 607813 KIAA0455
P06151 A0370 Mm.29324 150000 Ldha ~x~
P16125 A0369 Mm.9745 150100 Ldhb X
P21396 A3672 Mm.21108 309850 Maoa
Q99MR8 A3604 Mm.249016 210200 Mcccl
P48318 A0635 Mm.272120 605363 Gad1
P34884 _ Mm.2326 153620 Mif
P46935 A1245 Mm.279923 602278 Nedd4
Q7Z5F1 - Mm.98668 606384 NEDD4L
Q01768 - Mm.1260 156491 Nme2
Q91VJ8 - Mm.29824 606793 Npepps
Q9EQU4 A3635 Mm.27427 - Dhrs4
Q08642 _ Mm.2296 607935 Padi2
Q91ZA3 A3601 Mm.23876 232000 Pcca
P15259 _ Mm.219627 261670 PGAM2
Q9CXY9 A3622 Mm.331447 605087 Pigk
070172 _ Mm.313977 603140 Pip5k2a
070161 A3591 Mm.29836 606102 Pip5k1c
P53657 A0427 Mm.8359 266200 Pklr "x"
Q9CR08 - Mm.22284 606114 Pop4
Q99JY8 A3632 Mm.348326 607125 Ppap2b
Q9D7G0 A3631 Mm.287178 311850 Prpsl
Q922W5 A3657 Mm.127731 179035 Pycrl
P53534 A3588 Mm.222584 138550 Pygb
Q925F3 _ Mm.214932 _ Rnf144
Q9EPK2 A3625 Mm.288141 312600 Rp2h
P07153 A3639 Mm. 188544 180470 Rpn1
P25235 A3611 Mm.22130 180490 Rpn2
Q91YM8 _ Mm. 197486 180410 Rrm1
Q9QZX7 _ Mm.131443 606477 Sit
076062 A2012 Mm.301370 603414 TM7SF2
Q61171 A0372 Mm.270130 600538 Prdx2 IT
Q9CZY3 - Mm.278783 602995 Ube2v1
P56399 - Mm.3571 601447 Usp5
Mitochondrial enzymes P16858 A0331 Mm.333399 138400 Gapd I I XI z T
P30275 A3690 Mm.252145 123290 Ckmtl t±jT ZL±z
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Protein Class UniProt PPIDAcc Unigene OMIM Gene name MA mG AM
Acc cluster
008553 A0442 Mm.235283 602463 Dpysl2 x
_
-y-
P26443 A3680 Mm. 10600 138130 Gludl _x_
Q99KI0 A0429 Mm.154581 100850 Aco2 Z
~
XL
P39069 - Mm.29189 103000 Ak1 X
P05202 A0423 Mm.230169 138150 Got2
~
X
Q64428 A3683 Mm.200497 600890 Hadha
P17710 A3663 Mm. 196605 142600 Hk1
P08249 A3696 Mm.297096 154100 Mdh2
Q9WUM5 A3697 Mm.29845 - Suclql U
P17764 A3694 Mm.293233 203750 Acatl X
P29147 A3702 Mm.293470 603063 Bdh
Q91VA7 A3668 Mm.29590 604526 Idh3b
P97700 A3731 Mm.296082 604165 Slc25a11
P07895 - Mm.290876 147460 Sod2
Q9Z2I9 A3621 Mm.38951 603921 Sucla2
P32551 A3677 Mm.334206 191329 Uqcrc2
Q9QWW0 A0432 Mm.186185 602316 Prdx6 X
055028 - Mm.8903 - Bckdk
Q9CZU6 A3688 Mm.58836 118950 Cs
Q9D0M3 A3698 Mm.29196 123980 Cye1
P53395 A3675 Mm.3636 248610 Dbt
Q64591 A3699 Mm.24395 222745 Decrl
P08461 A0605 Mm.285076 109720 Dlat x
008749 A3674 Mm.3131 246900 Did
Q01205 A3682 Mm.296221 126063 Dlst
008600 A3783 Mm.4449 600440 Endog
Q9DCT9 A3779 Mm.28336 231675 Etfdh
P28492 A3670 Mm.30102 606365 Gls2
Q64521 A3667 Mm.3711 138430 Gpd2
070325 - Mm.332810 138322 Gpx4
Q60587 A3684 Mm.291463 143450 Hadhb
Q9EQK1 A3660 Mm.2966 147650 Idh2
Q9D6R2 A3629 Mm.279195 601149 Idh3a
P70404 A3669 Mm.14825 300089 Idh3q
Q8R2M5 A3780 Mm.331142 _ 2010002H18Rik
P00405 A3778 Mitochondrial 516040 Mtco2
Q60597 A3664 Mm.276348 203740 Ogdh
Q9ULD0 A3665 Hs. 17860 - KIAA1290
P04166 _ Mm.20242 _ Cyb5m
Q05920 A3662 Mm. 1845 266150 Pc
Q9Z0X1 A3781 Mm.240434 300169 Pdcd8
P35486 A3685 Mm.34775 312170 Pdhal
P49432 A3687 Mm.301527 179060 Pdhb
Q9CZ13 A3676 Mm.194811 191328 Uqcrcl
Transcription and Translation
—
Transcription Elements Q61336 A0439 Mm.36241 _ Bcap37 T z X
Q924D3 A3580 Mm. 154358 606323 Cyfip2 X
P42669 A3795 Mm.231802 600473 Pura X
P24142 A3793 Mm.263862 176705 Phb j I XI I
Q9R0S1 A3788 Mm.29827 602181 Snd1 A
Q9JK31 A3789 Mm.173271 _ Atf7ip
P46100 A2062 Mm.10141 300032 ATRX
Q9UIG0 A2168 Mm.40331 605681 BAZ1B
Q9JI19 A3798 Mm.329656 608296 Fibp
Q9D0E1 A3792 Mm.311439 160994 Hnrpm
054910 A1330 Mm.57043 604548 Nfkbie
Q9DCS3 A3794 Mm.192706 608205 Nrbfl
P59759 _ Mm.270643 _ Mrtfb
Q9Z1N2 A3790 Mm.294154 601902 Orel I
035295 A3796 Mm.296150 608887 Purb
P40646 A2191 Mm.42162 - Sox7
Q8C3V4 - Mm.277406 600555 Statl
P40630 A2186 Mm.229292 600438 Tfam
Q8K055 A3799 Mm.22786 602290 Trim32
Q9QZP7 A2922 Mm.254997 _ Zfp386
P58501 A0298 Mm.347 - Gcfc z X
Other nuclear/DNA binding 054962 _ Mm.299167 603811 Banfl ZL1
P47875 A1021 Mm. 196484 123876 Csrpl A
Q99MR0 _ Mm.31646 _ Actl6b
Q9Z1N7 A2027 Mm.350789 _ Arid3b
Q8NE35 _ Mm.371677 _ CPEB3
Q9CW03 A3213 Mm.14910 606062 Cspg6
Q9Z1X8 A2251 Mm.262287 607112 Fbxo2
Q8TF61 _ Hs.23158 - FBX041
P84249 A1373 Hs.546259 601128 H3-IX
Q8TDG4 A2152 Hs.480101 606769 HEL308
P43274 - Mm.14101 142220 Hist1h1e
P28001 - Mm.261665 602786 HIST1H2AE
Q811M0 _ Mm.227295 142750 Hist1h4h
Q9D2U9 - Mm.28022 601831 Hist3h2ba
070592 A2547 Mm.316306 _ APa
035737 - Mm.21740 601035 Hnrphl
P70333 _ Mm.315909 601036 Hnrph2
Q9NYF4 _ Mm.277906 _ JMJD1B
Q9QWV4 - Mm.10414 601402 Mlf1
Q969Z1 - Mm.218940 - MMS19L
P28656 _ Mm.337558 _ Nap111
Q9EPT6 - Mm.31979 607538 Ndell
Q60862 A3791 Mm.3411 601182 Orc2l
P60335 _ Mm.274146 601209 Pcbpl
000541 - Mm.28659 605819 PES1
Q86YI3 - Hs. 154658 602327 PSD
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Protein Class UniProt PPID Acc Unigene OMIM Gene name Consensus PSD 1 TO mGl AM
Acc cluster
Q61493 - Mm.288788 602776 Rev3l
Q9UJC5 - Hs. 302772 - SH3BGRL2
P28370 A2045 Mm.229151 300012 SMARCA1
Q60596 - Mm.333661 194360 Xrccl
Q99K28 - Mm.43636 606908 Zfp289
Q9Y4E5 - Mm.289103 - ZNF451 ■
Elongation /RNA binding P62632 A3801 Mm.2645 602959 Eef1 a2 _x_ I 1
P58252 A3804 Mm.289431 130610 Eef2 _x 1
P10126 A1820 Mm.196614 130590 Eef1a1 a |
070251 A3802 Mm.2718 600655 Eef1b _^H__
Q9D8N0 A1968 Mm.247762 130593 Eeflg
070194 A3805 Mm.3955 603915 Eif3s7
P10630 - Mm.260084 601102 Eif4a2
Q922K6 A3806 Mm.290022 603928 Eif4b It
P63074 A0973 Mm.3941 133440 Eif4e
P29341 A2508 Mm.371570 604679 Pabpcl
054725 - Mm.257276 605199 Sfpq
Ribosomal Proteins P47911 A3810 Mm.262021 603703 Rpl6 "x
P62909 A3816 Mm.236868 600454 Rps3 X
P09058 A3823 Mm.260904 600357 RPS8
P50878 A3808 Mm.280083 180479 Rpl4 X
P47962 A1222 Mm.4419 603634 Rpl5 X
P14148 A0366 Mm.290772 604166 Rpl7 X
_ _X_
P53026 A3813 Mm.336955 - RpMOa X
Q9CXW4 - Mm.276856 604175 Rpl11 X
P14869 A3807 Mm.5286 180510 RplpO _X_
Q9CZX8 - Mm.300281 603474 Rps19 _x
Q8BHL0 - Mm.4071 150370 Lamrl X
P12970 A3811 Mm.725 185640 Rpl7a X
Q9Z237 A3812 Mm. 30066 604177 Rpl8 X
P23358 Mm.286100 180475 Rpl12 X
P47963 A0367 Mm.319719 113703 Rpl13 X I X.
Q63507 A3814 Mm.289810 - Rpl14 X
P35980 - Mm.349277 604179 Rpl18 X
P14118 - Mm.309019 180466 RPL19 X
P67985 _ Mm.307846 180474 Rpl22 X
P23131 - Mm. 140380 603662 RPL23 X
Q9CSM4 - Mm.340658 607526 Rpl27 X. _
P25444 A3815 Mm.1129 603624 Rps2 X
P97351 A3817 Mm.6957 180478 Rps3a fill
P47961 A3818 Mm.66 312760 RPS4 III 1
P10660 - Mm.325584 180460 RPS6 llll
P46781 - Mm.13944 603631 RPS9 mi
P63326 A1668 Mm.275810 603632 Rps10
P62842 - Mm.288212 180535 RPS15
P62250 - Mm.702 603675 RPS16
P63274 - Mm.42767 180472 RPS17
P62270 _ Mm.371578 180473 RPS18
Q63742 A3286 Mm. 172720 _ RBP34
P27659 - Mm.290899 604163 Rpl3
P51410 - Mm.300271 603686 Rpl9
Q6PDV7 _ Mm.100113 312173 RpHO
Q6ZWZ7 - Mm.276337 603661 Rpl17
P62751 - Mm.244545 602326 RPL23A
P83731 _ Mm.282814 604180 RPL24
P62889 - Mm.358632 180467 RPL30
P62900 - Mm.298467 - RPL31
P47964 - Mm. 11376 - Rpl36
P63174 - Mm.238817 604182 RPL38
P47955 - Mm.3158 180520 Rplpl
P02401 - Mm.341719 180530 Rplp2
P46782 - Mm.5291 603630 RPS5
P23821 _ Mm.371579 603658 RPS7
P63324 - Mm.371846 603660 Rps12
P62278 - Mm. 14798 180476 RPS13
P62264 - Mm.43778 130620 RPS14
Q921M2 - Mm.21938 603682 Rps20
P63221 _ Mm.289669 180477 RPS21
P25111 _ Mm.292027 180465 RPS25
P24051 - Mm.270283 603702 Rps27l
P49664 - Mm. 180003 191343 Rps27a
Q6ZWY3 - Mm.30120 -
P62858 - Mm.200920 603685 RPS28
P19253 A0368 Mm.180458 - Rpl13a
_ XL
Cytoskeletal and Cell Adhesion Molecules
Actin/ARP 035247 A0091 Mm. 196173 102560 Actin x
~
IT
015145 A0232 Mm.275942 604225 ARPC3 x. X
P59999 A0231 Mm.289306 604226 ARPC4 _X _ _x_
P53488 A0235 Mm.259045 604221 ACTR2 X
Q99JY9 A0234 Mm.183102 604222 Actr3 X
Q9R0Q6 A3287 Mm.34695 604220 Arpda X
015144 A0233 Mm.337038 604224 ARPC2 X
~
IT
Q9P1U1 A3339 Mm. 150319 - ARP3beta
Tubulin P68362 A0017 Mm.209290 602529 Tubal X
_ _x_ XL
actinin Q9Z1P2 A2341 Mm.253564 102575 Actnl ■OH
Q9JI91 A0007 Mm.37638 102573 Actn2 _\ T
~
~x~
P57780 A2344 Mm.276042 604638 Actn4 X X
088990 A2343 Mm.5316 102574 Actn3
_ _x_
Spectrin Q62261 A0010 Mm.123110 182790 Sptbnl
~
_x_
MAPs P34926 A0085 Mm.36501 600178 Mapla T ~x"
P20357 A0134 Mm.256966 157130 Map2 _x I XL X
Q9QXZ0 A2342 Mm.3350 608271 Macfl T
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P14873 A0625 Mm.4173 157129 Maplb _X x
P10638 A0135 Mm.1287 157140 Mapt "x
055129 A3376 Mm. 154087 601783 Stop x_
P27816 A0778 Mm.217318 157132 MAP4 ■
Q15555 A0654 Mm. 132237 605789 MAPRE2 ■
Catenins Q61301 A1914 Mm.34637 114025 Ctnna2 X
Q02248 A0112 Mm.291928 116806 Ctnnbl _x I X
035927 A0469 Mm.321648 604275 Ctnnd2 X
P30999 A0218 Mm.35738 601045 Ctnndl xf
P26231 A0089 Mm.18962 116805 Ctnnal
Myelin Q61885 A0351 Mm.210857 159465 Moq "x | X
Q62079 A0352 Mm. 1268 300401 Plp1 _x I x x
P04370 A0350 Mm.252063 159430 Mbp x 1 x
Q63912 A3590 Mm.93335 164345 Omg "x|~
P35802 A3425 Mm.241700 601275 Gpm6a
Cell recognition molecules P97685 A0663 Mm.326702 - Nfasc T rr —1
Q05546 A1074 Mm.337795 601995 Tnr rst±±z
P97547 A3607 Mm.15125 _ Sdfrl rmL
Q62701 A1525 Mm.980 187380 Tnc
Keratins Q9CWC9 A3741 Mm. 158190 - 2410039E07Rik
Q9CV17 A3825 Mm.46378 607742 2310058N18Rik
Q920F2 A1669 Mm.22657 148040 Krt2-5
Q9Z332 A3846 Mm.302399 148041 Krt6a
Other Cytoskeletal Proteins P46660 A0292 Mm.276251 605338 Ina X X
P08553 A0376 Mm.242832 162250 Nef3 x X
P08551 A0375 Mm.1956 162280 Nefl X X
088737 A0285 Mm.20425 604020 Bsn x_ ~X~
P30427 A1941 Mm.234912 601282 Pled si
Q9QYC0 A3876 Mm.289106 102680 Add1 X x
P47754 A0417 Mm.262039 601571 Capza2 X
~
x
P47757 A0418 Mm.2945 601572 Capzb X X
Q9QX74 A0081 Mm.323725 603290 Shank2 X X
Q9QXS6 A0438 Mm.19016 126660 Dbn1 X X
Q9EPW6 A3976 Mm.217161 602330 Abliml X x_
Q9QYB8 A0587 Mm.104155 102681 Add2 X x
Q01484 A3873 Mm.220242 106410 ANK2 X
Q61307 A3874 Mm.235960 600465 Ank3 X
015083 A3879 Mm.318004 - ERC2 X
P45592 A0999 Mm.4024 601442 Cfl1 X
Q99MI2 A3878 Mm.288860 607127 Rab6ip2 X
Q9JMB3 A3865 Mm.131135 605331 Epb4.1l3 X
Q9Z327 A3871 Mm.252321 - Synpo X x
P01831 A1218 Mm.3951 188230 Thy1 X
Q9ERQ9 A0148 Mm.41353 605035 Wasfl X
TQ9QYB5 A3877 Mm.44106 601568 Add3
P13020 A0419 Mm.21109 137350 Gsn £ I XQ61792 A3882 Mm.271967 602920 Laspl
035482 A0374 Mm.298283 162230 NF-H X
Q9Z0P4 A3883 Mm.34650 608134 Palm x_
P61164 A0660 Mm.3118 605143 ACTR1A x
Q9R1V7 A3881 Mm. 124892 603710 Adam23 X
Q02357 A0662 Mm.334444 182900 Ank1 X
P47753 _ Mm.19142 601580 Capzal _x _
Q8BVG1 - Mm.224189 - 4732477G22Rik A _
Q8C5W0 A3870 Mm.244078 - Clmn X
Q8VCQ5 A2142 Mm.260158 605269 Corolc A _
Q8R555 A3975 Mm.329851 606276 Crtacl X
Q9Z2H5 A3867 Mm.20852 602879 Epb41l1 X
Q96ID5 A3979 Hs.212511 - MGC15730 X
P/0b6b A0324 Mm.299//4 1/332b Jup X
Q14008 A4009 Mm.168478 - KIAA0097 X
035449 A3989 Mm.373627 - Ng5 X
Q99569 - Mm.260938 604276 PKP4 X
075145 A3869 Mm.277235 603144 PPFIA3 X
076049 - Mm.205647 603050 ABI1 X
P37805 - Mm.24183 607953 Taqln3 X
Q9ESJ4 A1027 Mm.192416 606671 Nckipsd X
Q80WK6 _ Mm.254446 - Ablim2
Q9R1V4 A3880 Mm.89854 155120 Adam 11
Q9R1V6 A0373 Mm.125477 603709 Adam22 x
Q91ZU0 _ Mm.34785 - Asb7
Q8R3F2 A3211 Mm.334999 _ Ckap4
089053 A2143 Mm.290482 605000 Corola
089046 A2141 Mm.276859 _ Corolb
Q9UQ03 A2139 Mm.335229 605002 C0R02B
Q60598 A0083 Mm.205601 164765 Cttn x
P48675 A0535 Mm.6712 125660 Des
Q61495 A0291 Mm.37953 125670 Dsgla x
P11531 A0462 Mm.275608 310200 Dmd
Q61167 A0654 Mm.57874 605789 Mapre3
Q15075 A2330 Mm.210035 605070 EEA1
Q8JZV5 _ Mm.210863 125305 Epb4.9
P26040 A0326 Mm.277812 123900 Vil2
Q61553 A0224 Mm.289707 602689 Fscnl
Q9QYE7 A1687 Rn.34728 - Itgad
Q9ERD4 A3875 Mm.250641 - Kidins220
P48679 A1374 Mm.243014 150330 Lmna
Q9D052 A3991 Mm. 130883 _ Lyric
P60853 _ Mm.334576 606551 Lztsl
P63005 A2074 Mm.56337 601545 Pafah1b1
Q96JQ0 _ Mm.334108 603057 DCHS1
Q91Y06 - Mm. 196700 606332 Pcdhb13
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075334 - Mm.252890 603143 PPFIA2
Q91Z80 - Mm.295105 603145 Ppfia4
Q9JJV2 - Mm.271744 176590 Pfn2
P70567 - Mm.249594 190930 Tmodl
Q9NSL0 A3872 Mm.29043 - DKFZp762B245
Q9UP98 A0446 Mm.22417 601342 CSE1L X
Q9JJ38 A0204 Mm.39046 300017 Fine X
P14733 A0430 Mm.4105 150340 Lmnbl
_ JL
Q8VC86 A0216 Mm.36769 602701 Slmap x_
Other Cell Adhesion Molecules P70587 A0150 Mm.132162 - Lrrc7 X
P15116 A0219 Mm.257437 114020 Cdh2 Y I Y
P23242 A0493 Mm.338720 121014 Gja1 x_
035889 A0101 Mm.181959 159559 Mllt4 X
054991 A0758 Mm.8021 602346 Cntnapl X
P12960 A0757 Mm.4911 600016 Cntnl X
Q61330 A1073 Mm.260861 190197 Cntn2 X
Q9QUP5 A3893 Mm.266790 115435 Haplnl x_
P55066 A3892 Mm.268079 600826 Cspg3 x_
P11627 A0290 Mm.260568 308840 L1cam X Y Y~
Q9JIA1 A0440 Mm.298251 604619 Lqi1 X x_
Q9Z0J8 A3888 Mm.317293 - Neqrl X
Q62765 A0129 Mm.316080 600568 Nlqnl X
Q62888 A3889 Mm.151293 606479 Nlqn2 X
Q62889 A3890 Mm.121508 300336 Nlqn3 X
Q07314 A3891 Mm.291005 600567 Nrxn3 1Q9Z251 A0141 Mm.268025 603380 Lin7a ~ Y
Q9Z252 A3899 Mm.20472 - Lin7b [Y|
Q61137 A3896 Mm.329586 600904 Astn X
Q9NR18 A0507 Mm.277354 606944 ERBB2IP _x
Q62718 A3887 Mm.283138 607938 Nt X
P13595 A3884 Mm.4974 116930 Ncaml X
Q9Z0E0 A1163 Mm.276466 608458 Ncdn X
Q9ULB1 A0130 Mm.329258 600565 NRXN1 X
P32736 A3886 Mm.39634 600632 Opcml _x.
Q61282 - Mm.358571 155760 Agc1 Y"
Q06890 A1276 Mm.200608 185430 Clu
P98203 - Mm.293599 602269 Arvcf
Q9UHW6 A3897 Mm.22786 - ASTN2
Q91ZU6 A1575 Mm.336625 - Dst
Q9Y6N8 - Mm.234715 604555 CDH10
Q9WTR5 - Mm.334841 601364 Cdh13
Q9QY32 A3895 Mm.38496 606775 Cspg5
P15924 A0454 Mm.355327 125647 DSP Y
P70689 - Mm.25652 604418 Gjb6
Q9ESM3 _ Mm.294467 - Hapln2
P20917 A3898 Mm.241355 159460 Mag
035136 A3885 Mm.258759 602040 Ncam2
P97798 A3894 Mm.42249 601907 Neo1
—
Q9EP53 - Mm.224354 605284 Tsc1
Synaptic Vesicles and Protein Transport
Clathrin P11442 A0119 Mm.254588 118955 Cite x_ I YY
P08081 A0122 Mm.298875 118960 Clta
P08082 A3901 Mm.290026 118970 Cltb
Synaptic vesicle 088935 A0161 Mm.370211 313440 Syn1 X
Q9QWV7 A3904 Mm.275845 600755 Syn2 1XI |
P46460 A0117 Mm.260117 601633 Nsf X I IE Y
P47708 A0212 Mm.181166 -- Rph3a _x X
P46096 A0039 Mm.289702 185605 Syt1 Y I IE
n17426 A0251 Mm.6877 601026 Ap2a1 Y
Q62768 A0560 Mm.334606 _ Unci 3a X
055125 A3914 Mm.293716 603249 Nipsnapl X
Q99NE5 A0035 Mm.328661 606629 Rimsl X
P60881 A0333 Mm.45953 600322 SNAP25 X I JL
Q9QXY3 A3903 Mm.342665 - P140 X Y
008599 A0238 Mm.278865 602926 Stxbpl X I IE Y
P52303 A0686 Mm.274816 600157 Ap1b1 I x I
P17427 A0252 Mm.253090 607242 Ap2a2 _X
P20172 A0254 Mm.18946 601024 AP2M1 £
054774 A1324 Mm.209294 607246 Ap3d1 Y
055126 A3913 Mm.12468 603004 Gbas I JL
Q9QXG3 A0040 Mm.6225 186590 Stxla !_ _x I IE
Q9Z270 A3937 Mm.266767 605703 Vapa
008838 A0121 Mm.101650 600418 Amph Y ~
008839 A1109 Mm.4383 601248 Bin1 X
Q9DBG3 A0253 Mm.39053 601025 Ap2b1 X Y
Q00380 A0255 Mm.333597 602242 Ap2s1 X
Q9EP81 A2346 Mm.255138 603432 Cyln2 X
Q61595 A3531 Mm.296457 600381 Ktn1 _x _
P28663 A3910 Mm.274308 - Napb X
Q9Z0W5 A0501 Mm.4926 606512 Pacsinl x
055011 A3927 Mm.235175 603025 Picalm X
Q9EQZ7 A1861 Mm.309296 606630 Rims2 X
Q64548 A0445 Mm.221275 600865 Rtn1 X I Y
Q02563 A3902 Mm.200365 185860 Sv2 X
Q9WVG8 A3933 Mm.26032 603927 Syngr3 JL _
Q62910 A0120 Mm. 187079 604297 Synjl pL _ Y
Q62277 A3941 Mm.223674 313475 Syp X
Q9R0N7 A3905 Mm. 182654 604146 Syt7 X
Q99JB2 A3942 Mm.26751 - Stoml2 X
Q91ZY8 - Mm. 184012 - Trim9 X
Q920Q4 A3908 Mm.276092 608550 Vps16 X
Q61123 A3909 Mm.296520 606931 Vps35 Y|~
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Times detected in PSDs i8 I 7 I 6 |5|4|3 2 | 1 |Complexes
Protein Class UniProt PPID Acc Unigene OMIM Gene name Consensus PSD 1 IMA mG AM
Acc cluster
P10107 A0647 Mm.248360 151690 Anxal
__
Q61548 A0684 Mm.281651 607923 Snap91
Q9JME5 _ Mm.322894 602166 Ap3b2
P53678 A3907 Mm.10647 _ Ap3m2
P35564 A0452 Mm.248827 114217 Canx
P-53621 A2102 Mm 30041 601924 OOPA
055029 A0237 Mm.261735 606990 Copb2
Q01469 A0441 Mm.741 605168 FABP5 ~X~
Q9QXY6 A1331 Mm.18526 605891 Ehd3
Q9Z1Z3 A3926 Mm. 139695 607263 Epn2
054922 A3921 Mm.22530 608163 Exoc7
054924 A3923 Mm.347360 _ Exo84
088630 A3936 Mm.20931 604026 Gosrl
Q9JKY5 A3906 Mm. 149954 605613 Hiplr
P97411 A2211 Mm.275683 147625 leal
088994 A4008 Mm. 177724 _ Mg87
Q9Y3A3 A3935 Mm.291037 - PREI3
Q8K0T7 _ Mm.41035 _ Unci 3c
P54921 A0596 Mm. 104540 603215 Napa
Q9CWZ7 A3911 Mm.292687 603216 Napg
Q62443 A1697 Mm.5142 602367 Nptxl
Q9JMB9 A3932 Mm.151332 _ Pex5l
Q80U40 - Mm.233996 - Rimbp2
Q8R361 _ Mm.220334 605536 Rip11
Q62991 A3928 Mm.216511 _ Scfdl
P97878 A3925 Mm.31607 604469 SeclOM
Q9D4R7 A3924 Mm. 159621 607880 Sec15l2
Q9D4H1 A3920 Mm.293510 _ Sec5l1
Q62825 A3922 Mm.261859 608186 Sec6l1
Q8VIL3 - Rn.7624 - Zwint
060493 _ Mm.277870 605930 SNX3
P61264 _ Mm.40343 _ Stx1b2
070439 A3940 Mm.248042 603217 Stx7
Q9ER00 A3939 Mm.28237 606892 Stx12
Q15431 A3863 Mm.243849 602162 SYCP1
Q9QZA3 - Mm.374805 602705 Syn3
055100 A0288 Mm.230301 603925 Syngrl T T
Q9DCD5 A4027 Mm.284594 - Tjp4
Q9Z152 A0562 Mm.286868 604586 Stxbp5
Q8IYF7 - Mm. 17436 605073 TRIM37
P63044 - Mm.28643 185881 Vamp2 ~x"
Q9QY76 A3938 Mm.260456 605704 Vapb
Q01853 A3918 Mm.262053 601023 Vcp
Q8BMZ7 - Mm.30028 - Vps28
Q9QZ88 - Mm.216528 606932 Vps29
Q63615 A3930 Mm.41372 _ Vps33a
Q9H348 A1326 Mm.27389 605485 HVPS41
P97390 A3929 Mm.263185 _ Vps45a
088384 A3934 Mm.265929 603207 Vtilb
Transporters P48962 A0395 Mm.16228 103220 Slc25a4 T
_ H
Q99LZ6 A3949 Mm.28023 _ Mtch2 l x i r
Q9JHY2 A3952 Mm.36169 _ Sfxn3 J£ ZL_
075746 A0443 Mm.30928 603667 SLC25A12 Tzt~ ~x~
Q9H936 A3773 Mm.33729 _ SLC25A22 _x zt_ _x_
P55096 A3946 Mm. 194462 170995 Abcd3
Q01405 A3945 Mm.209207 - Sec23a
Q925N0 A3954 Mm.121485 _ Sfxn5
P16036 A3//6 Mm.2ya bUU3/U Slc25a3
Q09073 A0396 Mm.658 300150 Slc25a5
"
~x~
P06795 _ Mm. 146649 _ Abcbl
Q9CXJ4 A3947 Mm.283914 605464 4833412N02Rik
Q9QZP4 A3948 Mm.285322 _ Mtchl
P47802 A3956 Mm.280943 600605 Mtx1
088441 A3957 Mm.292613 608555 Mtx2
008547 - Mm.2551 604029 Sec22l1
Q63965 A3951 Mm.134191 _ Sfxnl
P32089 A3750 Mm.229291 190315 Slc25a1
Q9QXX4 A3747 Mm.24513 603859 Slc25a13
P97441 A3943 Mm. 1396 602878 Slc30a3
Q9CZW5 A3950 Mm.213292 606081 Tomm70a
P40336 A3944 Mm.260703 605506 Vps26
Motor Proteins Q9QYF3 A0149 Mm. 3645 160777 Myo5a X
_ _x_
P70566 A3972 Mm.291880 602928 Tmod2 T
Q99JI3 A3970 Mm.222272 605853 Clasp2 ~x~
Q9D9F6 A3973 Mm.235123 600378 Immt X
Q8VDD5 A3166 Mm.29677 160775 Myh9 X
~
jr
Q9JMH9 A3964 Mm.341248 - Myo18a X
Q63608 A3965 Mm.121878 191010 Tpm1 _x
P38650 A0133 Mm.181430 600112 Dnchcl ir
P63168 A0514 Mm.256858 601562 DNCL1 JL
P28740 A3966 Mm.355686 602591 Kif2 X
Q9JLT0 A3961 Mm.218233 160776 Myh10 T
~
"T"
008638 A2331 Mm.250705 160745 Myh11 T
_ _x_
008788 A0658 Mm.6919 601143 Dctnl ~x
P21107 A3205 Mm.240839 191030 Tpm3 X
Q9R1R2 A1178 Mm.29290 605493 Trim3
P70611 A0561 Mm.266301 604567 Doc2a
088485 A0661 Mm.20893 603772 Dncil
P60521 - Mm.371666 607452 Gabarapl2
Q61768 A3967 Mm.223744 602809 Kif5b
Q63781 A4048 Mm.306770 - Mrlcb ttt11z
Q9H882 A3962 Mm.358743 608568 Myh14 tit
337
Analysis of the Molecular Components and Phosphorylation of Mouse Brain Proteomes
Appendix 8
Times detected in PSDs
8 7TT LILA.XL 1 |Complexes
Protein Class UniProt PPID Acc Unigene OMIM Gene name aflB7/'.j * ; MA mG AM
Acc cluster
Q60605 A4049 Mm.337074 - Myl6 x x~
P46735 A3958 Mm.3390 606537 Myolb X X_
Q64331 A3960 Mm.4040 600970 Myo6 T
P21807 A0459 Mm.2477 170710 Prph X
P31000 A0850 Mm.268000 193060 Vim _x
Q99KJ8 A0656 Mm. 167537 607376 Dctn2
Q9QUR2 A3969 Mm.272801 _ Dctn4
Q9D0M5 - Mm.246436 608942 Dlc2
Q8R1Q8 - Mm. 128627 - Dnclirf
088487 A2127 Mm.249479 603331 Dnci2
Q60780 _ Mm.40338 603127 Gas7
Q9Z0R4 A0571 Mm.40546 602442 Itsnl
P70188 - Mm.4651 601836 Kifap3
P28738 - Mm.256342 604593 Kif5c
~
088448 A3968 Mm.271648 - Klc2
P09541 - Mm.247636 160770 Myl4
Q63357 A3959 Mm.151948 606539 Myold
Q9NQX4 - Mm.41339 - MY05C
Q99MZ6 _ Mm.312342 606541 Myo7b
060313 A3971 Mm.274285 605290 OPA1
P30622 A2345 Mm.241109 179838 RSN
P46097 _ Mm.5102 600104 Syt2
035681 - Mm.4824 600327 Syt3
Q9R0N5 - Mm.358663 - Syt5
P58774 - Mm.646 190990 Tpm2
P16475 A4049 Mm.337074 - MYL6
061355 A3202 Mm.290003 160760 Mhc
~
T
Uncharacterised / novel Q9UNU4 _ Mm.261333 — SIPA1L1 XI I
Q920I9 A4010 Mm.30850 - Wdr7 1x1 r
Q9D5I5 A3994 Mm.20313 - 0710001 P09Rik XT
Q9D172 _ Mm.268691 601659 D10Jhu81e XT
035127 - Mm.3172 - C10 ~i U
Q9CRD2 A3977 Mm.244512 607722 Kiaa0103 13
Q9ULK3 - Hs.445885 - KIAA1217 u
Q9C0D0 - Mm.160124 - PHACTR1 u
Q8BJY6 - Mm.120298 - Nebl u
Q63128 - Mm.157716 _ CPG2 X
Q86TV6 _ Mm.295441 _ TTC7B T
Q9DCZ4 _ Mm.371632 _ 0610008C08Rik
Q8VD05 _ Mm.294159 _ 0610011D08Rik
Q8R570 - Mm.26680 - 1110031 B06Rik
Q78IS1 _ Mm.27606 _ 1200002G13Rik
Q8BMB1 _ Mm.41903 - 1200014J11Rik
Q9JKC6 - Mm.87027 - Bm88
Q9DB72 Mm.38347 - 1500005l02Rik
Q9CW19 - Mm.200385 - 1500041B16Rik
Q8QZT2 A3996 Mm. 157746 _ 1700054N08Rik
Q8WV67 _ Mm.318691 _ RBAF600
Q9D935 _ Mm.71682 _ 1810009B06Rik
Q80TP4 - Mm.285968 - Wdr47
Q6P069 _ Mm.96211 - Sri
Q8C9Z0 _ Mm.337339 _ 2310035C23Rik
Q8K1A7 - Mm.24829 - Fbxo31
Q922F4 _ Mm.181860 _ Tubb6
Q8BNN1 _ Mm.41459 _ 2610039E05Rik
Q9D023 - Mm. 195625 - 2610205H19Rik
Q9CZU2 A3995 Mm.61682 - 2610528A17Rik
Q9Z2D2 A3510 Mm. 102970 - Mtmr13
Q9CVR0 - Mm.227260 602660 4930542G03Rik
Q8C0R4 _ Mm.72926 _ 4932414J0
Q8BUY8 - Mm.271980 - 5330440H13Rik
Q8BP77 - Mm.355327 _ 5730453H04Rik
Q9CYH2 _ Mm.27227 - 5730469M10Rik
Q80T83 - Mm.274493 - 5730538E15Rik
Q8BX25 _ Mm.44490 - DCAMKL2
Q8BQV1 _ Mm.44355 - 6430514L14Rik
Q80Y24 - Mm.248820 608501 Prick I e2
Q9D217 A4003 Mm.257354 _ A330102H22Rik
Q8C409 _ Mm.204836 - A930041l02Rik
Q8C0J2 A2084 Mm.272972 _ Apq16l | X
Q8VDA6 _ Mm.30060 - Avpil
Q9CUI5 - Mm.92705 - Azi2
Q9D5J9 A4015 Mm. 199698 - 4930431B11 Rik I X
Q8K4U9 - Mm.240850 602968 Bcasl ■1
Q9HAA5 _ Hs.486708 _ C6ORF103
Q80W16 _ Mm.4880 - Cblnl
Q8VCR7 _ Mm.335427 - Cib
Q8C3Q5 _ Mm.347599 _ D430041B17
Q8BXF0 - Mm.291609 _ D430041 D05Rik
Q8C3K4 - Mm.35077 D630045J12Rik
Q8C8Q0 _ Mm. 196943 _ D6Ertd349e
Q9CU45 A3800 Mm.248687 - 6330407J23Rik
Q9H0C2 A3744 Mm.78691 _ DKFZp434N1235
Q8K2R1 A0281 Mm.23044 _ 9630050M13Rik I X
Q9NXY9 _ Hs.410889 - DKFZP564D166
Q8VD37 A3987 Mm.238094 _ 3110007P09Rik
Q8R1A4 A3986 Mm.260623 - Dock7
Q9CRB9 A3558 Mm.21501 - Chchd3
Q12914 A4002 Hs.502266 _ G2
Q9Y3I0 _ Mm.9257 _ HSPC117
Q96TC7 A3511 Mm.330492 - hucep-10
Q9HCQ3 A2325 Mm.37803 608793 HCMOGT-1
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Times detected iin PSDs i
8 I 7 | 6 |a 4|3 III1 | Complexes
Protein Class UniProt PPID Acc Unigene OMIM Gene name Consensus PSD 1 MA mG AM
Acc cluster
Q95KE9 _ - - Hypothetical protein
_
Q8R0L7 _ Mm.271717 606644 IgsfS
Q14700 A4000 Mm.271956 _ KIAA0090
Q922I2 A4006 Mm.260647 - C920006C1 ORik
Q92508 _ Mm.37324 - FAM38A
Q80U49 - Mm.23689 _ AW555464
060302 A3912 Mm. 134602 - KIAA0555
Q8C090 _ Mm. 134338 - AU040829
Q9Y2G0 A4035 Mm.210266 - KIAA0953
Q80TJ8 _ Mm.299442 _ AK122446
Q9ULT3 A3992 Mm. 166647 _ GPR158
Q9ULQ0 A3983 Mm.56097 _ FAM40B
Q96IB4 _ Hs.505516 _ KIAA1463
Q9HCM3 A3554 Hs.490294 - KIAA1549
Q8TDC3 - Hs.443752 - KIAA1811
Q96PY1 - Mm.296626 - KIAA1906
Q9JJK2 A3988 Mm.274904 _ Lancl2
Q9Z2I0 A4004 Mm.260538 604407 Letml
Q8NE86 A4023 Mm.69732 - C10orf42
Q8K4V0 A3999 Mm.217027 - Lrpprc
Q9HAY2 _ Hs.306123 - MAGEF1
Q8TB68 - Hs.130316 - PRR7
Q9D898 A3290 Mm.38155 - Arpc5l
035606 A4045 Mm. 196596 _ C18orf8
Q8IUF7 - Mm.289150 - mina53
Q99KX1 _ Mm.29737 601401 Mlf2
P56379 _ Mm.318 - Mp68
P61956 _ Mm.29923 603042 SMT3H2
Q8N8M3 _ Hs.5025 605491 NEBL
095897 _ Hs. 169743 _ OLFM2
Q9CRA1 _ Mm.275648 605903 Pdlim7
Q7TQG1 - Mm.253559 607771 Plekha6
P14200 - Mm. 179378 176795 Pmch
Q9NTK5 _ Mm.22661 - PTD004
P52823 _ Mm.20911 601185 STC1
Q9CUN3 A3993 Mm.260782 - 2810037C14Rik
054764 _ Mm. 14485 - Tex9
Q96Q82 - Hs. 12082 _ tigal
Q9CR67 _ Mm.23217 - Tmem33
Q16890 - Mm.7821 604069 TPD52L1
P14701 _ Mm.296922 600763 Tpt1
Q9EQN7 A3997 Mm.29729 605784 Ttyhl
Q9ER48 - Mm.29722 - Usmg5
Q80ZI9 _ Mm.2654 604734 Wdr1
Q8CBE3 - Mm.284654 - Wdr37
Removed from databases - - -- - qi:892272 x 1
_ - - qi:27733035 x| 1
_ .. _ gi:27712644
- - _ qi:27666466
_ .. - gi: 18601785
.. .. qi:27683621
_ - - gi:20909043
- - qi:27684483
- - - gi:27718001
- - - gi:20864488
- - - qi:27682685
- - - gi:20881893
- - - qi:20843007
- - qi:27689767
- - - qi:27677960
_ - - qi:20876984
- _ qi:20884391
- - - gi:27731499
_ _ - qi:27686085
Other cell origin P47819 A0534 Mm. 1239 137780 Gfap _X _
P08758 _ Mm.1620 131230 ANXA5 XT.jn
Q60771 A1892 Mm.4425 - Cldnl 1 I■
P23943 - Mm.284855 _ Edn2 1 XI
P58107 _ Mm.259929 - EPPK1
P14480 A1493 Mm.30063 - Fqb 1x8
P02680 A1494 Mm. 16422 - Fgg 1x8 ~
Q9ERL8 - Mm.87312 - Gmfb
P01946 A1741 Mm. 196110 - Hba1 8 XI ~
P02091 A1742 Mm.288567 - Hbb 1 x.l ~
P19637 A1496 Mm. 154660 173370 Plat
_
Appendix 8 - Summary of integrated PSD and multiprotein complex datasets. The
number of times a protein was found in the PSD (7 MS analyses of the PSD and individual
publications) is shown along with the components of 3 multiprotein complexes (MA, MASC;
mG, mGluR5 receptor complex and AM, AMPA receptor complex).
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Proteomics in the Neurosciences. In Proteomics: Biomedical and
Pharmaceutical Applications. Edited by Hondermarck, H.
(Kluwer Academic Press).
Chapter 3
Proteomics in the Neurosciences
MARK O COLLINS, HOLGER HUSI and SETH G N GRANT
Division ofNeuroscence, University ofEdinburgh, 1 George Square, Edinburgh, EH8 9JZ UK
1. INTRODUCTION
The field of proteomics aims to provide a comprehensive view of the
characteristics and function of every protein present within a given
biological system. The genome, which encodes the entire complement of
genes in an organism, has been seen as the fundamentally complex
component of cells. However it has emerged in recent years that its
complexity is overshadowed by that of the transcriptome, which describes
the full complement of mRNA transcripts transcribed from the genome of
the cell. This in turn gives rise to yet another level of complexity see in that
of the cellular proteome. This proteome is derived from the variety of
alternative splicing events that occur at the level of transcription and the use
of alternative start and stop sites and frame-shifting which occurs at the level
of translation. This complexity is compounded by the 300 or more different
protein modifications, which have been, reported (Aebersold and Goodlett
2001) of which phosphorylation and glycosylation are prototypic.
Comprehensive proteome analysis also seeks to elucidate protein sub¬
cellular distribution and protein-protein interactions, which are crucial in
determining the integration of large numbers of proteins into interaction
networks, and functional molecular complexes that ultimately perform a
myriad of cellular functions. Finally, the proteome is highly dynamic and
temporal and thus describes the complement of proteins expressed in a cell
at a single time point.
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Proteomic analysis in any system encompasses many areas and
integration of this data into biologically meaningful knowledge is the
ultimate goal. The progress and future objectives of each area in relation to
the field of neuroscience is discussed and the future of bioinformatic
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Figure I. (a) Overview of the progress and objectives of proteomics and the structure of
PADB, a proteomic analysis database.
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2. GLOBAL NEUROPROTEOMICS: APPROACHES
& OBJECTIVES
2.1 Two-dimensional electrophoresis
The biochemical approach of two-dimensional electrophoresis which has
become the classical proteomic approach to whole proteome analysis has the
capacity to display a large number of proteins expressed the studied system
under given physiological conditions. Construction of global expression
maps for defined proteomes is the most widely used application of
proteomics and when used in combination with mass spectrometry (MS)
techniques can be a powerful approach. There have been a number of studies
focused on global neuroproteomics from whole brain analysis to the analysis
of synaptic components. Two-dimensional maps have been constructed for
whole human (Langen, Berndt et al. 1999) mouse (Gauss, Kalkum ct al.
1999) and rat brains (Fountoulakis, Schuller et al. 1999) to analyse the entire
brain proteome. These studies yielded more than 200 discrete proteins with
significant over lap between datasets. The mouse brain proteome study is the
largest to date with 8767 resolved spots and over 300 proteins identified by a
combination ofproteomics and genetic methods, (figure 2).
.... *•: \rL-r
. ;• ;•>/• •; ■ •
. r' '
,
Figure 2. Protein standard map of
the mouse brain supernatant fraction
obtained by large-gel 2-D electro¬
phoresis followed by densitometry
and computer-assisted spot detect¬
ion (image from Gauss, C., Kalkum,
M., Lowe, M., Lehrach, H. & Klose,
J. Analysis of the mouse proteome.
(I) Brain proteins: separation by
two-dimensional electrophoresis and
identification by mass spectrometry
and genetic variation. Electro¬
phoresis 20, 575-600. (1999)
v*. ■■. •
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A number of brain region proteomes have been studied to investigate
differences in protein expression. Preliminary analysis of the mouse
cerebellar proteome has identified 30 proteins (Beranova-Giorgianni,
Giorgianni et al. 2002) and analysis of the porcine cerebellum led to
identification of 56 spots (Friso and Wikstrom 1999). A developmental
proteomic study of the rat cerebellum yielded resolution of over 3000 spots
and identification of 67 of these (Taoka, Wakamiya et al. 2000). Most
proteins showed an increase in abundance as the cerebellum matured,
however, 42 spots appeared to be exclusively expressed in the immature
cerebellum. Some of the latter were identified by MS and included proteins
with defined roles in nervous system development.
Although, the approach of using 2D in conjunction with MS techniques is
a classical proteomic approach, it is evident that it falls short as a sole
platform for global proteomics. The range of biochemically different
proteins, co-migration of proteins and difficulty of resolution of low
abundance molecules has hampered the use of this technology to
comprehensively analyse highly complex mixtures of proteins present in
brain preparations. Problems associated with 2D resolution of membrane
proteins have been overcome to some extent (Santoni, Molloy et al. 2000),
however gel-free proteomic solutions such as multidimensional protein
identification technology (MudPIT) (Wu, MacCoss et al. 2003) allow greatly
increased coverage of the membrane proteome. However, 2D-
electrophoresis will remain a useful tool in proteomics, due to sophisticated
image analysis, software and fluorescent dyes, which now permit more
sensitive and accurate comparative proteome analysis.
2.2 Subcellular Proteomics
Another approach which has proved to be very successful in the
systematic identification of proteins, has been used to identify the molecular
constituents of the post-synaptic proteome (PSP) (Husi 2003). The post¬
synaptic density is an amorphous structure usually 400 nm long and 40 nm
wide and is located beneath the synaptic membrane, and is visible under the
electron microscope as tight complexes of post-synaptic junctional proteins
(figure 3). It is well established that the regulation of synaptic proteins that
occur in the PSP plays an important role in synaptic plasticity, a mechanism
which is believed to underlie the synaptic mechanism of learning and
memory (Kennedy 1993).
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Figure 3. PSDs appear as slightly
curved bars (open arrows indicate the
cytoplasmic side). Adhering postsyna¬
ptic membranes are absent. Although
little substructure is apparent,
occaisional rod-like elements (4.5 x
28nm, small arrows) can be seen.
(Image from Ziff, E.B. Enlightening
the postsynaptic density. Neuron 19,
1163-1174(1997))
The PSP was purified from mouse forebrain by density centrifugation as
described previously (Carlin, Grab et al. 1980) with minor modifications.
Protein samples were separated by SDS-PAGE, stained by Coomassie blue,
and the entire gel lane was excised into 42 individual protein bands, reduced,
alkylated and digested with trypsin . The resultant peptides were identified
by online LC-MS/MS analysis and corresponded to 620 unique proteins.
This approach has far exceeded past studies, one of which only identified 26
molecules in the post-synaptic density (Walikonis, Jensen et al. 2000).
Another study, which employed a 2D electrophoresis approach, resolved
1700 spots. MS identified a total of 90 spots, containing 47 different protein
species. Unsurprisingly, within the dataset reported by Husi et al, were many
previously described synaptic proteins including ion channels, scaffold
proteins, signaling enzymes and cytoskeletal proteins. The majority of the
proteins were not known to be postsynaptic proteins. Although this
proteomic strategy attempted to use a relatively unbiased strategy, it cannot
be completely comprehensive as low abundance proteins may escape
detection, and the selection of whole forebrain as starting material will
overlook molecules found in small subsets of neurons. A further limitation
imposed by the method of biochemical isolation is that some proteins may
be contaminants not normally found at synapses. Despite this concern they
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observed a significant number of known synaptic proteins and a lack of
many nuclear and other proteins that would not be expected. A systematic
study using electron microscopy would be necessary to confirm or exclude
each protein's synaptic localization.
This postsynaptic protein profile is useful in several ways. First, it
appears that many of these proteins appear to be excellent candidates for
various aspects of cell biology at the postsynaptic terminal. For example, 24
components of the protein synthetic machinery (elongation factors,
ribosomal proteins) were identified; proteins encoded by synaptically
localized mRNAs; cytoskeletal components and modulators of the
cytoskeleton; motor proteins involved with ion channel trafficking channels
(e.g. KIF proteins, NSF, AMPA); ubiquitination mechanisms and so on.
Since many of these proteins have well characterized functions in non-
neuronal settings, their identification may facilitate tests of their function at
synapses. A second insight relates to the overall organization of the
postsynaptic terminal into sets of macromolecular complexes. In addition to
components of NMDA receptor complexes and AMPA complexes, there are
ribosomal and other complexes, consistent with the view that the
postsynaptic terminal is organized into macromolecular machines. Third, a
number of proteins are involved with neurological diseases and this list may
prove useful in directing human genetic studies of synaptic pathology. In
addition to its use in understanding the biology of synapses, this dataset may
prove useful in guiding human genetic studies of the nervous system.
The approach of biochemical purification combined with high-resolution
mass spectrometry used for the definition of the PSP could be easily applied
to many other sub-cellular structures. Indeed, subcellular structures, such as
axo-glial junctions and nodes of Ranvier would be prime candidates for such
an approach. Also, refined or new biochemical approaches to isolate
structures such as dendrites, axons and growth cones would facilitate
definition of other neuronal proteomes.
2.3 Neuro-phosphoproteomics
Another global neuroproteomic study carried out by Collins et al,
(unpublished results) focused on the neurophosphoproteome, i.e. the
collection of phosphoproteins at the synapse. Protein phosphorylation is an
essential regulator of protein function and signaling mechanisms in any
biological system. It has been estimated that one third of all proteins are
phosphorylated in the mammalian cell and if it is assumed that one third of
all proteins are expressed in the brain, then a conservative estimate of the
number of phosphoproteins expressed in the brain would be in the order of
2000-3000. This is underpinned by the fact that up to 5% of the expressed
genome may code for kinases.
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Protein phosphorylation has been shown to be intimately involved in the
assembly and function of the post-synaptic density (Yamauchi 2002),
synaptic vesicle turnover (Turner, Burgoyne et al. 1999), LTP (Hedou and
Mansuy 2003) and synaptic plasticity/memory (Schulman 1995). It is
therefore obvious that study of protein phosphorylation on a proteomic
platform will yield a wealth of data relevant to the molecular basis of brain
function.
Identification of phosphoproteins and characterisation of phosphorylation
sites has proved difficult for many reasons, most notably due to the low
stochiometry and transient nature of protein phosphorylation. This has been
especially true for global analysis of phosphorylation and there was a need
for specific enrichment techniques to be developed to tackle these issues.
A large-scale phosphoprotein isolation strategy was developed using a
pre-existing methodology for phosphopeptide purification. Phosphoproteins
were purified by large-scale metal affinity chromatography (Andersson and
Porath 1986)' (Muszynska, Andersson et al. 1986) from denatured
synaptosomes which contain the pre- and post-synaptic terminals, including
the postsynaptic density. Purified phosphoproteins were digested in solution
and analysed by DRA-LC-MS-MS. This approach has yielded the largest
mammalian proteomic dataset to date, identifying 236 potential
phosphoproteins from many protein classes (channels, transporters/
transporting ATPases, scaffolding and adaptor proteins, kinases,
phosphatases, small G-proteins and modulators, other signaling molecules,
metabolic enzymes, cell adhesion and cytoskeletal proteins,
nuclear/transcriptional, ribosomal and novel proteins. 28 phosphopeptides
were detected and characterised and contained 37 phosphorylated residues.
Of these 236 putative phosphoproteins it was shown by extensive literature
mining that 81 of these had been shown previously to be phosphorylated,
thus bringing confidence to the purification strategy used.
This dataset has considerable overlap with the post-synaptic density
proteome, with one hundred common proteins (Husi 2003), fifty-four of
which, are known to be phosphorylated. Also, thirty-one proteins contained
in the MAGUK-associated signaling complex (MASC) (Husi 2003) are
found in this phosphoproteomic dataset with twenty-four of these proteins
known to be phosphorylated. This phosphoproteomic approach is being
optimised in a number of ways, from using a double IMAC strategy, i.e.
sequential purification of phosphoproteins and then phosphopeptides, to
using more refined MS techniques such as precursor-ion scanning. These
changes should yield much better coverage and depth to the synaptic
phosphoproteome. Integration of this data on dynamic regulation of proteins
into phosphorylation networks (figure 4), and in also into the PSP network
will add an extra dimension and understanding to the organisation and
dynamism of the post-synaptic density.
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Figure 4. Literature based kinase substrate interaction map of proteins identified in the
phosphoproteomic dataset by Collins et al. Proteins shown in red were not detected but
included to show interactions with their substrates within the dataset.
The next major challenge for phosphoproteomics will be identification of
cognate kinases and phosphatases for the potential wealth of phosphorylation
sites which will arise from large-scale phosphorylation site studies. Also,
other functional aspects of protein phosphorylation will need to be addressed
in a high throughput fashion, namely the effects of phosphorylation on
protein-protein interactions and protein stability. The development of high-
density peptide and protein arrays (Lesaicherre, Uttamchandani et al. 2002)
should facilitate the study of some of these aspects of the functional
consequences of protein phosphorylation in a large-scale manner.
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3. MULTIPROTEIN COMPLEXES: A PROTEOMIC
APPROACH
3.1 NMDA receptor-adhesion protein signaling complex
Protein-protein interactions are the basis on which the cellular and
structure and function are built and interaction partners are an immediate
lead into biological function which can be exploited for therapeutic
purposes. Proteomics has been shown to make a crucial contribution to the
study of protein-protein interactions (Neubauer, Gottschalk et al. 1997).
Proteomic approaches to tackle multiprotein complexes usually involve
purification of the entire complex by a variety of affinity methods, and
protein identification by western blotting or mass spectrometry based
approaches. The first proteomic analysis of multiprotein complexes relevant
to the brain was the purification and identification of the molecular
constituents of the NMDA receptor-adhesion protein signaling complexes
(NRC) (Husi and Grant 2001) (Husi, Ward et al. 2000) and this will be
described as a prototypic approach to multiprotein complex proteomics.
3.1.1 Methodology
Similar to most neurotransmitter receptors, the NMDAR has a low
abundance in neurones compared with the overall protein content. Therefore,
it is important to generate highly enriched samples containing the target
molecule. This can be achieved by a variety of methods, generally involving
affinity chromatography steps. These can range from ligand affinity (drugs,
substrates or co-factors) to the more widely used approach of
immunoprecipitation, involving specific antibodies to the molecule of
interest. A major drawback in using antibody-based approaches for
proteomic analysis is the introduction of the IgG itself, which interferes with
the analysis by overshadowing proteins of interest that co-migrate during the
gel-separation. This same problem arises with protein-affinity based
methods, in which a recombinant protein carries one or several affinity-tags
(e.g. poly-histidines), or is expressed as a GST-fusion protein. This problem
can be eliminated using either the tandem affinity purification (TAP) method
(Rigaut, Shevchenko et al. 1999) or with the use of non-protein based
methods, which exploit substrate or ligand affinities, such as peptide-based
isolation procedures (Husi and Grant 2001). All of these ligands, groups or
proteins are then coupled to a resin either irreversibly (usually in the case of
small molecules), or through a secondary affinity linkage specific for the
bait-molecule. Neuronal extracts are then incubated with the resins bearing
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the bait and bound proteins separated from each other as well as from the
matrix by conventional gel analysis.
Identification of isolated proteins can be readily achieved using western
blotting or mass spectrometry. Western blotting (also known as
immunoblotting) utilizes specific antibodies to detect a protein that has been
transferred from a gel onto a membrane. A major advantage of western
blotting is its sensitivity and ability to detect amounts of protein beyond the
range of current sequencing-based or mass spectrometry methodologies. It is
obvious that this approach is biased by the assumption that a given molecule
might be present, and cannot be used to identify unknown or unsuspected
proteins. However, there is a large amount of neurobiological evidence
concerning the putative involvement of molecules that influence many target
proteins and such proteins pose ideal targets for western blotting approaches.
Additionally, changes in protein levels, as a result of modulation or
modification in the receptor's environment, can easily be visualized using
specific antibodies against the proteins under investigation. A disadvantage
of this method is its labour intensive nature and thus difficulty in performing
on a large scale.
The main approaches to protein identification are peptide-mass
fingerprinting using matrix-assisted laser desorption/ionization (MALDI)
(Refs [(Henzel, Billeci et al. 1993), (Shevchenko, Wilm et al. 1996)) and
electrospray ionization using a tandem mass spectrometer (Shevchenko,
Chernushevich et al. 1997) or a combination of both (Shevchenko, Loboda et
al. 2000). Recent developments led to new methodologies using direct liquid
chromatography/tandem mass spectrometry (LC/MS-MS) techniques, which
allow fast and reliable mapping of very low amounts of peptides in an almost
completely automated fashion (Shevchenko, Chernushevich et al. 2000).
Furthermore, using this method, it is also possible to determine if a protein
or peptide carries any post-translational modifications, such as glycosylation
or phosphorylation (Pandey, Podtelejnikov et al. 2000).
The sample is usually separated on a gel and the bands of interest excised
and treated with trypsin in order to generate fragments of proteins that can
subsequently be extracted from the gel slice. There are several reasons for
analyzing peptides rather than proteins. The peptide's mass can be measured
at much greater precision than the mass of intact proteins. Peptides give rise
to a library of molecular masses that are directly derived from the proteins,
which can be identified using computational techniques (Berndt, Hobohm et
al. 1999).
Using the approaches described above the NRC was shown to comprise
77 proteins organized into receptor, adaptor, signaling, cytoskeletal and
novel proteins, of which 30 are implicated from binding studies and another
19 participate in NMDAR signaling (Figure 5) (Husi, Ward et al. 2000).
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Figure 5. Schematic diagram of synaptic multiprotein complexes. Post-synaptic complexes of
proteins associated with the NMDA receptor and PSD-95, found at excitatory mammalian
synapses, are shown. Individual proteins are illustrated with arbitrary shapes and known
interactions indicated. Proteins shown in colour are those found in a proteomic screen,
whereas those shown in grey are inferred from bioinformatic studies. The specific protein-
protein interactions are predicted, based on published reports from yeast two-hybrid studies.
Membrane proteins (such as receptors, channels and adhesion molecules) are attached to a
network of intracellular scaffold, signaling and cytoskeletal proteins, as indicated.
NMDAR and metabotropic glutamate receptor subtypes were linked to
cadherins and LI cell-adhesion molecules in complexes lacking AMPA
receptors. These neurotransmitter-adhesion receptor complexes were bound
to kinases, phosphatases, GTPase-activating proteins and Ras with effectors
including MAPK pathway components. A striking feature of the
composition is that there appears to be 'modules' or sets of signaling
proteins that are known to comprise key components of signal transduction
pathways that can be distinctly regulated. For example, all of the molecules
necessary to induce the phosphorylation of mitogen-activated protein kinase
(MAPK) following NMDAR stimulation are present in the NRC (including
CaMKII, SynGAP, Ras, MEK and ERK) (Figure 5). There modules may
allow the NMDAR and mGluR to integrate signals within the complex and
then couple to down stream cellular effector mechanisms, such as trafficking
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of AMPA receptors and cytoskeletal changes that mediate structural and
physiological plasticity. Furthermore, at least 18 NRC constituents are
regulated by synaptic activity indicating that the composition of the complex
is dynamic. In the hippocampus, these activity-dependent genes are known
to undergo specific temporal changes following the induction of plasticity.
Genetic or pharmacological interference with 15 NRC proteins impairs
learning and with 22 proteins alters synaptic plasticity in rodents. Mutations
in three human genes (NF1, Rsk-2, LI) are associated with learning
impairments, indicating the NRC also participates in human cognition.
This NRC dataset was further expanded using a combination of peptide
affinity chromatography and mass spectrometry identification of new
components of the complex (Husi H et al 2003). Purification of MASCs
(MAGUK-associated signaling complexes) was achieved by peptide affinity
chromatography using a hexapeptide corresponding to the C-terminus of the
NMDA-R2B subunit. This approach extended the NRC dataset to comprise
184 proteins which constitute the MASC(Husi 2003). Also, a-amino-3-
hyroxy-5-methyklisoxazole-4-proprionic acid (AMPA) complexes were
purified using immuno-afflnity chromatography, resulting in the
identification of ten unique proteins. These two receptor complex datasets,
together with the PSD provides for the first time a general composition of
the postsynaptic proteome, which totaled 698 distinct proteins. The main
overlap was seen between MASC and the PSD, with 108 common proteins.
3.2 Other Membrane Receptor Complexes
Since the characterisation of the NRC, two other receptor complexes
have been reported. P2X receptors are ATP-gated ion channels in the plasma
membrane, and activation of the P2X7 receptor also leads to rapid
cytoskeletal re-arrangements such as membrane blebbing. 11 proteins in
human embryonic kidney cells that interact with the rat P2X7 receptor were
identified by affinity purification followed by mass spectroscopy and
immunoblotting (Kim, Jiang et al. 2001). Also using a proteomic approach
based on peptide affinity chromatography followed by mass spectrometry
and immunoblotting, another study identified 15 proteins that interact with
the C- terminal tail of the 5-hydroxytryptamine 2C (5-HT (2C)) receptor, a
GPCR (Becamel, Alonso et al. 2002). These proteins include several
synaptic multidomain proteins containing one or several PDZ domains
(PSD-95 and the proteins of the tripartite complex Veli3-CASK-Mintl),
proteins of the actin/spectrin cytoskeleton and signaling proteins. Co-
immunoprecipitation experiments showed that 5-HT (2C) receptors interact
with PSD-95 and the Veli3-CASK- Mintl complex in vivo. Electron
microscopy also indicated a synaptic enrichment of Veli3 and 5-HT (2C)
receptors and their co-localisation in microvilli of choroidal cells. These
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results indicate that the 5-HT (2C) receptor is associated with protein
networks that are important for its synaptic localization and its coupling to
the signaling machinery (Becamel, Alonso et al. 2002).
It is now emerging that multiprotein signaling complexes or "signaling
machines", of which the NRC is prototypic, are responsible for orchestrating
the complex signaling events at ionotrophic glutamate receptors (Husi, Ward
et al. 2000), ATP receptors (Kim, Jiang et al. 2001) and G-protein coupled
receptors (Becamel, Alonso et al. 2002). They seem to share a common
organisation of receptor, protein scaffold, (in which the signaling molecules
are localised) and membrane to cytoskeletal interactions. Therefore, study of
individual receptor multiprotein complexes such as the NRC will most likely
provide a mechanistic basis that will be very useful and applicable for the
systematic identification and study of membrane receptor complexes
associated with the estimated 100 other receptor types believed to exist in
the brain.
4. DISEASE PROTEOMICS OF THE BRAIN
4.1 Alzheimer's Disease as a case study
The main approach of proteomic analysis of brain pathology is to use
comparative 2D-page separation of constituent proteins in diseased versus
normal samples. This is usually followed by gel image analysis to identify
alterations in the intensity of specific spots compared to the normal state and
subsequent excision of the abnormal spots and identification by mass
spectrometry or peptide sequencing. The main types of samples, which have
been analysed by these means, are human biopsies or postmortem samples
and mouse models of human disease.
There have been a number of studies focused on Alzheimer's disease
(AD), an increasingly prevalent neurodegenerative disease. Comparative
proteome analysis was performed on post-mortem brain tissue samples from
patients with AD and compared with profiles from non-demented control
brain tissue (Schonberger, Edgar et al. 2001). Proteins were resolved by 20-
PAGE and identified by NH2-terminal sequencing. Thirty-seven proteins
differed significantly between AD and normal tissue and could be grouped
into several functional categories. A number of proteins identified in this
study, such as a-crystallin, superoxide dismutase, glyceraldehyde-3-
phosphate dehydrogenase, and dihydropyrimidinase-related protein had been
implicated previously in the pathogenesis of AD.
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This work has been complemented by studies of mouse models of AD,
namely mice transgenically overexpressing glycogen synthase kinase-3p
(GSK-3p) and microtubule-associated protein tau, both of which have been
implicated in the pathogenesis of AD. A proteomic approach was used to
identity cellular abnormalities in mice over expressing human tau with the
aim of understanding the role of tau in the pathogenesis of AD. Proteins
were resolved by 2D-PAGE and 34 proteins whose expression levels in
wild-type and tau transgenic mice differed at least 1.5 fold were identified by
ESI-MS (Tilleman, Van den Haute et al. 2002). A similar study by the same
group was performed on GSK-3P overexpressing mice (Tilleman, Stevens et
al. 2002). GSK-3P is a serine-threonine protein kinase capable of
phosphorylating tau and hyperphosphorylated tau is a principle component
of neurofibrillary tangles, which are characteristic of AD brains. It is
regulated by serine (Inhibitory) and tyrosine (stimulatory) phosphorylation
and also by protein complex formation and its intracellular localisation.
GSK-3P is a key regulator of regulating neuronal plasticity and gene
expression controlling the function of many metabolic, signaling and
structural proteins. It also regulates cell survival, as it facilitates a variety of
proapoptotic mechanisms (Harwood 2001). It has been linked to all of the
primary abnormalities associated with AD and was shown to interact with
components of the plaque producing amyloid system (Grimes and Jope
2001).
A comparison between GSK-3P transgenic mice and wild type revealed
51 proteins whose expression differed significantly. Twenty-five of these
proteins have been identified to be present in the postsynaptic proteome, 14
of which are components of NMDAR-PSD-95 complexes that constitute
MASCs.
There was a significant decrease in the relative abundance of cytoskeletal
and energy metabolism proteins and a significant increase in proteins
involved in signal transduction and oxidative stress in the GSK-3P
transgenic mice. A comparison of the profile of proteins with altered
expression in the tau and GSK-3P transgenic mice showed that there were a
number of proteins with similar changes consistent with the mutual
involvement of these two proteins in the process of neurodegeneration.
Complementary large-scale approaches to the study of AD and other
brain diseases have been developed, notably cDNA microarrays. These
arrays can detect thousands of mRNA transcripts present in the biological
sample and can be used in a similar way as 2D-PAGE for detecting
alterations in diseased versus normal tissues. The use of microarrays is now
routine and due to the facile methodology can be used as a first step in
detecting alterations in transcript levels in various pathologies. However, the
correlation between mRNA levels and protein levels can be poor, so
microarray data should be interpreted with caution and confirmed by looking
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at protein levels by methods previously discussed. A recent example of the
use of cDNA microarrays for the study of AD was reported by Colangelo et
al. in which they profiled 12633 genes in human post-mortem hippocampal
CA1 in normal versus AD patients (Colangelo, Schurr et al. 2002). They
found decreases in transcript levels of 19 genes encoding metal ion-sensitive
factors, transcription and neurotrophic factors, and signal-transduction
elements involved in synaptic plasticity and organisation which correlated
well with previously reported down-regulation of such function categories in
AD. Also, they found increases in transcript levels of 19 genes involved in
proapoptotic activities and inflammation, also consistent with AD pathology.
Interpretation and integration of such data with that obtained from proteomic
experiments is presently difficult as specific changes in transcripts and
protein levels are not seen in many consistent sets of proteins/genes. Also,
expression levels (mRNA/protein) seen in normal versus diseased
experiments can be due to secondary effects and not central to the
pathogenesis. However, consolidation of mRNA/protein expression data for
a particular disease in a database, may uncover common disturbances in
pathways relevant to the actual pathology and not due to secondary effects.
4.2 Networks and psychiatric disease
Complex diseases are ideally suited for study by proteomic approaches.
Their complexity of causation requires a global approach and an example of
one such study relates to the work described earlier on MASC.
The identification of MASC and its network properties provides a unique
opportunity to explore human cognition and its disorders. Although it is
generally accepted that cognitive mechanisms are conserved between mice
and humans, it is unclear how much the rodent molecular studies map onto
human psychiatric conditions. The possibility that MASC proteins may be
involved with human psychiatric and neurological disorders was investigated
and it was found that 46 MASC proteins implicated in mental illness in the
literature (figure 6). Although all mental disorders were searched 26 were
found in schizophrenia, 18 in mental retardation, 7 in Bipolar disorder and 6
in depressive illness. This apparent bias toward schizophrenia and mental
retardation could be biologically relevant since they both have a major
cognitive component to their primary symptoms unlike the affective
disorders.
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Figure 6. Network representation of MASC proteins with phenotypic annotation. 97 MASC
proteins with known direct protein interactions to other MASC proteins are plotted. The
NMDA receptor subunits (NR1, NR2A, NR2B) are centrally located. The association of each
protein with plasticity, rodent behaviour or human psychiatric disorders is shown in the colour
of the node. Key: Black - no known association; Red - Psychiatric Disorder; Green -
Plasticity; Blue - Rodent Behaviour; Yellow - Psychiatric Disorders and Plasticity; Cyan -
Plasticity and Rodent Behaviour; White - all three phenotypes. Orange for Psychiatric
Disorders and Rodent Behaviour alone had no hits.
The network provides a common connection or association between these
disease molecules. Network simulations also show that disruption of
combinations of proteins produce more severe effects on the network. This
suggests that combinations of proteins (or mutant alleles) underpin the
polygenic nature of the disorder.
4.3 Future perspectives
The number of comparative 2D/MS studies of disease and disease models
has increased over the last number of years. This has led to the accumulation
of lists of proteins whose expression levels have been shown to be altered in
the particular system, but with little integration of these lists to provide a
global view. This is emerging problem in the study of complex diseases, not
only at the level of proteomics but also at the level of study of individual
protein function in relation to disease. The pathogenesis of
neurodegenerative diseases such as AD is likely to consist of a number of
initial pathways converging to form the distinctive pathology of amyloid
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plaques and NFT's (neurofibrillary tangles) characteristic of AD. Proteins
implicated in this pathogenesis may also be characteristic of the stage of
progression of the disease and may be transiently altered. The components
and formation of amyloid plaques and NFT's are reasonably well understood
but the many pathways leading to this end point are still elusive. It is clear
that there is a need to integrate the large amount of data concerning proteins
involved in the pathogenesis of AD into a coherent global view of the
disease.
Bioriformatics integration of proteomc data
Figure 7. Overview of levels of proteomic complexity
It may be quite likely that an understanding of the fundamental
components and mechanisms of the pathways leading to AD pathology will
be gained from a holistic view that can be obtained by using a proteomic
strategy combined with bioinformatics and network analysis (figure 7).
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5. BIOINFORMATICS: INTEGRATION OF
PROTEOMIC DATA
It is evident that there is a growing need for bioinformatic tools and
databases to deal with the wealth of data being generated by proteomic
analyses. Increased image resolution and reproducibility in 2D-
electrophoresis is allowing 2D maps to be generated for particular systems
(http://us.expasy.org/ch2d/). The samples and the protocols used to generate
these maps are being standardised to allow easy cross-referencing between
gels. Comprehensive protein identification by MS allows assignment of
protein spots on these master maps yielding a characteristic spot position for
each protein species. This kind of approach, in which a proteome is defined
on a 2D map, will allow rapid comparative analysis. This will be particularly
useful in disease proteomics, as it will bypass the necessity for routine MS.
Integrative proteomic databases such as PADB (http://www.PPID.org)
(Husi 2002) will be essential for the analysis of proteomic data. The ability
to submit MS datasets to such databases and retrieve comprehensive protein
information, including protein-protein interactions will greatly reduce the
current bottleneck of manual analysis of large numbers of proteins. As
discussed for the MASC and PSP, such assembly of proteins into networks
has been facilitated by this tailored proteomic database and such insights into
global basic biology would not be possible in its absence. Bioinformatic
analysis of proteomes is in its infancy, it can be seen in figure 1 that the
future objectives of the many proteomes that exist are ambitious, but
necessary.
Proteomic data must be dealt with in a holistic way if any meaningful
biological questions are to be answered. Basic information on protein-
protein interactions, protein modifications and multiprotein complexes must
be obtained for relevant subcellular structures in various cell types and brain
regions and integrated with previously published functional information.
Within this framework of biological knowledge, complex biological
problems and pathologies can be addressed in a less biased and
comprehensive way than ever possible. Integration of diverse proteomic data
to provide the ultimate global view is a formidable long-term task, which
will only be achieved by standardisation of data, very powerful
bioinformatic tools and comprehensive databases.
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Reversible protein phosphorylation mediated by kinases, phosphatases, and regulatory molecules is an essential
mechanism of signal transduction in living cells. Although phosphorylation is the most intensively studied of the
several hundred known posttranslational modifications on proteins, until recently the rate of identification of
phosphorylation sites has remained low. The use of tandem mass spectrometry has greatly accelerated the iden¬
tification of phosphorylation sites, although progress was limited by difficulties in phosphoresidue enrichment
techniques. We have improved upon existing immobilized metal-affinity chromatography (IMAC) techniques for
capturing phosphopeptides, to selectively purify phosphoproteins from complex mixtures. Combinations of phos-
phoprotein and phosphopeptide enrichment were more effective than current single phosphopeptide purification
approaches. We have also implemented iterative mass spectrometry-based scanning techniques to improve de¬
tection of phosphorylated peptides in these enriched samples. Here, we provide detailed instructions for imple¬
menting and validating these methods together with analysis by tandem mass spectrometry for the study of
phosphorylation at the mammalian synapse. This strategy should be widely applicable to the characterization of
protein phosphorylation in diverse tissues, organelles, and in cell culture.
Protein phosphorylation is an essential regulator of protein function, and signaling pathways rely on this mechanism to regulate pro¬
tein activity and protein-protein interactions. Phosphorylation can function as a reversible tag of activity by which information can be
transduced from one protein to another in response to an appropriate stimulus. Alternatively, phosphorylation can serve to promote
specific protein-protein interactions mediated by protein domains that recognize phosphorylated amino acid-containing sequences.
Signal transduction is fundamentally important to many cellular processes and, consequently, is highly complex and intricately regu¬
lated. Signaling pathways are often initiated by multiprotein complexes that translate a stimulus (for example, receptor stimulation) to
downstream effectors. Multiprotein signaling complexes, or "signaling machines," are responsible for orchestrating complex signaling
events at glutamate receptors (1,2), ATP receptors (5), cytokine receptors (4), growth factor receptors (5), and heterotrimeric guanine
nucleotide-binding protein (G protein)-coupled receptors (6). They seem to share the common organization of a membrane-bound
receptor embedded in a protein scaffold with interacting signaling and cytoskeletal proteins. Phosphorylation is employed to modulate
protein function and stability and to mediate phosphorylation-dependent protein-protein interactions, for example, binding phospho-
inositide 3-kinase (PI3K) through its Src homology 2 (SH2) domain to the NR2B subunit of the jV-methyl-D-aspartate (NMDA)-type
glutamate receptor) (7). These phosphorylation-dependent interactions confer a higher-order level of regulation of such protein com¬
plexes than that imparted by changes in protein expression.
Historically, phosphorylation and its importance in regulating signal transduction and protein function have been studied at the level
of single molecules (8, 9), but new proteomic strategies lend themselves to the global characterization of the signaling properties of
the proteome. The systematic characterization of kinase and phosphatase substrates is necessary to extend current knowledge of
known signaling pathways, and it will inevitably reveal many more pathways. It is now apparent that the extent of phosphorylation
in a proteome far exceeds original estimates, with the majority of proteins capable of being phosphorylated at multiple sites. Up to
20 to 30 phosphoresidues in a single protein have been reported (10, 11). Of the estimated 100,000 possible phosphorylation sites in
the human proteome, only 3 to 4% are presently known, highlighting the daunting task ahead (12). The use of mass spectrometry to
characterize phosphorylation has rapidly increased, with a 5000% increase in phosphorylation sites defined by this approach from
1992 to 2002 (13). Although mass spectrometry-based strategies for phosphorylation site identification have clear advantages over
traditional techniques [for a review, see Mann et al. (14)], it is not yet routine to analyze complex phosphoprotein samples. Analysis
ofphosphoproteins is not straightforward, for a number of reasons. First, the stoichiometry ofphosphorylation is generally low. Sec¬
ond, the phosphorylated sites on proteins might vary, implying that any given phosphoprotein is heterogeneous. Third, many classes
ofproteins are present at low abundance within cells, mandating enrichment before analysis. Fourth, most analytical techniques used
for studying protein phosphorylation have a limited dynamic range, meaning that minor sites might be difficult to identify. Finally,
endogenous phosphatases could dephosphorylate proteins and peptides unless their activity is inhibited during sample preparation.
Sample preparation is crucial for the success of any mass spectrometry-based phosphoproteomic analysis, and numerous approaches
have been developed to overcome the problems associated with sample preparation. These include phosphoresidue enrichment
strategies such as affinity purification with phospho-specific antibodies or immobilized metal affinity chromatography (IMAC),
labeling strategies such as 32P-ATP, and chemical modification with subsequent biotin tagging [for a review, see Mann et al. (14)].
IMAC enrichment, which is based on the affinity of metals [usually Fe(III) or Ga(III)] to negatively charged phosphate groups, has
become the most common approach for in vivo phosphorylation site identification (13). This is largely due to improvements made in
the specificity of IMAC brought about by chemical derivatization of carboxylic acid groups to methyl esters, which decreases non¬
specific binding of acidic peptides (15). Recent phosphoproteomic studies have utilized peptide IMAC protocols together with
methyl-esterification to enrich for phosphopeptides prior to mass spectrometry. This approach has been used successfully to study
phosphorylation in yeast (15), Arabidopsis (16), and cell lines (17); however, the use of these IMAC approaches on mammalian sub¬
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The strategy employed for phosphorylation analysis depends on the type of mass spectrometer; the most commonly used are ESI
mass spectrometers (usually nanoelectrospray) in conjunction with one- or two-dimensional liquid chromatography separation (13).
Triple quadrupole mass spectrometers were the first to be widely used for phosphorylation studies, particularly with the nanoelec¬
trospray source (20). This instrument was particularly well suited to linked scanning modes: Neutral loss and precursor ion scanning
were useful for detecting phosphopeptides in the presence of much larger amounts of unmodified peptide. The triple quadrupole for
proteomics work was largely superseded by the more sensitive quadrupole time-of-flight (Q-Tof) geometry, which could not perform
linked scans by the very nature of the geometry. Postprocessing of the data could extract phosphopeptide information (and, indeed,
information on many other types of posttranslational modification), and the increased sensitivity of the Q-Tof made this trade-off
acceptable. A new generation of instruments based on linear traps offer new scanning possibilities for phosphopeptides similar to
those originally available with triple quadrupoles. It should be noted that no one mass spectrometer type would cover all eventuali¬
ties. In particular, we point out that matrix-assisted laser desorption ionization (MALDI) still has a very useful role in studying
phosphopeptides, and with enrichment methods may be better suited to the detection of multiphosphorylated peptides (21). The
work described here was carried out on either a Q-ToF Ultima (Waters) or a 4000 Q-Trap (AB). Specific mass spectrometry scan¬
ning modes, such as neutral loss and precursor ion scanning, have been developed to improve the detection of phosphorylation in
highly complex peptide mixtures. Gas phase P elimination of phosphorylated serine and threonine residues produce a loss of phos¬
phate that can be monitored in neutral loss mode, and sequence information can be obtained in the same experiment. When phos-
phoserine-, phosphothreonine-, or phosphotyrosine-containing peptides are fragmented by collision-induced dissociation (CID) in
the negative ion mode, a characteristic P03~ ion (m/z = -79) can be detected by precursor ion scanning. Once this ion is detected, the
mass spectrometer can be set to automatically switch to positive ion mode, to conduct tandem mass spectrometry (MS/MS) for
sequencing.
In this Protocol, we describe improvements to traditional IMAC- and liquid chromatography tandem mass spectrometry (LC-
MS/MS)-based strategies to study the synaptic phosphoproteome by implementing multistage proteome fractionation and phospho-
proteome enrichment and iterative mass spectrometry-based scanning approaches (Fig. 1). This Protocol should be usefhl for re¬




membranes Fig. 1. Schematic overview of the methodology. The target pro¬
teome, in this case a subcellular fraction, is phase-partitioned by its
differential solubility in 6 M urea. The soluble fraction can be pro¬
cessed in two ways. Traditionally, this fraction is digested in solu¬
tion, desalted, applied to a peptide IMAC column (green arrows)
with or without methyl-esterification, and analyzed by LC-MS/MS. In
addition, we have developed a top-down enrichment step in which
the soluble proteins are applied to a protein IMAC column (blue ar¬
rows), and the eluted phosphoproteins are digested and also ana¬
lyzed by LC-MS/MS. A novel combination of these two approaches
(orange arrow), in which a two-step enrichment of phosphoproteins
and phosphopeptides and analysis by LC-MS/MS, results in im¬
proved identification of phosphorylation sites. The urea-insoluble
fraction, which represents tightly bound or integral membrane pro¬
teins, can be analyzed by direct digestion in 2 M urea to release
peptides from cytoplasmic and extracellular domains of these
proteins, which then can be applied to a peptide IMAC column to
isolate phosphopeptides. These combined strategies, when applied
to the synapse phosphoproteome, yielded identification of over 650
phosphorylation events corresponding to 331 phosphorylation sites
(10). This combined strategy of phase-partitioning and sequential
enrichment of phosphoresidues allows comprehensive analysis of a
complex sample.
Science's www.stke.org/cgi/content/full/sigtrans;2005/298/pl6 Page 3
363


















ECL Plus Western blotting detection reagents (Amersham Bioscience, #RPN2132)
Ethylene diamine tetraacetic acid (EDTA)
Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA)
Formic acid
Gallium chloride GaCI3, 5-g vials (Sigma-Aldrich, #25,419-3, or Avocado Research Chemicals, #43879)
Glycerol













Pro-Q Diamond Phosphoprotein gel stain kit (Molecular Probes, #M-33306)














Urea, ultra grade (Sigma, #U0631)
Enzymes and Proteins
Peppermint-Stick phosphoprotein molecular weight standards (Molecular Probes, #P-33350)
Trypsin Gold, Mass Spectrometry Grade (Promega, #V5280)
Plastics
1.5-ml microcentrifuge tubes
38-ml polycarbonate centrifuge tubes (Nalgene, #306/0258/08)
Columns and Resins
Analytical column: PepMap C18 3 pm 100 A, 75 pm i.d. x 15 cm (LC Packings, #160321)
Note: Other column types of similar performance may also be used.
Bio-Spin chromatography columns (BioRad, #732-6025)
C 10/10 chromatography column (Amersham Bioscience, #19-5001 -01)
Fast-flow chelating sepharose with iminodiacetic acid (IDA) (Amersham Biosciences, #17-0575-01)
RESOURCE 15RPC 1 ml reversed phase chromatography column (Amersham Bioscience, #17-1181-01)
Self Pack POROS 20 MC media (Applied Biosystems, #1-5428-02)
Trap column: BetaMax Neutral 5 pm, 180 pm i.d. x 30 mm (Thermo Hypersil-Keystone, #95005-030215)
Trap column: PepMap C18 3 pm, 100 A, 300 pm i.d. x 5 mm (LC Packings)
Vivaspin 6 PES membrane spin column (Vivascience)
Vivaspin 20 PES membrane 5000 MWCO (Vivascience, #VS2011)
Other
Hyperfilm ECL (Amersham Bioscience, #RPN2103K)
Micro BCA Protein Assay Kit (Pierce, #23235)
Totallab software (Nonlinear Dynamics)
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4000 Q TRAP (Applied Biosystems)
AKTA fast-performance liquid chromatography (FPLC; Amersham Bioscience, #18-1900-256)
Dounce homogenizer (VWR, #406/0315/10)
Liquid nitrogen dewar flask
Mascot V2.0 (Matrix Science) server
Mass spectrometer: Q-Tof Ultima API with nanospray source (Micromass)
Note: Other types of Q-Tof API or tandem mass spectrometers that give similar performance can also be used.
Microcentrifuge
Mini-PROTEAN il Multi-Screen apparatus (BioRad, #170-4017)
Nano flow HPLC system with an autosampler and a valve switch unit, such as the Ultimate gradient pump equipped with FAMOS
autosampler and Switchos II (LC Packings), or CapLC with nano stream selected module (Waters)




Sorvall Discovery 100SE ultracentrifuge with swinging bucket rotor AH-629 (36 ml) or equivalent




Recipe 1: Synaptosome Buffer A
50 mM Tris-acetate, pH 7.4 (from 0.5 M stock)
10% (w/v) sucrose
5 mM EDTA (from 0.5 M stock)
1 mM PMSF
2 pg/ml aprotinin (from 2 mg/ml stock)
2 pg/ml leupeptin (from 2 mg/ml stock)
1 mM sodium ortho-vanadate
Add FI2O to 50 ml. Combine components in a 50-ml tube, rotate to dissolve sucrose, and chill at 4°C.
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Recipe 2: Synaptosome Buffer B
5 mM Tris-acetate, pH 8.1 (from 0.5 M stock)
1 mM PMSF
2 pg/ml aprotinin (from 2 mg/ml stock)
2 pg/ml leupeptin (from 2 mg/ml stock)
1 mM sodium ortho-vanadate
Add H20 to 50 ml. Combine components in a 50-ml tube and chill at 4°C.
Recipe 3: Synaptosome Buffer C
50 mM Tris-acetate, pH 7.4 (from 0.5 M stock)
10% (w/v) sucrose
Combine components in a 50-ml tube, rotate to dissolve sucrose, and chill at 4°C.
Recipe 4: Synaptosome Buffer D
50 mM Tris-acetate, pH 7.4 (from 0.5 M stock)
28.5% (w/v) sucrose
Combine components in a 50-ml tube, rotate to dissolve sucrose, and chill at 4°C.
Recipe 5: EDTA-EGTA Solution
Make a solution of 100 mM EDTA and 100 mM EGTA in H20.
Recipe 6:100 mM GaCI3
Carefully break off the glass seal of the vial of GaCI3 powder (5 g) and immerse in 284 ml of distilled H20 in a glass beaker. Once
dissolved, store in at 4°C.
Note: Caution must be exercised when dissolving GaCi3 in water, as it is an exothermic reaction, which sputters and evolves
HCI gas. Wear protective clothing and perform in a fume hood.
Recipe 7: Protein IMAC Wash Buffer
6 M urea
50 mM Tris-acetate, pH 7.4
Adjust volume to 1 liter and pass through a 0.2-micron filter.
Recipe 8: Protein IMAC Elution Buffer
6 M urea




Dissolve the urea in approximately 800 ml of H20 by stirring on a heated magnetic stirrer. Add the EDTA and EGTA powder and
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Tris-acetate stock (100 ml of 0.5 M) to the dissolved urea and add NaOH pellets to raise the pH to 7.5 to dissolve the EDTA and
EGTA. Adjust volume to 1 liter with H20 and pass through a 0.2-micron filter.
Recipe 9: 5x Reducing Sample Buffer
0.5 M Tris-HCI, pH 6.8 1 ml
Glycerol 1 ml
10% SDS 1.6 ml
2-ME 0.4 ml
0.1% bromophenol blue 0.2 ml
H20 4 ml
Note: 20 mM DTT (0.32 ml of 0.5 M stock) can be used in place of the 2-ME.




Add H20 to 500 ml. Store at 4°C or at room temperature.
1.5 MTris,pH 8.8
Tris-base 90.75 g
Prepare in 400 ml of H20, adjust pH to 8.8 with 1 M HCI, and add H20 to 500 ml. Store at room temperature.
0.5 M Tris-HCI pH 6.8
Tris-base 30 g
Prepare in 400 ml of H20, adjust pH to 6.8 with 1 M HCI, and add H20 to 500 ml. Store at room temperature.
10% SDS (w/v)
SDS (sodium salt) 10 g
Add H20 for a final volume of 100 ml. Store at room temperature.
10% APS (w/v)
Ammonium persulfate 0.1 g
Add H20 to a final volume of 1 ml. Store at room temperature and discard after 1 week.




Add H20 to 1 liter final volume.
Note: Buffer should be 8.3: if it is not, adjust as needed.
Recipe 12: Phosphoprotein Gel Fixing Solution
Prepare a solution of 50% methanol and 10% acetic acid.
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Recipe 13: Phosphoprotein Gel Destain Solution
1 M sodium acetate, pH 4.0 50 ml
Ultrapure water 750 ml
Acetonitrile 200 ml
Combine and mix thoroughly.
Recipe 14: SYPRO Wash Solution
Prepare a 100-ml solution of 10% methanol and 7% acetic acid.
Recipe 15: Transfer Solution
Make a solution of 10% (v/v) methanol in 10 mM CAPS, pH 11.0 at 4°C.
Recipe 16: 20x PBS
NaCI 160 g
KCI 4 g
Na2HP04 (anhydrous) 12.2 g
KH2P04 4 g
Make in H20 at a final volume of 1 liter. Store at 4°C or room temperature.
Note: At 4°C, a precipitate may form. Warm and dissolve before use if necessary.
Recipe 17: PBS-Tween
Prepare a 1x solution of PBS [use 20x PBS (Recipe 16)] supplemented with 0.1%Tween-20.
Recipe 18: Chemiluminescence Solutions
Luminol Stock
Make a solution of 250 mM luminol (44.3 g/l) in DMSO. Store at -20°C.
p-Coumaric Acid Stock
Make a solution of 90 mM p-coumaric acid (14.8 g/l) in DMSO. Store at -20°C.
Solution A
Luminol stock 5 ml
p-Coumaric acid stock 5 ml
1.5 M Tris, pH 8.8 12.5 ml
0.5 M Tris, pH 6.8 12.5 ml
Add 215 ml of H20. Store at 4°C in the dark.
Solution B
250 pi 30% H202
250 ml H20
Store at 4°C in the dark. Mix Solutions A and B at a ratio of 1:1 just prior to blot development.
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Recipe 19:Tryptic Digest Buffer
1 M urea
0.125 M thiourea
25 mM NH4HCO3, pH 8
Use this solution to dilute protein or phosphoprotein sample.
Note: Trypsin is reconstituted with 50 mM acetic acid and is added (in a 1:20 ratio to protein or phosphoprotein) to this




Note: H20 must be HPLC gradient grade.




Note: H20 must be HPLC gradient grade.
Recipe 22: 2 M Methanolic HCI
Add 160 pi of acetyl chloride slowly with stirring to 1 ml of methanol in a dropwise fashion.
Note: Caution must be exercised during the addition of acetyl chloride, because this reaction generates heat. Perform opera¬
tion in fume hood using safety glasses and gloves.
Recipe 23: High Organic Loading Buffer
1:1:1 of acetonitrile, methanol and H20
pH should be 2.5 to 3.
Note: H20 must be HPLC gradient grade.
Recipe 24: Aqueous Loading Buffer
0.3% acetic acid
pH should be 2.5 to 3.
Note: H20 must be HPLC gradient grade.
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Add [Glu1]-fibrinopeptide B to a 500 fmol/pl concentration.




Add [Glu1]-fibrinopeptide B to a 100 fmol/pl concentration.
Recipe 28: 0.1% Formic Acid
99.9% H20
0.1% formic acid




Note: Both acetonitrile and H20 must be HPLC gradient grade.




Recipe 31: 0.5% Formic Acid
99.5% H20
0.5% formic acid
Recipe 32: IMAC LC-MS/MS Mobile Phase A
99.9% H20
0.1% formic acid
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Purification of Synaptosomes by Subcellular Fractionation
This section briefly describes purification of synaptosomes from mouse forebrains. Although this method has been well docu¬
mented (22), we have made several modifications.
1. Rapidly dissect mouse forebrains and freeze immediately in liquid nitrogen, and store at -80°C.
2. Cool all Synaptosome Buffers (Recipes 1 through 4) and the homogenizer to 4°C.
3. Add 16 mouse forebrains to Synaptosome Buffer A (Recipe 1) using 9 ml of buffer per gram of tissue in a 50 ml Dounce
homogenizer.
4. Homogenize with 15 strokes.
5. Collect the extract and centrifuge at 800g for 20 min.
Note: All centrifugation steps in this section should be performed at 4°C.
6. Centrifuge the supernatant at 16,000g for 30 min.
7. Resuspend the pellet in Synaptosome Buffer B (Recipe 2) in 5 ml ofbuffer per gram of original tissue starting material.
8. Homogenize with three strokes.
9. Incubate the extract in the homogenizer at 4°C for 45 min.
10. Homogenize with 10 strokes.
11. Add sucrose to 34% (w/v).
12. Prepare sucrose gradients by addition of 10 ml of Synaptosome Buffer C [Recipe 3; 10% sucrose (w/v)] to 38-ml polycar¬
bonate centrifuge tubes, followed by careful introduction of 10 ml of Synaptosome Buffer D [Recipe 4; 28.5% sucrose (w/v)]
from the bottom of the tube.
13. Add 10 ml of extract from step 11 [in 34% sucrose (w/v)] to the bottom of the tube, such that the gradients are 10%, 28.5%,
and 34% sucrose (w/v) from the top to the bottom.
14. Centrifuge at 60,000g for 120 min.
15. Collect the protein-containing band that forms between the 34% and 28.5% sucrose gradients, and dilute with 50 mM Tris-
acetate pH 7.4 to 10% sucrose.
16. Centrifuge at 48,000g for 30 min.
17. Discard the supernatant.
18. Resuspend this synaptosome pellet in 50 mM Tris-acetate, pH 7.4, remove a small aliquot (2 pi) for subsequent protein con¬
centration determination (MicroBCA kit, Pierce) and store at -80°C.
Note: This is the synaptosomal protein sample.
Protein IMAC Sample Preparation
In this protein IMAC Protocol, a cell lysate or subcellular fraction is solubilized in 6 M urea and is incubated with a metal-
charged sepharose-based resin. Specific elution is achieved by a stopped-flow elution with chelating buffer, and eluted phospho-
proteins can be concentrated and washed. When performed with an FPLC system, this method permits large-scale purification,
which is necessary for subsequent phosphopeptide analysis by mass spectrometry (Fig. 2). Batch purification in microcentrifuge
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tubes can also be performed, which can be useful for rapid purification of smaller quantities of phosphoprotein for gel or Western
blot analysis. We recommend a working concentration of approximately 1 mg/ml for the protein extract and a ratio of 10:1 of ex¬
tract to resin to ensure specific binding of phosphoproteins.
1. Strip the fast-flow chelating sepharose with IDA of any bound metal by incubation with EDTA-EGTA Solution (Recipe 5)
for 1 hour with gentle agitation.
2. Clamp a C 10/10 chromatography column to a retort stand and connect to a peristaltic pump.
















Fig. 2. FPLC chromatogram of a protein IMAC purification.
Unbound protein is washed off the IMAC column with 20 col¬
umn volumes of Protein IMAC Wash Buffer (Recipe 7) (that
is, set pump A to 100% Protein IMAC Wash Buffer) at a flow
rate of 1 ml/min until the A280 > 0.25 mAU. Then the flow is
switched to Protein IMAC Elution Buffer (Recipe 8) (set pump
B to 100% Protein IMAC Elution Buffer) and run at 0.5
ml/min. A stopped-flow elution with a chelating buffer is per¬
formed to elute the phosphoproteins in a discrete peak (P).
The arrow indicates the point of stopped-flow.
4. Wash the resin with 10 column volumes of H2Q using the pump at a flow rate of 1 ml/min.
5. Remove the resin, add to 50 ml of 100 mM GaCl3 (Recipe 6), and incubate at room temperature on a roller-mixer overnight.
6. Wash the charged resin with 10 resin volumes of H20 using the pump at a flow rate of 1 ml/min.
7. Store the charged resin in an equal volume of H20 (50% H20) at 4°C and use within 1 week.
8. Solubilize the synaptosomal protein sample in 6 M urea (12.5 mg protein/10 ml) in 1.5-ml microfuge tubes for 20 min with
mixing.
9. Centrifuge at 16,000g for 5 min and retain the supernatant.
10. Load 1 ml of washed, gallium-charged resin into a C 10/10 column and equilibrate the resin by washing the column with five
bed volumes of Protein IMAC Wash Buffer (Recipe 7).
11. Incubate the urea-soluble supernatant (about 9.5 ml) with 1 ml of resin for 1 hour at room temperature on a roller shaker.
12. Equilibrate an FPLC (AKTA) system with 5 ml of Protein IMAC Elution Buffer (Recipe 8) and then 5 ml of Protein IMAC
Wash Buffer (Recipe 7) at room temperature.
13. Pack the resin-protein mixture into a C 10/10 column and attach to the FPLC, avoiding introduction of air bubbles into the
system.
14. Wash unbound protein from the column with 20 column volumes of Protein IMAC Wash Buffer (Recipe 7) (that is, set pump
A to 100% Protein IMAC Wash Buffer) at a flow rate of 1 ml/min until the A280 > 0.25 mAU.
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15. Set pump A to 0% Protein IMAC Wash Buffer (Recipe 7) and switch the flow to 100% Protein IMAC Elution Buffer (Recipe
8) (pump B) and run at 0.5 ml/min, and start to collect 1-ml fractions.
16. Once the A280 reaches ~ 10 mAU, change pump B to 0% Protein IMAC Elution Buffer (Recipe 8) (no flow) for 10 min.
17. Switch pump B to 100% Protein IMAC Elution Buffer (Recipe 8) and run at 0.5 ml/min and start to collect 1 ml fractions.
Note: This stoppedflow elution results in a discrete elution peak; see Fig. 2.
18. Pool four or five fractions surrounding the phosphoprotein peak and wash with Protein IMAC Elution Buffer (Recipe 8)
using a 1:4 dilution of the sample to Protein IMAC Wash Buffer (Recipe 7) in a Vivaspin 6 PES membrane spin column.
19. Concentrate the sample to 200 pi and repeat this wash step to further reduce concentration of EDTA and EGTA in the
sample.
Validation of Phosphoprotein Purification
This section describes validation of the protein IMAC enrichment, which is advisable before further purification or analysis by
mass spectrometry. Validation can be achieved by phosphoprotein staining of protein IMAC-purified phosphoproteins on an
SDS-polyacrylamide gel (Fig 3). Alternatively, Western blotting with phospho-specific antibodies or antibodies to known phos¬
phoproteins should show clear enrichment in the protein IMAC-purified sample (Fig. 3). Because elements of these two tech¬
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Fig. 3. Validation of IMAC phosphoprotein isolation strategy.
(a) Overlay of Pro-Q diamond phosphoprotein and Ruby to¬
tal protein stains of an SDS-PAGE gel for different resin and
metal IMAC combinations used to selectively isolate phos¬
phoproteins from a urea-soluble synaptosomal extract. The
corresponding unbound fractions are included for compari¬
son. Twenty percent of eluted protein from each purification
was separated on a 12% SDS-PAGE gel, stained, and im¬
aged sequentially. Phosphorylated protein appears pink to
black, whereas unphosphorylated protein appears green.
Lane 1 (far left) shows Peppermint Stick molecular weight
markers in which proteins of molecular weight 23 and 45 kD
are phosphorylated and those of 55 and 116 kD are not
phosphorylated, thus serving as an internal control for se¬
lective staining of phosphorylated proteins. A 25-kD band
(green arrow) consists of ribosomal proteins, which were re¬
tained on the IMAC resins due to ion-exchange effects. (b)
Western blots of equal amounts of IMAC enriched (I) versus
synaptosomal (S) protein for eight synaptic phosphopro¬
teins. A substantial enrichment for all phosphoproteins was
observed in the protein IMAC sample, and a specific enrich¬
ment for the phosphorylated form of mitogen-activated pro¬
tein kinase kinase (pMEK) was seen using a phospho-
specific antibody.
Electrophoresis and phosphoprotein staining of SDS-PAGE gels
1. Boil 10% (20 pi) of the eluted phosphoprotein and molecular weight markers in tightly closed microcentrifuge tubes in 5x
Reducing Sample Buffer (Recipe 9).
2. Separate on an SDS-PAGE (Recipes 10 and 11) minigel for 50 min at 200 V
Note: All of thefollowing incubation steps are performed at room temperature with gentle agitation.
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3. Fix the gel by incubating twice for 30 min, each time in 100 ml of Phosphoprotein Gel Fixing Solution (Recipe 12).
4. Wash the gel three times for 10 min, each time in 100 ml of H20.
5. Stain the gel with 50 ml of Pro-Q Diamond phosphoprotein gel stain in the dark for 90 min.
6. Destain the gel three times for 30 min, each time with 100 ml of Phosphoprotein Gel Destain Solution (Recipe 13).
7. Wash the gel twice with H20 for 5 min each.
8. Scan the gel with a Typhoon scanner using an excitation maximum at 555 nm and an emission maximum at 580 nm.
9. Rinse the gel twice with H20 for 5 min each.
10. Incubate the gel in 50 ml SYPRO Ruby Gel Stain Solution overnight.
11. Wash in SYPRO Wash Solution (Recipe 14) for 30 min and then twice with H20 for 5 min each.
12. Scan the gel with a Typhoon scanner using an excitation maximum at 280/450 nm and an emission maximum at 610 nm.
13. Overlay the phosphoprotein and total protein images of the gel using Totallab software.
Western blotting
Western blotting of protein IMAC-enriched samples and whole synaptosome samples for a selected set of phosphoproteins can
be performed using a Mini-PROTEAN 11 Multi-Screen apparatus (Fig. 3). This apparatus allows screening of up to 40 different
antibodies on a single membrane and requires much less of each individual antibody compared to traditional Western blotting.
This offers a high-throughput approach for validating a set of proteins, but a conventional Western blotting apparatus will suffice
in its absence.
1. Adapt an SDS-PAGE gel-casting comb to cast a single well across the gel.
Note: This can be done by taping over the teeth or by using a specialized comb consisting ofa single tooth.
2. Separate the samples on a 12% SDS-PAGE minigel and transfer to PVDF membrane at 4°C for 90 min at 75 V in Transfer
Solution (Recipe 15).
3. Block the membrane with 1% BSA in PBS-Tween (Recipe 17) overnight at 4°C.
4. Wash the membrane three times for 5 min, each time with 20 ml of PBS-Tween (Recipe 17).
5. Place the membrane onto the base of the Multi-Screen apparatus; tighten screws to clamp.
6. Use optimal dilutions of primary antibodies in PBS-Tween (Recipe 17), 550 p.1 per well, and incubate for 2 hours with gentle
agitation at room temperature.
Note: Antibody concentrations must be empirically determined or, for commercially available antibodies, use the recom¬
mended concentration for Western blotting.
7. Wash each well three times for 5 min, each time with 0.5 ml of PBS-Tween (Recipe 17).
8. Add 0.6 ml of peroxidase-linked secondary antibody diluted 1:5000 in 1% BSA with PBS-Tween (Recipe 17) and incubate
for 2 hours at room temperature.
9. Wash each well three times with 0.5 ml of PBS-Tween (Recipe 17) for 5, 10, and 15 min each.
10. Detect the antibodies by enhanced chemiluminescence using Chemiluminescence Solutions A and B (Recipe 18); just before
developing the blot, mix enough of solutions A and B at a 1:1 ratio to cover.
Note: ECL Plus Western blotting detection reagents (Amersham Biosciences) may be used instead ofRecipes 17 and 18.
In-Solution Protein Digestion
1. Dilute the 3 mg of the protein IMAC-enriched sample in Tryptic Digest Buffer (Recipe 19) to a final volume of400 pi.
Note: 6 M Urea insoluble membranes can be digested by increasing the urea concentration in the digestion buffer to 2 M.
This will result in reduced activity of trypsin but will allow better solubility and thus digestion of these proteins.
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2. Add Trypsin Gold in a ratio of 1:20 in 50 mM acetic acid.
3. Incubate at 37°C for 3 hours.
Note: We recommend mass spectrometry grade Trypsin Gold, because it has high activity and good specificity. Sequencing-
grade trypsin (Roche) can also be used, but an overnight incubation is necessary for complete proteolysis. We have also
used sequencing grade modifiedporcine trypsin (Promega); in our experience, it produces semi-tryptic ends, but this can be
accommodated by specifying "semi-trypsin " in Mascot's search parameters.
4. Terminate the reaction by freezing in liquid nitrogen, then lyophilize.
Reversed Phase Desalting of Protein Digests
Digested protein samples, whole lysate, or protein IMAC-enriched that are to be further processed to peptide 1MAC samples are
desalted on a 1-ml bed volume RESOURCE 15RPC reversed phase chromatography column. Peptides for analysis by mass spec¬
trometry are desalted on-line, as described in the LC-MS/MS section to follow.
1. Wash and equilibrate the column first with 5 column volumes of Reversed Phase Mobile Phase A (Recipe 20), then 5 column
volumes of Reversed Phase Mobile Phase B (Recipe 21), and bring back to baseline with Reversed Phase Mobile Phase A
again.
2. Load the tryptic digest into the injection loop and introduce into the column at 0.5 ml/min.
3. Wash with Reversed Phase Mobile Phase A (Recipe 20) until baseline is reached, about 10 column volumes.
4. Elute desalted peptides with a 0 to 95% gradient of Reversed Phase Mobile Phase B (Recipe 21) over 5 min.
5. Collect fractions corresponding to the peptide peak (absorbance at 215 nm), pool, and lyophilize.
Peptide IMAC Sample Preparation
Peptide IMAC was carried out as described (15) with some modifications. A number of conditions in this Protocol can affect the
yield and population of phosphopeptides obtained. First, the choice of metal used to perform peptide IMAC can affect specificity
and recovery. The most commonly used metals are Fe3~ and Ga3+ (15, 23, 24), and these display different efficiencies of capture
and release of phosphopeptides (23). However, we found that Ga3 performed the best in protein IMAC experiments (10), so we
recommend using Ga3" in the peptide IMAC step of a sequential phosphoprotein and phosphopeptide purification to minimize
losses due to differences in specificity. Acidic peptides affect the specificity of peptide IMAC purifications, and methyl-esterifi-
cation of peptide side chains improves the specificity (15). We have observed a 30% reduction in the number of acidic amino
acids in phosphopeptides that have been detected in peptide IMAC of methyl-esterified samples compared to unmodified
samples (25). However, other studies have found that contaminating peptides do not have any different physiochemical properties
than phosphopeptides in the sample, but were actually from highly abundant proteins in the sample (23).
In addition, peptide chemical modification reactions do not go to completion, and we have observed that methyl-esterification in
particular never occurs on 100% of peptides. This has the effect of diluting any particular sample into populations of modified
and unmodified peptides, which effectively reduces the amount of any given peptide and increases the sample complexity over¬
all. We recommend performing peptide IMAC on both methyl-esterified and unmodified versions of a sample to increase overall
phosphopeptide coverage.
Next, the buffer in which peptides are solubilized and applied to the column affects the population of phosphopeptides recovered.
In sequential protein and peptide IMAC experiments, we used a high-organic (equal volumes of acetonitrile, methanol, and
water, pH 2.5 to 3) and an aqueous (0.3% acetic acid, pH 2.5 to 3) buffer to solubilize and load peptides onto the peptide IMAC
column. Phosphopeptides found in both conditions represented a small fraction of the total phosphopeptides detected, with 37%
and 60% of the double IMAC dataset found in the high organic and aqueous experiments, respectively (25). The reason for this
differential appearance based on the solvent can be explained by looking at the grand average hydrophobicity (GRAVY) (26)
values of these peptides (Fig. 4). Phosphopeptides found in aqueous-solubilized samples are overall less hydrophobic than those
found in the high-organic-solvent-solubilized samples. This would indicate that in previous studies, such as that of the yeast
phosphoproteome (15), in which only a high-organic loading buffer was used, a substantial subpopulation of phosphopeptides
may have been lost at this step. It is clear that in any complex sample, there are populations of peptides that favor different
solubilization conditions depending on their hydrophobicity, so it is recommended that different conditions be used to achieve
greater coverage of the peptide population.
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Methyl-esterification of peptide digests
1. For methyl-esterification, reconstitute the lyophilized desalted peptide digest with 0.5 mg/ml of 2 M Methanolic HC1 (Recipe
22).
2. Incubate with gentle agitation for 2 hours at room temperature.
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Fig. 4. Comparison of peptide IMAC solubi¬
lization and loading buffers. Grand average of
hydrophobicity (GRAVY) versus isoelectric
point for phosphopeptides found in two pep¬
tide IMAC experiments are plotted. In one
double IMAC experiment, peptides were solu-
bilized and loaded onto a peptide IMAC col¬
umn in a high organic buffer (1:1:1 of acetoni-
trile:methanol:H20) (data indicated by blue
diamonds), and, in the other, peptides were
solubilized and loaded in an aqueous buffer
(0.3% acetic acid) (data indicated by red
squares). These two buffers enable identifica¬
tion of two populations of phosphopeptides
differing in their hydrophobicity.
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IMAC enrichment
1. Incubate 0.5 ml (bed volume) of POROS MC with 100 mM EDTA and 100 mM EGTA (Recipe 5) on a roller mixer
overnight to remove any trace metals from the resin.
2. Transfer the resin to a C 10/10 column and wash with lOvolumes ofH20.
3. Incubate with 5 ml of 100 mM GaCl3 (Recipe 6) at room temperature on a roller mixer overnight.
4. Wash the charged resin with 10 bed volumes of H20.
Note: The charged resin (in 50% H20) may be stored at 4 °C and should be used within I week.
5. Reconstitute the peptide sample (methyl-esterified peptide digest or unmodified desalted peptide digest) in either a High Or¬
ganic Loading Buffer (Recipe 23) or an Aqueous Loading Buffer (Recipe 24).
Note: For phosphoprotein digests, apply 3 mg ofdigested phosphoprotein in 1 ml ofHigh Organic Loading Buffer (Recipe
23) to a 100-pi bed volume ofgallium-charged POROS MC. A higher concentration ofwhole cell lysate may be applied to a
similar resin volume, because the percentage phosphopeptide content will be lower. For example, 6 mg ofdigested whole
synaptosomes may be applied in 1 ml ofHigh Organic Loading Buffer to a 100-pi bed volume ofgallium-charged POROS
MC.
6. Centrifuge the peptide solution at 13,000 rpm for 10 min in a microcentrifuge to remove any unsolubilized material.
7. Incubate the solubilized peptides with 200 pi of pre-equilibrated gallium-charged POROS MC slurry (100-pl bed volume)
for 1 hour at room temperature with gentle agitation.
8. Load the peptide-resin slurry into a pre-equilibrated spin column and centrifuge in a picofuge briefly to elute the unbound
peptides.
9. Wash by addition and removal in a picofuge with 10 resin volumes of the loading buffer (Recipe 23 or Recipe 24) used to
load the peptide onto the column.
10. Elute the phosphopeptides with 100 pi of Peptide IMAC Elution Buffer (Recipe 25) by incubating the peptide-resin slurry for
5 min, centrifuging briefly in a picofuge, and then collecting the eluted phosphopeptides.
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11. Repeat the elution (step 10) and pool eluted phosphopeptides.
Note: The concentration ofNa2HP04 used to elute phosphopeptides from the peptide IMAC column may be reduced to 50
mM, ifvolume reduction by partial lyophilization is necessary.
12. Rapidly freeze at -80°C.
Double IMAC Sample Preparation
This Protocol is a combination of protein and peptide IMAC steps described above and provides the obvious advantage of two
rounds of enrichment for phosphorylated molecules. The application of a single protein IMAC strategy to the synaptic phospho-
proteome resulted in the detection of 105 phosphorylation events, but selective enrichment of the phosphopeptides derived from
these purified phosphoproteins improved the detection of phosphorylation threefold, with the detection of 308 phosphorylation
events (10).
1. Digest 3 mg of protein IMAC purified phosphoprotein with 1:20 ratio of Trypsin Gold for 3 hours in Tryptic Digest Buffer
(Recipe 19).
2. Desalt the digest as described in the Reversed Phase Desalting of Protein Digests section.
3. Perform methyl-esterification if desired (see Peptide IMAC Section).
4. Reconstitute in either a High Organic Loading Buffer (Recipe 23) or an Aqueous Loading Buffer (Recipe 24). Incubate 1 ml of
this peptide mixture with 200 pi of pre-equilibrated POROS-Ga slurry (100 pi bed volume) for 1 hour at room temperature.
5. Load the resin into a spin-column and wash with 10 volumes of the same Loading Buffer used to load the peptide onto the
column.
6. Elute the phosphopeptides with 100 pi of Peptide IMAC Elution Buffer (Recipe 25) by incubating the peptide-resin slurry for
5 min, centrifuging briefly in a picofuge, and then collecting the eluted phosphopeptides.
7. Repeat and pool the eluted phosphopeptides.
LC-MS/MS Analysis
For LC-MS/MS analysis, a nanoflow HPLC system with valve switch unit is needed, so that the trap column can be placed for
loading and desalting the sample efficiently. This is particularly true for desalting phosphopeptide samples in high salt [for exam¬
ple, the 200 mM Na2HP04 in Peptide IMAC Elution Buffer (Recipe 25)] with a large volume size (100 to 200 pi). Using a flow
at 10 pl/min, we found it took up to 1 hour to desalt the sample. We used an Ultimate nanoflow gradient pump equipped with
FAMOS autosampler and Switchos II (LC Packings), or CapLC with nanostream selected module (Waters) coupled to Q-Tof hy¬
brid tandem mass spectrometer. Mass accuracy in MS/MS spectra in assigning the phosphorylation sites was important.
Before sample analysis on LC-MS/MS, we always perform a systematic check; this process is described.
LC-MS/MS systematic check
1. Optimize the nanospray position and instrument parameters with 500 fmol/pl [Glul]'-fibrinopeptide B in Standard for Q-Tof
Optimization (Recipe 26) or 100 fmol/pl in Standard for Q-Tof Ultima Optimization (Recipe 27).
2. Calibrate the instrument with the [Glul]'-fibrinopeptide B solution prepared in step 1.
3. Systematically perform LC-MS/MS system checks with a tryptic digest of BSA, such as chromatographic resolution, mass
accuracy, and sequence coverage of BSA. For Q-Tof, use either 100 or 200 fmol BSA; for Q-Tof Ultima, 100 ffnol.
Note: If the analytical sample is a small quantity, then the system should be tested using BSA at 10fmol or lower.
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LC-MS/MS analysis of a tryptic digest of IMAC-purified phosphoproteins on a Q-Tof Ultima
MS acquisition starts at t = 3.0 min when desalting is finished. The instrument is operated in automated data-dependent acquisi¬
tion (DDA) mode using MassLynx. In DDA mode, the instrument continues to scan at Tof-MS survey and only switches to Tof-
MS/MS scan when multiply charged ions (precursor ions) in the Tof-MS survey spectrum meet the criterion for fragmentation.
This is because majority of ions generated from tryptic peptides is at a charge status of at least 2. Details for the instrument set¬
tings are described.
1. Load the protein digest through the autosampler to the trap column on the valve switch unit and desalt with 0.1% Formic
Acid (Recipe 28) at a flow rate of 10 or 20 |t.l/min (depending on the column).
Note: When using a PepMap C18 3 pm 100 A, 300 pm i.d. x 5 mm (LC Packings) trap column, the flow rate can be at 20
pl/min. If the trap is BetaMax Neutral 5 pm, 180 pm i.d. x 30 mm (Thermo Hypersil-Keystone), the flow rate should be set
at 10 pl/min.
2. Switch valve after 3 min to connect the trap column on-line with the analytical column.
3. Run a gradient as shown in Table 1 to reverse elute the peptides from the trap and separate on the analytical column using
Tryptic Digest LC-MS/MS Mobile Phases A and B (Recipes 29 and 30) (run 1). The flow rate through the columns should
be 250 to 300 nl/min.
Table 1. Liquid chromatography conditions for analysis of phosphoprotein digest.
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Trap and analytical column off-line
to equilibrate separately
4. Acquire Tof-MS survey over the mass range m/z 400 to 1500 at 1 s per scan.
Note: The switching criterion from Tof-MS to Tof-MS/MS is dependent on precursor ion intensity and charge state (+2 and
+3 selected), each for 5 s. The collision energy used to perform Tof-MS/MS is automatically varied according to the m/z and
the charge state ofthe precursor ion.
5. Acquire data for Tof-MS/MS over the mass range m/z 50 to 2000.
6. Perform Tof-MS/MS on up to three multiply charged ions of the highest intensity with a dynamic exclusion time of 120 s.
Note: Depending on the complexity of the sample, more precursor ions can be selectedfrom the Tof-MS survey spectrum to
subject to Tof-MS/MS. For a highly complex sample, two LC-MS/MS runs with the same LC gradient may be used.
7. After the first standard LC-MS/MS run is finished (run 1), examine the survey data.
8. Select up to five multiply charged ions above the intensity threshold from each survey spectrum that had not been subjected
to MS/MS in run 1 and incorporate into an inclusion list for the second run (run 2).
9. Perform the run 2 analysis using the same conditions as in run 1, except that the MS switching to MS/MS should be directed
to analyze only multiply charged ions from the "including list."
Note: We term this LC-MS/MS approach, incorporating a primary analysis followed by a repeat experiment based on an in¬
clusion list, targeted repeat analysis (TRA).
10. Process both LC-MS/MS datasets to pkl files using Proteinlynx in Masslynx, and then merge to a single mgf file with the
software (merge) provided by Matrix Science and submit results to Mascot, a search engine that searches protein sequence
databases to match peptide spectra to protein sequences (http://www.matrixscience.com).
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LC-MS/MS analysis of a tryptic digest of IMAC-purified phosphoproteins on a 4000 Q TRAP
Although we have found that the majority ofproteins in protein IMAC samples are phosphorylated, the molar ratio ofphosphory-
lated to nonphosphorylated species is reduced upon tryptic digestion. An alternative to performing a second round of enrichment
of phosphopeptides is to selectively monitor phosphopeptides in the mass spectrometer. The specific behavior of phosphopep-
tides in a mass spectrometer can be exploited in a number of ways for analysis of very complex peptide mixtures with a low
abundance of phosphorylated peptides: (i) Neutral loss of 98 in MS/MS for those phosphopeptides containing phosphoserine and
phosphothreonine in positive electrospray ionization mode; (ii) 216 fragment ion for phosphopeptides containing phosphotyro-
sine in positive electrospray ionization mode; and (iii) 79 fragment ion for phosphopeptides in negative electrospray ionization
mode. By setting the mass spectrometer to specifically monitor precursor ions of the fragment ions, phosphopeptides can be se¬
lectively identified. We found that monitoring the precursor of 79 fragment ion in the negative mode was the most efficient ap¬
proach, and the use of the 4000 Q TRAP, which is capable of fast auto-switching between negative and positive ionization mode,
is well suited for this.
Two precursor-scanning approaches based on monitoring the precursor of 79 fragment ion can be adopted on the 4000 Q TRAP
to selectively analyze phosphopeptides. The LC conditions are the same as that used for IMAC-purified phosphoprotein digest,
described above.
Approach 1: Conventionalprecursor of 79fragment ion scanning
1. Set the instrument in negative ion mode (-ESI) to scan for the precursors of m/z 79 (P03~).
2. When a precursor ion for m/z 79 is detected, the instrument is automatically switched to positive mode (+ESI) and MS/MS
fragmentation, the detected precursors proceeds.
3. Reset the instrument to -ESI and scan for precursors of m/z 79 (P03~).
4. Upon detection of a precursor ion for m/z 79, the instrument automatically switches to +ESI, and MS/MS fragmentation
proceeds.
Note: This process is repeated until all precursor ionsfor m/z 79 have been scanned.
Approach 2: TRA precursor of 79 fragment ion scanning
1. Analyze one-third of the sample in negative mode (-ESI) to detect precursors of m/z 79.
2. Examine the data to generate the inclusion list for the second run in positive ion mode (+ESI).
3. Analyze the remaining two-thirds of the sample in information-dependent acquisition (IDA) mode with the above inclusion
list.
LC-MS/MS analysis of IMAC-enriched phosphopeptides
This procedure is performed in a similar way to that described above for digested IMAC-purified phosphoproteins, with a few
exceptions. The majority of phosphopeptides elute at very low organic percentage compared to those isolated by liquid chro¬
matography separations of a phosphoprotein digests (Fig. 5).
1. Load phosphopeptides to the trap column and desalt with 0.5% Formic Acid (Recipe 31) at a flow rate of 10 pl/minute for 30
to 60 min, depending on salt amount in the sample.
Note: We suggest using the trap column BetaMax Neutral 5 pm, 180 pm i.d. ? 30 mm (Thermo Hypersil-Keystone).
2. Separate phosphopeptides with the gradient shown in Table 2, using IMAC LC-MS/MS Mobile Phases A and B (Recipes 32
and 33) using a flow rate of 150 nl/min.
Note: The high flow rate is due to the high pressure when the trap and analytical columns are set up on-line.
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Fig. 5. Base peak intensity
(BPI) chromatographs of run 1
for a protein I MAC digest (A)
and for peptide IMAC purified
phospnopeptides (B). The red
dashed line represents the
gradient plot in each chro-
matogram. A standard gradi¬
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jority of peptides eluted by
30% Buffer B (32% organic).
As most phosphopeptides iso¬
lated in a peptide IMAC are
multiply phosphorylated and
hence quite hydrophilic, a
shallow gradient of Buffer B is
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We recommend a Mascot V2.0 (Matrix Science) server for iterative searching of a custom, nonidentical, combined human,
mouse, and rat protein sequence [International Protein Index (IPI) database (http://www.ebi.ac.uk/IPI/)]. We will next describe
the parameters and settings for using the Mascot V2.0. An example of a mass spectrum of a methyl-esterified, diphosphorylated
peptide is shown in Fig. 6.
1. Select trypsin with a maximum of two miscleavage sites when using Trypsin Gold (Promega) or sequencing-grade trypsin
(Roche); select semi-trypsin with maximum of two miscleavage sites for Promega's sequencing-grade modified trypsin, be¬
cause this trypsin produces some semi-tryptic fragments.
2. Select correct database with the appropriate taxonomy.
3. Set following variable modifications:
Carbamyl (N-term)
Carbamyl (K)
Methyl ester (C-term) - when peptides are methyl esterified




4. Select monoisotopic mass.
5. Set peptide tolerance at 0.4 Da and MS/MS tolerance at 0.3 Da
Note: The majority ofthe molecular weight errors should be less than 0.2 dalton ifcalibration is correct.
6. Select data format as Micromass (.pkl) file when data file is generated by Proteinlynx in Masslynx; for merged file as de¬
scribed previously, select "Mascot generic."
7. Verify the phosphorylation sites output by Mascot (protein identifications with peptides matching details) by manually
checking the spectra using PEAKS software.
Table 2. Liquid chromatography conditions for analysis of a phosphopeptide mixture isolated by a peptide IMAC purification.
Time (min) Percent A Percent B Comments












Trap and analytical column
on-line for gradient separation;
MS acquisition in this section
Trap and analytical column
off-line to equilibrate
separately
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Fig. 6. Mass spectrum of a methyl-esterified phos-
phopeptide derived from Bassoon protein (Swiss-
Prot accession 088737) showing phosphorylated
serine residues 2860 and 2866. Phosphorylation
of serine 2860 was identified by the mass differ¬
ence between the b(2) and b(3) ions caused by
neutral loss of phosphate in the mass spectrome¬
ter. 167 daltons (phosphoserine) minus 98 daltons
(H3PO4) results in a mass difference of 69 daltons,
which is characteristic of dehydroalanine, and
therefore phosphoserine prior to neutral loss. Simi¬
larly, phosphorylation of serine 2866 was identified
by the mass difference between the y(10) and
y(11) ions that was caused by neutral loss of phos¬
phate, resulting in a mass difference of 69 daltons.
Troubleshooting
Low Yield in Protein or Peptide IMAC Preparation
In our experience, the protein IMAC Protocol is very reproducible, but a number of parameters should be checked if problems
are encountered. The most likely reason for failure or low yields in protein or peptide IMAC purifications is sample or buffer
contamination. Small amounts of chelating chemicals, such as EDTA or EGTA, will strip the metal from the resin, and contami¬
nation of the buffer with the metal used as the affinity reagent will result in reduced or no phosphoprotein yield. In the event of a
low-yield IMAC purification, all buffers should be replaced, and the efficiency of purification monitored by Western blotting or
phosphoprotein staining.
Nonphosphorylated Protein Contamination
Reduction of the protein extract concentration or extract to resin ratio may result in nonspecific binding and thus contamination
with nonphosphorylated proteins. In addition, contamination by nonspecific protein binding may be observed if the phosphopro-
teins are eluted from the resin by boiling (as opposed to specific chelating elution) in at 97°C for 5 min in 5x Reducing Sample
Buffer (Recipe 9).
Integral or Membrane-Associated Proteins
The applicability of protein IMAC to integral membrane or membrane-associated proteins is limited by their solubility in 6 M
urea. We recommend that partial proteolysis with trypsin or endoproteinase Lys-C be performed to release the cytoplasmic and
extracellular domains of such proteins for subsequent protein and/or peptide IMAC purification.
Nonspecific Contaminants in the Peptide IMAC Preparation
Traditional peptide IMAC suffers to varying degrees from nonspecific binding of acidic peptides. This can be reduced by the
conversion of peptides to corresponding methyl-esters. However, this reaction does not usually go to completion and introduces
other problems, such as dilution of a peptide species into modified and unmodified forms. Nonspecific interactions due to hy¬
drophobic and ionic effects can be reduced by performing IMAC at pH 2.5 to 3, at which most glutamic and aspartic acid
residues are protonated, and by including up to 30% acetonitrile in the loading buffer, which decreases nonspecific interactions
and helps peptide solubilization. We recommend these low pH, acetonitrile-containing conditions with and without methyl-esteri-
fication for greatest coverage of a phosphopeptide population in a sample.
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It is generally accepted that, currently, no single approach for enrichment and analysis of phosphoproteins or phosphopeptides will
enable identification of all phosphorylation sites (27). We support the idea that a multifaceted approach such as that we have de¬
scribed in this Protocol is necessary to achieve higher phosphoproteome coverage. It is also clear that a portion of the phosphopro-
teome is hidden from analysis in basal state conditions. These phosphoproteomic approaches, which have been developed in the last
number of years, should be applied to numerous activation and treatment states in a given system to reveal more of the low-abun¬
dance and transient phosphoproteome.
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In the nervous system, protein phosphorylation is an
essential feature of synaptic function. Although protein
phosphorylation is known to be important for many syn¬
aptic processes and in disease, little is known about
global phosphorylation of synaptic proteins. Heteroge¬
neity and low abundance make protein phosphorylation
analysis difficult, particularly for mammalian tissue
samples. Using a new approach, combining both protein
and peptide immobilized metal affinity chromatography
and mass spectrometry data acquisition strategies, we
have produced the first large scale map of the mouse
synapse phosphoproteome. We report over 650 phospho¬
rylation events corresponding to 331 sites (289 have
been unambiguously assigned), 92% of which are novel.
These represent 79 proteins, half of which are novel
phosphoproteins, and include several highly phospho¬
rylated proteins such as MAP1B (33 sites) and Bassoon
(30 sites). An additional 149 candidate phosphoproteins
were identified by profiling the composition of the pro¬
tein immobilized metal affinity chromatography enrich¬
ment. All mqjor synaptic protein classes were observed,
including components of important pre- and postsynap¬
tic complexes as well as low abundance signaling pro¬
teins. Bioinformatic and in vitro phosphorylation assays
of peptide arrays suggest that a small number of kinases
phosphorylate many proteins and that each substrate is
phosphorylated by many kinases. These data substan¬
tially increase existing knowledge of synapse protein
phosphorylation and support a model where the syn¬
apse phosphoproteome is functionally organized into a
highly interconnected signaling network.
The molecular architecture of the synaptic junction has been
studied intensely for many years, yielding information on its
composition and function based on studies of individual recep¬
tors or small groups of proteins (1). In recent years, with the
advent of proteomic technologies, a coherent map of the mam¬
malian synapse proteome has been emerging. Mass spectrom¬
etry (MS)1-based analysis of the postsynaptic density (PSD)
* This work was spported by the Wellcome Trust (to H. H., J. S. C.,
L. Y., M. O. C., M. P. C., and S. G. N. G.) and the Biotechnology and
Biological Sciences Research Council (to M. O. C.). The costs of publi¬
cation of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
fsl The on-line version of this article (available at http://www.jbc.org)
contains an additional figure and four tables.
** To whom correspondence should be addressed: Wellcome Trust
Sanger Institute, Hinxton, Cambridgeshire CB10 ISA, United King¬
dom. Tel.: 44-1223-494-908; Fax: 44-1233-494-919; E-mail: sg3@
sanger.ac.uk.
1 The abbreviations used are: MS, mass spectrometry; IMAC, immo¬
bilized metal affinity chromatography; IDA, iminodiacetic acid; TRA,
has established for the first time a detailed list of its molecular
components (2-4). Systematic analysis of functional multipro-
tein complexes embedded in the PSD (5) has also added to our
knowledge of the overall organization of the postsynaptic
proteome.
Central to the functioning of signaling complexes and in¬
deed the most basic signaling pathways is the process of
reversible phosphorylation. The propagation of an appropri¬
ate synaptic response to receptor stimulation is highly regu¬
lated by phosphorylation cascades. This is exemplified by the
process of synaptic plasticity, a process whereby glutamate
receptor activation results in diverse signaling cascades,
which ultimately lead to activation of transcription factors
and modulation of gene expression. Phosphorylation is also
employed to modulate protein function and stability and to
mediate phosphorylation-dependent protein-protein interac¬
tions (e.g. Src homology 2 binding of phosphatidylinositol
3-kinase to NR2B) (6), conferring a higher order level of
regulation in such protein complexes.
Historically, synapse phosphorylation and its importance in
regulating neuronal signal transduction and brain function has
been studied at the level of single molecules (7, 8), but new
proteomic strategies lend themselves to the global character¬
ization of the signaling properties of the synapse proteome.
Phosphopeptides can be purified from complex protein mix¬
tures using immobilized metal affinity chromatography
(IMAC) (9) and identified using MS (10). Recent phosphopro-
teomic studies have utilized various peptide IMAC approaches,
sometimes with methyl esterification, to enrich and improve
specificity for phosphopeptides prior to MS. This approach has
been successfully used to study phosphorylation in yeast (10),
Arabidopsis (11), and cell lines (12). However, the application
of these approaches to complex mammalian subcellular or¬
ganelles such as the synapse has yet to be established.
MS, although a powerful tool for analysis of protein phos¬
phorylation, has several on-going technical challenges. In par¬
ticular, these result from heterogeneity arising from dynamic
site occupancy, multiple phosphorylation sites in the same low
abundance peptide, and inherently poor fragmentation of phos¬
phopeptides. Continued improvements in three critical areas,
unbiased sample enrichment methods, high sensitivity MS,
and data analysis methods, are required to fully harness the
potential of MS. The field is in a phase of rapid development,
and various strategies for protein or modification centric ana¬
lyzes are being explored (13, 14).
Here, we describe the use of a combination of cellular ffac-
targeted repeat analysis; NMDA, IV-methyl-D-aspartate; NRC, NMDA
receptor complex; IP3, inositol triphosphate; PSD, postsynaptic den¬
sity; LC, liquid chromatography; ESI, electrospray ionization; MOPS,
4-morpholinepropanesulfonic acid; PKA, protein kinase A; PKC, protein
kinase C; SH3, Src homology 3.
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tionation procedures with large scale IMAC phosphoprotein
and phosphopeptide enrichment protocols and complementary
MS analytical strategies to characterize mouse forebrain syn-
aptosomes. This has resulted in the unambiguous identifica¬
tion of 289 sites of phosphorylation in 79 synaptic proteins
involved in important pre- and postsynaptic multiprotein com¬
plexes and signaling pathways. Large scale in vitro phospho¬
rylation screening on peptide arrays for 95 sites with seven
kinases identified 28 phosphorylated sites and a total of 52
phosphorylation events. The simultaneous identification of
large numbers of sites of phosphorylation and identification of
responsible kinases, as exemplified by this study, is a powerful
approach to expand the current knowledge of cell signaling in a
particular system.
EXPERIMENTAL PROCEDURES
Isolation of Synaptosomes—Synaptosomes were prepared as de¬
scribed by Carlin et al. (1980) (15) with minor modifications. In brief,
mouse forebrains were homogenized in a cold buffer containing 50 mM
Tris acetate pH 7.4,10% (w/w) sucrose, 5 mM EDTA, 1 mM phenylmeth-
ylsulfonyl fluoride, 2 mg/ml aprotinin, and 2 mg/ml leupeptin. The
sample was then centrifuged for 20 min at 800 x g, and the resulting
supernatant was centrifuged again for 30 min at 16,000 x g. The pellet
was then resuspended in 5 mlJg of original weight in a buffer containing
5 mM Tris acetate, pH 8.1,1 mM phenylmethylsulfonyl fluoride, 2 mg/ml
aprotinin, and 2 mg/ml leupeptin, quickly homogenized, and incubated
for 45 min on ice. After a further homogenization step and the addition
of sucrose to 34% (w/w), the sample was overlaid with solutions con¬
taining 28.5% (w/w) sucrose in 50 mM Tris acetate, pH 7.4, and 10%
(w/w) sucrose in 50 mM Tris acetate, pH 7.4, and centrifuged for 2 h at
60,000 x g at 4 °C. The protein-containing band, which formed between
the 34 and 28.5% sucrose gradients, was collected and diluted with 50
mM Tris acetate, pH 7.4, to 10% sucrose and then centrifuged for 30 min
at 48,000 x g. The pellet was then resuspended in 50 mM Tris acetate,
pH 7.4, and homogenized gently to form the synaptosomal preparation.
Protein IMAC of Urea-soluble Synaptosomal Fraction—Fast-flow
chelating Sepharose with iminodiacetic acid (IDA) (Amersham Bio¬
sciences) or nitrilotriacetic acid (Qiagen) chelating groups were charged
with GaCl3 or FeCl3. Synaptosomal proteins (12.5 mg) were solubilized
in 6 M urea, and the supernatant was removed and incubated with 2 ml
of the metal charged resin with mixing for 1 h at room temperature. The
unbound protein was washed with buffer A (6 M urea, 50 mM Tris
acetate) to base line, and the phosphoproteins were specifically eluted
with buffer B (6 M urea, 50 mM Tris acetate, 100 mM EDTA, 100 mM
EGTA). The fractions were collected, concentrated, and washed with
buffer B in a Vivaspin 6 PES membrane spin column (Vivascience). 13.4
/xg of protein was diluted with buffer C (1 M urea, 0.125 M thiourea, 5%
(v/v) CH3CN, and 0.1 M NH4HC03) to a final volume of 400 /xl. Trypsin
(sequence grade; Roche Applied Science) was added to the sample in a
ratio of 1:20, and the mixture was incubated at 37 °C for 2 h and then
dried in a SpeedVac (Thermo Life Science). The sample was reconsti¬
tuted in 50 mM NH4HC03, and one-quarter was injected for each on-line
LC-MS/MS analysis.
Double IMAC of Urea-soluble Synaptosomal Fraction—3 mg of pro¬
tein IMAC purified sample was digested with modified porcine or gold
trypsin (Promega) in a ratio of 1:20 in buffer D (1 M urea and 25 mM
NH4HC03) at 37 °C for 4 h. The resultant digest was desalted and
dried, and methyl esterification was performed with 2 M methanolic
HC1 (10) when needed. Self Pack POROS® 20 MC media (Applied
Biosystems) for phosphopeptide purification was charged with GaCl3 as
described above for the IDA/nitrilotriacetic acid resins. Peptide digests
(with and without methyl esterification) were reconstituted in buffer E
(equal volumes of acetonitrile, methanol, and water, pH 2.5-3). 1 ml of
this peptide mixture was incubated with 200 /xl of POROS-Ga slurry for
1 h at room temperature. The resin was then loaded into a spin column
and washed with 10 volumes of buffer E. Phosphopeptides were eluted
with 2 X 100 /xl of 200 mM Na2HP04.
Peptide IMAC of Whole and Urea-insoluble Synaptosomal Frac¬
tions—2.5 mg of the 6 M urea insoluble pellet left after removal of the
supernatant was digested with trypsin in buffer F (2 M urea and 25 mM
NH4HC03). The resultant digest was desalted, methyl-esterified, and
subjected to a peptide IMAC step as described previously. Similarly, 6
mg of whole synaptosomal proteins were digested in buffer F, desalted,
methyl-esterified, and subjected to a peptide IMAC step.
Phosphoprotein Staining and Image Analysis—IMAC-enriched
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Table I
LC gradient for separation ofphosphoprotein digest
Solvent A was 95% H20, 5% ACN, 0.1% formic acid; solvent B was
95% ACN, 5% H20, 0.1% formic acid. Flow rate through the columns in
the separation was 200-250 nl/min.
Solvent 0 min 180 min 240 min 242 min 247 min
A (%) 94 30 50 20 20
B (%) 6 70 50 80 80
phosphoprotein samples were separated on a 12% SDS-polyacryl-
amide gel and sequentially stained with Pro-Q diamond (phosphopro¬
tein) and SYPRO Ruby (total protein) stains (Molecular Probes, Inc.,
Eugene, OR). Peppermint Stick phosphoprotein molecular weight
standards (Molecular Probes) served as a molecular weight marker
and internal control. Images were captured with a Typhoon scanner
(Amersham Biosciences) and overlaid using TotaLab software (Non¬
linear Dynamics).
On-line Nano-LC-MS /MS—A nanoflow high pressure liquid chroma¬
tography system, Ultimate™ (LC Packings) or CapLC (Waters), was
coupled to a Q-ToF 1, Q-ToF Ultima (Waters/Micromass), or 4000
QTRAP (Applied Biosystems). Tryptic peptides from the phosphopro¬
tein digest were loaded in 0.1% aqueous formic acid and desalted on
PepMap C18 trapping cartridge (LC Packings). BetaMax Neutral
(Thermo Hypersil-Keystone) was used to trap the IMAC-enriched phos¬
phopeptides in 0.5% aqueous formic acid. Peptides on the trap were
back-flushed to and separated on the analytical column (PepMap C18,
75-/xm inner diameter x 15 cm; LC Packings). The gradients are shown
in Tables I and II.
In the LC-MS/MS analysis of the phosphoprotein digest, the Q-ToF
Ultima was operated in automated data-dependent acquisition mode.
Each cycle had a 1-s MS survey (m/z 400-1500), and up to three of the
highest intensity multiply charged ions (+2 and +3) were selected for
MS/MS (m/z 50-2000), each for 5 s. The collision energy in MS/MS was
varied according to the m/z and the charge state of the precursor ion.
Due to the high complexity of the sample, there were two LC-MS/MS
rims with the same LC gradient. After the first standard run (Run 1),
survey data were examined, and multiply charged ions above the in¬
tensity threshold that had not been subjected to MS/MS in Run 1 were
incorporated into the inclusion list for the second run (Run 2). We term
this latter LC-MS/MS approach, incorporating a primary analysis fol¬
lowed by a repeat experiment based on an inclusion list, targeted repeat
analysis (TRA).
Analysis of IMAC-enriched phosphopeptides was performed on the
Q-ToF using similar acquisition parameters to those for the Q-ToF
Ultima. Two different precursor-scanning approaches were adopted on
the 4000 QTRAP to selectively analyze phosphopeptides. In the first
approach, the instrument was used in negative ion mode (—ESI) to scan
for the precursors of m/z 79 (POj) with automatic switching to positive
mode (+ESI) for MS/MS for the detected precursors. In the second
approach, we applied TRA strategy. First, one-third of the sample was
analyzed in negative mode for detecting precursors of m/z 79. Data were
examined to generate the inclusion list for the second run in positive ion
mode (+ESI) using the remaining two-thirds ofthe sample in information-
dependent acquisition mode. Raw data were processed to give a peak
list file and submitted to a local Mascot version 2.0 (Matrix Science)
server for iterative searching on a custom, nonidentical, combined hu¬
man and mouse IPI data base (EBI). Assignment of phosphorylation
sites was verified manually with the aid of PEAK Studio (Bioinformat-
ics Solutions) software.
Peptide Array Phosphorylation Assays—Jerini Phosphosite detec¬
tor™ peptide arrays (Jerini Peptide Technologies, Gmbh) were used to
determine which of the MS-identified phosphorylation sites (95 selected
sites) could be phosphorylated by seven kinases in an in vitro assay.
15-amino acid-long peptides that encompassed the selected sites were
synthesized on cellulose membranes in a parallel manner using SPOT
technology (16) deposited to glass slides and were covalently immobi¬
lized to the glass slide surface. Each peptide was present in triplicate on
the chip, and seven full-length proteins that are capable of being phos¬
phorylated were also included. Negative control peptides for each phos¬
phorylation site were included, replacing serine or threonine with ala¬
nine or valine, respectively, and positive control peptide sequences for
each kinase were present.
Peptide arrays were sealed with Gene-Frame™ incubation cham¬
bers (Abgene house, Surrey, UK), and the chambers were filled with 330
/xl of kinase buffer (20 mM MOPS, pH 7.2, 25 mM /3-glycerol phosphate,
5 mM, EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 100 /xM
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LC gradient for IMAC-enriched phosphopeptide analysis
Solvent A was 100% H20, 0.1% formic acid; solvent B was 70% ACN,
30% H20, 0.1% formic acid. Flow rate through the columns in the
separation was 150 nl/min.
Solvent 0 30 75 105 125 135 145 150 160
A (%) 99 98 97 95 90 80 50 5 5
B (%) 1 2 3 5 10 20 50 95 95
ATP, 15 mM MgCl2, and 10 pM [-y-32P]ATP). Recombinant active kinases
(Upstate Biotechnology, Inc., Lake Placid, NY) (3 pg of PKA catalytic
subunit (with 2 pM cAMP), 2 pg ofAktl (A PH, S473D), 2 pg of Erkl, 3
pg of p38a, 3 pg of CKII, 3 pg of Cdk5/p35, and 1.5 pg of PKC (a, (3, y))
were included in the appropriate kinase assays. In the case of PKC, a
modified kinase buffer was used (10 mM MOPS, pH 7.2, 12.5 mM
0-glycerol phosphate, 2.5 mM EGTA, 0.5 mM sodium orthovanadate, 0.5
mM dithiothreitol, 0.5 mM CaCl2, 0.1 mg/ml phosphatidylserine, 25
pg/ml diacylglycerol).
After a 45-min incubation at 32 °C, the peptide microarrays were
washed six times, alternating between 0.1 M phosphoric acid and dis¬
tilled water. y-32P incorporation in the immobilized peptide spots was
detected on a Typhoon 8600 Phosphorlmager (50-p.m resolution; Am-
ersham Biosciences). Image analysis and signal quantification was
carried out using ImageQuant TL (Amersham Biosciences), and posi¬
tive signals were defined after background subtraction.
Bioinformatic Analysis—All proteins detected in this study were
classified according to Swiss-Prot keywords (available on the World
Wide Web at ca.expasy.org/sprot/). Known phosphoproteins in Supple¬
mentary Table I were annotated by extensive literature mining of
PubMed. Scansite (available on the World Wide Web at scansite.mit.
edu/) was used in high stringency mode to predict if proteins in Sup¬
plementary Table I were likely to be phosphorylated, and responsible
kinases are indicated. TMHMM Server version 2.0 (available on the
World Wide Web at www.cbs.dtu.dk/services/TMHMM/) was used to
predict the occurrence of transmembrane helices. Scansite and Net-
PhosK (available on the World Wide Web at www.cbs.dtu.dk/services/
NetPhos/) were both used for predicting phosphorylation sites by cog¬
nate kinases and on those peptides where the phosphorylation sites
could not be unambiguously assigned by MS data (Supplemental Table
III). Scansite was also used to check the presence of phosphorylation
sites in Pfam protein domains and to predict whether phosphorylation
sites were localized in phosphodependent interaction domains (Supple¬
mental Table III). Graphical illustrations of the location of identified
sites in relation to protein domain structure, three-dimensional struc¬
ture, and information on homologs and paralugs of identified phospho¬
rylation sites can be found on the World Wide Web at
www.ppo4.org/phospho/synaptosome.html.
Network Construction—Protein-protein interactions for the iV-meth-
yl-D-aspartate (NMDA) receptor complex proteins were obtained from
PPID (available on the World Wide Web at www.PPID.org). Each pro¬
tein (node) that had interaction (edge) information was used to plot a
network graph using InterViewer, a network graphing program. Ki-
nase-substrate edges were manually superimposed onto the protein-
protein interaction network.
RESULTS
Several approaches capable of identifying large numbers of
in vivo phosphorylated proteins have been used to functionally
annotate the mouse synaptic proteome. A summary of this is
shown in Fig. L4. In the first approach, a mouse synaptosomal
preparation was digested with trypsin and phosphopeptides
captured by peptide IMAC. The enriched sample was analyzed
by nano-flow LC-MS/MS. Despite the enrichment, the majority
of identifications corresponded to unphosphorylated peptides.
In the second approach, the synaptosomes were first divided
into urea soluble and insoluble fractions, the latter containing
mostly membrane-bound components. Peptide IMAC and MS
was performed on the insoluble fraction in a comparable man¬
ner to the first approach. For the urea-soluble fraction, a new
strategy was adopted, entailing an additional stage of enrich¬
ment by capture of the phosphoproteins. A two-pronged route
was taken for subsequent analysis of the trypsin digest of this
enriched fraction. The first route is based on rigorous MS using
(a) LC-MS/MS peptide identification based on a TRA approach
described under "Experimental Procedures" and (b) precursor
ion scanning to identify phosphopeptides prior to sequencing.
The second route used a further peptide IMAC followed by
LC-MS/MS. Using these combined approaches and implement¬
ing a previously unreported strategy of sequential protein and
peptide IMAC, we have identified 228 potential synaptic phos¬
phoproteins (Supplementary Table I) and characterized over
350 phosphopeptides containing 331 sites of phosphorylation
(Supplemental Tables II and III).
Synaptic Phosphoprotein Analysis
Protein IMAC Protocol—Unlike peptide IMAC that is widely
used for phosphoproteomic analysis, to our knowledge protein
IMAC approaches have not been reported. In order to develop
a protein IMAC protocol, we tested two resins; Sepharose-IDA
(a tridentate ligand) and agarose-nitrilotriacetic acid (a
quadradentate ligand) and two metal ions, FeCl3 and GaCl3
(Fig. IS), to isolate phosphoproteins from urea-soluble prepa¬
rations. The IDA resin with both metal ions showed marked
enrichment indicated by specific phosphoprotein staining on
SDS-polyacrylamide gels. The Ga3+ resin showed more effec¬
tive depletion of phosphoprotein from the unbound fraction
together with stronger phosphostaining of the purified sample
(Fig. 1C) and therefore was used in all subsequent protein
IMAC experiments.
Analysis of tryptic peptides from the protein IMAC enrich¬
ment by LC-MS/MS identified 152 proteins and 19 phosphopep¬
tides (Supplementary Tables I and II). TRA extended this by an
additional 30 protein identifications and 21 phosphopeptides. A
further 28 different phosphopeptides from these samples were
identified using the precursor-scanning approach, applied in
the routine as well as the targeted manner as described under
"Experimental Procedures." Clearly, the TRA strategy is effec¬
tive in both standard LC-MS/MS and precursor scanning
modes for extending both protein and phosphorylation map¬
ping from complex peptide mixtures.
186 proteins have been identified in the protein IMAC
sample. 105 of these have been confirmed as phosphoproteins
in the literature and by phosphorylation sites identified in
this study (Fig. 2). This suggests that whereas a small pro¬
portion may represent contaminating proteins, the majority
are probably phosphoproteins. The identified components
represent a diverse range of protein classes (Fig. 2B and
Supplemental Table I), and low abundance protein classes,
such as kinases, phosphatases, and small G-proteins and
modulators, are well represented even in the presence ofvery
abundant cytoskeletal proteins.
The protein IMAC approach presents important benefits for
phosphorylation analysis. It offers the opportunity to use basic
protein identification to identify many candidate phosphopro¬
teins, which are of low abundance and would not have been in
the dynamic range required for direct phosphorylation analy¬
sis. The majority ofphosphopeptides characterized in MS analy¬
ses of the phosphoprotein mixture cover single phosphorylation
events (Fig. 3) and thus are complementary to measurements
made from the peptide IMAC approach that better represents
highly phosphorylated peptides. A further important benefit is
that it provides scope for two stages of sample enrichment, at
the protein level and subsequently at the peptide level.
Double IMAC Protocol—LC-MS/MS analysis of phosphopep¬
tide from double IMAC yielded identification and characteriza¬
tion of 176 phosphopeptides (Fig. 2A and Supplemental Table
II) derived from 41 phosphoproteins. The results from the dou¬
ble IMAC protocol significantly extended those from the pro¬
tein IMAC protocol on several levels. First, of the 25 validated
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phosphoproteins found in the protein IMAC experiments, we
found an additional 115 phosphopeptides on 16 proteins, indi¬
cating greater depth ofanalysis. We also identified a further 14
phosphopeptides corresponding to seven proteins detected in
the protein IMAC sample. Second, 19 phosphoproteins contain¬
ing 37 phosphopeptides that were not characterized in the
protein IMAC were observed in the double IMAC protocol.
Third, the increased depth of phosphorylation coverage
through overlapping peptides reflects variability in site occu¬
pation that can occur on a protein and a level of heterogeneity
associated with this type of modification. This is well illus¬
trated in Bassoon, for which we found 15 phosphorylation sites
(10 peptides) in the protein IMAC protocol and 16 new sites (16
peptides) in the double IMAC protocol (Supplemental Table
III). It is evident that combination of protein and double IMAC
strategies enables identification and characterization of phos¬
phoproteins across a wider range of protein abundance and
phosphorylation states.
Synaptic Membrane Phosphoproteomic Analysis—Integral
membrane proteins are usually difficult to analyze, since de¬
tergent-based extraction methods are not readily compatible
with subsequent purification strategies and LC-MS/MS analy¬
sis. However, for a phosphoproteomic analysis, cytoplasmic
domains of integral membrane proteins are sufficient, since
they contain the phosphorylation sites involved in intracellular
signaling. Therefore, we digested 6 m urea-insoluble fractions of
synaptosomes; the supernatant was desalted and esterified as
described above and was subjected to a single peptide IMAC
and LC-MS/MS analysis (Fig. 1A). This approach allowed iden¬
tification and characterization of 60 phosphopeptides from 31
proteins (Supplemental Table II), of which 12 are predicted to
be integral membrane proteins and many others, such as
PSD-95 and Adapter-related protein complex-2 a-1, are known
to be membrane-associated. 10 of the identified membrane
proteins were not previously known to be phosphoproteins. Of
these 31 phosphoproteins, 18 were not detected in either pro¬
tein or double IMAC protocols (Fig. 3A).
Complementarity ofAnalytical Approaches—Inspection of the
summarized data (Figs. 2A and 3) shows that the combination of
subcellular fractionation and IMAC protocols with MS analyses
are complementary, both in terms of the protein identification
and phosphorylation site characterization. Overall, we sequenced
350 phosphopeptides covering 653 phosphorylation events. These
correspond to a total of 331 phosphorylation sites, of which 289
were localized unambiguously (Fig. LA). The phosphorylation
sites were found in 79 synaptic proteins, and we identified a
further 149 candidate phosphoproteins. Interestingly, the large
numbers of phosphorylation events characterized by the double
IMAC approach mainly correspond to greater coverage of a small
set of proteins. The phosphopeptide-based methods, in contrast,
cover a proportionately larger number of proteins but with fewer
representative sites.
Further complementarity is observed in the frequency of
Fig. 1. A, schematic representation of the protein and peptide puri¬
fication strategy used. Alternative starting material was derived from
the differential solubility of synaptosomes in 6 M urea. Large scale
protein identification was achieved by TRA LC-MS/MS analysis of the
IMAC-purified phosphoproteins from the urea-soluble fraction with
some of the most abundant phosphopeptides characterized at this step.
Further phosphopeptide identification was achieved by sequential pro¬
tein and peptide IMAC purification with esterification and single pep¬
tide IMAC with esterification of the urea-insoluble fraction and ofwhole
synaptosomal digests. B, development of IMAC phosphoprotein isola¬
tion strategy. Overlay of Pro-Q diamond phosphoprotein/Ruby total
protein stains of resin/metal IMAC combinations used to selectively
isolate phosphoproteins from urea-soluble synaptosomal extract. The
corresponding unbound fractions are included for comparison. 20% of
eluted protein from each purification was separated on a 12% SDS-
polyacrylamide gel and stained and imaged sequentially. Phosphoryl-
ated protein appears pink to black, whereas unphosphorylated protein
appears green. Lane 1 shows Peppermint Stick molecular mass markers
in which proteins of molecular mass 23 and 45 kDa are phosphorylated,
and those of 55 and 116 kDa are not phosphorylated, thus serving as an
internal control for selective staining of phosphorylated proteins. A
25-kDa band (see arrow) was shown to consist of ribosomal proteins,
which were retained on the IMAC resins due to ion exchange effects and
therefore removed from the data set. C, relative signal intensities of the
Pro-Q diamond phosphoprotein stained image used in the overlay in B.
Phosphoprotein signals for lanes 2-5 in B are shown and plotted versus
molecular weight. IDA-Ga has the highest overall signal intensity and
thus is the most enriched in phosphoprotein.
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Fig. 2. A, Venn diagram of phosphopro¬
teins detected in the protein, double, and
peptide IMAC protocols. Data from pep¬
tide IMAC experiments on whole synap¬
tosomal digests and urea-insoluble synap¬
tosomal digests were combined to simplify
the comparison. Values in brackets indi¬
cate the number of phosphoproteins in
each set for which evidence of their phos¬
phorylation was found in the literature.
B, class distribution of phosphoproteins
identified. Phosphoproteins were cross-
referenced with six MS-based studies of
the postsynaptic density and with the
NRC. Proteins in which we found phos¬
phorylation sites (experimental) and





































Protein class Proteins Proteins Phosphoproteins Total
Channels/receptors 4 0 7 7
Transporters/transporting ATPascs 5 2 9 12
Scaffolding and adaptors 17 10 17 21
Kinases 14 5 17 19
Phosphatases 4 1 2 4
Small G-protcins and modulators 12 0 8 18
Other signaling molecules 6 5 7 10
Other enzymes 12 5 8 20
Cell adhesion and cytoskeletal 55 16 51 69
Nuclear/transcriptional 0 0 6 10
Translations! 2 0 2 3
Novel/uncharacterised proteins 3 0 14 35
Total 134 44 148 228
A
Protein IMAC (urea soluble)
■ Double IMAC (urea soluble)
Peptide IMAC (urea insoluble)
- Peptide IMAC (whole digest)
-a—
4 tST
2 3 4 5 6
Number ofphosphates per phosphopeptides
Fig. 3. Distribution of the number
of phosphates present per phos-
phopeptide identified. The values are
representative of all phosphopeptides de¬
tected by each approach and therefore
contain some peptides covering overlap¬
ping sequences in proteins but with dif¬
fering numbers of phosphates attached.
phosphorylation of peptides detected using the different proto¬
cols (Fig. 3). Peptide IMAC approaches have been reported to
enrich for multi- phosphorylated peptides (10,11), and we have
also observed this. In contrast, protein IMAC shows a shift in
specificity favoring detection of monophosphorylated peptides.
The combination of protein and peptide IMAC results in more
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representative coverage, with very similar preferences for
mono- and diphosphorylated peptides together with improved
detection of higher phosphorylated states. Another approach,
using strong cation exchange and exploiting the net charge on
phosphopeptides at low pH, has a bias toward singly phospho¬
rylated peptides (17). This approach yielded peptides with an
average of 1.15 phosphates/peptide, compared with our 1.85
phosphates/peptide. It is likely that our combination of protein
and peptide protocols is more representative of the distribution
of phosphorylation sites in vivo.
Interestingly, the peptide-based approach on the membrane
fraction shows more multiply phosphorylated peptides (up to
six sites) than the other methods. Moreover, the average num¬
ber of phosphorylation sites per peptide detected in the direct
peptide IMAC (2.53) on the membrane fraction is higher than
that of whole synaptosomes (2.05) and is greater that that
observed for the protein IMAC (1.44) and double IMAC (1.75)
analysis of the urea-soluble fraction (Fig. 3). The enrichment of
multiphosphorylated peptides in the urea-insoluble fraction
may reflect clusters ofphosphorylation sites, often found on the
intracellular domains of membrane proteins.
Of the total 331 sites defined, 281 correspond to phospho-
serine phosphorylation events, and 43 and 8 can be attributed
to phosphothreonine and phosphotyrosine, respectively. Tyro¬
sine phosphorylation is usually associated with a higher gain in
signals because it is less abundant and more tightly regulated.
We have observed more tyrosine phosphorylation sites than
would be expected from previous reports in other large scale
studies (11-13). Since most of the phosphotyrosines we char¬
acterized are on multiphosphorylated peptides that were iden¬
tified by the protein or double IMAC approach, this increased
coverage can be attributed to increased phosphoprotein enrich¬
ment, together with the improvements in analysis of mul¬
tiphosphorylated peptides.
Literature Mining and Bioinformatic Assessment
Literature mining and bioinformatic analysis of the 228 pro¬
teins that we have identified in this study clearly indicate an
enrichment of phosphoproteins (Fig. 2 and Supplementary Ta¬
ble I). Systematic PubMed searching on the identified compo¬
nents revealed that 110 have been described in the literature
as phosphoproteins (Supplemental Table I and Fig. 2). Of the
79 synaptic phosphoproteins characterized here, only 41 were
previously reported as phosphorylated, the present work rep¬
resenting a 2-fold increase to the published literature. We also
report an additional 149 putative phosphoproteins, which we
have characterized based on protein identifications in the pro¬
tein IMAC samples. 69 (46%) of these components have been
reported as phosphorylated in the literature, thereby strongly
indicating that further mapping of these proteins will produce
confirmation of their phosphorylation (Fig. 2A) and further
validation of this approach. Within our data set, we have also
identified phosphorylation sites in 14 novel or uncharacterized
proteins, adding functional annotation in an unbiased manner
not possible in single protein focused studies.
To further explore the putative phosphoproteins as well as
phosphopeptides with ambiguous site assignment, we utilized
phosphorylation prediction software that provides information
on sites and cognate kinases. We found that prediction pro¬
grams were particularly useful for assigning specific sites to
phosphopeptides with multiple potential phosphorylation sites.
For example, the peptide 44IG(S)(T)(T)NPFLDIPHDPNAAV-
YK64 from mKIAA0942 protein was detected in the protein
IMAC analysis and contained one p(S/T) phosphorylation site.
Scansite predicted that the most likely site to be phosphoryl¬
ated in this sequence (by PKCS) was Ser46, and this site was
subsequently confirmed when it was detected again in the
double IMAC analysis. We have observed accurate predictions
in many similar cases, which support the use of in silico local¬
ization of the remaining 43 ambiguous phosphorylation sites
(Supplemental Table III).
Based on bioinformatic prediction and, in a few cases, data
from the literature, we identified the kinases that were most
likely to phosphorylate 289 defined sites (Supplementary Table
III). All sites could be accounted for by a minimum set of 23
kinases (Fig. 4), and 14 of these are shown in the literature to
phosphorylate proteins in our data set. The predicted kinases
emerged as two groups: those that phosphorylate multiple sites
on proteins (phosphate/substrate ratio >1 (nine kinases)) (left
of the dashed line; Fig. 4) and those that phosphorylate a single
site per protein (phosphate/substrate ratio = 1 (14 kinases)).
Nine kinases could each phosphorylate 10 or more sites on
multiple substrates and together could account for 258 of the
observed sites, and eight kinases could phosphorylate 10 or
more distinct synaptic substrates. In agreement with another
report, we noted that the majority of sites cluster outside char¬
acterized protein domains (18) (Supplemental Table III). 25
phosphorylation sites corresponded to residues predicted to
mediate phosphorylation-dependent protein-protein interac¬
tions such as 14-3-3 and Src homology 2 domains.
In Vitro Phosphorylation Assays
Peptide array technology was employed to evaluate kinase
specificity and multiplicity inferred from bioinformatic analy¬
sis of the synaptic phosphorylation data set. 190 peptides were
synthesized that encompassed 95 phosphorylation sites from
the described MS analyses. Control peptides were used to con¬
firm enzymatic activity for each kinase, and analytical spot
signals were only considered positive when they were positive
after background subtraction and when serine/threonine sub¬
stitutions on control peptides eliminated or significantly re¬
duced the resultant signal. Seven kinases (PKA, Akt, PKC (a,
/3, and y), CK2, p38 mitogen-activated protein kinase, extracel¬
lular signal-regulated kinase 1, and Cdk5) were used to screen
for positive signals across 190 peptides, arrayed in triplicate.
Robust positive signals for 28 unique phosphorylation sites
were detected, resulting in 52 kinase substrate site identifica¬
tions (Supplementary Fig. 1A) with an observed kinase/sub-
strate site ratio of 1.9. To evaluate the agreement of this in
vitro data with the in silico kinase predictions by Scansite and
NetPhosK, predictions were made with both programs for the
seven kinases used on the 28 positive sites in the peptide array
experiments. Scansite and NetPhosK predicted 58 and 63% of
sites, respectively (Supplemental Fig. LB). The overlap of pos¬
itive predictions by Scansite and NetPhosK for this set of
phosphorylation sites was 26%, strongly indicating that nei¬
ther algorithm is sufficient and that both must be used to
obtain good coverage of a data set.
The number of kinases and binding sites with known con¬
sensus sequences constrains global predictions; however, in
combination with data sets of defined in vivo phosphorylation
sites and in vitro phosphorylation data, they point to the fact
that multiple synaptic substrates may exist for each kinase,
and a complex regulatory network may arise.
DISCUSSION
The Synapse Phosphoproteome—The aim of this study was to
establish an in vivo map of the synaptic phosphoproteome. We
therefore examined the representation of phosphorylation data
across synaptic proteins and important synaptic subcompo¬
nents and organelles. Our data set contained postsynaptic com¬
ponents, including the postsynaptic density (134 proteins) and
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Fig. 4. Predicted kinase multiplicity for 289 defined synaptic phosphorylation sites. Scansite and NetPhosK kinase predictions and in
a few cases data from the literature were used to evaluate the number of phosphorylation sites and distinct substrates for 23 kinases on 289 sites
in synapse proteins. The total number of predicted sites (filled bars) and substrate proteins (cross-hatched bars) are shown on the x axis for a given
kinase. The dashed vertical line between CamKII and extracellular signal-regulated kinase divides the kinases into two groups; the left-hand set
has kinase/substrate ratio of >1, and the right-hand set has a kinase/substrate ratio of 1.
presynaptic components, of which the most striking examples
were Piccolo-Bassoon transport vesicles.
Presynaptic Multiprotein Complexes—A number of protein
complexes have been identified at the presynaptic active zone,
a region where synaptic vesicles dock, fuse, and release their
neurotransmitters into the synaptic cleft (19). It is well known
that phosphorylation is critical to the regulation of calcium-
regulated synaptic vesicle exocytosis (20), and we have identi¬
fied a number of phosphoproteins known to play a role in this
process (Fig. 5). Piccolo-Bassoon transport vesicles have been
shown to be putative precursor vesicles in the active zone (21)
and contain a number of proteins functionally coupled to syn¬
aptic vesicle exocytosis. Bassoon, a presynaptic protein with
homology to Piccolo, is intimately involved in vesicle release
(21) and, together with Piccolo and Rim-1/2, constitutes half of
the protein content of Piccolo-Bassoon transport vesicles. We
have detected 30 phosphorylation sites on Bassoon and a fur¬
ther 16 sites on Piccolo.
We have identified a number of phosphorylation sites on
Rim-1, a Rab3 effector involved in the regulation of synaptic
vesicle fusion that is associated with Piccolo-Bassoon transport
vesicles (21). PKA phosphorylation of an isoform of Riml reg¬
ulates presynaptic long term potentiation (22), highlighting the
regulatory importance of such presynaptic molecules. In addi¬
tion to the main constituents of Piccolo-Bassoon transport ves¬
icles, we mapped phosphorylation sites on Munc-18. Phospho¬
rylation of Munc-18 by PKC has been shown to disassemble
Munc-18-syntaxin 1A complexes and may have a regulatory
role in presynaptic plasticity (23). We have identified a number
of phosphorylation sites in components of other presynaptic
multiprotein complexes such as cysteine string protein,
SNAP25-interacting protein, and the Rabll-interacting pro¬
tein, Ripll (Fig. 5).
Postsynaptic Multiprotein Complexes and Pathways—The
neurotransmitter glutamate activates synaptic plasticity pri¬
marily via the ionotropic NMDA receptor and metabotropic
(mGluR) receptors. This leads to Ca2+ elevation in the den¬
dritic spine and signal transduction to a-amino-3-hydroxy-5-
methylisoxazole-4-propionate receptors and other effector
mechanisms. Proteomic analysis of proteins associated with
the NMDA receptor revealed that a multiprotein complex of
over 180 proteins is embedded in the postsynaptic density (5,
24). We have identified 115 phosphopeptides derived from 17
NMDA receptor complex (NRC) proteins, most of which have
been also identified as PSD proteins and an additional 142
phosphopeptides from another 29 PSD proteins (Figs. 2 and 4).
Phosphopeptides derived from three PDZ domain-containing
proteins (Shankl, PSD-93/ChapsynllO, and PSD-95) were de¬
tected in this study. PDZ domain-containing proteins are im¬
portant components of the NRC and the postsynaptic density
and form protein scaffolds that support and regulate many
essential synaptic signaling processes (25). We found a phos¬
phorylation site in PSD-93 (Ser414), which was also found in
MS analyses of purified NRC complexes.2 Since this site was
detected in the NRC with no specific enrichment for phospho¬
proteins, it must be highly phosphorylated and enriched in this
complex, in agreement with another study of PSD-93 phospho¬
rylation in the NRC (26).
Three phosphorylation sites were mapped in PSD-95 within
a 20-amino acid stretch, two Ser(P) just before its SH3 domain
and Tyr(P)432 located at the start of its SH3 domain in the /}1
sheet. Structural analysis of the SH3 and guanylate kinase
domains of PSD-95 (27, 28) showed that there is an intermo-
2 H. Husi, J. S. Choudhary, W. P. Blackstock, and S. G. N. Grant,
unpublished results.
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Fig. 5. Schematic illustration of phosphoproteins and their interaction partners at the synapse. Selected phosphoproteins charac¬
terized in this study were used to construct a synaptic interaction diagram. Protein-protein interaction information was gathered from PPID
(available on the World Wide Web at www.ppid.org). All phosphoproteins are colored, and proteins shaded in gray are known synaptic proteins and
are included for protein-protein interaction completeness. Proteins with novel phosphorylation sites are marked with a red star, and novel
phosphoproteins are marked with a blue star.
lecular interaction between the SH3 and guanylate kinase
domains involving the formation of a /3-sheet, including resi¬
dues N- and C-terminal to the SH3 domain. Tyr432 is located in
this hydrophobic core mediating this interaction and is itself
interacting with His461. Introduction of a negative charge by
phosphorylation of Tyr432 could disturb this interaction and
may have a regulatory role in the formation of an SH3 and
guanylate kinase intermolecular interaction and also affect the
interaction ofother proteins, such as AKAP79, that bind to this
region (29). It has been proposed that this intermolecular in¬
teraction is a conserved feature of the membrane-associated
guanylate kinase superfamily based on mutational data avail¬
able for different membrane-associated guanylate kinase pro¬
teins (28). These phosphorylated sequences in PSD-95 are also
present in two paralogous proteins, SAP97 and SAP102, rep¬
resenting a possible conservation of regulatory functions.
There is a growing body of evidence that scaffold proteins are
regulated by phosphorylation (30), which is consistent with the
number of identified scaffold phosphoproteins identified in this
study. In fact, we have identified two phosphorylation sites on
PKA-RIIa, which map to a defined 15-amino acid sequence,
which has been shown to interact with MAP2 (31). This inter¬
action is believed to influence cytoskeletal localization of the
PKA holoenzyme (31), and phosphorylation of the binding site
could modulate this interaction and ultimately the localization
of PKA.
The usefulness of a differential urea extraction strategy is
shown by identification of phosphorylation sites in a number of
integral membrane or membrane-associated proteins. We have
found sites in cell adhesion molecules such as neural cell ad¬
hesion molecule and neurofascin, potassium channels, and a
number of other known membrane proteins. However, the
value of such a targeted extraction procedure is exemplified by
the identification of components of a plasma membrane to
intracellular membrane signaling complex associated with
mGluR5 (32) (Fig. 5). We have identified phosphorylation sites
in mGluR5 (group I metabotropic glutamate receptor) and IR-
BIT (membrane-associated inositol trisphosphate (IP3) recep¬
tor-binding protein) in the urea-insoluble synaptosomal frac¬
tion and phospholipase C-/3 in the urea-soluble fraction.
Activation of mGluR5 results in the hydrolysis of membrane
phosphatidylinositol bisphosphate to diacylglycerol, which ac¬
tivates PKC, and IP3, which in turn activates the IP3 receptor
to release intracellular calcium (33). IRBIT binds to the IP3
receptor via its N terminus and is released from the IP3 recep¬
tor upon IP3 binding. The N-terminal region of IRBIT respon¬
sible for this interaction contains three novel phosphorylation
sites, and phosphorylation in this region has been postulated to
regulate this interaction (34). mGluR5, G-proteins, and phos¬
pholipase C-/3 form a multiprotein complex with the IP3 recep¬
tor and IRBIT via the scaffolding properties of Homer (35). This
complex seems to facilitate a signaling pathway from mGluR5
to modulation of intracellular calcium, which is known to reg¬
ulate a myriad of intercellular signaling activities.
mGluR5 has a critical role in NMDA receptor-dependent
forms of synaptic plasticity and excitotoxicity. Co-activation of
mGluR5 and NMDA receptors is required for potentiation of
excitatory synaptic transmission in hippocampal neurons (36),
and this process requires IP3 receptor-mediated mobilization of
intracellular calcium and activation of PKC for maintenance of
potentiation. As well as being functionally coupled, there is
evidence to suggest that these receptors are physically associ¬
ated; mGluR5 is a component of the NMDA receptor complex
(5), NR2A (an NMDA receptor subunit) is present in the
mGluR5 receptor complex (32), and 20 other proteins are com¬
mon to these complexes. Functional analysis of novel phospho¬
rylation sites on mGluR5 and other components of the associ¬
ated pathway to calcium release and PKC activation may
provide novel insights into the functional interaction of these
two important glutamate receptors.
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Fig. 6. A, network illustration of protein-protein interactions and kinase-substrate interactions in the NRC. Protein-protein interaction data
(248 binary interactions from PPID) for 104 NRC proteins was used to construct a protein-protein interaction network. Each node (colored circle
representing a protein) is color-coded, according to its protein class. Kinase-substrate data from MS-identified phosphorylation sites and peptide
array experiments, for eight NRC proteins, were superimposed onto the protein-protein interaction network. Red network edges (lines connecting
two proteins) represent kinases present within the NRC, which phosphorylate NRC substrates, and blue network edges represent kinases not
presently known to be present within the NRC, which phosphorylate NRC substrates. Substrates are numbered as follows: 1, MAP2; 2, mGlur5;
3, PSD-93/ChapsynllO; 4, PSD-95; 5, SAPAP1 and -2; 6, myelin basic protein; 7, Bassoon; 8, CaMK2B. B, illustration of path lengths from PKA
to its NRC substrates (PSD-95, PSD-93/ChapsynllO, and SAPAP1 and -2). These PKA substrates are important synaptic scaffolders, which are
closely associated with each other, and their proximity to this kinase within the NRC would imply a physiological context for their phosphorylation.
Peptide Array-based Kinase Screen—Oriented peptide librar¬
ies were first used in the study of protein phosphorylation to
map target specificity of kinases. This approach has contrib¬
uted much of the kinase consensus information currently
known and constitutes the basis of a widely used phosphoryl¬
ation prediction algorithm (37). It is thought that many phos¬
phorylation sites tend to occur in accessible and flexible regions
in three-dimensional protein structures, and in agreement with
another study (18), the majority of phosphorylation sites (65%)
we identified are predicted to be outside structural domains.
This would indicate that phosphorylation of linear peptide se¬
quences in vitro should be similar to phosphorylation of the
intact protein for the majority of sites. Data derived from
immobilized peptide array experiments are consistent with
known kinase consensus sequences (38, 39) and therefore rep¬
resent a useful tool for studying phosphorylation.
Peptide array screening of a limited set of phosphorylation
sites with seven kinases resulted in the identification of 52
kinase phosphorylation site sets. Kinase data for two phospho¬
rylation sites screened on peptide arrays were available in the
literature. Microtubule-associated protein Tau was shown to be
phosphorylated at Ser493 by Cdk5 (40). This site was identified
and was hyperphosphorylated only in p25-overexpressing mice
(increased activation of Cdk5) and along with other hyperphos¬
phorylated residues contributed to neurodegeneration and for¬
mation ofneurofibrillary tangles (40). We identified this site in
vivo in wild type mice and have shown that it can be phospho¬
rylated by Cdk5 on a peptide array. Also, Myelin basic protein
is phosphorylated at Ser144 by PKA and PKC (41), in agree¬
ment with our peptide array observations for this site. The
reported validation and use of peptide arrays in the literature
and confirmation of cognate kinases for these two sites sup¬
ports the value ofusing peptide array technology as a screening
tool for in vivo identified phosphorylation sites. We recognize
that these in vitro data are not sufficient on their own to
definitively prove that a kinase may phosphorylate a given site
in vivo; however, because these phosphorylation sites were
identified from in vivo preparations, it is reasonable to use this
peptide array technology as a first approach to screen for pos¬
sible substrates.
Large scale screening of kinase substrates directly in a pro¬
tein complex is currently not feasible due to technical limita¬
tions. However, an alternative strategy would be to first assign
kinases to phosphorylation sites using peptide array screening,
PSD-93
PKA AKAP79 PSD-95 SAPAP 1/2
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which is very scalable, and then for example, phospho-specific
antibodies or specific MS-based approaches could be used to
assess the relevance of a substrate phosphorylation in a par¬
ticular complex or organelle. Since phosphoproteomic ap¬
proaches are beginning to yield unprecedented numbers of
phosphorylation site identifications, peptide array-based
screening of cognate kinases may prove to be very useful for
selecting and prioritizing phosphorylation sites or phosphopro-
teins for further functional investigation.
Kinase Association—An important issue in assigning ki¬
nases to specific phosphorylation sites on substrates is one of
kinase proximity. The potential of a substrate to be phospho-
rylated by a kinase depends on the presence of the appropriate
consensus sequence as well as the presence of the kinase in the
microenvironment of the substrate. Kinases can be targeted to
their substrates via adapter proteins {e.g. a membrane-associ¬
ated guanylate kinase-AKAP79 complex recruits PKA to the
postsynaptic membrane to phosphorylate the a-amino-3-hy-
droxy-5-methylisoxazole-4-propionate receptor subunit GluRl
(29)). Furthermore, it is probable that a given phosphorylation
site can be phosphorylated by multiple kinases in an in vitro
assay, but either the site is specific for a given kinase in a given
complex or, in some cases, the substrate would not usually be in
proximity to that kinase in physiological circumstances.
We addressed this issue of proximity by focusing on protein-
protein interactions in the NRC. A network of interacting NRC
proteins was constructed, and kinase-substrate data from MS
and peptide array experiments were superimposed onto this net¬
work (Fig. 6A). Six kinases were shown to phosphoiylate nine
NRC components on the peptide array. It should be noted that
three of these kinases (AKT1, p38 mitogen-activated protein
kinase, and Cdk5) were not found in the NRC; perhaps these
kinases are transiently associated with the NRC (thus beyond
detection limits), or they phosphorylate NRC components in a
different physiological context. Certain substrates such as SA-
PAP1/2 act as phosphorylation hubs, being phosphorylated on
various sites by all six kinases, whereas others are phosphoryl¬
ated by a single kinase. It is apparent that some kinases such as
PKA act on sets of interacting proteins (Fig. 6B). PKA is linked to
four interacting substrates (PSD-95, PSD-93, and SAPAP1 and
-2) via AKAP79, a kinase anchor protein that recruits PKA to the
postsynaptic membrane in proximity to its physiological sub¬
strates. The layering of kinase-substrate data onto protein-pro¬
tein interaction networks such as this can result in the identifi¬
cation of interacting substrates, which are more likely to be
physiologically important and therefore should be prioritized for
further functional annotation. A prerequisite for this kind of
approach is a well defined and functionally relevant interactome
such as the NRC, and layering dynamic aspects of phosphoryla¬
tion such as phosphorylation time courses, in response to stimuli,
will certainly advance the dissection of complex synaptic signal¬
ing pathways.
Synaptic Plasticity and Disease—In addition to identifying
and characterizing phosphoprotein components in important
synaptic multiprotein complexes, we have found phosphoryla¬
tion sites in a number ofproteins, which are directly implicated
in synaptic plasticity and disease (Supplemental Table IV). It is
generally accepted that phosphorylation is important in the
regulation of synaptic plasticity, a process that is believed to be
involved in learning and memory (42), drug addiction (43), and
pain (44). Functional studies have shown that seven phospho-
proteins we identified are involved in synaptic plasticity, and
perturbations of five in rodents show impairments in learning
and memory. Also, seven of the top 11 kinases predicted to
phosphorylate our total phosphoprotein data set are known to
be intimately involved in synaptic plasticity. We have identi¬
fied eight phosphoproteins that have been linked to schizophre¬
nia and other mental disorders. Finally, we have detected at
least seven known phosphorylation sites on microtubule-asso-
ciated protein tau (and one novel site), many of which have
been shown to be involved in neurodegeneration and the devel¬
opment of neurofibrillary pathology (40).
We have described large scale analysis of phosphorylation of
synaptic proteins using multiple complementary approaches at
the levels of protein extraction, phosphoprotein and phos-
phopeptide enrichment, analysis by MS, in vitro phosphoryla¬
tion assays, and network analysis. This integrated large scale
approach has several advantages over more traditional meth¬
ods, where a single protein or site is characterized, and in
particular it can be used to derive a picture of the global
organization of the synapse phosphoproteome. The establish¬
ment of phosphorylation maps will provide the basis for nu¬
merous functional studies, which will aid the understanding of
complex signaling pathways at the synapse. In addition to
enhancing this map of the synapse phosphoproteome with fur¬
ther studies, there is an important need to develop novel func¬
tional assays to monitor the regulation of multiple phosphoryl¬
ation events in a physiological context.
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Abstract
Characterization of the composition of the postsynaptic prot¬
eome (PSP) provides a framework for understanding the
overall organization and function of the synapse in normal and
pathological conditions. We have identified 698 proteins from
the postsynaptic terminal of mouse CNS synapses using a
series of purification strategies and analysis by liquid chro¬
matography tandem mass spectrometry and large-scale
immunoblotting. Some 620 proteins were found in purified
postsynaptic densities (PSDs), nine in AMPA-receptor
immuno-purifications, 100 in isolates using an antibody against
the NMDA receptor subunit NR1, and 170 by peptide-affinity
purification of complexes with the C-terminus of NR2B.
Together, the NR1 and NR2B complexes contain 186 proteins,
collectively referred to as membrane-associated guanylate
kinase-associated signalling complexes. We extracted data
from six other synapse proteome experiments and combined
these with our data to provide a consensus on the composition
of the PSP. In total, 1124 proteins are present in the PSP, of
which 466 were validated by their detection in two or more
studies, forming what we have designated the Consensus
PSD. These synapse proteome data sets offer a basis for
future research in synaptic biology and will provide useful
information in brain disease and mental disorder studies.
Keywords: a-Amino-3-hydroxy-5-methylisoxazole-4-propion-
ate, mass spectrometry, /V-methyl-D-aspartate; postsynaptic
density, synapse.
J. Neurochem. (2005) 10.1111/j.1471-4159.2005.03507.x
An important goal of cognitive science is to identify neural
mechanisms for processing information. The synapse both
transmits information between cells and processes it by
detecting specific patterns of neural activity and converting
this electrical activity into intracellular biochemical events
that change the properties of the neuron (Greengard 2001;
Kandel 2001). In recent years it has become clear that
synapses, like other cell-cell interactions in metazoans,
utilize signal transduction complexes and pathways with a
high degree of molecular complexity and cross-talk (Pawson
and Nash 2003; Sheng and Kim 2002). A major challenge is
to devise strategies that extract emergent physiological
properties and simple biological principles from highly
complex genomic and proteomic data sets, and shed light on
both mechanisms and disease processes. The synapse
proteome is a suitable prototype to explore these general
issues for several reasons. First, it contains a highly localized
set of proteins found in dendritic spines. Second, an
important role for signalling complexes and pathways has
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postsynaptic density; 1CAT, Isotope-coded affinity tag; LC-MS/MS,
liquid chromatography tandem mass spectrometry; MAGUK, mem¬
brane-associated guanylate kinase; MASC, MAGUK-associated signal¬
ling complex; (m)GluR, (metabotropic) glutamate receptor; MS, mass
spectrometry; NR, NMDA receptor; NRC, NMDA receptor complex;
PSD, postsynaptic density; PSP, postsynaptic proteome; SDS- PAGE,
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
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been established. Third, signalling can be studied using
patterns of action potentials and, finally, genetic and
pharmacological perturbations result in behavioural changes.
However, the molecular complexity and global organization
is not well understood.
The postsynaptic density (PSD) is a structural component
of the synapse that can be observed under the electron
microscope, beneath the postsynaptic membrane (Cotman
et al. 1974). Recent proteomic efforts have given an insight
into the complexity of the PSD and its subcomponents (Husi
and Grant 2001; Walikonis et al. 2000; Yamauchi 2002;
Yoshimura et al. 2004; Jordan et al. 2004; Peng et al. 2004;
Li et al. 2004; Collins et al. 2005). Advances in mass
spectrometry (MS) techniques have enabled large-scale
investigations of the protein content of organelles with
similar complexity to the PSD (for reviews see Jeong et al.
2000; Taylor et al. 2003).
The neurotransmitter glutamate activates synaptic plasti¬
city primarily via the ionotropic NMDA receptor and
metabotropic (mGluR) receptors. This leads to an increased
Ca2+ level in the dendritic spine and signal transduction to
a-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)
receptors and other effector mechanisms. The cytoplasmic
C-termini of NMDA receptor subunits (NR2A/el, NR2B/s2)
bind PDZ domains of PSD-95, a membrane-associated
guanylate kinase (MAGUK) protein. Previous proteomic
analysis of NMDA receptor-PSD-95 complexes identified 77
proteins including mGluR receptors, whereas AMPA recep¬
tors were found in different complexes (Husi et al. 2000).
These complexes are embedded in the postsynaptic terminal
of excitatory synapses with other postsynaptic proteins.
Here we present a large-scale proteomic analysis of the
postsynaptic proteome (PSP) of mouse brain. We have
performed a MS-based analysis of MAGUK-associated
signalling complexes (MASCs), AMPA receptor complexes
(ARCs) and isolated PSDs, and validated a set of MASC and
PSD proteins by large-scale immunoblotting. In addition to
generating novel data, we have systematically compiled data
from publicly available sources to produce a comprehensive
data set of the composition of the PSP. This includes data on
the PSD and various subcomponents, namely NMDA
receptor complexes (NRCs), ARCs and MASCs.
Experimental procedures
Biochemistry
MASCs were isolated using a peptide affinity method modeled on the
PDZ binding domain of NR2 subunits as reported elsewhere (Husi
et al. 2000). ARCs were isolated using immuno-precipitation of
AMPA-rcceptor subunits with an anti-GluR2 antibody (BD
Biosciences, Oxford, UK). PSD fractions were prepared as described
previously (Carlin et al. 1980). Protein samples were separated
by sodium dodccyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and stained with colloidal Coomassie blue. The entire
gel lane was excised into 42 individual protein bands, reduced,
alkylated and digested with trypsin.
MS
The resulting peptide mixtures were analysed by on-line liquid
chromatography tandem MS (LC-MS/MS) to generate peptide
sequence information (Link et al. 1999). Chromatographic separa¬
tions of the peptide mixture were performed on a 180-pm (intensely
stained bands) and 75-pm (weakly stained bands) PepMap column
using an Ultimate LC system (LC Packings, Amsterdam, The
Netherlands) delivering a gradient of formic acid (0.05%) and
acetonitrile. The LC column was connected directly to a micro-
elcctrospray interface on a Q-TOF mass spectrometer (Micromass
Ltd, Manchester, UK). The mass spectrometer operated in automa¬
ted function switching mode, selecting precursor ions based on
intensity for peptide sequencing by tandem MS. Several hundred
MS/MS spectra could be generated per ran allowing the analysis of
complex mixtures without any prior interpretation. The search
engine used in this work was Mascot (http://www.matrix-
science.com/). Data were reduced to MassLynx 'PKL' format peak
lists before searching. Proteins were identified based on matching
the MS/MS data with mass values calculated for selected ion scries
of a peptide. The searches on an in-house non-identical protein
database were performed without applying any constraints on
molecular weight or species of origin. Most proteins were identified
with several peptide matches, although a few proteins were assigned
on the basis of a single peptide provided that a near-complete
peptide sequence had been obtained.
Immunoblotting
Protein samples were subjected to reducing SDS-PAGE and
transferred to polyvinyldifluoride membrane (Bio-Rad, Hercules,
CA, USA) at 4°C for 90 min at 75 V in 10% (v/v) methanol, 10 mM
3-(cyclohexylamino)-1-propane-sulfonic acid (CAPS), pH 11.0.
Dilution of primary antibodies was between 1 : 100 and 1 : 1000,
depending on the quality of the IgGs. Detection of signals was
carried out using peroxidasc-linked secondary IgGs and enhanced
chemiluminescence.
Results
Composition of the PSP
We isolated MASCs using a previously described peptide
affinity method (Husi and Grant 2001). We used a peptide
corresponding to the six C-terminal residues of NR2B that
binds MAGUK proteins (including PSD-95), as a specific
affinity ligand to isolate NMDA receptor-MAGUK-contain-
ing complexes. Purified complexes were separated by SDS-
PAGE, and bands were excised and digested and analysed by
MS. Western blotting of peptide-purified complexes for
candidate proteins was also performed. These complexes are
similar in composition to NRCs and MAGUK complexes
isolated with antibodies (Husi and Grant 2001; Husi et al.
2000). Of the 100 proteins previously identified in the NRC
© 2005 International Society for Neurochemistry, J. Neurochem. (2005) 10.1111/j. 1471-4159.2005.03507.x
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by analysis of anti-NRl immuno-purifications, 84 were also
found by the peptide approach. In addition, 86 new proteins
were identified by the peptide approach, many of which were
in the molecular weight range obscured by the contaminating
antibody chains in the immuno-purification strategy. Because
of the large overlap, we combined data sets of proteins found
in both the NRC and the MAGUK-pep (NR2B peptide-
affinity purification) under the term MASCs. Ninety-five
MASC proteins were detected by western blotting ofpurified
complexes and 35 of these were validated by MS data. The
MASC set represents a comprehensive account of NMDA
receptor-MAGUK complexes identified by large-scale west¬
ern blotting and MS-based analyses of both antibody and
peptide affinity-based purifications.
We performed immuno-precipitation of the ARC with an
antibody directed against the GluR2 subunit and found a
significantly smaller complex of nine proteins by MS
analysis, which included all four AMPA receptor subunits.
In order to gain an overall view of the PSP and to validate
the components of the MASCs and ARCs, we performed
a systematic analysis of purified PSDs. PSD proteins were
separated by SDS-PAGE (Fig. 1) and 37 gel slices were
analysed by LC-MS/MS. Some 7402 peptides were identi¬
fied, corresponding to 620 non-redundant protein identifi¬
cations (hereafter referred to as the G2C PSD data set), with
an average of 34 proteins identified per gel slice (correspond¬
ing to an average of 16.7 unique proteins per gel slice)
(Supplementary Table 1). These data sets are available at
http://www.genes2cognition.org/science/proteomics/synapse.
html.
Integration of PSP data sets
To evaluate the coverage of our PSD data set, we compiled
data from six published proteomic studies of the PSD and
119 individual papers reporting proteins localized to the
PSD. A number of different sequence databases were used in
these studies for searching peptide mass spectra searching
and, as a result, we decided to use UniProt (http://www.
expasy.uniprot.org/) as our standard protein identifier. In a
few cases protein identifiers could not be mapped to UniProt,
so their original identifiers were retained. We observed
redundancy in data sets, with the same protein accession
kDa MW PSD
250
# Peptides # Proteins
25 45
# TM Proteins








Fig. 1 Distribution of peptide and protein identifications of PSD pro¬
teins by MS analysis of gel slices. Coomassie-stained SDS-poly-
acrylamide gel lane containing purified mouse forebrain PSD proteins.
The numbers of peptides, proteins and transmembrane proteins
identified in each gel slice by LC-MS/MS analysis are shown. One-
dimensional SDS-PAGE offers effective protein separation of complex
mixtures with an average of 34 proteins identified per gel slice and an
average of 12 peptides characterized for each protein. The number of
peptides detected per gel slice increases proportionally with molecular
weight. One-dimensional SDS-PAGE is very compatible with mem¬
brane samples as membrane proteins can enter the gel easily and the
distribution of proteins with transmembrane (TM) regions is shown.
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Table 1 Summary of PSD protein classifications
Total PSD G2C PSD cPSD
Channels and receptors 80 60 39
MAGUKs/adaptors/scaffolders 54 31 33
Serine/threonine kinases 46 23 20
Tyrosine kinase 3 3 2
Protein phosphatases 18 13 11
G proteins and modulators 77 40 34
Signalling molecules and enzymes 278 167 98
Transcription and translation 119 36 41
Cytoskeletal and cell adhesion 153 99 97
molecules
Synaptic vesicles and protein 159 119 76
transport
Novel 107 29 11
Other 30 0 4
Summary 1124 620 466
Proteins found in the Total PSD data set, our PSD data set and the
cPSD data set are classified functionally to show protein class
enrichment. The distributions of our PSD data set and cPSD protein
classes are similar except for signalling molecules and enzymes,
which are particularly enriched in our PSD data set. In addition, the
main contribution of low-abundance proteins such as tyrosine kinases
and phosphatases to the Total PSD data set is from our PSD data set.
In fact, our study was the only one to identify tyrosine kinases in the
PSD, further supporting the increased sensitivity of our approach.
Details for individual proteins and further subclassifications are found
in Supplementary Table 2.
numbers present numerous times, as well as many accession
numbers corresponding to the same gene product. We then
mapped UniProt accession numbers to Unigene (http://
www.ncbi.nlm.nih.gov/) via EMBL and Entrez Gene to
cluster the merged Total PSD data set to remove redundancy.
This process enabled grouping of numerous entries into
Unigene clusters and resulted in reduction of the dataset to
1124 non-redundant entries (Supplementary Tables 2 and 4).
An evaluation of the relative coverage of each component
PSD data set is presented in Supplementary Table 3. This
matrix of percentage coverage shows that the G2C data set
has the highest coverage of each data set in the group,
indicating that this set of proteins is the most representative
and complete single data set.
We addressed the issue of bias arising from the use of
different methodologies by comparing the distribution of
protein identifications. The analytical approaches used in
these six studies varied from use of one- and two-
dimensional electrophoresis for protein separation, ICAT
(Isotope-coded affinity tag) for sample simplification, to a
number of peptide chromatographic methods and MS
methods (Supplementary Table 3). We compared our data
set (one-dimensional SDS-PAGE and LC-MS/MS); the data
set of Yoshimura et al. (2004) (multi dimensional liquid
chromatography-MS/MS) and the data set of Li et al. (2004)
(two-dimensional gel/ICAT and matrix-assisted laser desorp-
tion ionization-time of flight, LC-MS/MS) by generating a
two-dimensional scatter plot of log Mr versus pi (Supple¬
mentary Fig. 1). It can be seen that the two-dimensional LC-
MS/MS approach used by Yoshimura et al. (2004) has the
benefit of identifying many low molecular weight proteins as
this approach does not utilize any gel electrophoresis step in
which these proteins would be lost. Our data set is biased
towards integral membrane proteins, with this class repre¬
senting 24% of our data set. Both two-dimensional LC and
two-dimensional gel electrophoresis are poorer approaches
for identifying membrane proteins, with a representation of
17 and 7% transmembrane proteins respectively.
The distribution of protein identifications in the T otal PSD
data set shows that the majority of proteins were detected
only once (58%) (Fig. 2a) and that 198 proteins (18%) were
detected twice. The number of proteins detected five times or
1 2 3 4 5 6 7 8
Number of protein identifications
'*/ ✓ < * s//4C? Dataset \>
Fig. 2 Definition of a cPSD set of proteins by integration of multiple
synaptic data sets, (a) Analysis of the distribution of proteins identified
reveals that the majority of PSD proteins were identified only once.
Proteins identified in two or more studies may represent a higher-
confidence and, most likely, a high-abundance cPSD data set. (b)
Contributions of each PSD data set to the cPSD (red) and Total PSD
(blue) data sets. The G2C PSD analysis has the highest coverage of
the cPSD at 78% and also contributes the most unique proteins to the
Total PSD data set.
© 2005 International Society for Neurochemistry, J. Neurochem. (2005) 10.1111/J. 1471 -4159.2005.03507.x
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more was just 72 (6%), although this value is limited by the
smaller data sets included in the Total PSD data set. In order
to define a set of higher-confidence proteins we placed
proteins that were identified two or more times (466 proteins)
in a group termed the Consensus PSD (cPSD). Wc reasoned
that the majority these proteins are abundant, so are more
likely to be detected in multiple analyses, and that the set of
proteins detected once are perhaps of lower abundance or
may reflect differences in sample preparation. The coverage
of each individual data set with respect to the consensus and
Total PSD data sets is illustrated in Fig. 2(b). Some 363
proteins in our data set have been validated by their presence
in one or more of the other data sets, representing 78%
coverage of the cPSD. In addition, our data set contains 257
unique proteins, representing 39% of proteins detected once.
Verification of PSP proteins
We sought to verify the subcellular location of a selected set
of PSD and MASC proteins by large-scale immunoblotting
of whole extract, synaptosomes and PSDs from mouse
forebrains. Forty-eight commercially available antibodies
were tested on these three fractions to demonstrate the
presence and enrichment of postsynaptic proteins (Supple¬
mentary Table 5). Overall, we found that 21 proteins (44%)
were clearly enriched, eight (17%) showed similar abun¬
dance, 13 (27%) were present but not enriched and six (12%)
were undetectable in isolated PSDs compared with other
brain fractions (Supplementary Figs 2 and 3). Thirty-three of
the 48 proteins tested are cPSD proteins and 15 of these
displayed enrichment in the PSD fraction. Proteins contained
in the MASC data set were identified in purifications from
whole-brain extract and, although 144 of of 186 have been
verified by their identification in the PSD fraction, the
remainder of this data set requires validation. Fifteen
antibodies against MASC proteins were used to confirm
their presence in the PSD; of these eight were not shown to
be PSD proteins, by MS, and seven were found in the PSD
once by MS. We confirmed the PSD localization of 14 of the
15 MASC proteins tested (Supplementary Figs 2 and 3),
indicating that the majority of MASC proteins are probably
bona fide PSD proteins.
In addition to verification by immunoblotting, we per¬
formed extensive searching in PubMed for PSD localization
data for these 1124 proteins (Supplementary Table 2). We
found that 119 (10.6%) of these proteins have been
previously reported to be localized in PSD. As shown in
Supplementary Table 3, we identified more known PSD
proteins (66% of PSD proteins from the literature) in our
analysis of the PSD than did other similar analyses,
indicating the high coverage of our data set.
Classification of PSP proteins
The initial approach to characterizing the organization of the
PSP was to classify the proteins into categories that describe
The postsynaptic proteome 5
their known functional properties (Table 1). Within the
overall PSP, representatives of many classes of proteins
representing a broad range of cell biological functions were
observed: membrane-bound receptors, adhesion proteins and
channels; a plethora of signalling proteins and adaptors; and
proteins involved with regulation of transport, RNA meta¬
bolism, translation and transcription. The cPSD contains
similar numbers of proteins in most classes as our PSD data
set, with the exception of channels and receptors, signalling
proteins and synaptic vesicle proteins. This becomes evident
when the cPSD is compared with the Total PSD; the reduced
presence of these protein classes in the cPSD is most
probably due to the lower abundance of these proteins, and
thus a decreased likelihood of detection. This supports the
idea that the cPSD represents a consensus of protein
identifications which, on one hand, decreases individual data
set bias for contaminating proteins (nuclear or mitochondrial)
but, on the other, has limited coverage of some protein
classes because of abundance issues. It is worth noting that
the G2C PSD data set contributed all three tyrosine kinases
found in the PSD, an indication of the sensitivity of our
approach as tyrosine kinases are of relatively low abundance.
The G2C PSD data set also has more coverage of most
protein classes than individual data sets that constitute the
Total PSD.
Protein domain analysis
Do synapse proteomes contain particular functional subsets
of proteins? We examined their protein domain profiles using
the InterPro resource (http://www.ebi.ac.uk/interpro). All
domains in three PSD data sets [G2C PSD (594 proteins
with 1709 domains), the Total PSD (1032 proteins with 2786
domains and the cPSD (447 proteins with 1298 domains)]
were identified and ranked by frequency (% of proteins in
each PSD data set with a specific domain) and compared
with the UniProt mouse proteome (http://www.ebi.ac.uk/
integr8). The enrichment of the top 10 domains found in the
cPSD was compared with the Total and our PSD data set
(Supplementary Fig. 4). The greatest enrichment in these
data sets is for protein interaction domains and, in particular,
the cPSD has a striking enrichment of PDZ and SH3 domains
(7.7- and 7.2-fold respectively). This is in agreement with the
notion that the cPSD contains abundant proteins such as
synaptic scaffolders containing PDZ and SH3 domains. The
most common domains in all three data sets are associated
with kinase function and the enrichment profile for these
domains is similar across these data sets. This enrichment in
kinase domains correlates with enrichment in other domains
commonly found in protein kinases, which allow them to
interact in networks (e.g. SH3, PDZ interaction domains
(Manning et al. 2002).
Importantly, domains involved with Ca2+-dependent sig¬
nalling, a major feature of postsynaptic signal transduction,
were also highly abundant (C2, C2 calcium/lipid-binding).
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Similarly, members of the Ras GTPase superfamily were
enriched by over 5-fold in the Total PSD data set.
Conversely, some domains that are highly abundant in the
mouse proteome were absent from all PSD data sets, such as
olfactory receptor homeobox domains (second and 19th most
abundant domains respectively). The same signalling
domains enriched at the synapse are known to have expanded
in the genome with the evolutionary step from single to
multicellular organisms (Manning et al. 2002). Some 62% of
domains found in proteins contained in the Total PSD are
present in Saccharomyces cerevisiae, indicating that a large
proportion of the basic building blocks of mammalian
synaptic proteins are conserved from before the metazoan
expansion. The complement of these domains increases after
this expansion with Caenorhabditis elegant, Danio rerio and
Drosophila melanogaster having 85, 86 and 87% of Total
PSD protein domains respectively. This indicates that after
this expansion there was an increase in the order of 20-30%
in the appearance of new domains as well as domain
shuffling to produce new proteins.
Multiprotein complexes in the PSD
Previous proteomic studies showed that NMDA receptor-
PSD-95 complexes were 2-3-MDa particles, which included
mGluR receptors, and that AMPA receptors were in different
complexes (Husi and Grant 2001; Garry et al. 2003). The
mGluR5 receptor complex has recently been characterized in a
similar fashion to the MASC and was found to contain 76
proteins, including the NMDA receptor subunit NR2A (Farr
et al. 2004). The majority of proteins in all three glutamate
receptor complexes have been independently identified as PSD
proteins (Fig. 3). These complexes also contain proteins that
have not yet been detected in PSD analyses, presumably owing
to abundance issues in analyses ofPSD preparations compared
with enriched protein complexes. We have validated the
presence ofseven such proteins in the PSD by immunoblotting
and this has been taken into account in the numbers shown in
Fig. 3. It is interesting to note that the majority of the
components of these complexes have been validated as PSD
proteins and that overlap between these complexes occurs in
the cPSD (Fig. 3), supporting the notion that the cPSD is an
important subset of the Total PSD data set. This is consistent
with a postsynaptic organization in which the MASC is
connected to multiple cell biological effector mechanisms
organized into their respective complexes. In addition to
MASCs and ARCs, components of other complexes, such as
cell adhesion, growth factor, cytoskeletal, transport and
ribosomal complexes, were detected.
Discussion
We have presented a comprehensive analysis of isolated
PSDs and embedded multiprotein complexes associated with
NMDA and AMPA receptors. We have combined existing
AMPA-R
Fig. 3 Multiprotein complexes at the PSD. Venn diagram illustrating
the overlap of three glutamate receptor complexes with the Total PSD
and cPSD data sets. Most of the overlap between components of
these complexes and the PSD occurs in the high-confidence cPSD
data set. Proteins detected in these multiprotein complexes that were
not found in any of the PSD data sets are generally of low abundance
and enriched in immuno-purifications of complexes compared with
whole-PSD analyses.
synapse proteomic data with that reported here to provide the
most complete picture of the PSP to date. To our knowledge,
the PSP is one ofthe most complicated subcellular structures in
the eukaryotic cell but, unlike other subcellular structures, the
PSP appears to hold a high degree of cellular autonomy. The
composition ofthe PSP in terms of functional protein classes is
diverse, with the necessary molecular machinery for not only
classical synaptic processes and a myriad of signalling
pathways, but for a host of supporting activities such as
protein synthesis and degradation, transport and metabolism.
Moreover, 10% of PSP proteins are novel and may participate
in synaptic processes that are currently unknown.
It is clear that there are a large number of proteins at the
postsynaptic membrane that coordinate a wide variety of
cellular processes. Is there evidence of functional organiza¬
tion at the postsynaptic membrane? We have observed
organization at many levels; from the classes of proteins
present at the PSD, the enrichment of scaffolding and
signalling domains in PSD proteins, to macromolecular
organization in terms of multiprotein complexes. These
levels of organization contribute to, or are dependent on,
protein-protein interactions and so mapping and understand¬
ing protein-protein interactions in the PSP will be very
useful. Protein interactions are essential to the functionality
of proteomes because proteins rarely act alone, but rather in
complexes. Large-scale mapping of protein interactions in
the yeast proteome reveals highly complex networks of
protein interactions (Fromont-Racine et al. 1997; Gavin
et al. 2002). To facilitate analysis of the organization of the
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PSP at the level of protein interactions we have constructed
an in-house database (http//:http://www.PPlD.org). This
database is a mammalian (mouse, rat, human) Protein-
Protein Interaction Database (PP1D) describing approxi¬
mately 8000 biochemically defined protein interactions for
more than 2000 proteins. So far we have performed literature
mining for PSP protein interactions and have found 650
protein-protein interactions for 281 PSP proteins (of which
the majority are MASC proteins). We are using these data to
perform network analyses to investigate protein interaction
network architecture in the PSP (Grant 2003a). In addition to
literature mining, we are performing immuno-affinity purif¬
ications on PSP proteins to map additional multiprotein
complexes at the synapse.
The large number of proteins found at the PSD, and the
presence of many ribosomal, mitochondrial and nuclear
proteins, has prompted speculation over the purity of isolated
PSD fractions used in proteomic analyses. There are
numerous examples of such proteins being validated as true
PSD proteins. Some proteins, such as voltage-dependent
anion channel 1, which was originally found in the outer
mitochondrial membrane, is present in the PSD (Moon et al.
1999). Nuclear proteins such as AIDA-1 A, mKIAA0417
and hnRNP localize to both the nucleus and the PSD (Jordan
et al. 2004). It is apparent that many proteins do not exist in
discrete locations or indeed possess the same functions in
different cellular contexts.
The data presented and compiled in this study represent a
draft of an average isolated PSD. The starting material for the
analyses incorporated into our draft PSP are from different
species (mouse and rat) and from different brain regions
(forebrain and whole brain) and encompass hundreds of
neuronal cell types. In addition, it is probable that some
components of the MASC are interacting with NMDA
receptors during their trafficking, localization and internal¬
ization. It is now is becoming feasible to compare different
types of synapse proteomes. This could be achieved by
subtractive proteomics (Andersen et al. 2003), a quantitative
approach whereby synaptosomes and isolated PSDs could be
isotopically tagged (1CAT or iTRAQ (isotopic tags for
relative and obsolute quantification)) and the resulting
quantitative MS data would indicate enrichment or depletion
of proteins in the PSD compared with synaptosomes. This
type of analysis would provide confident assignment of true
PSD proteins, highlight contaminating proteins and would
validate the PSD localization ofproteins currently considered
to be restricted to other cellular compartments.
In addition, isolated PSDs or protein complexes from
different brain regions or cultured cell types could be compared
quantitatively using isotopic labelling. Alternatively, peptides
derived from SILAC (stable isotope labelling with amino acids
in cell culture)-labelled cells could be used quantitatively to
compare the expression of proteins in many tissue samples
(Ishihama et al. 2005). Using these approaches, proteins
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enriched in a particular cell type or brain region would be
identified as being potentially more relevant to the physiology
of that particular cell or tissue type. It is at this stage that
systematic immuno-cytochemistry of these enriched proteins
would be feasible and would provide complementary infor¬
mation regarding their specific protein localization at the PSD
and throughout the cell type in question. Current projects, such
as Gene Expression Nervous System Atlas (GENSAT), in
which large-scale in situ hybridization and Bacteriol Artificial
Chromosome (BAC) transgenic reporter genes are being used
to map gene expression in neuronal cell types, will provide
complementary information to the proteomic experiments
suggested here.
This draft PSP data set constitutes a candidate gene list for
the Genes to Cognition research programme in which the
functions of a large number of these genes are being studied
by systematic targeted mutations in mice (Grant 2003b).
Comprehensive phenotypic analysis of these mutants in
terms of biochemistry, electrophysiology, cell biology and
behaviour is allowing functional annotation of PSP compo¬
nents. This approach, together with single-nucleotide poly¬
morphism screening in humans for all genes in the PSP,
will produce systematic data relevant to synaptic physiology
and disease. Establishment of this PSP data set (avail¬
able at http://www.genes2cognition.org/science/proteomics/
synapse.html) is essential for the progression of synapse
proteomics and, with new quantitative proteomic strategies
that may be applied to activated or diseased states of the
synapse, will also provide a benchmark for analysis of
dynamic aspects of the synapse proteome.
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